CA3095136A1 - Use of exosomes for targeted delivery of therapeutic agents - Google Patents
Use of exosomes for targeted delivery of therapeutic agents Download PDFInfo
- Publication number
- CA3095136A1 CA3095136A1 CA3095136A CA3095136A CA3095136A1 CA 3095136 A1 CA3095136 A1 CA 3095136A1 CA 3095136 A CA3095136 A CA 3095136A CA 3095136 A CA3095136 A CA 3095136A CA 3095136 A1 CA3095136 A1 CA 3095136A1
- Authority
- CA
- Canada
- Prior art keywords
- exosomes
- cancer
- protein
- disorder
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 512
- 239000003814 drug Substances 0.000 title claims abstract description 45
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 28
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 271
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 234
- 210000004027 cell Anatomy 0.000 claims abstract description 190
- 238000000034 method Methods 0.000 claims abstract description 122
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 37
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 31
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 31
- 239000003102 growth factor Substances 0.000 claims abstract description 25
- 206010028980 Neoplasm Diseases 0.000 claims description 103
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 97
- 230000001225 therapeutic effect Effects 0.000 claims description 66
- 201000010099 disease Diseases 0.000 claims description 56
- 201000011510 cancer Diseases 0.000 claims description 55
- 239000013612 plasmid Substances 0.000 claims description 46
- 208000035475 disorder Diseases 0.000 claims description 41
- 108020004459 Small interfering RNA Proteins 0.000 claims description 32
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 31
- 239000004055 small Interfering RNA Substances 0.000 claims description 31
- 108020004999 messenger RNA Proteins 0.000 claims description 26
- 238000002560 therapeutic procedure Methods 0.000 claims description 22
- 210000002966 serum Anatomy 0.000 claims description 21
- 238000004520 electroporation Methods 0.000 claims description 17
- 238000009169 immunotherapy Methods 0.000 claims description 16
- 230000002401 inhibitory effect Effects 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 239000000427 antigen Substances 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 14
- 230000003834 intracellular effect Effects 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 13
- 210000001124 body fluid Anatomy 0.000 claims description 13
- 239000010839 body fluid Substances 0.000 claims description 13
- 238000001959 radiotherapy Methods 0.000 claims description 10
- 238000002512 chemotherapy Methods 0.000 claims description 9
- 239000011159 matrix material Substances 0.000 claims description 9
- 208000020084 Bone disease Diseases 0.000 claims description 8
- 102000009465 Growth Factor Receptors Human genes 0.000 claims description 8
- 108010009202 Growth Factor Receptors Proteins 0.000 claims description 8
- 239000002299 complementary DNA Substances 0.000 claims description 8
- 230000001394 metastastic effect Effects 0.000 claims description 8
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 8
- 208000017520 skin disease Diseases 0.000 claims description 8
- 229940126586 small molecule drug Drugs 0.000 claims description 8
- 230000008685 targeting Effects 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 102000040945 Transcription factor Human genes 0.000 claims description 7
- 108091023040 Transcription factor Proteins 0.000 claims description 7
- 238000010362 genome editing Methods 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- 210000002700 urine Anatomy 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims description 6
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims description 6
- 102000001253 Protein Kinase Human genes 0.000 claims description 6
- 210000001185 bone marrow Anatomy 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 239000002679 microRNA Substances 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 108060006633 protein kinase Proteins 0.000 claims description 6
- 238000010453 CRISPR/Cas method Methods 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 claims description 5
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 claims description 5
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 5
- 230000006378 damage Effects 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 238000001794 hormone therapy Methods 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 208000017169 kidney disease Diseases 0.000 claims description 5
- 210000003296 saliva Anatomy 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000035473 Communicable disease Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 4
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 4
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 4
- 206010057644 Testis cancer Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 238000000315 cryotherapy Methods 0.000 claims description 4
- 208000010643 digestive system disease Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 210000000416 exudates and transudate Anatomy 0.000 claims description 4
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 210000002751 lymph Anatomy 0.000 claims description 4
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 4
- 108091070501 miRNA Proteins 0.000 claims description 4
- 206010038038 rectal cancer Diseases 0.000 claims description 4
- 201000001275 rectum cancer Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 201000003120 testicular cancer Diseases 0.000 claims description 4
- 206010044285 tracheal cancer Diseases 0.000 claims description 4
- 238000001890 transfection Methods 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 206010046766 uterine cancer Diseases 0.000 claims description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 3
- 108700020796 Oncogene Proteins 0.000 claims description 3
- 208000025609 Urogenital disease Diseases 0.000 claims description 3
- 239000012216 imaging agent Substances 0.000 claims description 3
- 239000002407 tissue scaffold Substances 0.000 claims description 3
- 239000002924 silencing RNA Substances 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 53
- 235000018102 proteins Nutrition 0.000 description 212
- 230000014616 translation Effects 0.000 description 70
- 241000282414 Homo sapiens Species 0.000 description 69
- -1 e.g. Substances 0.000 description 68
- 239000000203 mixture Substances 0.000 description 62
- 239000005090 green fluorescent protein Substances 0.000 description 61
- 239000002502 liposome Substances 0.000 description 58
- 108091033409 CRISPR Proteins 0.000 description 57
- 239000003795 chemical substances by application Substances 0.000 description 55
- 238000011282 treatment Methods 0.000 description 49
- 150000002632 lipids Chemical class 0.000 description 46
- 108090000765 processed proteins & peptides Proteins 0.000 description 45
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 44
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 43
- 239000004698 Polyethylene Substances 0.000 description 38
- 230000000694 effects Effects 0.000 description 37
- 238000013519 translation Methods 0.000 description 37
- 238000010354 CRISPR gene editing Methods 0.000 description 35
- 238000004458 analytical method Methods 0.000 description 35
- 239000000284 extract Substances 0.000 description 34
- 238000003119 immunoblot Methods 0.000 description 34
- 238000013518 transcription Methods 0.000 description 33
- 230000035897 transcription Effects 0.000 description 33
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 32
- 239000000523 sample Substances 0.000 description 31
- 102000004196 processed proteins & peptides Human genes 0.000 description 30
- 239000011324 bead Substances 0.000 description 29
- 230000027455 binding Effects 0.000 description 29
- 230000037396 body weight Effects 0.000 description 29
- 238000011534 incubation Methods 0.000 description 27
- 229940024606 amino acid Drugs 0.000 description 26
- 150000001413 amino acids Chemical class 0.000 description 26
- 108020004414 DNA Proteins 0.000 description 25
- 235000001014 amino acid Nutrition 0.000 description 25
- 230000000638 stimulation Effects 0.000 description 25
- 230000003211 malignant effect Effects 0.000 description 24
- 229920001184 polypeptide Polymers 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 20
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 18
- 239000013642 negative control Substances 0.000 description 18
- 150000003904 phospholipids Chemical class 0.000 description 18
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 17
- 238000011068 loading method Methods 0.000 description 17
- 239000002773 nucleotide Substances 0.000 description 17
- 125000003729 nucleotide group Chemical group 0.000 description 17
- 229940045513 CTLA4 antagonist Drugs 0.000 description 16
- 102100033067 Growth factor receptor-bound protein 2 Human genes 0.000 description 16
- 101000871017 Homo sapiens Growth factor receptor-bound protein 2 Proteins 0.000 description 16
- 210000001744 T-lymphocyte Anatomy 0.000 description 16
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 15
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 15
- 102000037865 fusion proteins Human genes 0.000 description 15
- 108020001507 fusion proteins Proteins 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000003112 inhibitor Substances 0.000 description 14
- 239000008188 pellet Substances 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 230000007935 neutral effect Effects 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 12
- 102100040250 Transcription elongation factor A protein-like 1 Human genes 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 239000002105 nanoparticle Substances 0.000 description 12
- 230000037361 pathway Effects 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 238000005199 ultracentrifugation Methods 0.000 description 12
- 201000009030 Carcinoma Diseases 0.000 description 11
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 11
- 101710163270 Nuclease Proteins 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 230000009368 gene silencing by RNA Effects 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 238000006366 phosphorylation reaction Methods 0.000 description 11
- 102000040430 polynucleotide Human genes 0.000 description 11
- 108091033319 polynucleotide Proteins 0.000 description 11
- 239000002157 polynucleotide Substances 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 238000001356 surgical procedure Methods 0.000 description 11
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 239000013613 expression plasmid Substances 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 238000004949 mass spectrometry Methods 0.000 description 10
- 229960004452 methionine Drugs 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 230000026731 phosphorylation Effects 0.000 description 10
- 238000001243 protein synthesis Methods 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
- 108020005004 Guide RNA Proteins 0.000 description 9
- 108091030071 RNAI Proteins 0.000 description 9
- 239000005557 antagonist Substances 0.000 description 9
- 239000002246 antineoplastic agent Substances 0.000 description 9
- 230000004927 fusion Effects 0.000 description 9
- 238000002955 isolation Methods 0.000 description 9
- 239000006166 lysate Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 238000011002 quantification Methods 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 8
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 208000009956 adenocarcinoma Diseases 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 229960002621 pembrolizumab Drugs 0.000 description 8
- 238000003753 real-time PCR Methods 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 7
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 7
- 239000000232 Lipid Bilayer Substances 0.000 description 7
- 244000097202 Rathbunia alamosensis Species 0.000 description 7
- 235000009776 Rathbunia alamosensis Nutrition 0.000 description 7
- 102100040879 Tumor susceptibility gene 101 protein Human genes 0.000 description 7
- 101710134332 Tumor susceptibility gene 101 protein Proteins 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000033228 biological regulation Effects 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 239000000470 constituent Substances 0.000 description 7
- 239000000032 diagnostic agent Substances 0.000 description 7
- 229940039227 diagnostic agent Drugs 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 6
- 108090000331 Firefly luciferases Proteins 0.000 description 6
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 6
- 102000010956 Glypican Human genes 0.000 description 6
- 108050001154 Glypican Proteins 0.000 description 6
- 108050007238 Glypican-1 Proteins 0.000 description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 108010058846 Ovalbumin Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- 108091028113 Trans-activating crRNA Proteins 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 229910052796 boron Inorganic materials 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 229940127089 cytotoxic agent Drugs 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 6
- 230000005012 migration Effects 0.000 description 6
- 238000013508 migration Methods 0.000 description 6
- 102000035118 modified proteins Human genes 0.000 description 6
- 108091005573 modified proteins Proteins 0.000 description 6
- 230000004899 motility Effects 0.000 description 6
- 210000002487 multivesicular body Anatomy 0.000 description 6
- 229960003301 nivolumab Drugs 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 108010085238 Actins Proteins 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 5
- 102100027221 CD81 antigen Human genes 0.000 description 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 5
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 5
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 5
- 102000009572 RNA Polymerase II Human genes 0.000 description 5
- 108010009460 RNA Polymerase II Proteins 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 230000004075 alteration Effects 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 238000000326 densiometry Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 238000007847 digital PCR Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 5
- 229940121354 immunomodulator Drugs 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 229960005386 ipilimumab Drugs 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 102000010893 ATP-binding cassette subfamily A member 6 Human genes 0.000 description 4
- 108050001070 ATP-binding cassette subfamily A member 6 Proteins 0.000 description 4
- 108010043137 Actomyosin Proteins 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102100025222 CD63 antigen Human genes 0.000 description 4
- 102100037904 CD9 antigen Human genes 0.000 description 4
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 4
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102100023387 Endoribonuclease Dicer Human genes 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 4
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 4
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 4
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 4
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 4
- 102100027869 Moesin Human genes 0.000 description 4
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 4
- 102100025502 SLIT and NTRK-like protein 4 Human genes 0.000 description 4
- 101710117176 SLIT and NTRK-like protein 4 Proteins 0.000 description 4
- 241000193996 Streptococcus pyogenes Species 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 102100040871 Tetraspanin-4 Human genes 0.000 description 4
- 101710151654 Tetraspanin-4 Proteins 0.000 description 4
- 108020004566 Transfer RNA Proteins 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000011319 anticancer therapy Methods 0.000 description 4
- 238000000376 autoradiography Methods 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 229960000310 isoleucine Drugs 0.000 description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 238000010232 migration assay Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000001613 neoplastic effect Effects 0.000 description 4
- 229940092253 ovalbumin Drugs 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 239000003531 protein hydrolysate Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000007634 remodeling Methods 0.000 description 4
- 239000004017 serum-free culture medium Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- 238000004627 transmission electron microscopy Methods 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 206010003571 Astrocytoma Diseases 0.000 description 3
- 102100037500 Bridging integrator 3 Human genes 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 102100029974 GTPase HRas Human genes 0.000 description 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 3
- 102000005720 Glutathione transferase Human genes 0.000 description 3
- 108010070675 Glutathione transferase Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 102100021642 Histone H2A type 2-A Human genes 0.000 description 3
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 3
- 101000712958 Homo sapiens Ras association domain-containing protein 1 Proteins 0.000 description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102000015695 Myristoylated Alanine-Rich C Kinase Substrate Human genes 0.000 description 3
- 108010063737 Myristoylated Alanine-Rich C Kinase Substrate Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 102100033243 Ras association domain-containing protein 1 Human genes 0.000 description 3
- 108010052090 Renilla Luciferases Proteins 0.000 description 3
- 239000012721 SDS lysis buffer Substances 0.000 description 3
- 102100032621 Secretagogin Human genes 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000011394 anticancer treatment Methods 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 230000031018 biological processes and functions Effects 0.000 description 3
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 3
- 229930195731 calicheamicin Natural products 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 230000008568 cell cell communication Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000035605 chemotaxis Effects 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 238000001085 differential centrifugation Methods 0.000 description 3
- 230000007783 downstream signaling Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 230000002121 endocytic effect Effects 0.000 description 3
- 210000001723 extracellular space Anatomy 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000003463 hyperproliferative effect Effects 0.000 description 3
- 238000003126 immunogold labeling Methods 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 230000005291 magnetic effect Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 208000037819 metastatic cancer Diseases 0.000 description 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 229920003259 poly(silylenemethylene) Polymers 0.000 description 3
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 108020001580 protein domains Proteins 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000001138 tear Anatomy 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- FVXDQWZBHIXIEJ-LNDKUQBDSA-N 1,2-di-[(9Z,12Z)-octadecadienoyl]-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC FVXDQWZBHIXIEJ-LNDKUQBDSA-N 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 102100038687 5'-nucleotidase domain-containing protein 3 Human genes 0.000 description 2
- 102100026750 60S ribosomal protein L5 Human genes 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 108010016281 ADP-Ribosylation Factor 1 Proteins 0.000 description 2
- 102000016954 ADP-Ribosylation Factors Human genes 0.000 description 2
- 108010053971 ADP-Ribosylation Factors Proteins 0.000 description 2
- 102100034341 ADP-ribosylation factor 1 Human genes 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 102100034163 Alpha-actinin-1 Human genes 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 102100031327 Ankyrin repeat domain-containing protein 62 Human genes 0.000 description 2
- 101710188831 Ankyrin repeat domain-containing protein 62 Proteins 0.000 description 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 2
- 101710144268 B- and T-lymphocyte attenuator Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102100038078 CD276 antigen Human genes 0.000 description 2
- 102100027217 CD82 antigen Human genes 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- 102100032378 Carboxypeptidase E Human genes 0.000 description 2
- 108010058255 Carboxypeptidase H Proteins 0.000 description 2
- 201000000274 Carcinosarcoma Diseases 0.000 description 2
- 102100032401 Charged multivesicular body protein 2a Human genes 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 101150076092 Chmp2a gene Proteins 0.000 description 2
- 108010049048 Cholera Toxin Proteins 0.000 description 2
- 102000009016 Cholera Toxin Human genes 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 102100033781 Collagen alpha-2(IV) chain Human genes 0.000 description 2
- 101710179387 Collagen alpha-2(IV) chain Proteins 0.000 description 2
- 108010002947 Connectin Proteins 0.000 description 2
- 102100028233 Coronin-1A Human genes 0.000 description 2
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 101100506758 Drosophila melanogaster hid gene Proteins 0.000 description 2
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 2
- 102100039629 E3 ubiquitin-protein ligase RNF166 Human genes 0.000 description 2
- 101710162507 E3 ubiquitin-protein ligase RNF166 Proteins 0.000 description 2
- 102100032020 EH domain-containing protein 2 Human genes 0.000 description 2
- 102000006539 ELAV-Like Protein 4 Human genes 0.000 description 2
- 108010008802 ELAV-Like Protein 4 Proteins 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 2
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 2
- 102100033902 Endothelin-1 Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 102000002241 Eukaryotic Initiation Factors Human genes 0.000 description 2
- 108010014863 Eukaryotic Initiation Factors Proteins 0.000 description 2
- 102100020903 Ezrin Human genes 0.000 description 2
- 102100028408 FERM and PDZ domain-containing protein 1 Human genes 0.000 description 2
- 101710155973 FERM and PDZ domain-containing protein 1 Proteins 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 2
- 108010008945 General Transcription Factors Proteins 0.000 description 2
- 102000006580 General Transcription Factors Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- 102100041036 Golgin subfamily A member 7 Human genes 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 102100028893 Hemicentin-1 Human genes 0.000 description 2
- 101710142180 Hemicentin-1 Proteins 0.000 description 2
- 101710132521 Histone H2A type 2-A Proteins 0.000 description 2
- 102100039236 Histone H3.3 Human genes 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 101000691083 Homo sapiens 60S ribosomal protein L5 Proteins 0.000 description 2
- 101000799406 Homo sapiens Alpha-actinin-1 Proteins 0.000 description 2
- 101000739614 Homo sapiens Bridging integrator 3 Proteins 0.000 description 2
- 101000914469 Homo sapiens CD82 antigen Proteins 0.000 description 2
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 2
- 101000921226 Homo sapiens EH domain-containing protein 2 Proteins 0.000 description 2
- 101000925493 Homo sapiens Endothelin-1 Proteins 0.000 description 2
- 101001039317 Homo sapiens Golgin subfamily A member 7 Proteins 0.000 description 2
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 2
- 101001050274 Homo sapiens Keratin, type I cytoskeletal 9 Proteins 0.000 description 2
- 101001046936 Homo sapiens Keratin, type II cytoskeletal 2 epidermal Proteins 0.000 description 2
- 101001027628 Homo sapiens Kinesin-like protein KIF21A Proteins 0.000 description 2
- 101001051207 Homo sapiens L-lactate dehydrogenase B chain Proteins 0.000 description 2
- 101000780208 Homo sapiens Long-chain-fatty-acid-CoA ligase 4 Proteins 0.000 description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
- 101000721756 Homo sapiens Olfactory receptor 51E1 Proteins 0.000 description 2
- 101000693238 Homo sapiens PDZ domain-containing protein 2 Proteins 0.000 description 2
- 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 2
- 101000876829 Homo sapiens Protein C-ets-1 Proteins 0.000 description 2
- 101001133607 Homo sapiens Protein kinase C and casein kinase substrate in neurons protein 3 Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 101000654764 Homo sapiens Secretagogin Proteins 0.000 description 2
- 101000740417 Homo sapiens Secretory carrier-associated membrane protein 2 Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 101000803689 Homo sapiens Vacuolar protein sorting-associated protein 4B Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102100023913 Involucrin Human genes 0.000 description 2
- 102100021646 Isobutyryl-CoA dehydrogenase, mitochondrial Human genes 0.000 description 2
- 102000012322 Junction plakoglobin Human genes 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 102100022971 Katanin p60 ATPase-containing subunit A-like 2 Human genes 0.000 description 2
- 101710083000 Katanin p60 ATPase-containing subunit A-like 2 Proteins 0.000 description 2
- 102100021190 Kazrin Human genes 0.000 description 2
- 101710088828 Kazrin Proteins 0.000 description 2
- 102100023129 Keratin, type I cytoskeletal 9 Human genes 0.000 description 2
- 102100022854 Keratin, type II cytoskeletal 2 epidermal Human genes 0.000 description 2
- 102100037688 Kinesin-like protein KIF21A Human genes 0.000 description 2
- 101150105104 Kras gene Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 102100024580 L-lactate dehydrogenase B chain Human genes 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 102100027448 Laminin subunit beta-1 Human genes 0.000 description 2
- 101710186246 Laminin subunit beta-1 Proteins 0.000 description 2
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
- 102100034319 Long-chain-fatty-acid-CoA ligase 4 Human genes 0.000 description 2
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 2
- 102100025169 Max-binding protein MNT Human genes 0.000 description 2
- 206010027145 Melanocytic naevus Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102000005431 Molecular Chaperones Human genes 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 2
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- 101710147545 Myeloid cell surface antigen CD33 Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 102100025127 Olfactory receptor 51E1 Human genes 0.000 description 2
- 201000010133 Oligodendroglioma Diseases 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Natural products OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 102100025646 PDZ domain-containing protein 2 Human genes 0.000 description 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 2
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102100020864 Prostaglandin F2 receptor negative regulator Human genes 0.000 description 2
- 101710116300 Prostaglandin F2 receptor negative regulator Proteins 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 102100035251 Protein C-ets-1 Human genes 0.000 description 2
- 108091008611 Protein Kinase B Proteins 0.000 description 2
- 102100028588 Protein ZNRD2 Human genes 0.000 description 2
- 102100034315 Protein kinase C and casein kinase substrate in neurons protein 3 Human genes 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- 101710159340 Protocadherin beta-18 Proteins 0.000 description 2
- 102100030156 Putative protein C3P1 Human genes 0.000 description 2
- 102100040925 Putative protocadherin beta-18 Human genes 0.000 description 2
- 101710130987 Putative protocadherin beta-18 Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 102100025132 Ras-related protein Rab-5B Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 2
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 102000002278 Ribosomal Proteins Human genes 0.000 description 2
- 108010000605 Ribosomal Proteins Proteins 0.000 description 2
- 108010055623 S-Phase Kinase-Associated Proteins Proteins 0.000 description 2
- 102000000341 S-Phase Kinase-Associated Proteins Human genes 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 102100037233 Secretory carrier-associated membrane protein 2 Human genes 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 102000005782 Squalene Monooxygenase Human genes 0.000 description 2
- 108020003891 Squalene monooxygenase Proteins 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 238000003917 TEM image Methods 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 102100036407 Thioredoxin Human genes 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 102100026260 Titin Human genes 0.000 description 2
- 102100022607 Trafficking protein particle complex subunit 6A Human genes 0.000 description 2
- 101710105081 Trafficking protein particle complex subunit 6A Proteins 0.000 description 2
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 2
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 2
- 102100040080 Tripartite motif-containing protein 42 Human genes 0.000 description 2
- 101710154666 Tripartite motif-containing protein 42 Proteins 0.000 description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 101710195937 Tubulin beta-2B chain Proteins 0.000 description 2
- 102100026248 Tubulin beta-2B chain Human genes 0.000 description 2
- 102100033469 Tubulointerstitial nephritis antigen-like Human genes 0.000 description 2
- 101710159742 Tubulointerstitial nephritis antigen-like Proteins 0.000 description 2
- 101710075830 VPS37B Proteins 0.000 description 2
- 102100037940 Vacuolar protein sorting-associated protein 37B Human genes 0.000 description 2
- 102100035086 Vacuolar protein sorting-associated protein 4B Human genes 0.000 description 2
- 102000013625 Valine-tRNA Ligase Human genes 0.000 description 2
- 108700015935 Valine-tRNA ligases Proteins 0.000 description 2
- 108050003627 Wnt Proteins 0.000 description 2
- 101710185494 Zinc finger protein Proteins 0.000 description 2
- 102100023552 Zinc finger protein 37 homolog Human genes 0.000 description 2
- 101710142622 Zinc finger protein 37 homolog Proteins 0.000 description 2
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 102000035181 adaptor proteins Human genes 0.000 description 2
- 108091005764 adaptor proteins Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000002707 ameloblastic effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003474 anti-emetic effect Effects 0.000 description 2
- 229940125683 antiemetic agent Drugs 0.000 description 2
- 239000002111 antiemetic agent Substances 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003096 antiparasitic agent Substances 0.000 description 2
- 229940125687 antiparasitic agent Drugs 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 238000004630 atomic force microscopy Methods 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 102000055102 bcl-2-Associated X Human genes 0.000 description 2
- 108700000707 bcl-2-Associated X Proteins 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000008436 biogenesis Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 108091005948 blue fluorescent proteins Proteins 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 102000021178 chitin binding proteins Human genes 0.000 description 2
- 108091011157 chitin binding proteins Proteins 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000000749 co-immunoprecipitation Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000005757 colony formation Effects 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 238000011498 curative surgery Methods 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 108010082025 cyan fluorescent protein Proteins 0.000 description 2
- 230000021953 cytokinesis Effects 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 229940052760 dopamine agonists Drugs 0.000 description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000010201 enrichment analysis Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000025058 exit from host Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- 108010084448 gamma Catenin Proteins 0.000 description 2
- 210000003976 gap junction Anatomy 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 150000002327 glycerophospholipids Chemical class 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 101150052240 ihfA gene Proteins 0.000 description 2
- 239000012642 immune effector Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 2
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 108090000237 interleukin-24 Proteins 0.000 description 2
- 102000003898 interleukin-24 Human genes 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
- 108010052968 leupeptin Proteins 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 2
- 235000011285 magnesium acetate Nutrition 0.000 description 2
- 239000011654 magnesium acetate Substances 0.000 description 2
- 229940069446 magnesium acetate Drugs 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- 108010071525 moesin Proteins 0.000 description 2
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 2
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 208000007312 paraganglioma Diseases 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 108010091212 pepstatin Proteins 0.000 description 2
- 229950000964 pepstatin Drugs 0.000 description 2
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 150000008105 phosphatidylcholines Chemical class 0.000 description 2
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 2
- 229960000624 procarbazine Drugs 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 102000016914 ras Proteins Human genes 0.000 description 2
- 108010014186 ras Proteins Proteins 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000000822 sequential centrifugation Methods 0.000 description 2
- 230000001743 silencing effect Effects 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 108060008226 thioredoxin Proteins 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 230000007486 viral budding Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- YKIOPDIXYAUOFN-YACUFSJGSA-N (2-{[(2r)-2,3-bis(icosanoyloxy)propyl phosphonato]oxy}ethyl)trimethylazanium Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC YKIOPDIXYAUOFN-YACUFSJGSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- RVNZEJNWTUDQSC-JOCHJYFZSA-N (2r)-n-(6-aminohexyl)-1-tridecanoylpyrrolidine-2-carboxamide Chemical compound CCCCCCCCCCCCC(=O)N1CCC[C@@H]1C(=O)NCCCCCCN RVNZEJNWTUDQSC-JOCHJYFZSA-N 0.000 description 1
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- FLWWDYNPWOSLEO-HQVZTVAUSA-N (2s)-2-[[4-[1-(2-amino-4-oxo-1h-pteridin-6-yl)ethyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1C(C)N(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FLWWDYNPWOSLEO-HQVZTVAUSA-N 0.000 description 1
- WKJDWDLHIOUPPL-JSOSNVBQSA-N (2s)-2-amino-3-({[(2r)-2,3-bis(tetradecanoyloxy)propoxy](hydroxy)phosphoryl}oxy)propanoic acid Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCC WKJDWDLHIOUPPL-JSOSNVBQSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- CGMTUJFWROPELF-YPAAEMCBSA-N (3E,5S)-5-[(2S)-butan-2-yl]-3-(1-hydroxyethylidene)pyrrolidine-2,4-dione Chemical compound CC[C@H](C)[C@@H]1NC(=O)\C(=C(/C)O)C1=O CGMTUJFWROPELF-YPAAEMCBSA-N 0.000 description 1
- TVIRNGFXQVMMGB-OFWIHYRESA-N (3s,6r,10r,13e,16s)-16-[(2r,3r,4s)-4-chloro-3-hydroxy-4-phenylbutan-2-yl]-10-[(3-chloro-4-methoxyphenyl)methyl]-6-methyl-3-(2-methylpropyl)-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H](O)[C@@H](Cl)C=2C=CC=CC=2)C/C=C/C(=O)N1 TVIRNGFXQVMMGB-OFWIHYRESA-N 0.000 description 1
- XRBSKUSTLXISAB-XVVDYKMHSA-N (5r,6r,7r,8r)-8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxole-6-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(O)=O)=C1 XRBSKUSTLXISAB-XVVDYKMHSA-N 0.000 description 1
- XRBSKUSTLXISAB-UHFFFAOYSA-N (7R,7'R,8R,8'R)-form-Podophyllic acid Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C(CO)C2C(O)=O)=C1 XRBSKUSTLXISAB-UHFFFAOYSA-N 0.000 description 1
- AESVUZLWRXEGEX-DKCAWCKPSA-N (7S,9R)-7-[(2S,4R,5R,6R)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione iron(3+) Chemical compound [Fe+3].COc1cccc2C(=O)c3c(O)c4C[C@@](O)(C[C@H](O[C@@H]5C[C@@H](N)[C@@H](O)[C@@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO AESVUZLWRXEGEX-DKCAWCKPSA-N 0.000 description 1
- JXVAMODRWBNUSF-KZQKBALLSA-N (7s,9r,10r)-7-[(2r,4s,5s,6s)-5-[[(2s,4as,5as,7s,9s,9ar,10ar)-2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl]oxy]-4-(dimethylamino)-6-methyloxan-2-yl]oxy-10-[(2s,4s,5s,6s)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2 Chemical compound O([C@@H]1C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C2[C@@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@H]4O[C@@H]5O[C@@H](C)C(=O)C[C@@H]5O[C@H]4C3)[C@H](C2)N(C)C)C[C@]1(O)CC)[C@H]1C[C@H](N(C)C)[C@H](O)[C@H](C)O1 JXVAMODRWBNUSF-KZQKBALLSA-N 0.000 description 1
- INAUWOVKEZHHDM-PEDBPRJASA-N (7s,9s)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7-[(2r,4s,5s,6s)-5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1 INAUWOVKEZHHDM-PEDBPRJASA-N 0.000 description 1
- RCFNNLSZHVHCEK-IMHLAKCZSA-N (7s,9s)-7-(4-amino-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound [Cl-].O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)C1CC([NH3+])CC(C)O1 RCFNNLSZHVHCEK-IMHLAKCZSA-N 0.000 description 1
- NOPNWHSMQOXAEI-PUCKCBAPSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-(2,3-dihydropyrrol-1-yl)-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCC=C1 NOPNWHSMQOXAEI-PUCKCBAPSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 description 1
- AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
- XAXNKAGAUFXFDO-JVJDXIHNSA-N (e)-n-[(4r,4as,7ar,12br)-3-(cyclopropylmethyl)-9-hydroxy-7-oxo-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-4a-yl]-3-(4-chlorophenyl)prop-2-enamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)NC(=O)\C=C\C=2C=CC(Cl)=CC=2)CC1)O)CC1CC1 XAXNKAGAUFXFDO-JVJDXIHNSA-N 0.000 description 1
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 1
- LZLVZIFMYXDKCN-QJWFYWCHSA-N 1,2-di-O-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC LZLVZIFMYXDKCN-QJWFYWCHSA-N 0.000 description 1
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
- 229940083937 1,2-diarachidoyl-sn-glycero-3-phosphocholine Drugs 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 1
- KLFKZIQAIPDJCW-GPOMZPHUSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC KLFKZIQAIPDJCW-GPOMZPHUSA-N 0.000 description 1
- DSNRWDQKZIEDDB-SQYFZQSCSA-N 1,2-dioleoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-SQYFZQSCSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- OZSITQMWYBNPMW-GDLZYMKVSA-N 1,2-ditetradecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCC OZSITQMWYBNPMW-GDLZYMKVSA-N 0.000 description 1
- FONKWHRXTPJODV-DNQXCXABSA-N 1,3-bis[2-[(8s)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydro-3h-pyrrolo[3,2-e]indole-6-carbonyl]-1h-indol-5-yl]urea Chemical compound C1([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C4=CC(O)=C5NC=C(C5=C4[C@H](CCl)C3)C)=C2C=C(O)C2=C1C(C)=CN2 FONKWHRXTPJODV-DNQXCXABSA-N 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- RFVFQQWKPSOBED-PSXMRANNSA-N 1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCC RFVFQQWKPSOBED-PSXMRANNSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- BTOTXLJHDSNXMW-POYBYMJQSA-N 2,3-dideoxyuridine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)NC(=O)C=C1 BTOTXLJHDSNXMW-POYBYMJQSA-N 0.000 description 1
- JLVSRWOIZZXQAD-UHFFFAOYSA-N 2,3-disulfanylpropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(S)CS JLVSRWOIZZXQAD-UHFFFAOYSA-N 0.000 description 1
- BOMZMNZEXMAQQW-UHFFFAOYSA-N 2,5,11-trimethyl-6h-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate Chemical compound CC([O-])=O.C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 BOMZMNZEXMAQQW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- NEZDNQCXEZDCBI-UHFFFAOYSA-N 2-azaniumylethyl 2,3-di(tetradecanoyloxy)propyl phosphate Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCC NEZDNQCXEZDCBI-UHFFFAOYSA-N 0.000 description 1
- VNBAOSVONFJBKP-UHFFFAOYSA-N 2-chloro-n,n-bis(2-chloroethyl)propan-1-amine;hydrochloride Chemical compound Cl.CC(Cl)CN(CCCl)CCCl VNBAOSVONFJBKP-UHFFFAOYSA-N 0.000 description 1
- 101150098072 20 gene Proteins 0.000 description 1
- YIMDLWDNDGKDTJ-QLKYHASDSA-N 3'-deamino-3'-(3-cyanomorpholin-4-yl)doxorubicin Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1C#N YIMDLWDNDGKDTJ-QLKYHASDSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 101710092080 5'-nucleotidase domain-containing protein 3 Proteins 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
- 229960005538 6-diazo-5-oxo-L-norleucine Drugs 0.000 description 1
- YCWQAMGASJSUIP-YFKPBYRVSA-N 6-diazo-5-oxo-L-norleucine Chemical compound OC(=O)[C@@H](N)CCC(=O)C=[N+]=[N-] YCWQAMGASJSUIP-YFKPBYRVSA-N 0.000 description 1
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 1
- 101710154868 60 kDa heat shock protein, mitochondrial Proteins 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- WFPZSXYXPSUOPY-ROYWQJLOSA-N ADP alpha-D-glucoside Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WFPZSXYXPSUOPY-ROYWQJLOSA-N 0.000 description 1
- WFPZSXYXPSUOPY-UHFFFAOYSA-N ADP-mannose Natural products C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COP(O)(=O)OP(O)(=O)OC1OC(CO)C(O)C(O)C1O WFPZSXYXPSUOPY-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 101150107888 AKT2 gene Proteins 0.000 description 1
- 101150091066 AMHR2 gene Proteins 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 101150096411 AXIN2 gene Proteins 0.000 description 1
- 101150069931 Abcg2 gene Proteins 0.000 description 1
- 208000016557 Acute basophilic leukemia Diseases 0.000 description 1
- 208000004804 Adenomatous Polyps Diseases 0.000 description 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 102000007471 Adenosine A2A receptor Human genes 0.000 description 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 101150051155 Akt3 gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000012791 Alpha-heavy chain disease Diseases 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N Alternaria alternata Crofton-weed toxin Natural products CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 101100281515 Arabidopsis thaliana FOX1 gene Proteins 0.000 description 1
- 101000719121 Arabidopsis thaliana Protein MEI2-like 1 Proteins 0.000 description 1
- 108010031480 Artificial Receptors Proteins 0.000 description 1
- 206010065869 Astrocytoma, low grade Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 102100035683 Axin-2 Human genes 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 108010045634 B7 Antigens Proteins 0.000 description 1
- 102000005738 B7 Antigens Human genes 0.000 description 1
- 101150033765 BAG1 gene Proteins 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000035821 Benign schwannoma Diseases 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 101100064718 Borrelia bavariensis (strain ATCC BAA-2496 / DSM 23469 / PBi) fusA1 gene Proteins 0.000 description 1
- 241001504766 Bovichtus Species 0.000 description 1
- 241000714266 Bovine leukemia virus Species 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- 208000007690 Brenner tumor Diseases 0.000 description 1
- 206010073258 Brenner tumour Diseases 0.000 description 1
- 101710119124 Bridging integrator 3 Proteins 0.000 description 1
- 101150053567 Brinp3 gene Proteins 0.000 description 1
- MBABCNBNDNGODA-LTGLSHGVSA-N Bullatacin Natural products O=C1C(C[C@H](O)CCCCCCCCCC[C@@H](O)[C@@H]2O[C@@H]([C@@H]3O[C@H]([C@@H](O)CCCCCCCCCC)CC3)CC2)=C[C@H](C)O1 MBABCNBNDNGODA-LTGLSHGVSA-N 0.000 description 1
- KGGVWMAPBXIMEM-ZRTAFWODSA-N Bullatacinone Chemical compound O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@@H]1[C@@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@H]2OC(=O)[C@H](CC(C)=O)C2)CC1 KGGVWMAPBXIMEM-ZRTAFWODSA-N 0.000 description 1
- KGGVWMAPBXIMEM-JQFCFGFHSA-N Bullatacinone Natural products O=C(C[C@H]1C(=O)O[C@H](CCCCCCCCCC[C@H](O)[C@@H]2O[C@@H]([C@@H]3O[C@@H]([C@@H](O)CCCCCCCCCC)CC3)CC2)C1)C KGGVWMAPBXIMEM-JQFCFGFHSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 101150100936 CD28 gene Proteins 0.000 description 1
- 102100022002 CD59 glycoprotein Human genes 0.000 description 1
- 108010062802 CD66 antigens Proteins 0.000 description 1
- 101150077422 CDC25A gene Proteins 0.000 description 1
- 101150041972 CDKN2A gene Proteins 0.000 description 1
- 101150108055 CHMP2B gene Proteins 0.000 description 1
- 101150069031 CSN2 gene Proteins 0.000 description 1
- 101150110592 CTS1 gene Proteins 0.000 description 1
- 101150064066 CTSL gene Proteins 0.000 description 1
- 101150108228 CYLD gene Proteins 0.000 description 1
- 101150097016 Cadm3 gene Proteins 0.000 description 1
- 101100456282 Caenorhabditis elegans mcm-4 gene Proteins 0.000 description 1
- 101100209555 Caenorhabditis elegans vha-17 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 102100025580 Calmodulin-1 Human genes 0.000 description 1
- 102100021868 Calnexin Human genes 0.000 description 1
- 108010056891 Calnexin Proteins 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 108010031425 Casein Kinases Proteins 0.000 description 1
- 102000005403 Casein Kinases Human genes 0.000 description 1
- 101150100916 Casp3 gene Proteins 0.000 description 1
- 101150056960 Casp8 gene Proteins 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 101150069156 Cdkn2b gene Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000005575 Cellulases Human genes 0.000 description 1
- 108010084185 Cellulases Proteins 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102100038279 Charged multivesicular body protein 2b Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- XCDXSSFOJZZGQC-UHFFFAOYSA-N Chlornaphazine Chemical compound C1=CC=CC2=CC(N(CCCl)CCCl)=CC=C21 XCDXSSFOJZZGQC-UHFFFAOYSA-N 0.000 description 1
- 206010008583 Chloroma Diseases 0.000 description 1
- MKQWTWSXVILIKJ-LXGUWJNJSA-N Chlorozotocin Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC(=O)N(N=O)CCCl MKQWTWSXVILIKJ-LXGUWJNJSA-N 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 101150116827 Cnot6 gene Proteins 0.000 description 1
- 102100032370 Coiled-coil domain-containing protein 113 Human genes 0.000 description 1
- 102100035236 Coiled-coil domain-containing protein 146 Human genes 0.000 description 1
- 108010048623 Collagen Receptors Proteins 0.000 description 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 1
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 1
- 102000016782 Coronin 1C Human genes 0.000 description 1
- 108050006330 Coronin 1C Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229930188224 Cryptophycin Natural products 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108010076010 Cystathionine beta-lyase Proteins 0.000 description 1
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 1
- 102100035300 Cystine/glutamate transporter Human genes 0.000 description 1
- 102220605874 Cytosolic arginine sensor for mTORC1 subunit 2_D10A_mutation Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 1
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 102100038713 Death domain-containing protein CRADD Human genes 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010002156 Depsipeptides Proteins 0.000 description 1
- 108010086291 Deubiquitinating Enzyme CYLD Proteins 0.000 description 1
- 108700029231 Developmental Genes Proteins 0.000 description 1
- AUGQEEXBDZWUJY-ZLJUKNTDSA-N Diacetoxyscirpenol Chemical compound C([C@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@@H]1C=C(C)CC[C@@]13COC(=O)C)O2 AUGQEEXBDZWUJY-ZLJUKNTDSA-N 0.000 description 1
- AUGQEEXBDZWUJY-UHFFFAOYSA-N Diacetoxyscirpenol Natural products CC(=O)OCC12CCC(C)=CC1OC1C(O)C(OC(C)=O)C2(C)C11CO1 AUGQEEXBDZWUJY-UHFFFAOYSA-N 0.000 description 1
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 1
- KLFKZIQAIPDJCW-HTIIIDOHSA-N Dipalmitoylphosphatidylserine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC KLFKZIQAIPDJCW-HTIIIDOHSA-N 0.000 description 1
- 101100342473 Drosophila melanogaster Raf gene Proteins 0.000 description 1
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 1
- 101100300807 Drosophila melanogaster spn-A gene Proteins 0.000 description 1
- 102100037570 Dual specificity protein phosphatase 16 Human genes 0.000 description 1
- 208000037162 Ductal Breast Carcinoma Diseases 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 229930193152 Dynemicin Natural products 0.000 description 1
- 208000007033 Dysgerminoma Diseases 0.000 description 1
- 101150102539 E2F1 gene Proteins 0.000 description 1
- 102100035813 E3 ubiquitin-protein ligase CBL Human genes 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 102100031960 E3 ubiquitin-protein ligase TRIM71 Human genes 0.000 description 1
- 101710165240 E3 ubiquitin-protein ligase TRIM71 Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 101150083975 Eaf2 gene Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102100023362 Elongation factor 1-gamma Human genes 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 101710192245 Endoribonuclease Dicer Proteins 0.000 description 1
- 102400000686 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- AFMYMMXSQGUCBK-UHFFFAOYSA-N Endynamicin A Natural products C1#CC=CC#CC2NC(C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C3)=C3C34OC32C(C)C(C(O)=O)=C(OC)C41 AFMYMMXSQGUCBK-UHFFFAOYSA-N 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 206010014958 Eosinophilic leukaemia Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- OBMLHUPNRURLOK-XGRAFVIBSA-N Epitiostanol Chemical compound C1[C@@H]2S[C@@H]2C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OBMLHUPNRURLOK-XGRAFVIBSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 101150004694 Erbb4 gene Proteins 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Natural products O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 229930189413 Esperamicin Natural products 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 101710196289 Eukaryotic translation initiation factor 2-alpha kinase 1 Proteins 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 101150089023 FASLG gene Proteins 0.000 description 1
- 101150005998 FNTB gene Proteins 0.000 description 1
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 101150043246 GAST gene Proteins 0.000 description 1
- 102100022360 GATOR complex protein NPRL2 Human genes 0.000 description 1
- 101150111575 GSTT1 gene Proteins 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 102100030708 GTPase KRas Human genes 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 101150033270 Gadd45a gene Proteins 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 206010017708 Ganglioneuroblastoma Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000008999 Giant Cell Carcinoma Diseases 0.000 description 1
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 102100036263 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Human genes 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 101150007061 Gnai2 gene Proteins 0.000 description 1
- 102100032564 Golgin subfamily A member 2 Human genes 0.000 description 1
- 108010074556 Golgin subfamily A member 2 Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 208000005234 Granulosa Cell Tumor Diseases 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 101150062487 Gstm5 gene Proteins 0.000 description 1
- 108091059596 H3F3A Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101150112743 HSPA5 gene Proteins 0.000 description 1
- 208000002125 Hemangioendothelioma Diseases 0.000 description 1
- 208000006050 Hemangiopericytoma Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 101001023784 Heteractis crispa GFP-like non-fluorescent chromoprotein Proteins 0.000 description 1
- 102100029217 High affinity cationic amino acid transporter 1 Human genes 0.000 description 1
- 208000002291 Histiocytic Sarcoma Diseases 0.000 description 1
- 102100039268 Histone H2A type 1-A Human genes 0.000 description 1
- 101710132529 Histone H2A type 1-A Proteins 0.000 description 1
- 102100034535 Histone H3.1 Human genes 0.000 description 1
- 101710195388 Histone H3.1 Proteins 0.000 description 1
- 101710195387 Histone H3.2 Proteins 0.000 description 1
- 102100022103 Histone-lysine N-methyltransferase 2A Human genes 0.000 description 1
- 101150029182 Hmmr gene Proteins 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 102100027877 Homeobox protein Nkx-2.8 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000604531 Homo sapiens 5'-nucleotidase domain-containing protein 3 Proteins 0.000 description 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 1
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
- 101000984164 Homo sapiens Calmodulin-1 Proteins 0.000 description 1
- 101000868831 Homo sapiens Coiled-coil domain-containing protein 113 Proteins 0.000 description 1
- 101000737221 Homo sapiens Coiled-coil domain-containing protein 146 Proteins 0.000 description 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 1
- 101000860852 Homo sapiens Coronin-1A Proteins 0.000 description 1
- 101000957914 Homo sapiens Death domain-containing protein CRADD Proteins 0.000 description 1
- 101000931227 Homo sapiens DnaJ homolog subfamily A member 1 Proteins 0.000 description 1
- 101000881117 Homo sapiens Dual specificity protein phosphatase 16 Proteins 0.000 description 1
- 101001050451 Homo sapiens Elongation factor 1-gamma Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 101001001786 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Proteins 0.000 description 1
- 101000888201 Homo sapiens Glycogenin-1 Proteins 0.000 description 1
- 101001066435 Homo sapiens Hepatocyte growth factor-like protein Proteins 0.000 description 1
- 101000898905 Homo sapiens Histone H2A type 2-A Proteins 0.000 description 1
- 101001045846 Homo sapiens Histone-lysine N-methyltransferase 2A Proteins 0.000 description 1
- 101000632191 Homo sapiens Homeobox protein Nkx-2.8 Proteins 0.000 description 1
- 101000962530 Homo sapiens Hyaluronidase-1 Proteins 0.000 description 1
- 101000962526 Homo sapiens Hyaluronidase-2 Proteins 0.000 description 1
- 101001002470 Homo sapiens Interferon lambda-1 Proteins 0.000 description 1
- 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 description 1
- 101000853000 Homo sapiens Interleukin-26 Proteins 0.000 description 1
- 101000998139 Homo sapiens Interleukin-32 Proteins 0.000 description 1
- 101000677562 Homo sapiens Isobutyryl-CoA dehydrogenase, mitochondrial Proteins 0.000 description 1
- 101001034314 Homo sapiens Lactadherin Proteins 0.000 description 1
- 101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 description 1
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 1
- 101000835893 Homo sapiens Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
- 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101000583702 Homo sapiens Pleckstrin homology-like domain family A member 2 Proteins 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- 101000585703 Homo sapiens Protein L-Myc Proteins 0.000 description 1
- 101000573199 Homo sapiens Protein PML Proteins 0.000 description 1
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 description 1
- 101000794282 Homo sapiens Putative protein C3P1 Proteins 0.000 description 1
- 101000703443 Homo sapiens Putative rhophilin-2-like protein RHPN2P1 Proteins 0.000 description 1
- 101000763328 Homo sapiens RISC-loading complex subunit TARBP2 Proteins 0.000 description 1
- 101001061518 Homo sapiens RNA-binding protein FUS Proteins 0.000 description 1
- 101001077409 Homo sapiens Ras-related protein Rab-5B Proteins 0.000 description 1
- 101000857677 Homo sapiens Runt-related transcription factor 1 Proteins 0.000 description 1
- 101000739160 Homo sapiens Secretoglobin family 3A member 1 Proteins 0.000 description 1
- 101000880431 Homo sapiens Serine/threonine-protein kinase 4 Proteins 0.000 description 1
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 description 1
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 description 1
- 101000891113 Homo sapiens T-cell acute lymphocytic leukemia protein 1 Proteins 0.000 description 1
- 101000800488 Homo sapiens T-cell leukemia homeobox protein 1 Proteins 0.000 description 1
- 101000837626 Homo sapiens Thyroid hormone receptor alpha Proteins 0.000 description 1
- 101000813738 Homo sapiens Transcription factor ETV6 Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 101000629913 Homo sapiens Translocon-associated protein subunit beta Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 101000659267 Homo sapiens Tumor suppressor candidate 2 Proteins 0.000 description 1
- 101000912503 Homo sapiens Tyrosine-protein kinase Fgr Proteins 0.000 description 1
- 101001022129 Homo sapiens Tyrosine-protein kinase Fyn Proteins 0.000 description 1
- 101001047681 Homo sapiens Tyrosine-protein kinase Lck Proteins 0.000 description 1
- 101001054878 Homo sapiens Tyrosine-protein kinase Lyn Proteins 0.000 description 1
- 101001087422 Homo sapiens Tyrosine-protein phosphatase non-receptor type 13 Proteins 0.000 description 1
- 101000740759 Homo sapiens Voltage-dependent calcium channel subunit alpha-2/delta-2 Proteins 0.000 description 1
- 101000804798 Homo sapiens Werner syndrome ATP-dependent helicase Proteins 0.000 description 1
- 101000823778 Homo sapiens Y-box-binding protein 2 Proteins 0.000 description 1
- 101000818836 Homo sapiens Zinc finger protein 609 Proteins 0.000 description 1
- 101150003028 Hprt1 gene Proteins 0.000 description 1
- 101150117869 Hras gene Proteins 0.000 description 1
- 102100039283 Hyaluronidase-1 Human genes 0.000 description 1
- 102100039285 Hyaluronidase-2 Human genes 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 101150005343 INHA gene Proteins 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000007866 Immunoproliferative Small Intestinal Disease Diseases 0.000 description 1
- 208000001019 Inborn Errors Metabolism Diseases 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 102000012330 Integrases Human genes 0.000 description 1
- 102100025305 Integrin alpha-2 Human genes 0.000 description 1
- 102000000507 Integrin alpha2 Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 101800003050 Interleukin-16 Proteins 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 102100033096 Interleukin-17D Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108050009288 Interleukin-19 Proteins 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 108010066979 Interleukin-27 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 101710139824 Isobutyryl-CoA dehydrogenase, mitochondrial Proteins 0.000 description 1
- 101150069380 JAK3 gene Proteins 0.000 description 1
- 201000008869 Juxtacortical Osteosarcoma Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 101710101817 Keratin, type II cytoskeletal Proteins 0.000 description 1
- 102000019293 Kinesin-like proteins Human genes 0.000 description 1
- 108050006659 Kinesin-like proteins Proteins 0.000 description 1
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102100039648 Lactadherin Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010000851 Laminin Receptors Proteins 0.000 description 1
- 102000002297 Laminin Receptors Human genes 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 201000004462 Leydig Cell Tumor Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 208000000265 Lobular Carcinoma Diseases 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 108010011449 Long-chain-fatty-acid-CoA ligase Proteins 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 102100038225 Lysosome-associated membrane glycoprotein 2 Human genes 0.000 description 1
- 101710116771 Lysosome-associated membrane glycoprotein 2 Proteins 0.000 description 1
- 101150051655 Lyz2 gene Proteins 0.000 description 1
- 101150087808 MSMB gene Proteins 0.000 description 1
- 108700012912 MYCN Proteins 0.000 description 1
- 101150022024 MYCN gene Proteins 0.000 description 1
- 208000035771 Malignant Sertoli-Leydig cell tumor of the ovary Diseases 0.000 description 1
- 206010025538 Malignant ascites Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101150003941 Mapk14 gene Proteins 0.000 description 1
- VJRAUFKOOPNFIQ-UHFFFAOYSA-N Marcellomycin Natural products C12=C(O)C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C=C2C(C(=O)OC)C(CC)(O)CC1OC(OC1C)CC(N(C)C)C1OC(OC1C)CC(O)C1OC1CC(O)C(O)C(C)O1 VJRAUFKOOPNFIQ-UHFFFAOYSA-N 0.000 description 1
- 229930126263 Maytansine Natural products 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101710169959 Membrane protein 2 Proteins 0.000 description 1
- IVDYZAAPOLNZKG-KWHRADDSSA-N Mepitiostane Chemical compound O([C@@H]1[C@]2(CC[C@@H]3[C@@]4(C)C[C@H]5S[C@H]5C[C@@H]4CC[C@H]3[C@@H]2CC1)C)C1(OC)CCCC1 IVDYZAAPOLNZKG-KWHRADDSSA-N 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 201000009574 Mesenchymal Chondrosarcoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 101150086210 Mgat5 gene Proteins 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 101150092342 Mmp8 gene Proteins 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 1
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 1
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 101150033433 Msh2 gene Proteins 0.000 description 1
- 101150081086 Msh6 gene Proteins 0.000 description 1
- 206010057269 Mucoepidermoid carcinoma Diseases 0.000 description 1
- 208000010357 Mullerian Mixed Tumor Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 101100400864 Mus musculus Abcb1a gene Proteins 0.000 description 1
- 101100268648 Mus musculus Abl1 gene Proteins 0.000 description 1
- 101100009266 Mus musculus Dennd2b gene Proteins 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 101100393857 Mus musculus Gstm6 gene Proteins 0.000 description 1
- 101100284239 Mus musculus H2ax gene Proteins 0.000 description 1
- 101100494762 Mus musculus Nedd9 gene Proteins 0.000 description 1
- 101100478269 Mus musculus Spata13 gene Proteins 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 101150105944 Mutyh gene Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- LKQLRGMMMAHREN-YJFXYUILSA-N N-stearoylsphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)[C@H](O)\C=C\CCCCCCCCCCCCC LKQLRGMMMAHREN-YJFXYUILSA-N 0.000 description 1
- 101150019103 NAT2 gene Proteins 0.000 description 1
- 101150081841 NBN gene Proteins 0.000 description 1
- 101150019003 NCOA3 gene Proteins 0.000 description 1
- 101150111110 NKX2-1 gene Proteins 0.000 description 1
- 101150104466 NOCT gene Proteins 0.000 description 1
- 101150073096 NRAS gene Proteins 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 101100385413 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) csm-3 gene Proteins 0.000 description 1
- 101100238612 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) msh-3 gene Proteins 0.000 description 1
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
- SYNHCENRCUAUNM-UHFFFAOYSA-N Nitrogen mustard N-oxide hydrochloride Chemical compound Cl.ClCC[N+]([O-])(C)CCCl SYNHCENRCUAUNM-UHFFFAOYSA-N 0.000 description 1
- 102000005650 Notch Receptors Human genes 0.000 description 1
- 108010070047 Notch Receptors Proteins 0.000 description 1
- 101150074217 Nprl2 gene Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102100025193 OTU domain-containing protein 4 Human genes 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000007871 Odontogenic Tumors Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229930187135 Olivomycin Natural products 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 101000921214 Oryza sativa subsp. japonica Protein EARLY HEADING DATE 2 Proteins 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 206010073261 Ovarian theca cell tumour Diseases 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 101150095742 PLA2G2A gene Proteins 0.000 description 1
- 101150059340 PLG gene Proteins 0.000 description 1
- 101150023417 PPARG gene Proteins 0.000 description 1
- 101150115210 PTGER2 gene Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- VREZDOWOLGNDPW-ALTGWBOUSA-N Pancratistatin Chemical compound C1=C2[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@@H]3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-ALTGWBOUSA-N 0.000 description 1
- VREZDOWOLGNDPW-MYVCAWNPSA-N Pancratistatin Natural products O=C1N[C@H]2[C@H](O)[C@H](O)[C@H](O)[C@H](O)[C@@H]2c2c1c(O)c1OCOc1c2 VREZDOWOLGNDPW-MYVCAWNPSA-N 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 208000009077 Pigmented Nevus Diseases 0.000 description 1
- 101150063858 Pik3ca gene Proteins 0.000 description 1
- 208000019262 Pilomatrix carcinoma Diseases 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102100022427 Plasmalemma vesicle-associated protein Human genes 0.000 description 1
- 101710193105 Plasmalemma vesicle-associated protein Proteins 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 102100030926 Pleckstrin homology-like domain family A member 2 Human genes 0.000 description 1
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010059820 Polygalacturonase Proteins 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 229940127315 Potassium Channel Openers Drugs 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101150111533 Prkn gene Proteins 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710189610 Protein 2b Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 102100030128 Protein L-Myc Human genes 0.000 description 1
- 102100026375 Protein PML Human genes 0.000 description 1
- 102100032421 Protein S100-A6 Human genes 0.000 description 1
- 101710156983 Protein S100-A6 Proteins 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 108010001648 Proto-Oncogene Proteins c-ret Proteins 0.000 description 1
- 102000000813 Proto-Oncogene Proteins c-ret Human genes 0.000 description 1
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 description 1
- 101710091750 Putative protein C3P1 Proteins 0.000 description 1
- 102100030679 Putative rhophilin-2-like protein RHPN2P1 Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 102100026965 RISC-loading complex subunit TARBP2 Human genes 0.000 description 1
- 230000007022 RNA scission Effects 0.000 description 1
- 102100028469 RNA-binding protein FUS Human genes 0.000 description 1
- 101100440869 Rattus norvegicus Cyp2b2 gene Proteins 0.000 description 1
- 101001000212 Rattus norvegicus Decorin Proteins 0.000 description 1
- 101100523543 Rattus norvegicus Raf1 gene Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 102100021025 Regulator of G-protein signaling 19 Human genes 0.000 description 1
- 101710148108 Regulator of G-protein signaling 19 Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000242739 Renilla Species 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 101150001016 Rgs5 gene Proteins 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- OWPCHSCAPHNHAV-UHFFFAOYSA-N Rhizoxin Natural products C1C(O)C2(C)OC2C=CC(C)C(OC(=O)C2)CC2CC2OC2C(=O)OC1C(C)C(OC)C(C)=CC=CC(C)=CC1=COC(C)=N1 OWPCHSCAPHNHAV-UHFFFAOYSA-N 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- NSFWWJIQIKBZMJ-YKNYLIOZSA-N Roridin A Chemical compound C([C@]12[C@]3(C)[C@H]4C[C@H]1O[C@@H]1C=C(C)CC[C@@]13COC(=O)[C@@H](O)[C@H](C)CCO[C@H](\C=C\C=C/C(=O)O4)[C@H](O)C)O2 NSFWWJIQIKBZMJ-YKNYLIOZSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 1
- 102100025368 Runt-related transcription factor 2 Human genes 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 108091006229 SLC7A1 Proteins 0.000 description 1
- 108091006241 SLC7A11 Proteins 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 108060006706 SRC Proteins 0.000 description 1
- 101150001535 SRC gene Proteins 0.000 description 1
- 101150105664 SSTR5 gene Proteins 0.000 description 1
- 101150078538 ST7 gene Proteins 0.000 description 1
- 101150099493 STAT3 gene Proteins 0.000 description 1
- 101000702553 Schistosoma mansoni Antigen Sm21.7 Proteins 0.000 description 1
- 101000714192 Schistosoma mansoni Tegument antigen Proteins 0.000 description 1
- 108010089384 Secretagogins Proteins 0.000 description 1
- 102100037629 Serine/threonine-protein kinase 4 Human genes 0.000 description 1
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 1
- 102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 description 1
- 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 208000003252 Signet Ring Cell Carcinoma Diseases 0.000 description 1
- 229920000519 Sizofiran Polymers 0.000 description 1
- 208000009574 Skin Appendage Carcinoma Diseases 0.000 description 1
- 108700032504 Smad2 Proteins 0.000 description 1
- 101150102611 Smad2 gene Proteins 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 239000004280 Sodium formate Substances 0.000 description 1
- 102100022831 Somatoliberin Human genes 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 101150098540 Srpx gene Proteins 0.000 description 1
- 101150038447 Sstr2 gene Proteins 0.000 description 1
- 102000005465 Stathmin Human genes 0.000 description 1
- 108050003387 Stathmin Proteins 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 1
- 101710149950 Suppressor of silencing 2b Proteins 0.000 description 1
- BXFOFFBJRFZBQZ-QYWOHJEZSA-N T-2 toxin Chemical compound C([C@@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@H]1[C@]3(COC(C)=O)C[C@@H](C(=C1)C)OC(=O)CC(C)C)O2 BXFOFFBJRFZBQZ-QYWOHJEZSA-N 0.000 description 1
- 102100040365 T-cell acute lymphocytic leukemia protein 1 Human genes 0.000 description 1
- 102100033111 T-cell leukemia homeobox protein 1 Human genes 0.000 description 1
- 101150080074 TP53 gene Proteins 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- CGMTUJFWROPELF-UHFFFAOYSA-N Tenuazonic acid Natural products CCC(C)C1NC(=O)C(=C(C)/O)C1=O CGMTUJFWROPELF-UHFFFAOYSA-N 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- PNRAZZZISDRWMV-UHFFFAOYSA-N Terbucarb Chemical compound CNC(=O)OC1=C(C(C)(C)C)C=C(C)C=C1C(C)(C)C PNRAZZZISDRWMV-UHFFFAOYSA-N 0.000 description 1
- 108700031126 Tetraspanins Proteins 0.000 description 1
- 102000043977 Tetraspanins Human genes 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 102100028702 Thyroid hormone receptor alpha Human genes 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 241000283907 Tragelaphus oryx Species 0.000 description 1
- 102100039580 Transcription factor ETV6 Human genes 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102100026229 Translocon-associated protein subunit beta Human genes 0.000 description 1
- 102100021728 Transmembrane reductase CYB561D2 Human genes 0.000 description 1
- UMILHIMHKXVDGH-UHFFFAOYSA-N Triethylene glycol diglycidyl ether Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 description 1
- 101001037292 Triticum aestivum Bowman-Birk type trypsin inhibitor Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108010091356 Tumor Protein p73 Proteins 0.000 description 1
- 102000018252 Tumor Protein p73 Human genes 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- 102100039094 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 102100026150 Tyrosine-protein kinase Fgr Human genes 0.000 description 1
- 102100024036 Tyrosine-protein kinase Lck Human genes 0.000 description 1
- 102100026857 Tyrosine-protein kinase Lyn Human genes 0.000 description 1
- 101710098414 Tyrosine-protein phosphatase Proteins 0.000 description 1
- 102100033014 Tyrosine-protein phosphatase non-receptor type 13 Human genes 0.000 description 1
- 102100024250 Ubiquitin carboxyl-terminal hydrolase CYLD Human genes 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 102000003848 Uteroglobin Human genes 0.000 description 1
- 108090000203 Uteroglobin Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 102100023048 Very long-chain acyl-CoA synthetase Human genes 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 101710145727 Viral Fc-gamma receptor-like protein UL119 Proteins 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 102100037058 Voltage-dependent calcium channel subunit alpha-2/delta-2 Human genes 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 101100523549 Xenopus laevis raf1 gene Proteins 0.000 description 1
- 101150037250 Zhx2 gene Proteins 0.000 description 1
- 102100021355 Zinc finger protein 609 Human genes 0.000 description 1
- DSNRWDQKZIEDDB-GCMPNPAFSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-GCMPNPAFSA-N 0.000 description 1
- CWRILEGKIAOYKP-SSDOTTSWSA-M [(2r)-3-acetyloxy-2-hydroxypropyl] 2-aminoethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCCN CWRILEGKIAOYKP-SSDOTTSWSA-M 0.000 description 1
- SPJCRMJCFSJKDE-ZWBUGVOYSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 2-[4-[bis(2-chloroethyl)amino]phenyl]acetate Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)C(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 SPJCRMJCFSJKDE-ZWBUGVOYSA-N 0.000 description 1
- IFJUINDAXYAPTO-UUBSBJJBSA-N [(8r,9s,13s,14s,17s)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 1
- XZSRRNFBEIOBDA-CFNBKWCHSA-N [2-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-oxoethyl] 2,2-diethoxyacetate Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)C(OCC)OCC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 XZSRRNFBEIOBDA-CFNBKWCHSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 101150063830 abcB4 gene Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- ZOZKYEHVNDEUCO-XUTVFYLZSA-N aceglatone Chemical compound O1C(=O)[C@H](OC(C)=O)[C@@H]2OC(=O)[C@@H](OC(=O)C)[C@@H]21 ZOZKYEHVNDEUCO-XUTVFYLZSA-N 0.000 description 1
- 229950002684 aceglatone Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000006336 acinar cell carcinoma Diseases 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 108010036419 acyl-(acyl-carrier-protein)desaturase Proteins 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 229950004955 adozelesin Drugs 0.000 description 1
- BYRVKDUQDLJUBX-JJCDCTGGSA-N adozelesin Chemical compound C1=CC=C2OC(C(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C[C@H]4C[C@]44C5=C(C(C=C43)=O)NC=C5C)=CC2=C1 BYRVKDUQDLJUBX-JJCDCTGGSA-N 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 101150084233 ago2 gene Proteins 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 description 1
- 208000006431 amelanotic melanoma Diseases 0.000 description 1
- 208000010029 ameloblastoma Diseases 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940025131 amylases Drugs 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 description 1
- 229950000242 ancitabine Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001539 anorectic effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000708 anti-progestin effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000001572 anti-trichomonad Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940124345 antianginal agent Drugs 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 239000000504 antifibrinolytic agent Substances 0.000 description 1
- 229940082620 antifibrinolytics Drugs 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
- 239000002579 antinauseant Substances 0.000 description 1
- 229940125688 antiparkinson agent Drugs 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000003418 antiprogestin Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 229940121383 antituberculosis agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 201000007436 apocrine adenocarcinoma Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 150000008209 arabinosides Chemical class 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 238000012098 association analyses Methods 0.000 description 1
- 201000005476 astroblastoma Diseases 0.000 description 1
- 238000000089 atomic force micrograph Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 230000004009 axon guidance Effects 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 229950011321 azaserine Drugs 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- 201000007551 basophilic adenocarcinoma Diseases 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229950008548 bisantrene Drugs 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 229950006844 bizelesin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 208000007047 blue nevus Diseases 0.000 description 1
- 230000009045 body homeostasis Effects 0.000 description 1
- 201000011143 bone giant cell tumor Diseases 0.000 description 1
- 150000001639 boron compounds Chemical class 0.000 description 1
- 210000000069 breast epithelial cell Anatomy 0.000 description 1
- 201000003714 breast lobular carcinoma Diseases 0.000 description 1
- 201000011054 breast malignant phyllodes tumor Diseases 0.000 description 1
- 229960005520 bryostatin Drugs 0.000 description 1
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
- MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- MBABCNBNDNGODA-LUVUIASKSA-N bullatacin Chemical compound O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@@H]1[C@@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@@H](O)CC=2C(O[C@@H](C)C=2)=O)CC1 MBABCNBNDNGODA-LUVUIASKSA-N 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- 229950009908 cactinomycin Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229950009823 calusterone Drugs 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- 229930188550 carminomycin Natural products 0.000 description 1
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 229950001725 carubicin Drugs 0.000 description 1
- 229950007509 carzelesin Drugs 0.000 description 1
- BBZDXMBRAFTCAA-AREMUKBSSA-N carzelesin Chemical compound C1=2NC=C(C)C=2C([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)C3=CC4=CC=C(C=C4O3)N(CC)CC)=C2C=C1OC(=O)NC1=CC=CC=C1 BBZDXMBRAFTCAA-AREMUKBSSA-N 0.000 description 1
- 108010047060 carzinophilin Proteins 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 201000002891 ceruminous adenocarcinoma Diseases 0.000 description 1
- 208000024188 ceruminous carcinoma Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229950008249 chlornaphazine Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960001480 chlorozotocin Drugs 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 201000005217 chondroblastoma Diseases 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 201000010240 chromophobe renal cell carcinoma Diseases 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 208000011588 combined hepatocellular carcinoma and cholangiocarcinoma Diseases 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 101150055601 cops2 gene Proteins 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 238000002681 cryosurgery Methods 0.000 description 1
- 108010089438 cryptophycin 1 Proteins 0.000 description 1
- PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 description 1
- 108010090203 cryptophycin 8 Proteins 0.000 description 1
- PSNOPSMXOBPNNV-UHFFFAOYSA-N cryptophycin-327 Natural products C1=C(Cl)C(OC)=CC=C1CC1C(=O)NCC(C)C(=O)OC(CC(C)C)C(=O)OC(C(C)C2C(O2)C=2C=CC=CC=2)CC=CC(=O)N1 PSNOPSMXOBPNNV-UHFFFAOYSA-N 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960005052 demecolcine Drugs 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000003520 dendritic spine Anatomy 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229950003913 detorubicin Drugs 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 1
- 229950002389 diaziquone Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- BPHQZTVXXXJVHI-UHFFFAOYSA-N dimyristoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-UHFFFAOYSA-N 0.000 description 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- FVJZSBGHRPJMMA-UHFFFAOYSA-N distearoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
- 229930188854 dolastatin Natural products 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 229960005501 duocarmycin Drugs 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- 229930184221 duocarmycin Natural products 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- AFMYMMXSQGUCBK-AKMKHHNQSA-N dynemicin a Chemical compound C1#C\C=C/C#C[C@@H]2NC(C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C3)=C3[C@@]34O[C@]32[C@@H](C)C(C(O)=O)=C(OC)[C@H]41 AFMYMMXSQGUCBK-AKMKHHNQSA-N 0.000 description 1
- 230000002196 ecbolic effect Effects 0.000 description 1
- FSIRXIHZBIXHKT-MHTVFEQDSA-N edatrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
- 229950006700 edatrexate Drugs 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- XOPYFXBZMVTEJF-PDACKIITSA-N eleutherobin Chemical compound C(/[C@H]1[C@H](C(=CC[C@@H]1C(C)C)C)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O XOPYFXBZMVTEJF-PDACKIITSA-N 0.000 description 1
- XOPYFXBZMVTEJF-UHFFFAOYSA-N eleutherobin Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(=CCC1C(C)C)C)C1C=C2COC1OCC(O)C(O)C1OC(C)=O XOPYFXBZMVTEJF-UHFFFAOYSA-N 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 229950000549 elliptinium acetate Drugs 0.000 description 1
- 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- JOZGNYDSEBIJDH-UHFFFAOYSA-N eniluracil Chemical compound O=C1NC=C(C#C)C(=O)N1 JOZGNYDSEBIJDH-UHFFFAOYSA-N 0.000 description 1
- 229950010213 eniluracil Drugs 0.000 description 1
- 239000002792 enkephalinase inhibitor Substances 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 201000010877 epithelioid cell melanoma Diseases 0.000 description 1
- 229950002973 epitiostanol Drugs 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- 150000003883 epothilone derivatives Chemical class 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- ITSGNOIFAJAQHJ-BMFNZSJVSA-N esorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 1
- 229950002017 esorubicin Drugs 0.000 description 1
- LJQQFQHBKUKHIS-WJHRIEJJSA-N esperamicin Chemical compound O1CC(NC(C)C)C(OC)CC1OC1C(O)C(NOC2OC(C)C(SC)C(O)C2)C(C)OC1OC1C(\C2=C/CSSSC)=C(NC(=O)OC)C(=O)C(OC3OC(C)C(O)C(OC(=O)C=4C(=CC(OC)=C(OC)C=4)NC(=O)C(=C)OC)C3)C2(O)C#C\C=C/C#C1 LJQQFQHBKUKHIS-WJHRIEJJSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- QSRLNKCNOLVZIR-KRWDZBQOSA-N ethyl (2s)-2-[[2-[4-[bis(2-chloroethyl)amino]phenyl]acetyl]amino]-4-methylsulfanylbutanoate Chemical compound CCOC(=O)[C@H](CCSC)NC(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 QSRLNKCNOLVZIR-KRWDZBQOSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229960005237 etoglucid Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 210000003020 exocrine pancreas Anatomy 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 108010055671 ezrin Proteins 0.000 description 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 201000001169 fibrillary astrocytoma Diseases 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 201000008825 fibrosarcoma of bone Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 238000012632 fluorescent imaging Methods 0.000 description 1
- 108010021843 fluorescent protein 583 Proteins 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000030414 genetic transfer Effects 0.000 description 1
- 201000002264 glomangiosarcoma Diseases 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 201000007574 granular cell carcinoma Diseases 0.000 description 1
- 101150098203 grb2 gene Proteins 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 108010002430 hemicellulase Proteins 0.000 description 1
- 239000002607 heparin antagonist Substances 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 102000043321 human CTLA4 Human genes 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 239000000864 hyperglycemic agent Substances 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 230000005746 immune checkpoint blockade Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
- 229950008097 improsulfan Drugs 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 229940125700 inflammatory bowel disease agent Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000015978 inherited metabolic disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 230000035990 intercellular signaling Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 108090000681 interleukin 20 Proteins 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 108010074109 interleukin-22 Proteins 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 108010033564 involucrin Proteins 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 238000001948 isotopic labelling Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000003368 label free method Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- YROQEQPFUCPDCP-UHFFFAOYSA-N losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 1
- 229950008745 losoxantrone Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000000014 lung giant cell carcinoma Diseases 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 201000010953 lymphoepithelioma-like carcinoma Diseases 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 230000006674 lysosomal degradation Effects 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 102000033952 mRNA binding proteins Human genes 0.000 description 1
- 108091000373 mRNA binding proteins Proteins 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 208000018013 malignant glomus tumor Diseases 0.000 description 1
- 201000004102 malignant granular cell myoblastoma Diseases 0.000 description 1
- 201000006812 malignant histiocytosis Diseases 0.000 description 1
- 206010061526 malignant mesenchymoma Diseases 0.000 description 1
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
- 201000002338 malignant struma ovarii Diseases 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 1
- 229950008612 mannomustine Drugs 0.000 description 1
- 208000000516 mast-cell leukemia Diseases 0.000 description 1
- 201000008749 mast-cell sarcoma Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 101150024228 mdm2 gene Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 229950009246 mepitiostane Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- VJRAUFKOOPNFIQ-TVEKBUMESA-N methyl (1r,2r,4s)-4-[(2r,4s,5s,6s)-5-[(2s,4s,5s,6s)-5-[(2s,4s,5s,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-(dimethylamino)-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7,10-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylat Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1 VJRAUFKOOPNFIQ-TVEKBUMESA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 229960003539 mitoguazone Drugs 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 201000010225 mixed cell type cancer Diseases 0.000 description 1
- 208000029638 mixed neoplasm Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 238000011201 multiple comparisons test Methods 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 201000005987 myeloid sarcoma Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- 208000014761 nasopharyngeal type undifferentiated carcinoma Diseases 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000027831 neuroepithelial neoplasm Diseases 0.000 description 1
- 208000029974 neurofibrosarcoma Diseases 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000000842 neuromuscular blocking agent Substances 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 231100001221 nontumorigenic Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 208000027825 odontogenic neoplasm Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- CZDBNBLGZNWKMC-MWQNXGTOSA-N olivomycin Chemical class O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1)O[C@H]1O[C@@H](C)[C@H](O)[C@@H](OC2O[C@@H](C)[C@H](O)[C@@H](O)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@H](O)[C@H](OC)[C@H](C)O1 CZDBNBLGZNWKMC-MWQNXGTOSA-N 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008527 organismal homeostasis Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000012221 ovarian Sertoli-Leydig cell tumor Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 239000002863 oxytocic agent Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000011499 palliative surgery Methods 0.000 description 1
- VREZDOWOLGNDPW-UHFFFAOYSA-N pancratistatine Natural products C1=C2C3C(O)C(O)C(O)C(O)C3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 201000010210 papillary cystadenocarcinoma Diseases 0.000 description 1
- 208000024641 papillary serous cystadenocarcinoma Diseases 0.000 description 1
- 201000001494 papillary transitional carcinoma Diseases 0.000 description 1
- 208000031101 papillary transitional cell carcinoma Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 108020004410 pectinesterase Proteins 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 239000000906 photoactive agent Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 208000021857 pituitary gland basophilic carcinoma Diseases 0.000 description 1
- BLFWHYXWBKKRHI-JYBILGDPSA-N plap Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](N)CCC(O)=O BLFWHYXWBKKRHI-JYBILGDPSA-N 0.000 description 1
- 208000031223 plasma cell leukemia Diseases 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 101150067958 plk-3 gene Proteins 0.000 description 1
- 229920002946 poly[2-(methacryloxy)ethyl phosphorylcholine] polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 210000002729 polyribosome Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- GUUBJKMBDULZTE-UHFFFAOYSA-M potassium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[K+].OCCN1CCN(CCS(O)(=O)=O)CC1 GUUBJKMBDULZTE-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 108010005709 protein kinase C kinase Proteins 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 230000025220 protein targeting to vacuole Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 201000008520 protoplasmic astrocytoma Diseases 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- WOLQREOUPKZMEX-UHFFFAOYSA-N pteroyltriglutamic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-UHFFFAOYSA-N 0.000 description 1
- 238000010379 pull-down assay Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 description 1
- 229960000460 razoxane Drugs 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009719 regenerative response Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000017610 release of virus from host Effects 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- OWPCHSCAPHNHAV-LMONGJCWSA-N rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229950004892 rodorubicin Drugs 0.000 description 1
- MBABCNBNDNGODA-WPZDJQSSSA-N rolliniastatin 1 Natural products O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@H]1[C@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@@H](O)CC=2C(O[C@@H](C)C=2)=O)CC1 MBABCNBNDNGODA-WPZDJQSSSA-N 0.000 description 1
- IMUQLZLGWJSVMV-UOBFQKKOSA-N roridin A Natural products CC(O)C1OCCC(C)C(O)C(=O)OCC2CC(=CC3OC4CC(OC(=O)C=C/C=C/1)C(C)(C23)C45CO5)C IMUQLZLGWJSVMV-UOBFQKKOSA-N 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 229930182947 sarcodictyin Natural products 0.000 description 1
- 208000014212 sarcomatoid carcinoma Diseases 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 239000003229 sclerosing agent Substances 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 230000018448 secretion by cell Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 125000005630 sialyl group Chemical group 0.000 description 1
- 201000008123 signet ring cell adenocarcinoma Diseases 0.000 description 1
- 229950001403 sizofiran Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000002078 skin pilomatrix carcinoma Diseases 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
- 235000019254 sodium formate Nutrition 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 102000004052 somatostatin receptor 2 Human genes 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 230000007046 spindle assembly involved in mitosis Effects 0.000 description 1
- 229950006315 spirogermanium Drugs 0.000 description 1
- ICXJVZHDZFXYQC-UHFFFAOYSA-N spongistatin 1 Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(OC(C)=O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC(Cl)=C)OC1C2C ICXJVZHDZFXYQC-UHFFFAOYSA-N 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 208000028210 stromal sarcoma Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 208000030457 superficial spreading melanoma Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 101150047061 tag-72 gene Proteins 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 208000001644 thecoma Diseases 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 208000015191 thyroid gland papillary and follicular carcinoma Diseases 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- 229950011457 tiamiprine Drugs 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 208000029335 trabecular adenocarcinoma Diseases 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 210000003956 transport vesicle Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- 229950001353 tretamine Drugs 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960004560 triaziquone Drugs 0.000 description 1
- PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
- 229930013292 trichothecene Natural products 0.000 description 1
- 150000003327 trichothecene derivatives Chemical class 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- HDZZVAMISRMYHH-LITAXDCLSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
- 230000007485 viral shedding Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940053867 xeloda Drugs 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Abstract
Provided herein are methods of using exosomes that function like minicells to deliver therapeutic agents to diseased or disordered cells. In particular, the exosomes can be targeted to particular areas of the body using growth factor gradients. These gradients also serve to trigger expression of proteins inside the exosomes, from transfected nucleic acids, at the desired target.
Description
DESCRIPTION
USE OF EXOSOMES FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS
REFERENCE TO RELATED APPLICATIONS
100011 The present application claims the priority benefit of United States provisional application number 62/649,057, filed March 28, 2018, the entire contents of which is incorporated herein by reference.
REFERENCE TO A SEQUENCE LISTING
100021 The instant application contains a Sequence Listing, which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on March 21, 2019, is named UTFC.P1363W0_5T25.txt and is 3 kilobytes in size.
BACKGROUND
1. Field 100031 The present invention relates generally to the fields of biology, medicine, and oncology. More particularly, it concerns the use of exosomes to target delivery of therapeutic agents to diseased or disordered cells.
USE OF EXOSOMES FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS
REFERENCE TO RELATED APPLICATIONS
100011 The present application claims the priority benefit of United States provisional application number 62/649,057, filed March 28, 2018, the entire contents of which is incorporated herein by reference.
REFERENCE TO A SEQUENCE LISTING
100021 The instant application contains a Sequence Listing, which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on March 21, 2019, is named UTFC.P1363W0_5T25.txt and is 3 kilobytes in size.
BACKGROUND
1. Field 100031 The present invention relates generally to the fields of biology, medicine, and oncology. More particularly, it concerns the use of exosomes to target delivery of therapeutic agents to diseased or disordered cells.
2. Description of Related Art 100041 Exosomes are small extracellular vesicles (EVs) with a lipid bilayer that contain proteins and polynucleotides, including messenger RNAs (mRNAs), non-coding RNAs and double-stranded genomic DNA (Kalluri, 2016; Raposo and Stoorvogel, 2013).
After their initial discovery as byproducts of reticulocyte differentiation (Harding et al., 1984;
Raposo and Stoorvogel, 2013), it is now generally accepted that exosomes are secreted by virtually all mammalian cells and found in all body fluids (El-Andaloussi et al., 2013;
Kalluri, 2016).
100051 Exosomes are part of a larger group of extracellular vesicles, which also include microvesicles and apoptotic bodies (Colombo et al., 2014). Amongst extracellular vesicles, exosomes are typically distinguished through their unique biogenesis via the endocytic pathway. Endocytic vesicles mature into late endosomes, also known as multivesicular bodies, which contain a number of intracellular vesicles (ILVs) generated through invagination of the endosomal membrane. Through a likely fusion of these multivesicular bodies with the plasma membrane, exosomes are released into the extracellular space and enter circulation (Bastos et al., 2017; Colombo et al., 2014). As a result of their endocytic origin, exosomes membranes have a similar polarity to cellular membranes, containing membrane proteins anchored with their intracellular domains facing the lumen and the extracellular domains facing the extracellular space. While the protein content of exosomes varies depending on their cellular origin, several proteins seem to be generally enriched. These include members of the tetraspanin family and components of the endocytic and ELV maturation pathways, such as Rab proteins and members of the ESCRT
complex.
Interestingly, different proteomics studies performed with exosomes derived from many different cell types have identified many constituents associated with the protein translation machinery, such as eukaryotic initiation factors, ADP ribosylation factors, ribosomal proteins (Pisitkun et al., 2004; Valadi et al., 2007). Additionally, a subset of transcriptional and translation regulators identified in exosomes by proteomic analysis has been suggested to be delivered to recipient cells, altering their pattern of gene and protein expression (Ung et al., 2014).
100061 Amongst the proteins commonly identified in exosomes are growth factor receptors, such as the epithelial growth factor receptor (EGFR). EGFR is a member of the ErbB family of growth factor receptors, which also includes HER2, HER3 and (Seshacharyulu et al., 2012). Upon binding one of its ligands, such as the epitheial growth factor (EGF), the receptor dimerizes, forming either homodimers or heterodimers with other members of the ErbB family (Seshacharyulu et al., 2012). This dimerization activates the receptor's intrinsic kinase activity, leading to the autophosphorylation of different key tyrosine residues on its cytoplasmic domain. This authophosphorylation reaction recruits different adaptor proteins containing SH2 and PTB (phosphotyrosine binding) domains, such as Shc and GRB2, which mediate different downstream signaling activities, including the synthesis of relevant proteins (Normanno et al., 2006; Tomas et al., 2014).
Phosphorylated EGFR is ultimately ubiquitinated and transported to the endosomal pathway, from which it will either recycle back to the membrane or remain in the late endosomal pathway leading to integration into multivesicular bodies or lysosomal degradation (Tomas et al., 2014). Since multivesicular bodies originate exosomes, it is likely that the post-phosphorylation recycling of EGFR (and other growth factors) contribute to their membrane localization in these extracellular vesicles.
100071 EGFR signaling has been shown to be important for the progression of different malignancies, such as glioblastoma, lung cancer, and breast cancer (Lim et al., 2016;
Liu et al., 2012; Masuda et al., 2012; Morgillo et al., 2016; Westphal et al., 2017; Zhang et al., 2013). Perhaps for this reason, most studies of EGFR in exosomes have been performed in the context of cancer development. EGFR signaling has particularly been implicated in the patterns of cellular uptake and secretion of exosomes from different origins.
In mantle cell carcinoma cells, incubation with gefitinib (an EGFR inhibitor) has been shown to dramatically decrease the rate of exosomes uptake (Hazan-Halevy et al., 2015).
Treatment of lung cancer cells with gefitinib leads to an increased secretion of exosomes, which mediate horizontal transfer of cisplatin resistance (Li et al., 2016). The transfer of EGFR via cancer cell-derived exosomes has also been known to cause alterations in components of the microenvironment, such as endothelial cells and T cells (Al-Nedawi et al., 2009; Huang et al., 2013). More recently, exosomes derived from gastric cancer cells containing EGFR were shown to be delivered to stromal cells in the liver, mediating metastasis (Zhang et al., 2017).
Finally, exosomes derived from breast cancer cells were shown to contain functional phosphorylated forms of EGFR, which can be transferred to monocytes mediating their survival through activation of the ERK pathway (Song et al., 2016).
100081 While the delivery of EGFR and members of the protein translation machinery by exosomes seems to have clear biological importance in the context of cell-cell communications, these properties may be harnessed to target the delivery of therapeutic agents to certain tissues and to induce therapeutic protein production at the desired delivery site.
SUMMARY
100091 Here, protein synthesis was induced in exosomes through growth factor stimulation. Exosomes that contain DNA, RNA, and proteins, can respond to biological stimuli, and initiate properties such as migration, multiplication, initiation of signaling network/cascade, transcription, and protein translation. Thus, in one embodiment, provided herein are exosomes with the ability to function like minicells. As discussed further below,
After their initial discovery as byproducts of reticulocyte differentiation (Harding et al., 1984;
Raposo and Stoorvogel, 2013), it is now generally accepted that exosomes are secreted by virtually all mammalian cells and found in all body fluids (El-Andaloussi et al., 2013;
Kalluri, 2016).
100051 Exosomes are part of a larger group of extracellular vesicles, which also include microvesicles and apoptotic bodies (Colombo et al., 2014). Amongst extracellular vesicles, exosomes are typically distinguished through their unique biogenesis via the endocytic pathway. Endocytic vesicles mature into late endosomes, also known as multivesicular bodies, which contain a number of intracellular vesicles (ILVs) generated through invagination of the endosomal membrane. Through a likely fusion of these multivesicular bodies with the plasma membrane, exosomes are released into the extracellular space and enter circulation (Bastos et al., 2017; Colombo et al., 2014). As a result of their endocytic origin, exosomes membranes have a similar polarity to cellular membranes, containing membrane proteins anchored with their intracellular domains facing the lumen and the extracellular domains facing the extracellular space. While the protein content of exosomes varies depending on their cellular origin, several proteins seem to be generally enriched. These include members of the tetraspanin family and components of the endocytic and ELV maturation pathways, such as Rab proteins and members of the ESCRT
complex.
Interestingly, different proteomics studies performed with exosomes derived from many different cell types have identified many constituents associated with the protein translation machinery, such as eukaryotic initiation factors, ADP ribosylation factors, ribosomal proteins (Pisitkun et al., 2004; Valadi et al., 2007). Additionally, a subset of transcriptional and translation regulators identified in exosomes by proteomic analysis has been suggested to be delivered to recipient cells, altering their pattern of gene and protein expression (Ung et al., 2014).
100061 Amongst the proteins commonly identified in exosomes are growth factor receptors, such as the epithelial growth factor receptor (EGFR). EGFR is a member of the ErbB family of growth factor receptors, which also includes HER2, HER3 and (Seshacharyulu et al., 2012). Upon binding one of its ligands, such as the epitheial growth factor (EGF), the receptor dimerizes, forming either homodimers or heterodimers with other members of the ErbB family (Seshacharyulu et al., 2012). This dimerization activates the receptor's intrinsic kinase activity, leading to the autophosphorylation of different key tyrosine residues on its cytoplasmic domain. This authophosphorylation reaction recruits different adaptor proteins containing SH2 and PTB (phosphotyrosine binding) domains, such as Shc and GRB2, which mediate different downstream signaling activities, including the synthesis of relevant proteins (Normanno et al., 2006; Tomas et al., 2014).
Phosphorylated EGFR is ultimately ubiquitinated and transported to the endosomal pathway, from which it will either recycle back to the membrane or remain in the late endosomal pathway leading to integration into multivesicular bodies or lysosomal degradation (Tomas et al., 2014). Since multivesicular bodies originate exosomes, it is likely that the post-phosphorylation recycling of EGFR (and other growth factors) contribute to their membrane localization in these extracellular vesicles.
100071 EGFR signaling has been shown to be important for the progression of different malignancies, such as glioblastoma, lung cancer, and breast cancer (Lim et al., 2016;
Liu et al., 2012; Masuda et al., 2012; Morgillo et al., 2016; Westphal et al., 2017; Zhang et al., 2013). Perhaps for this reason, most studies of EGFR in exosomes have been performed in the context of cancer development. EGFR signaling has particularly been implicated in the patterns of cellular uptake and secretion of exosomes from different origins.
In mantle cell carcinoma cells, incubation with gefitinib (an EGFR inhibitor) has been shown to dramatically decrease the rate of exosomes uptake (Hazan-Halevy et al., 2015).
Treatment of lung cancer cells with gefitinib leads to an increased secretion of exosomes, which mediate horizontal transfer of cisplatin resistance (Li et al., 2016). The transfer of EGFR via cancer cell-derived exosomes has also been known to cause alterations in components of the microenvironment, such as endothelial cells and T cells (Al-Nedawi et al., 2009; Huang et al., 2013). More recently, exosomes derived from gastric cancer cells containing EGFR were shown to be delivered to stromal cells in the liver, mediating metastasis (Zhang et al., 2017).
Finally, exosomes derived from breast cancer cells were shown to contain functional phosphorylated forms of EGFR, which can be transferred to monocytes mediating their survival through activation of the ERK pathway (Song et al., 2016).
100081 While the delivery of EGFR and members of the protein translation machinery by exosomes seems to have clear biological importance in the context of cell-cell communications, these properties may be harnessed to target the delivery of therapeutic agents to certain tissues and to induce therapeutic protein production at the desired delivery site.
SUMMARY
100091 Here, protein synthesis was induced in exosomes through growth factor stimulation. Exosomes that contain DNA, RNA, and proteins, can respond to biological stimuli, and initiate properties such as migration, multiplication, initiation of signaling network/cascade, transcription, and protein translation. Thus, in one embodiment, provided herein are exosomes with the ability to function like minicells. As discussed further below,
3
4 these minicell-like exosomes can be employed in numerous therapeutic means to treat various disease and/or disorders.
100101 In one embodiment, provided herein are methods of treating a disease or disorder in a patient in need thereof, the method comprising (a) obtaining exosomes having a growth factor receptor on their surface; (b) transfecting the exosomes with a nucleic acid encoding a therapeutic protein; (c) administering the transfected exosomes to a patient; (d) providing a growth factor gradient at a site of the disease or disorder to attract the exosomes to the site and stimulate production of the therapeutic protein at the site, thereby treating the disease in the patient.
100111 In some aspects, the method is further defined as a method of administering a therapeutic protein to a diseased cell in a patient. In some aspects, the exosomes obtained in step (a) are obtained from a body fluid sample obtained from the patient. In some aspects, the body fluid sample is blood, lymph, saliva, urine, cerebrospinal fluid, bone marrow aspirates, eye exudate/tears, or serum. In some aspects, the nucleic acid is an mRNA, a plasmid, or a cDNA.
100121 In some aspects, the disease or disorder is cancer, an injury, an autoimmune disorder, a neurological disorder, a gastrointestinal disorder, an infectious disease, a kidney disease, a cardiovascular disorder, an ophthalmic disorder, a skin disease or disorder, a urogenita1 disorder, or a bone disease or disorder. In certain aspects, the cancer is a breast cancer, lung cancer, head & neck cancer, prostate cancer, esophageal cancer, tracheal cancer, brain cancer, liver cancer, bladder cancer, stomach cancer, pancreatic cancer, ovarian cancer, uterine cancer, cervical cancer, testicular cancer, colon cancer, rectal cancer or skin cancer.
In some aspects, the site of the disease or disorder is a tumor. In some aspects, the cancer is metastatic. In certain aspects, the site of the disease or disorder is a metastatic node.
100131 In some aspects, the therapeutic protein is a kinase, a phosphatase, or a transcription factor. In certain aspects, the therapeutic protein corresponds to a wildtype version of a protein that is mutated or inactivated in a cell at the site of the disease or disorder. In certain aspects, the therapeutic protein corresponds to a dominant negative version of a protein that is hyperactive in a cell at the site of the disease or disorder. In certain aspects, the disease or disorder is cancer, wherein the therapeutic protein is a tumor suppressor. In some aspects, the exosomes comprise CD47 on their surface. In some aspects, transfection comprises electroporation.
100141 In some aspects, the method further comprises administering at least a second therapy to the patient. In some aspects, the second therapy comprises a surgical therapy, chemotherapy, radiation therapy, cryotherapy, hormonal therapy, or immunotherapy.
100151 In one embodiment, methods are provided of treating a disease or disorder in a patient in need thereof, the method comprising (a) obtaining exosomes having a growth factor receptor on their surface; (b) transfecting the exosomes with therapeutic agent; (c) administering the transfected exosomes to a patient; (d) providing a growth factor gradient at a site of the disease or disorder to attract the exosomes to the site and deliver the therapeutic agent to the site, thereby treating the disease in the patient.
100161 In some aspects, the method is further defined as a method of administering a therapeutic agent to a diseased cell in a patient. In some aspects, the exosomes obtained in step (a) are obtained from a body fluid sample obtained from the patient. In certain aspects, the body fluid sample is blood, lymph, saliva, urine, cerebrospinal fluid, bone marrow aspirates, eye exudate/tears, or serum.
100171 In some aspects, the therapeutic agent is a therapeutic protein, an antibody, an inhibitory RNA, a gene editing system, or a small molecule drug. In certain aspects, the antibody binds an intracellular antigen. In certain aspects, the antibody is a full-length antibody, an scFv, a Fab fragment, a (Fab)2, a diabody, a triabody, or a minibody. In certain aspects, the inhibitory RNA is a siRNA, shRNA, miRNA, or pre-miRNA. In certain aspects, the gene editing system is a CRISPR/Cas system. In certain aspects, the therapeutic protein is a kinase, a phosphatase, or a transcription factor. In certain aspects, the therapeutic protein corresponds to a wildtype version of a protein that is mutated or inactivated in a cell at the site of the disease or disorder. In certain aspects, the therapeutic protein corresponds to a dominant negative version of a protein that is hyperactive in a cell at the site of the disease or disorder. In some aspects, the small molecule drug is an imaging agent.
100181 In some aspects, the disease or disorder is cancer, an injury, an autoimmune disorder, a neurological disorder, a gastrointestinal disorder, an infectious disease, a kidney disease, a cardiovascular disorder, an ophthalmic disorder, a skin disease or disorder, a urogenital disorder, or a bone disease or disorder. In certain aspects, the cancer is a breast
100101 In one embodiment, provided herein are methods of treating a disease or disorder in a patient in need thereof, the method comprising (a) obtaining exosomes having a growth factor receptor on their surface; (b) transfecting the exosomes with a nucleic acid encoding a therapeutic protein; (c) administering the transfected exosomes to a patient; (d) providing a growth factor gradient at a site of the disease or disorder to attract the exosomes to the site and stimulate production of the therapeutic protein at the site, thereby treating the disease in the patient.
100111 In some aspects, the method is further defined as a method of administering a therapeutic protein to a diseased cell in a patient. In some aspects, the exosomes obtained in step (a) are obtained from a body fluid sample obtained from the patient. In some aspects, the body fluid sample is blood, lymph, saliva, urine, cerebrospinal fluid, bone marrow aspirates, eye exudate/tears, or serum. In some aspects, the nucleic acid is an mRNA, a plasmid, or a cDNA.
100121 In some aspects, the disease or disorder is cancer, an injury, an autoimmune disorder, a neurological disorder, a gastrointestinal disorder, an infectious disease, a kidney disease, a cardiovascular disorder, an ophthalmic disorder, a skin disease or disorder, a urogenita1 disorder, or a bone disease or disorder. In certain aspects, the cancer is a breast cancer, lung cancer, head & neck cancer, prostate cancer, esophageal cancer, tracheal cancer, brain cancer, liver cancer, bladder cancer, stomach cancer, pancreatic cancer, ovarian cancer, uterine cancer, cervical cancer, testicular cancer, colon cancer, rectal cancer or skin cancer.
In some aspects, the site of the disease or disorder is a tumor. In some aspects, the cancer is metastatic. In certain aspects, the site of the disease or disorder is a metastatic node.
100131 In some aspects, the therapeutic protein is a kinase, a phosphatase, or a transcription factor. In certain aspects, the therapeutic protein corresponds to a wildtype version of a protein that is mutated or inactivated in a cell at the site of the disease or disorder. In certain aspects, the therapeutic protein corresponds to a dominant negative version of a protein that is hyperactive in a cell at the site of the disease or disorder. In certain aspects, the disease or disorder is cancer, wherein the therapeutic protein is a tumor suppressor. In some aspects, the exosomes comprise CD47 on their surface. In some aspects, transfection comprises electroporation.
100141 In some aspects, the method further comprises administering at least a second therapy to the patient. In some aspects, the second therapy comprises a surgical therapy, chemotherapy, radiation therapy, cryotherapy, hormonal therapy, or immunotherapy.
100151 In one embodiment, methods are provided of treating a disease or disorder in a patient in need thereof, the method comprising (a) obtaining exosomes having a growth factor receptor on their surface; (b) transfecting the exosomes with therapeutic agent; (c) administering the transfected exosomes to a patient; (d) providing a growth factor gradient at a site of the disease or disorder to attract the exosomes to the site and deliver the therapeutic agent to the site, thereby treating the disease in the patient.
100161 In some aspects, the method is further defined as a method of administering a therapeutic agent to a diseased cell in a patient. In some aspects, the exosomes obtained in step (a) are obtained from a body fluid sample obtained from the patient. In certain aspects, the body fluid sample is blood, lymph, saliva, urine, cerebrospinal fluid, bone marrow aspirates, eye exudate/tears, or serum.
100171 In some aspects, the therapeutic agent is a therapeutic protein, an antibody, an inhibitory RNA, a gene editing system, or a small molecule drug. In certain aspects, the antibody binds an intracellular antigen. In certain aspects, the antibody is a full-length antibody, an scFv, a Fab fragment, a (Fab)2, a diabody, a triabody, or a minibody. In certain aspects, the inhibitory RNA is a siRNA, shRNA, miRNA, or pre-miRNA. In certain aspects, the gene editing system is a CRISPR/Cas system. In certain aspects, the therapeutic protein is a kinase, a phosphatase, or a transcription factor. In certain aspects, the therapeutic protein corresponds to a wildtype version of a protein that is mutated or inactivated in a cell at the site of the disease or disorder. In certain aspects, the therapeutic protein corresponds to a dominant negative version of a protein that is hyperactive in a cell at the site of the disease or disorder. In some aspects, the small molecule drug is an imaging agent.
100181 In some aspects, the disease or disorder is cancer, an injury, an autoimmune disorder, a neurological disorder, a gastrointestinal disorder, an infectious disease, a kidney disease, a cardiovascular disorder, an ophthalmic disorder, a skin disease or disorder, a urogenital disorder, or a bone disease or disorder. In certain aspects, the cancer is a breast
5 cancer, lung cancer, head & neck cancer, prostate cancer, esophageal cancer, tracheal cancer, brain cancer, liver cancer, bladder cancer, stomach cancer, pancreatic cancer, ovarian cancer, uterine cancer, cervical cancer, testicular cancer, colon cancer, rectal cancer or skin cancer.
In some aspects, the site of the disease or disorder is a tumor. In some aspects, the cancer is metastatic. In some aspects, the site of the disease or disorder is a metastatic node. In some aspects, the disease or disorder is cancer, wherein the therapeutic protein is a tumor suppressor. In some aspects, the disease or disorder is cancer, wherein the therapeutic agent is an inhibitory RNA targeting an oncogene.
100191 In some aspects, the exosomes comprise CD47 on their surface In some aspects, transfection comprises electroporation. In some aspects, the method further comprises administering at least a second therapy to the patient. In some aspects, the second therapy comprises a surgical therapy, chemotherapy, radiation therapy, cryotherapy, hormonal therapy, or immunotherapy.
100201 In further aspects, exosomes for use according to the embodiments are comprised in a tissue scaffold matrix. For example, such a matrix may be a synthetic matrix, such a matrix that degradable or can be absorbed in tissues. In further aspects, the matrix may be a living tissue matrix. In some aspects, a exosomes of the embodiments are cultured in a matrix.
100211 As used herein, "essentially free," in terms of a specified component, is used herein to mean that none of the specified component has been purposefully formulated into a composition and/or is present only as a contaminant or in trace amounts. The total amount of the specified component resulting from any unintended contamination of a composition is therefore well below 0.01%. Most preferred is a composition in which no amount of the specified component can be detected with standard analytical methods.
100221 As used herein the specification, "a" or "an" may mean one or more. As used herein in the claim(s), when used in conjunction with the word "comprising,"
the words "a"
or "an" may mean one or more than one.
100231 The use of the term "or" in the claims is used to mean "and/or" unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and "and/or." As used herein "another" may mean at least a second or more.
In some aspects, the site of the disease or disorder is a tumor. In some aspects, the cancer is metastatic. In some aspects, the site of the disease or disorder is a metastatic node. In some aspects, the disease or disorder is cancer, wherein the therapeutic protein is a tumor suppressor. In some aspects, the disease or disorder is cancer, wherein the therapeutic agent is an inhibitory RNA targeting an oncogene.
100191 In some aspects, the exosomes comprise CD47 on their surface In some aspects, transfection comprises electroporation. In some aspects, the method further comprises administering at least a second therapy to the patient. In some aspects, the second therapy comprises a surgical therapy, chemotherapy, radiation therapy, cryotherapy, hormonal therapy, or immunotherapy.
100201 In further aspects, exosomes for use according to the embodiments are comprised in a tissue scaffold matrix. For example, such a matrix may be a synthetic matrix, such a matrix that degradable or can be absorbed in tissues. In further aspects, the matrix may be a living tissue matrix. In some aspects, a exosomes of the embodiments are cultured in a matrix.
100211 As used herein, "essentially free," in terms of a specified component, is used herein to mean that none of the specified component has been purposefully formulated into a composition and/or is present only as a contaminant or in trace amounts. The total amount of the specified component resulting from any unintended contamination of a composition is therefore well below 0.01%. Most preferred is a composition in which no amount of the specified component can be detected with standard analytical methods.
100221 As used herein the specification, "a" or "an" may mean one or more. As used herein in the claim(s), when used in conjunction with the word "comprising,"
the words "a"
or "an" may mean one or more than one.
100231 The use of the term "or" in the claims is used to mean "and/or" unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and "and/or." As used herein "another" may mean at least a second or more.
6 100241 Throughout this application, the term "about" is used to indicate that a value includes the inherent variation of error for the device, the method being employed to determine the value, or the variation that exists among the study subjects.
100251 Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
100261 The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
100271 FIGS. IA-E. EGFR phosphoiylation in exosomes. FIG. 1A ¨ Immunoblot of EGFR expression on exosomes obtained from different human and murine cell lines. The exosomes marker CD81 is used as a loading control, and to confirm the exosomal origin of protein extracts. FIG. 1B ¨ Immunoblot showing phosphorylation of EGFR on exosomes derived from MDA-MB-231 cells, but not MCF10A cells, after incubation with 500 ng/ml rhEGF for 15 minutes at 37 C. Phosphorylation levels are detected using an antibody specific for the Tyr] 068 residue of EGFR. EGFR levels are shown as a loading control, to confirm differences in phosphorylation. Band densitometry quantification was performed using ImageJ software. FIG. IC ¨ Immunoblot showing the presence of EGFR adaptor proteins Shc and GRB2, as well increased levels of phosphorylated-ERK protein, in exosomes derived from MDA-MB-231 cells, with and without rhEGF stimulation for 15 minutes at 37 C. The exosomes marker CD81 is used as a loading control, and to confirm the exosomal origin of protein extracts. FIG. 1D ¨ GRB immunecomplexes were obtained from protein extracts of /VIDA-MB-23 1 exosomes, with and without incubation with 500 ng/ml rhEGF for 15 minutes at 37 C, using a GRB2 specific antibody. Immunoblot analysis of the immunocomplexes shows association of GRB2 with EGFR only upon rhEGF stimulation. Non-specific isotype control IgG was used as a negative control for the GRB2 pulldown. Equal volumes of the
100251 Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
100261 The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
100271 FIGS. IA-E. EGFR phosphoiylation in exosomes. FIG. 1A ¨ Immunoblot of EGFR expression on exosomes obtained from different human and murine cell lines. The exosomes marker CD81 is used as a loading control, and to confirm the exosomal origin of protein extracts. FIG. 1B ¨ Immunoblot showing phosphorylation of EGFR on exosomes derived from MDA-MB-231 cells, but not MCF10A cells, after incubation with 500 ng/ml rhEGF for 15 minutes at 37 C. Phosphorylation levels are detected using an antibody specific for the Tyr] 068 residue of EGFR. EGFR levels are shown as a loading control, to confirm differences in phosphorylation. Band densitometry quantification was performed using ImageJ software. FIG. IC ¨ Immunoblot showing the presence of EGFR adaptor proteins Shc and GRB2, as well increased levels of phosphorylated-ERK protein, in exosomes derived from MDA-MB-231 cells, with and without rhEGF stimulation for 15 minutes at 37 C. The exosomes marker CD81 is used as a loading control, and to confirm the exosomal origin of protein extracts. FIG. 1D ¨ GRB immunecomplexes were obtained from protein extracts of /VIDA-MB-23 1 exosomes, with and without incubation with 500 ng/ml rhEGF for 15 minutes at 37 C, using a GRB2 specific antibody. Immunoblot analysis of the immunocomplexes shows association of GRB2 with EGFR only upon rhEGF stimulation. Non-specific isotype control IgG was used as a negative control for the GRB2 pulldown. Equal volumes of the
7 stimulated and unstimulated extracts were probed for f3-actin as input control. FIG. 1E -Similar experiment using an Shc antibody for the pull down experiment in duplicates, also showing association with EGFR only after stimulation with 500 ng/ml rhEGF for 15 minutes at 37 C. Non-specific isotype control IgG was used as a negative control for the Shc pulldown. Equal volumes of the stimulated and unstimulated extracts were probed for bactin as an input control.
100281 FIGS. 2A-G. EGFR phosphorylation alters the content of exosomes. FIG
.2A
- Luciferase-based ATP determination assay ran on protein extracts obtained from exosomes either unstimulated or after rhEGF stimulation for 15 minutes at 37 C.
Luciferin-derived .. luminescence was measured in a plate reader and is presented as arbitrary units. Significance was determined with a Mann-Whitney test (n = 4). FIG. 2B - Immunoblot analysis of exosomes from MDA-MB-231 cells incubated with 500 ng/ml rhEGF at 37 C for 48 h, showing an increase in both pEGFR and GRB2 levels when compared to unstimulated exosomes. FIG. 2C - Cellular component association analysis of mass spectrometry data obtained for MDA-MB-231 exosomes unstimulated or after incubation with 500 ng/ml EGF
at 37 C for 48 h. A list of significant proteins identified for stimulated and unstimulated exosomes was obtained and used as input for the open access FunRich functional enrichment analysis tool in order to identify the subcellular origin of the identified proteins. FIG. 2D -Venn diagram depicting the overlap in proteins identified in control IvIDA-MB-231 exosomes and exosomes incubated with 500 ng/ml rhEGF at 37 C for 48 h. FIG. 2E -Individual EGFR
and GRB2 protein scores obtained from mass spectrometry analysis of MDA-MB-231 exosomes with or without incubation with 500 ng/ml rhEGF for 48 h. FIG. 2F -BCA
analysis of protein extracts obtained from control MDA-MB-231 exosomes and exosomes incubated with 500 ng/ml rhEGF at 37 C for 48 h. Significance was determined with a Mann-Whitney test (n = 3). FIG. 2G - Immunoblot analysis of 0-actin expression on protein extracts obtained from control MDA-MB-231 exosomes and exosomes incubated with ng/ml and 1000 ng/ml rhEGF at 37 C for 48 h. (*p < 0.05, **p < 0.01, ***p <
0.005, ****p <0.0001).
100291 FIGS. 3A-F. Exosomes contain functional components for transcription and translation. FIG. 3A - Ultra-performance liquid chromatography-mass spectrometry (UPLCMS) was used to detect free amino acids in MCF10A-, MDA-MB-231-, HDF, E
10-, and NIH-3T3-derived exosomes. Data are represented as a HeatMap using normalized signal
100281 FIGS. 2A-G. EGFR phosphorylation alters the content of exosomes. FIG
.2A
- Luciferase-based ATP determination assay ran on protein extracts obtained from exosomes either unstimulated or after rhEGF stimulation for 15 minutes at 37 C.
Luciferin-derived .. luminescence was measured in a plate reader and is presented as arbitrary units. Significance was determined with a Mann-Whitney test (n = 4). FIG. 2B - Immunoblot analysis of exosomes from MDA-MB-231 cells incubated with 500 ng/ml rhEGF at 37 C for 48 h, showing an increase in both pEGFR and GRB2 levels when compared to unstimulated exosomes. FIG. 2C - Cellular component association analysis of mass spectrometry data obtained for MDA-MB-231 exosomes unstimulated or after incubation with 500 ng/ml EGF
at 37 C for 48 h. A list of significant proteins identified for stimulated and unstimulated exosomes was obtained and used as input for the open access FunRich functional enrichment analysis tool in order to identify the subcellular origin of the identified proteins. FIG. 2D -Venn diagram depicting the overlap in proteins identified in control IvIDA-MB-231 exosomes and exosomes incubated with 500 ng/ml rhEGF at 37 C for 48 h. FIG. 2E -Individual EGFR
and GRB2 protein scores obtained from mass spectrometry analysis of MDA-MB-231 exosomes with or without incubation with 500 ng/ml rhEGF for 48 h. FIG. 2F -BCA
analysis of protein extracts obtained from control MDA-MB-231 exosomes and exosomes incubated with 500 ng/ml rhEGF at 37 C for 48 h. Significance was determined with a Mann-Whitney test (n = 3). FIG. 2G - Immunoblot analysis of 0-actin expression on protein extracts obtained from control MDA-MB-231 exosomes and exosomes incubated with ng/ml and 1000 ng/ml rhEGF at 37 C for 48 h. (*p < 0.05, **p < 0.01, ***p <
0.005, ****p <0.0001).
100291 FIGS. 3A-F. Exosomes contain functional components for transcription and translation. FIG. 3A - Ultra-performance liquid chromatography-mass spectrometry (UPLCMS) was used to detect free amino acids in MCF10A-, MDA-MB-231-, HDF, E
10-, and NIH-3T3-derived exosomes. Data are represented as a HeatMap using normalized signal
8 intensities (log10), with hotter colors corresponding to higher intensity levels, as represented in the color legend. FIG. 3B ¨ Immunoblot of elF4A1, elF3A, and elF1A in protein extracts of exosomes obtained from El 0-, NIH-3T3-, MCF10A-, HDF-, and MDA-MB-231-derived exosomes. CD9 was used as a loading control. FIG. 3C ¨ In vitro translation assay using protein lysates from MCF10A- and MDA-MB-231-derived exosomes incubated with the pEMT7-GFP cDNA expression plasmid. Protein lysates obtained from cells were used as controls. FIG. 3D ¨ Immunoblot analysis of RNA Polymerase II in exosomes protein extracts, with CD9 shown as a loading control. FIG. 3E ¨ Autoradiography of exosomes derived from MDA-MB-231 and E10 cells cultured in the presence of 35S-methionine.
Exosomes only, as well as exosomes cultured in the presence of 35S-methionine and cycloheximide, were used as controls. FIG. 3F ¨ BCA quantification of protein extracts obtained from exosomes immediately after isolation, or after incubation in cell-free conditions for 24 h and 48 h. Significance was determined with a one-way ANOVA
followed by Tukey's multiple comparisons test (*p <0.05, **p <0.01, ***p < 0.005, ****p < 0.0001, n = 3).
100301 FIGS. 4A-J. Exosomes synthesize new proteins through DNA transcription and cap-dependent mRNA translation. FIG. 4A ¨ qPCR analysis of GFP mRNA levels in exosomes isolated from /vIDA-MB-231 cells and either non-electroporated, mock electroporated, or electroporated with a pCMV-GFP plasmid with or without the presence of a-amanitin. Expression levels were normalized to GAPDH. FIG. 4B Transmission electron microscopy images of immunogold labeling, using anti-GFP antibody, of exosomes electroporated with GFP plasmid and incubated in cell-free conditions for 48 h (bottom row).
Secondary antibody only was used as a negative control (top row). Gold particles are depicted as black dots. Scale bar, 100 nm. FIG. 4C ¨ Immunoblot of GFP protein expression in exosomes electroporated with a pCMV-GFP plasmid and incubated for 12 hours, 2 days, or 1 week at 37 C. Exosomes only and mock-electroporated exosomes were used as negative controls. The exosomes marker TSG101 was used as a loading control for the presence of exosomes. FIG. 4D ¨ Immunoblot of GFP protein expression in exosomes electroporated with GFP plasmid and incubated for several periods of time up to one month.
Non-electroporated exosomes were used as negative controls. The exosomes marker CD63 was used as a loading control for the presence of exosomes. FIG. 4E ¨ Immunoblot of GFP
protein expression in exosomes electroporated with a GFP plasmid immediately after isolation (0 h) or after incubation in cell-free conditions (24 h) and cultured as previously
Exosomes only, as well as exosomes cultured in the presence of 35S-methionine and cycloheximide, were used as controls. FIG. 3F ¨ BCA quantification of protein extracts obtained from exosomes immediately after isolation, or after incubation in cell-free conditions for 24 h and 48 h. Significance was determined with a one-way ANOVA
followed by Tukey's multiple comparisons test (*p <0.05, **p <0.01, ***p < 0.005, ****p < 0.0001, n = 3).
100301 FIGS. 4A-J. Exosomes synthesize new proteins through DNA transcription and cap-dependent mRNA translation. FIG. 4A ¨ qPCR analysis of GFP mRNA levels in exosomes isolated from /vIDA-MB-231 cells and either non-electroporated, mock electroporated, or electroporated with a pCMV-GFP plasmid with or without the presence of a-amanitin. Expression levels were normalized to GAPDH. FIG. 4B Transmission electron microscopy images of immunogold labeling, using anti-GFP antibody, of exosomes electroporated with GFP plasmid and incubated in cell-free conditions for 48 h (bottom row).
Secondary antibody only was used as a negative control (top row). Gold particles are depicted as black dots. Scale bar, 100 nm. FIG. 4C ¨ Immunoblot of GFP protein expression in exosomes electroporated with a pCMV-GFP plasmid and incubated for 12 hours, 2 days, or 1 week at 37 C. Exosomes only and mock-electroporated exosomes were used as negative controls. The exosomes marker TSG101 was used as a loading control for the presence of exosomes. FIG. 4D ¨ Immunoblot of GFP protein expression in exosomes electroporated with GFP plasmid and incubated for several periods of time up to one month.
Non-electroporated exosomes were used as negative controls. The exosomes marker CD63 was used as a loading control for the presence of exosomes. FIG. 4E ¨ Immunoblot of GFP
protein expression in exosomes electroporated with a GFP plasmid immediately after isolation (0 h) or after incubation in cell-free conditions (24 h) and cultured as previously
9 described. Mock electroporated exosomes were used as negative controls. The exosomes marker TSG101 was used as a loading control for the presence of exosomes. FIG.
Immunoblot of GFP protein expression in exosomes electroporated with a pCMV-GFP
plasmid and cultured with the translation inhibitor cycloheximide. Exosomes only and exosomes mock electroporated were used as negative controls. TSG101 was used as a loading control for the presence of exosomes. Band densitometry was performed using ImageJ software. FIG. 4G - Immunoblot of GFP protein expression in exosomes electroporated with a GFP plasmid and cultured with the transcription inhibitor a-amanitin.
Exosomes only and exosomes mock electroporated were used as negative controls.
was used as a loading control for the presence of exosomes. Band densitometry was performed using ImageJ software. FIG. 4H - Schematic representation of the bicistronic plasmid used as a reporter for cap-dependent or cap-independent translation (pCDNA3-rLuc-polIRESfLuc). FIG. 41 - Activities of renilla (r-Luc) and firefly luciferase (f-Luc) measured by bioluminescence after 48 h incubation of exosomes electroporated with the bicistronic plasmid. Non-electroporated exosomes were used as negative controls. FIG. 4J -Luminescence counts measured from exosomes incubated for 48 h after electroporation with or without a plasmid with firefly luciferase expressed under a CMV promoter.
100311 FIGS. 5A-E. Protein translation in exosomes generates functional proteins and can be increased by growth factor stimulation. FIG. 5A - Confocal microscopy showing the presence of GFP in MCF10A electroporated cells as well as in MCF10A cells, previously treated with cycloheximide, incubated with MDA-MB-231-derived exosomes electroporated with a pCMV-GFP plasmid and pre-incubated for 48 h. MCF10A cells treated with non-electroporated MDA-MB-231-derived exosomes were used as a negative control.
FIG. 5B -Immunoblot analysis of GFP expression on protein lysates from MDA-MB-231-derived exosomes electroporated with a p53-GFP expression plasmid. Non-electroporated exosomes were used as negative controls. TSG101 was used as a loading control for the presence of exosomes. FIG.5C - p21 mRNA expression in MDA-MB-231 cells treated with mock electroporated MDA-MB-231-derived exosomes or exosomes electroporated with the p53-GFP plasmid with and without the presence of cycloheximide. Expression levels were normalized to the housekeeping gene GAPDH. FIG. 5D - Immunoblot of exosomes isolated from MDA-MB-231 cells, incubated with 100 [tg/m1 of the translation inhibitor cycloheximide. Exosomes lysates were probed for I3-actin and GAPDH. Band densitometry quantification was performed using ImageJ software. FIG. 5E - Immunoblot of GFP protein expression in exosomes electroporated with a pCMV-GFP plasmid, and then incubated in the presence of different concentrations of rhEGF at 37 C for 48 h. Exosomes mock electroporated and exosomes without rhEGF incubation are shown as negative controls. The exosomes marker CD81 is used as a loading control. Band densitometry quantification was performed using ImageJ software.
100321 FIG. 6A-C. Exosomes derived from MDA-MB-231 cells demonstrate chemotaxis towards a gradient of growth factors. FIG. 6A - Schematic demonstrating the set up for exosomes retrograde migration assay. In short, 10 x 109 exosomes isolated from MDA-MB-231 cells were placed in the bottom well of a Corning Transwell system. An HIS Transwelle insert with 400 nm pores was placed on top of the exosomes suspension containing either PBS, 20% FBS, or 10,000 ng/ml rhEGF and incubated at 37 C.
The number of exosomes on the top insert was measured by Nanosight NTA after different time points to assess exosomes motility. FIGS. 6B&6C - Quantification of MDA-MB-231 exosomes on the top insert of the retrograde migration assay, after 4 h (FIG. 6B) and 24 h (FIG. 6C) incubation at 37 C, by Nanosight NTA. Significance was determined with a one-way ANOVA
followed by Newman-Keuls multiple comparison test. (*p <0.05, **p <0.01, ***p <0.005, ****p <
0.0001, n = 3).
100331 FIGS. 7A-D. Tumor-bearing mice show increased protein synthesis in delivered exosomes. FIG. 7A - Schematic depicting the experimental plan for the in vivo translation experiment. In short, female Balb/C mice were injected with 411 tumor orthotopically and the tumor was allowed to grow to 500 mm3, after which mice were injected with 30 billion MDA-MB-231 exosomes electroporated with a pCMV-mCherry plasmid. The mice were euthanized 12 h after exosomes injection and serum was collected for exosomes extraction. FIG. 7B - Graphic showing the tumor growth of mice injected with 411 tumors and electroporated exosomes, or 411 tumors alone, showing comparable growth kinetics. FIG. 7C - Nanosight NTA analysis of exosomes extracted from the serum of healthy mice injected with electroporated exosomes, as well as 411 tumor-bearing mice injected with electroporated exosomes and 411 tumor bearing mice with no exosomes injection.
All exosomes show similar size peaks, around 100 nm. FIG. 7D - Nanosight NTA
quantification of serum exosomes shown in FIG. 7C, showing no significant differences in the exosomes amount obtained from the serum of different animals, but a trend towards more exosomes in 411 tumor-bearing mice injected with MDA-MB-231 electroporated exosomes.
100341 FIGS. 8A-G. Exosomes characterization. FIG. 8A ¨ Nanoparticle tracking analysis of exosomes collected from MDA-MB-231 cells, obtained using the Nanosight NTA
2.1 Analytical Software. Left graph represents the size distribution of particles in solution showing a mean size of 104 nm and also showing no peaks at larger sizes. Right graph represents the distribution by size and concentration of particles in solution. FIG. 8B ¨
Atomic Force Microscopy image of exosomes (left image). Right graph represents the distribution of particles in the area analyzed. FIG. 8C ¨ Transmission electron micrograph of MDA-MB-231 exosomes. Scale bar ¨ 100 nm. FIG. 8D ¨ Transmission electron micrograph of immunogold labeled MDA-MB-231 exosomes using anti-CD9 antibody. Gold particles are depicted as black dots. Scale bar ¨ 100 nm. FIG. 8E ¨ Immunoblot analysis of exosomes markers CD9, CD63, and TSG101 in protein extracts of exosomes obtained from different cell lines. FIG. 8F ¨ Imaging Flow Cytometry analysis of exosomes from MDA-MB-cells coupled to 0.4 gm beads, using antibodies for markers CD9, CD81, CD82, and CD63.
FIG. 8G ¨ Representative images of LB culture plates incubated with E. coli and either MDA-MB-231 (top) or MCF10A (bottom) exosomes, showing colony formation on the E.
coli inoculated sides (left) and not on the exosomes inoculated sides (right).
100351 FIGS. 9A-B. EGFR phosphorylation and downstream biological activity in exosomes from MDA-MB-231 cells. FIG. 9A ¨ Immunoblot of protein extracts obtained from MDA-MB-231 cells and probed for p-EGFR and GRB2. 13-actin is used as a loading control. FIG. 9B ¨ Immunoblot of immunocomplexes obtained with an anti-EGFR
antibody pull down of protein lysates from MDA-MB-231 exosomes with or without incubation with 500 ng/ml at 37 C for 15 minutes. Immuncomplexes were probed for GRB2. Non-specific isotype control IgG was used as a negative control for the GRB2 pulldown.
Equal volumes of the stimulated and unstimulated extracts were probed for -actin as input control.
100361 FIG. 10. Proteomics analysis of exosomes derived from various cells.
Heatmap representing the binary identification of all individual proteins included in the Protein Translation pathway in the Reactome (Croft et al., 2014) database, in mass spectrometry data obtained from mouse liver cells (Valadi et al., 2007), mouse fibroblasts (Luga et al., 2012), human colorectal cancer cells (Choi et al., 2012), human plasma (Kalra et al., 2013), human thymic tissue (Skogberg et al., 2013), and human urine (Gonzales et al., 2009). Black represents the presence and white represents the absence of each protein in each dataset. The summary column represents how ubiquitous each protein is in all analyzed datasets, with warmer colors representing a more widespread distribution among different types of exosomes.
100371 FIGS. 11A-B. Proteomics analysis of exosomes from various origins. FIG.
11A ¨ Heatmap representing the number of proteins identified in mass spectrometry data obtained from mouse liver cells (Valadi et al., 2007), mouse fibroblasts (Luga et al., 2012), human colorectal cancer cells (Choi et al., 2012), human plasma (Kalra et al., 2013), human thymic tissue (Skogberg et al., 2013), and human urine (Gonzales et al., 2009) that associate with different pathways related to protein translation in the Reactome (Croft et al., 2014) database. Warmer colors represent higher numbers of proteins identified per pathway. FIG.
11B ¨ Heatmap representing the protein score of proteins associated with protein translation identified in mass spectrometry obtained from exosomes isolated from HDF, NIH
3T3, MDA-MB231, MCF10A, and E10 cells. Warmer colors represent a higher protein score.
100381 FIGS. 12A-C. Exosomes contain nucleic acids and proteins associated with the protein translation machinery. FIG. 12A ¨ RNA extracted from exosomes of NTH-3T3, E10, 67NR, 4T1, HDF, MCF10A, MCF7, and MDA-MB-231 cell lines were used to quantify 18S and 28S rRNAs by qPCR. Expression levels of the rRNAs were normalized to snRNA expression. The bars in each group represent, from left to right, N1H
313, E10, 67NR, 4T1, HDF, MCF10A, MCF7, and IvIDA-MB-231. FIG. 12B ¨ RNA extracted from 4T1 exosomes and cells were used to identify the presence of tRNAMet, tRNAGly, tRNALeu, tRNASer, and tRNAVal by digital qPCR. The bars in each group represent, from left to right, Leu, Met, Val, Ser, and Gly. FIG. 12C ¨ Immunoprecipitation of eIF4A1 showing presence of elF3A MCF10A and MDA-MB-231-derived exosomes. MB231 and MCF10A cell lysates were used as positive controls. The exosomes marker CD82 was used as a loading control.
100391 FIGS. 13A-E. DNA transcription and mRNA translation in exosomes derived from MCF10A and MDA-MB-231 cells. FIG. 13A ¨ Immunoblot of GFP protein expression in exosomes isolated from MCF10A cells, electroporated with a pCMV-GFP plasmid and incubated at 37 C for different periods of time. Exosomes only and mock electroporated exosomes were used as negative controls. CD63 was used as a loading control and to confirm the presence of exosomes. FIG. 13B ¨ Plot depicting the amount of green exosomes detected by NanoSight in MCF10A-derived exosomes electroporated with a GFP plasmid.
MCFIOA-derived exosomes, MCF 10A-derived mock electroporated exosomes as well as exosomes electroporated with a-amanitin and cycloheximide were used as negative controls. FIG. 13C
¨ Flow cytometry analysis of beads attached to exosomes after electroporation with a GFP
plasmid using increasing voltages, showing the percentages of beads with green fluorescent signal. FIG. 13D ¨ Immunoblot of ovalbumin protein levels in MDA-MB-231 exosomes electroporated with a pCMV-Ova plasmid and incubated at 37 C for 48 h. 0-actin was used as a loading control. FIG. 13E ¨ p21 mRNA expression in MDA-MB-231 cells treated with mock electroporated MDA-MB-231-derived exosomes or exosomes electroporated with the p53-GFP plasmid and either added to the cells immediately (0 h) or allowed to incubate in cell conditions at 37 C for 48 h before treatment (48 h). Exosomes were added to the cells for either 30 minutes or 48 hours before RNA extraction. Expression levels were normalized to the housekeeping gene GAPDH.
DETAILED DESCRIPTION
[0040] Extracellular vesicles (EVs), including exosomes, are nano-sized intercellular communication vehicles having a lipid bilayer that encloses cytosol-like material. Exosomes participate in several physiological processes and contain DNA, RNA, and proteins. It is generally assumed that all contents in exosomes are derived from cells and they remain as such in the exosomes until they enter other cells and deposit their contents.
Exosomes are released by all cells in large numbers and are considered as garbage bags that carry cellular constituents into the extracellular space as a payload without any biological significance for exosomes themselves per se.
[0041] Provided here are exosomes that behave like minicells and exhibit the ability to biologically respond to stimuli and multiply and migrate just as cells do but without a defined nucleus. These exosomes exhibit chemotaxis towards serum factors and upon stimulation with growth factors such as EGF, will phosphorylate the EGFR
receptor on their surface and initiate a signaling cascade that leads to transcription and translation of new proteins. When these exosomes are injected into tumor bearing mice, they preferentially accumulate in the tumors. Collectively, the capacity for protein translation and growth factor response by these exosomes provides them a functional role in tissue homeostasis and modulation of disease.
I. Aspects of the Present invention 100421 Extracellular vesicles, and in particular exosomes, have gained much attention over the last few years with identification of several constituents such as DNA, RNA, and proteins. Moreover, exosomes have been implicated in influencing many diverse biological processes via transfer of its content into recipient cells in different tissues, and facilitating a unique form of cell-cell communication (Bastos et al., 2017). Alternatively, the potential of exosomes as delivery vehicles for therapeutics, particularly in the context of cancer or neurological pathologies was also reported (El-Andaloussi et al., 2012;
Kamerkar et al., 2017). However, the exact patterns of systemic distribution and organ tropism of exosomes are still not fully understood.
100431 However, the nuclear and cytoplasmic components of the exosomes are not just used for passive transfer to recipient cells but can respond to external stimuli to phosphorylate growth factor receptors, such as EGFR, and generate new proteins via active transcription and translation. External stimulation of exosomes can initiate de novo biological activities such as retrograde migration. It is conceivable that exosomes may function like mini cells, albeit primitive with respect to their fine-tuned operations in response to external stimuli. In fact, recently it has been suggested that exosomes could potentially constitute extant representations of protocellular ribosomes, for which they would need to contain rRNAs, which is confirm in this study (Sinkovics, 2015). Exosomes are biologically responsive and migrate towards growth factor gradients in an active manner.
Actin remodeling might be involved. The patterns of actin polymerization could therefore constitute an interesting target in the modulation of exosomes biodistribution.
100441 Vesicles such as prostasomes obtained from different species have been shown to contain different components of the glycolytic pathway, which allow them to produce ATP
in cell-free conditions (Ronquist et al., 2013a; Ronquist et al., 2013b).
While direct transcription in exosomes has not been previously reported, a study showed that exosomes from bovine milk infected with bovine leukemia virus have been shown to exhibit reverse transaiptase activity (Yamada et al., 2013). It was also recently demonstrated that independent production of mature miRNAs in exosomes isolated from cancer cells is possible (Melo et al., 2014). Here, exosomes were demonstrated to possess an intrinsic capacity for de novo synthesis of functional proteins via DNA transcription coupled with mRNA
translation.
Platelets can translate proteins from mRNA molecules remaining within them after megakaryocyte differentiation (Weyrich et al., 2004). Nevertheless, DNA
transcription resulting in new mRNA molecules is not reported in platelets. Additionally, foci of mRNA
translation activity, associated with polyribosomes and mRNA binding proteins, is observed in dendritic spines even when severed from the major body of the cell (Aakalu et al., 2001;
Smith et al., 2001; Steward and Levy, 1982). It is therefore clear that some cellular structures have preserved the capacity for protein biosynthesis in the absence of a nucleus, perhaps in order to support their specific biological functions in a rapid manner. Apart from protein translation, exosomes are capable of DNA transcription via RNA polymerase II.
It is well established that basic transcription of naked DNA in nucleosome-free regions is possible with minimal components of transcriptional machinery, namely only RNA Pol II and a cocktail of six general transcription factors (GTFs) (Lorch et al., 2014; Nagai et al., 2017). It has also been shown that exosomes contain a plethora of transcription factors that can be delivered to cells in order to alter their patterns of protein expression (Ung et al., 2014). It is therefore conceivable that exosomes contain naked DNA residues unbound by chromatin, which could undergo transcription in the presence of these minimal transcriptional components.
100451 This study also suggests that the required components for transcription/translation are likely exhausted within 24 h, resulting in a limited rate of transcription and translation. Since it has been suggested that different subpopulations of exosomes may possess distinct molecular characteristics (Willms et al., 2016), it is possible that only a small subset of exosomes possess the capacity for de novo protein synthesis. The newly synthetized proteins in exosomes are functionally active, suggestive of an appropriate protein conformation. It has been shown that exosomes contain not only the components of ribosomes, but also several molecular chaperones, such as Hsp60 and Hsp70. The ribosome itself has an important role in co-translational protein folding, for instance, it can promote the formation of secondary structures in newly formed proteins. The ribosome also acts as a platform for the association of chaperones that can assist with the appropriate folding of nascent proteins (Kramer et al., 2009). It is conceivable that these exosomes components could contribute to the stabilization of newly formed proteins. Physical confinement, as would be the case in the lumen of exosomes, can also have a stabilizing effect on the folding of proteins (Rao and Cruz, 2013). The possibility, however, cannot be ruled out that many proteins might exhibit inappropriate conformation or mis-folding. These could still have important biological implications, as demonstrated with the recent unraveling of unexpected features of the "dark proteome" (Perdigao et al., 2015), which suggested that proteins with unknown structure or intrinsically disordered regions may have important physiological functions.
100461 A meticulous and quantitative identification of the proteins naturally synthetized in exosomes is necessary to fully appreciate the biological significance of this process. It is clear, however, that this could have significant impact in re-evaluating the understanding of eukaryotic biology. Recent studies suggest that cells can selectively incorporate mRNAs into exosomes (Raposo and Stoorvogel, 2013). This raises the possibility that mRNAs selectively packaged into exosomes could be translated into proteins whose expression is repressed in their cell of origin, as shown in this study as a proof of concept.
The identification of newly synthetized proteins in exosomes up to one month after translation, suggests that exosomes-mediated production of proteins could lead to a significantly increased protein half-life, possibly due to lower levels of protein degradation enzymes.
100471 Taken together, these results collectively demonstrate exosomes possess previously unappreciated biological activity with a potentially profound impact on body homeostasis and tissue pathogenesis. One could speculate that growth factor gradients could play a role on the systemic tropism of exosomes in the body. A disruption of the naturally occurring pattern of growth factor production could have immediate consequences on both the redistribution and delivery patterns of exosomes. These patterns of response could have potential implications in determining cell-cell communication, particularly between distant body sites. The fact that they can change their patterns of protein expression in response to these extracellular cues would suggest that exosomes could act as the primary responders in tissue injury. In conclusion, these findings provide a novel insight into the basic biology of exosomes and inform on their biological functions in organism homeostasis and their potential impact in disease states.
I. Lipid-based Nanoparticles 100481 In some embodiments, a lipid-based nanoparticle is a liposomes, an exosomes, lipid preparations, or another lipid-based nanoparticle, such as a lipid-based vesicle (e.g., a DOTAP:cholesterol vesicle). Lipid-based nanoparticles may be positively charged, negatively charged or neutral. Lipid-based nanoparticles may comprise the necessary components to allow for transcription and translation, signal transduction, chemotaxis, or other cellular functions.
A. Liposomes 100491 A "liposome" is a generic term encompassing a variety of single and multilamellar lipid vehicles formed by the generation of enclosed lipid bilayers or aggregates.
Liposomes may be characterized as having vesicular structures with a bilayer membrane, generally comprising a phospholipid, and an inner medium that generally comprises an aqueous composition. Liposomes provided herein include unilamellar liposomes, multilamellar liposomes, and multivesicular liposomes. Liposomes provided herein may be positively charged, negatively charged, or neutrally charged. In certain embodiments, the liposomes are neutral in charge.
100501 A multilamellar liposome has multiple lipid layers separated by aqueous medium. Such liposomes form spontaneously when lipids comprising phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before the formation of closed structures and entrap water and dissolved solutes between the lipid bilayers. Lipophilic molecules or molecules with lipophilic regions may also dissolve in or associate with the lipid bilayer.
100511 In specific aspects, a polypeptide, a nucleic acid, or a small molecule drug may be, for example, encapsulated in the aqueous interior of a liposome, interspersed within the lipid bilayer of a liposome, attached to a liposome via a linking molecule that is associated with both the liposome and the polypeptide/nucleic acid, entrapped in a liposome, complexed with a liposome, or the like.
100521 A liposome used according to the present embodiments can be made by different methods, as would be known to one of ordinary skill in the art. For example, a phospholipid, such as for example the neutral phospholipid dioleoylphosphatidylcholine (DOPC), is dissolved in tert-butanol. The lipid(s) is then mixed with a polypeptide, nucleic acid, and/or other component(s). Tween 20 is added to the lipid mixture such that Tween 20 is about 5% of the composition's weight. Excess tert-butanol is added to this mixture such that the volume of tert-butanol is at least 95%. The mixture is vortexed, frozen in a dry ice/acetone bath and lyophilized overnight. The lyophilized preparation is stored at -20 C
and can be used up to three months. When required the lyophilized liposomes are reconstituted in 0.9% saline.
100531 Alternatively, a liposome can be prepared by mixing lipids in a solvent in a container, e.g., a glass, pear-shaped flask. The container should have a volume ten-times greater than the volume of the expected suspension of liposomes. Using a rotary evaporator, the solvent is removed at approximately 40 C under negative pressure. The solvent normally is removed within about 5 min to 2 h, depending on the desired volume of the liposomes.
The composition can be dried further in a desiccator under vacuum. The dried lipids generally are discarded after about 1 week because of a tendency to deteriorate with time.
100541 Dried lipids can be hydrated at approximately 25-50 niM phospholipid in sterile, pyrogen-free water by shaking until all the lipid film is resuspended. The aqueous liposomes can be then separated into aliquots, each placed in a vial, lyophilized and sealed under vacuum.
100551 The dried lipids or lyophilized liposomes prepared as described above may be dehydrated and reconstituted in a solution of a protein or peptide and diluted to an appropriate concentration with a suitable solvent, e.g., DPBS. The mixture is then vigorously shaken in a vortex mixer. Unencapsulated additional materials, such as agents including but not limited to hormones, drugs, nucleic acid constructs and the like, are removed by centrifugation at 29,000 x g and the liposomal pellets washed. The washed liposomes are resuspended at an appropriate total phospholipid concentration, e.g., about 50-200 tnM. The amount of additional material or active agent encapsulated can be determined in accordance with standard methods. After determination of the amount of additional material or active agent encapsulated in the liposome preparation, the liposomes may be diluted to appropriate concentrations and stored at 4 C until use. A pharmaceutical composition comprising the liposomes will usually include a sterile, pharmaceutically acceptable carrier or diluent, such as water or saline solution.
100561 Additional liposomes which may be useful with the present embodiments include cationic liposomes, for example, as described in W002/100435A1, U.S
Patent 5,962,016, U.S. Application 2004/0208921, W003/015757A1, W004029213A2, U.S.
Patent 5,030,453, and U.S. Patent 6,680,068, all of which are hereby incorporated by reference in their entirety without disclaimer.
100571 In preparing such liposomes, any protocol described herein, or as would be known to one of ordinary skill in the art may be used. Additional non-limiting examples of preparing liposomes are described in U.S. Patents 4,728,578, 4,728,575, 4,737,323, 4,533,254, 4,162,282, 4,310,505, and 4,921,706; International Applications PCT/US85/01161 and PCT/U589/05040, each incorporated herein by reference.
100581 In certain embodiments, the lipid based nanoparticle is a neutral liposorne (e.g., a DOPC liposome). "Neutral liposomes" or "non-charged liposomes", as used herein, are defined as liposomes having one or more lipid components that yield an essentially-neutral, net charge (substantially non-charged). By "essentially neutral" or "essentially non-charged", it is meant that few, if any, lipid components within a given population (e.g., a population of liposomes) include a charge that is not canceled by an opposite charge of another component (i.e., fewer than 10% of components include a non-canceled charge, more preferably fewer than 5%, and most preferably fewer than 1%). In certain embodiments, neutral liposomes may include mostly lipids and/or phospholipids that are themselves neutral under physiological conditions (i.e., at about pH 7).
100591 Liposomes and/or lipid-based nanoparticles of the present embodiments may comprise a phospholipid. In certain embodiments, a single kind of phospholipid may be used in the creation of liposomes (e.g., a neutral phospholipid, such as DOPC, may be used to generate neutral liposomes). In other embodiments, more than one kind of phospholipid may be used to create liposomes. Phospholipids may be from natural or synthetic sources.
Phospholipids include, for example, phosphatidylcholines, phosphatidylglycerols, and phosphatidylethanolamines; because phosphatidylethanolamines and phosphatidyl cholines are non-charged under physiological conditions (i.e., at about pH 7), these compounds may be particularly useful for generating neutral liposomes. In certain embodiments, the phospholipid DOPC is used to produce non-charged liposomes. In certain embodiments, a lipid that is not a phospholipid (e.g., a cholesterol) may be used 100601 Phospholipids include glycerophospholipids and certain sphingolipids.
Phospholipids include, but are not limited to, dioleoylphosphatidylycholine ("DOPC"), egg phosphatidylcholine ("EPC"), di lauryloylphosphati dyl choline ("DLPC"), dimyristoylphosphatidylcholine ("DMPC"), dipalmitoylphosphafidylcholine ("DPPC"), di stearoylphosphatidylcholi ne (" DSPC"), 1-my ri stoy1-2-palmitoyl phosphatidyl choline ("MPPC"), 1-palmitoy1-2-myristoyl phosphatidylcholine ("PMPC"), 1-palmitoy1-2-stearoyl ph osphati dylch ol i ne ("PSPC"), 1-stearoy1-2-pal mitoyl phosphatidylcholine ("SPPC"), dilauryloylphosphatidylglycerol ("DLPG"), dimyristoylphosphatidylglycerol ("DMPG"), di pal mi toylphosph atidylgl ycerol ("DPPG"), di stearoylphosphati dyl gl y cerol ("DSPG"), di stearoyl sphingomyelin ("DSSP"), di stearoyl phophati dylethanol ami ne ("DSPE"), dioleoylphosphatidylglycerol ("DOPG"), dimyristoyl phosphatidic acid ("DMPA"), dipalmitoyl phosphatidic acid ("DPPA"), dimyristoyl phosphatidylethanolamine ("DMPE"), dipalmitoyl phosphatidylethanolamine ("DPPE"), dimyristoyl phosphatidylserine ("DMPS"), dipalmitoyl phosphatidylserine ("DPPS"), brain phosphatidylserine ("BPS"), brain sphingomyelin ("BSP"), dipalmitoyl sphingomyelin ("DPSP"), dimyristyl ph osphati dylch ol i ne (" DMPC"), 1,2-di stearoyl-sn-glycero-3-phosphocholi ne ("DAPC"), 1,2-diarachidoyl-sn-glycero-3-phosphocholine ("DBPC"), 1,2-dieicosenoyl-sn-glycero-3-phosphochol me ("DEPC"), di ol eoyl ph osphati dylethanol am i ne ("DOPE"), pal mitoyloeoyl phosphatidylcholine ("POPC"), palmitoyloeoyl phosphatidylethanolamine ("POPE"), lysophosphatidylcholine, lysophosphatidylethanolamine, and dilinoleoylphosphatidylcholine.
B. Exosomes 100611 The terms "microvesicle" and "exosomes," as used herein, refer to a membranous particle having a diameter (or largest dimension where the particles is not spheroid) of between about 10 nm to about 5000 nm, more typically between 30 nm and 1000 nm, and most typically between about 50 nm and 750 nm, wherein at least part of the membrane of the exosomes is directly obtained from a cell. Most commonly, exosomes will have a size (average diameter) that is up to 5% of the size of the donor cell.
Therefore, especially contemplated exosomes include those that are shed from a cell.
100621 Exosomes may be detected in or isolated from any suitable sample type, such as, for example, body fluids. As used herein, the term "isolated" refers to separation out of its natural environment and is meant to include at least partial purification and may include substantial purification. As used herein, the term "sample" refers to any sample suitable for the methods provided by the present invention. The sample may be any sample that includes exosomes suitable for detection or isolation. Sources of samples include blood, bone marrow, pleural fluid, peritoneal fluid, cerebrospinal fluid, urine, saliva, amniotic fluid, malignant ascites, broncho-alveolar lavage fluid, synovial fluid, breast milk, sweat, tears, joint fluid, and bronchial washes. In one aspect, the sample is a blood sample, including, for example, whole blood or any fraction or component thereof. A blood sample suitable for use with the present invention may be extracted from any source known that includes blood cells or components thereof, such as venous, arterial, peripheral, tissue, cord, and the like. For example, a sample may be obtained and processed using well-known and routine clinical methods (e.g., procedures for drawing and processing whole blood). In one aspect, an exemplary sample may be peripheral blood drawn from a subject with cancer.
100631 Exosomes may also be isolated from tissue samples, such as surgical samples, biopsy samples, tissues, feces, and cultured cells. When isolating exosomes from tissue sources it may be necessary to homogenize the tissue in order to obtain a single cell suspension followed by lysis of the cells to release the exosomes. When isolating exosomes from tissue samples it is important to select homogenization and lysis procedures that do not result in disruption of the exosomes. Exosomes contemplated herein are preferably isolated from body fluid in a physiologically acceptable solution, for example, buffered saline, growth medium, various aqueous medium, etc 100641 Exosomes may be isolated from freshly collected samples or from samples that have been stored frozen or refrigerated. In some embodiments, exosomes may be isolated from cell culture medium. Although not necessary, higher purity exosomes may be obtained if fluid samples are clarified before precipitation with a volume-excluding polymer, to remove any debris from the sample. Methods of clarification include centrifugation, ultracentrifugation, filtration, or ultrafiltration. Most typically, exosomes can be isolated by numerous methods well-known in the art. One preferred method is differential centrifugation from body fluids or cell culture supernatants. Exemplary methods for isolation of exosomes are described in (Losche et al., 2004; Mesri and Alfieri, 1998; Morel et al., 2004).
Alternatively, exosomes may also be isolated via flow cytometry as described in (Combes et al., 1997).
100651 One accepted protocol for isolation of exosomes includes ultracentrifugation, often in combination with sucrose density gradients or sucrose cushions to float the relatively low-density exosomes. Isolation of exosomes by sequential differential centrifugations is complicated by the possibility of overlapping size distributions with other microvesicles or macromolecular complexes. Furthermore, centrifugation may provide insufficient means to separate vesicles based on their sizes. However, sequential centrifugations, when combined with sucrose gradient ultracentrifugation, can provide high enrichment of exosomes.
100661 Isolation of exosomes based on size, using alternatives to the ultracentrifugation routes, is another option. Successful purification of exosomes using ultrafiltration procedures that are less time consuming than ultracentrifugation, and do not require use of special equipment have been reported. Similarly, a commercial kit is available (EXOMIRTm, Bioo Scientific) which allows removal of cells, platelets, and cellular debris on one microfilter and capturing of vesicles bigger than 30 nm on a second microfilter using positive pressure to drive the fluid. However, for this process, the exosomes are not recovered, their RNA content is directly extracted from the material caught on the second microfilter, which can then be used for PCR analysis. HPLC-based protocols could potentially allow one to obtain highly pure exosomes, though these processes require dedicated equipment and are difficult to scale up. A significant problem is that both blood and cell culture media contain large numbers of nanoparticles (some non-vesicular) in the same size range as exosomes. For example, some miRNAs may be contained within extracellular protein complexes rather than exosomes; however, treatment with protease (e.g., proteinase K) can be performed to eliminate any possible contamination with "extraexosomal" protein.
100671 In another embodiment, cancer cell-derived exosomes may be captured by techniques commonly used to enrich a sample for exosomes, such as those involving immunospecific interactions (e.g., immunomagnetic capture). Immunomagnetic capture, also known as immunomagnetic cell separation, typically involves attaching antibodies directed to proteins found on a particular cell type to small paramagnetic beads. When the antibody-coated beads are mixed with a sample, such as blood, they attach to and surround the particular cell. The sample is then placed in a strong magnetic field, causing the beads to pellet to one side. After removing the blood, captured cells are retained with the beads. Many variations of this general method are well-known in the art and suitable for use to isolate exosomes. In one example, the exosomes may be attached to magnetic beads (e.g., aldehyde/sulphate beads) and then an antibody is added to the mixture to recognize an epitope on the surface of the exosomes that are attached to the beads.
Exemplary proteins that are known to be found on cancer cell-derived exosomes include ATP-binding cassette sub-family A member 6 (ABCA6), tetraspanin-4 (TSPAN4), SLIT and NTRK-like protein 4 (SLITRK4), putative protocadherin beta-18 (PCDHB18), myeloid cell surface antigen CD33 (CD33), and glypican-1 (GPC1). Cancer cell-derived exosomes may be isolated using, for example, antibodies or aptamers to one or more of these proteins.
100681 As used herein, analysis includes any method that allows direct or indirect visualization of exosomes and may be in vivo or ex vivo. For example, analysis may include, but not limited to, ex vivo microscopic or cytometric detection and visualization of exosomes bound to a solid substrate, flow cytometry, fluorescent imaging, and the like.
In an exemplary aspect, cancer cell-derived exosomes are detected using antibodies directed to one or more of ATP-binding cassette sub-family A member 6 (ABCA6), tetraspanin-4 (TSPAN4), SLIT and NTRK-like protein 4 (SLITRK4), putative protocadherin beta-18 (PCDHB18), myeloid cell surface antigen CD33 (CD33), glypican-1 (GPC1), Histone H2A type 2-A
(HIST1H2AA), Histone H2A type 1-A (HI ST1H1AA), Histone H3.3 (H3F3A), Histone H3.1 (HI5T1H3A), Zinc finger protein 37 homolog (ZFP37), Laminin subunit beta-1 (LAMB1), Tubulointerstitial nephritis antigen-like (TINAGL1), Peroxiredeoxin-4 (PRDX4), Collagen alpha-2(IV) chain (COL4A2), Putative protein C3P1 (C3P1), Hemicentin-1 (HMCN1), Putative rhophilin-2-like protein (RHPN2P1), Ankyrin repeat domain-containing protein 62 (ANKRD62), Tripartite motif-containing protein 42 (TRIM42), Junction plakoglobin (JUP), Tubulin beta-2B chain (TUBB2B), Endoribonuclease Dicer (DICER1), E3 ubiquitin-protein ligase TRIM71 (TRI1v171), Katanin p60 ATPase-containing subunit A-like 2 (KATNAL2), Protein S100-A6 (S100A6), 5'-nucleotidase domain-containing protein 3 (NT5DC3), Valine-tRNA ligase (VARS), Kazrin (KAZN), ELAV-like protein 4 (ELAVL4), RING finger protein 166 (RNF166), FERM and PDZ domain-containing protein 1 (FRMPD1), 78 kDa glucose-regulated protein (HSPA5), Trafficking protein particle complex subunit 6A
(TRAPPC6A), Squalene monooxygenase (SQLE), Tumor susceptibility gene 101 protein (TSG101), Vacuolar protein sorting 28 homolog (VPS28), Prostaglandin F2 receptor negative regulator (PTGFRN), Isobutyryl-CoA dehydrogenase, mitochondrial (ACAD8), 26S
protease regulatory subunit 6B (PS/vIC4), Elongation factor 1-gamma (EEF1G), Titin (TTN), Tyrosine-protein phosphatase type 13 (PTPN13), Triosephosphate isomerase (TPI1), or Carboxypeptidase E (CPE) and subsequently bound to a solid substrate and/or visualized using microscopic or cytometric detection.
100691 It should be noted that not all proteins expressing in a cell are found in exosomes secreted by that cell (see FIG. 11). For example, calnexin, GM130, and LAMP-2 are all proteins expressed in MCF-7 cells but not found in exosomes secreted by MCF-7 cells (Baietti et al., 2012). As another example, one study found that 190/190 pancreatic ductal adenocarcinoma patients had higher levels of GPC1+ exosomes than healthy controls (Melo et al., 2015, which is incorporated herein by reference in its entirety).
Notably, only 2.3% of healthy controls, on average, had GPC1+ exosomes.
1. Exemplary Protocol for Collecting Exosomes from Cell Culture 100701 On Day 1, seed enough cells (e.g., about five million cells) in T225 flasks in media containing 10% FBS so that the next day the cells will be about 70%
confluent. On Day 2, aspirate the media on the cells, wash the cells twice with PBS, and then add 25-30 mL
base media (i.e., no PenStrep or FBS) to the cells. Incubate the cells for 24-48 hours. A 48 hour incubation is preferred, but some cells lines are more sensitive to serum-free media and so the incubation time should be reduced to 24 hours. Note that FBS contains exosomes that will heavily skew NanoSight results.
100711 On Day 3/4, collect the media and centrifuge at room temperature for five minutes at 800 x g to pellet dead cells and large debris. Transfer the supernatant to new conical tubes and centrifuge the media again for 10 minutes at 2000 x g to remove other large debris and large vesicles. Pass the media through a 0.2 gm filter and then aliquot into ultracentrifuge tubes (e.g., 25 x 89 mm Beckman Ultra-Clear) using 35 mL per tube. If the volume of media per tube is less than 35 mL, fill the remainder of the tube with PBS to reach 35 mL. Ultracentrifuge the media for 2-4 hours at 28,000 rpm at 4 C using a SW
32 Ti rotor (k-factor 266.7, RCF max 133,907). Carefully aspirate the supernatant until there is roughly 1-inch of liquid remaining. Tilt the tube and allow remaining media to slowly enter aspirator pipette. If desired, the exosomes pellet can be resuspended in PBS and the ultracentrifugation at 28,000 rpm repeated for 1-2 hours to further purify the population of exosomes.
100721 Finally, resuspend the exosomes pellet in 210 ML PBS. If there are multiple ultracentrifuge tubes for each sample, use the same 210 ML PBS to serially resuspend each exosomes pellet. For each sample, take 10 pi and add to 990 pi, H20 to use for nanoparticle tracking analysis. Use the remaining 200 gL exosomes-containing suspension for downstream processes or immediately store at -80 C.
2. Exemplary Protocol for Extracting Exosomes from Serum Samples 100731 First, allow serum samples to thaw on ice. Then, dilute 250 ML of cell-free serum samples in 11 mL PBS; filter through a 0.2 gm pore filter.
Ultracentrifuge the diluted sample at 150,000 x g overnight at 4 C. The following day, carefully discard the supernatant and wash the exosomes pellet in 11 mL PBS. Perform a second round of ultracentrifugation at 150,000 x g at 4 C for 2 hours. Finally, carefully discard the supernatant and resuspend the exosomes pellet in 100 !IL PBS for analysis C. Exemplary Protocol for Electroporation of Exosomes and Liposomes 100741 Mix 1 x 108 exosomes (measured by NanoSight analysis) or 100 nm liposomes (e.g., purchased from Encapsula Nano Sciences) and 1 1.1g of siRNA
(Qiagen) or shRNA in 400 jiL of electroporation buffer (1.15 mM potassium phosphate, pH
7.2, 25 mM
potassium chloride, 21% Optiprep). Electroporate the exosomes or liposomes using a 4 mm cuvette (see, e.g., Alvarez-Erviti et a, 2011; El-Andaloussi et al., 2012).
After electroporation, treat the exosomes or liposomes with protease-free RNAse followed by addition of 10x concentrated RNase inhibitor. Finally, wash the exosomes or liposomes with PBS under ultracentrifugation methods, as described above.
H. Diagnosis, Prognosis, and Treatment of Diseases 190751 Certain aspects of the present invention provide for treating a patient with exosomes that express or comprise a therapeutic agent or a diagnostic agent. A
"therapeutic agent" as used herein is an atom, molecule, or compound that is useful in the treatment of cancer or other conditions. Examples of therapeutic agents include, but are not limited to, drugs, chemotherapeutic agents, therapeutic antibodies and antibody fragments, toxins, radioisotopes, enzymes, nucleases, hormones, immunomodulators, anti sense oligonucleotides, chelators, boron compounds, photoactive agents, and dyes. A
"diagnostic agent" as used herein is an atom, molecule, or compound that is useful in diagnosing, detecting or visualizing a disease. According to the embodiments described herein, diagnostic agents may include, but are not limited to, radioactive substances (e.g., radioisotopes, radionuclides, radiolabels or radiotracers), dyes, contrast agents, fluorescent compounds or molecules, bioluminescent compounds or molecules, enzymes and enhancing agents (e.g., paramagnetic ions).
100761 In some aspects, a therapeutic recombinant protein may be a protein having an activity that has been lost in a cell of the patient, a protein having a desired enzymatic activity, a protein having a desired inhibitory activity, etc. For example, the protein may be a transcription factor, an enzyme, a proteinaceous toxin, an antibody, a monoclonal antibody, etc. The monoclonal antibody may specifically or selectively bind to an intracellular antigen.
The monoclonal antibody may inhibit the function of the intracellular antigen and/or disrupt a protein-protein interaction. Other aspects of the present invention provide for diagnosing a disease based on the presence of cancer cell-derived exosomes in a patient sample.
100771 As exosomes are known to comprise the machinery necessary to complete mRNA transcription and protein translation (see PCT/US2014/068630, which is incorporated herein by reference in its entirety), mRNA or DNA nucleic acids encoding a therapeutic protein may be transfected into exosomes. Alternatively, the therapeutic protein itself may be electroporated into the exosomes or incorporated directly into a liposome.
Exemplary therapeutic proteins include, but are not limited to, a tumor suppressor protein, peptides, a wild type protein counterparts of a mutant protein, a DNA repair protein, a proteolytic enzyme, proteinaceous toxin, a protein that can inhibit the activity of an intracellular protein, a protein that can activate the activity of an intracellular protein, or any protein whose loss of function needs to be reconstituted. Specific examples of exemplary therapeutic proteins include 123F2, Abcb4, Abccl, Abcg2, Actb, Ada, Ahr, Akt, Aktl, Akt2, Akt3, Amhr2, Anxa7, Apc, Ar, Atm, Axin2, B2m, Bardl, Bc1211, Becnl, Bhlhal5, Binl, Blm, Braf, Brcal, Brca2, Brca3, Brat Brcata, Brinp3, Bripi, Bublb, Bwscrla, Cadm3, Cascl, Casp3, Casp7, Casp8, Cavl, Ccam, Ccndl, Ccr4, Ccsl, Cd28, Cdc25a, Cd95, Cdhl, Cdknla, Cdknlb, Cdkn2a, Cdkn2b, CdIcn2c, Cftr, Chekl, Chek2, Crcsl, Crcs10, Crcsl 1, Crcs2, Crcs3, Crcs4, Crcs5, Crcs6, Crcs7, Crcs8, Crcs9, Ctnnbl, Ctsl, Cyplal, Cyp2a6, Cyp2b2, Cyld, Dcc, Dkcl, Dicerl, Dmtfl, Dnmtl, Dpc4, E2f1, Eaf2, Eefl al, Egfr, Egfr4, Erbb2, Erbb4, Ercc2, Ercc6, Ercc8, Errfil, Esrl, Etv4, Faslg, Fbxol 0, Fcc, Fgfr3, Fntb, Foxml, Foxnl, Fus1, Fzd6, Fzd7, Fzrl, Gadd45a, Gast, Gnai2, Gpcl, Gpr124, Gpr87, Gprc5a, Gprc5d, Grb2, Gstml, Gstm5, Gstpl, Gstt1, H19, H2afx, Hck, Lims1, Hdac, Hexa, Hid, Hini, Hmmr, Hnpcc8, Hprt, Hras, Htatip2, 111b, 1110, 112, 116, 118rb Inha, Itgav, Jun, Jak3, Kit, Klf4, Kras, Kras2, Kras2b, Ligl, Lig4, Lkbl, Lmo7, Lncrl, Lncr2, Lncr3, Lncr4, Ltbp4, Lucal, Luca2, Lyz2, Lztsl, Madill, Mad211, Madr2/Jv18, Mapk14, Mcc, Mcm4, Menl, Men2, Met, Mgat5, Mif, Mlhl, Mlh3, Mmacl, Mmp8, Mnt, Mpo, Msh2, Msh3, Msh6, Msmb, Mthfr, Mtsl, Mutyh, Myhll, Nat2, Nbn, Ncoa3, Neill, Nfl, Nf2, Nfe211, Nhej 1, Nkx2-1, Nkx2-9, Nkx3-1, Npr12, Nqol, Nras, Nudtl, Oggl, Oxgrl, p16, p19, p21, p27, p27mt, p57, p 1 4ARF, Pa1b2, Park2, Pggtlb, Pgr, Pi3k, Pik3ca, Piwil2, P16, Pla2g2a, Plg, Plk3, Pmsl, Pms2, Poldl, Pole, Ppard, Pparg, Ppfia2, Ppmld, Prdm2, Prdxl, Prkarl a, Ptch, Pten, Prom 1, Psca, Ptchl, Ptfl a, Ptger2, Ptpn13, Ptprj, Rara, Rad51, Rassfl, Rb, Rbl, Rblccl, Rb12, Recg14, Ret, Rgs5, Rhoc, Rintl, Robol, Rp138, Si 00a4, SCGB 1 Al, Skp2, Smad2, Smad3, Smad4, Smarcbl, Smo, Snx25, Spata13, Srpx, Ssic I, Sstr2, Sstr5, Stat3, St5, St7, St14, Stkl 1, Suds3, Tapl, Tbx21, Terc, Tnf, Tp53, Tp73, Trpm5, Tsc2, Tscl, Vhl, Wrn, Wtl, Wt2, Xrccl, Xrcc5, Xrcc6, and Zacl.
100781 One specific type of protein that it may be desirable to introduce into the intracellular space of a diseased cell is an antibody (e.g., a monoclonal antibody). Such an antibody may disrupt the function of an intracellular protein and/or disrupt an intracellular protein-protein interaction. Exemplary targets of such monoclonal antibodies include, but are not limited to, proteins involved in the RNAi pathway, telomerase, transcription factors that control disease processes, kinases, phosphatases, proteins required for DNA
synthesis, protein required for protein translation. Specific examples of exemplary therapeutic antibody targets include proteins encoded by the following genes: Dicer, Ago!, Ago2, Trbp, Ras, raf, wnt, btk, BcI-2, Akt, Sis, src, Notch, Stathmin, mdm2, abl, hTERT, c-fos, c-jun, c-myc, erbB, HER2/Neu, HER3,VEGFR, PDGFR, c-kit, c-met, c-ret, flt3, API, AML1, axl, alk, fins, fps, gip, lck, Stat, Hox, MLM, PRAD-I, and trk. In addition to monoclonal antibodies, any antigen binding fragment there of, such as a scFv, a Fab fragment, a Fab', a F(ab')2, a Fv, a peptibody, a diabody, a triabody, or a minibody, is also contemplated. Any such antibodies or antibody fragment may be either glycosylated or aglycosylated.
100791 As exosomes are known to comprise DICER and active RNA processing RISC complex (see PCT PubIn. WO 2014/152622, which is incorporated herein by reference in its entirety), shRNA transfected into exosomes can mature into RISC-complex bound siRNA with the exosomes themselves. Alternatively, mature siRNA can itself be transfected into exosomes or liposomes. Thus, by way of example, the following are classes of possible target genes that may be used in the methods of the present invention to modulate or attenuate target gene expression: wild-type or mutant versions of developmental genes (e.g., adhesion molecules, cyclin kinase inhibitors, Wnt family members, Pax family members, Winged helix family members, Hox family members, cytokines/lymphokines and their receptors, growth or differentiation factors and their receptors, neurotransmitters and their receptors), tumor suppressor genes (e.g., APC, CYLD, HIN-1, KRAS2b, p16, p19, p21, p27, p27mt, p53, p57, p73, PTEN, Rb, Uteroglobin, Skp2, BRCA-1, BRCA-2, CHK2, CDKN2A, DCC, DPC4, MADR2/JV18, MEN1, MEN2, MTS1, NF1, NF2, VHL, WRN, WTI, CFTR, C-CAM, CTS-1, zacl, ras, MMAC1, FCC, MCC, FUS1, Gene 26 (CACNA2D2), PL6, Beta* (BLU), Luca-1 (HYAL1), Luca-2 (HYAL2), 123F2 (RASSF1), 101F6, Gene 21 (NPRL2), or a gene encoding a SEM A3 polypeptide), pro-apoptotic genes (e.g.. CD95, caspase-3, Bax, Bag-1, CRADD, TSSC3, bax, hid, Bak, MKP-7, PARP, bad, bc1-2, MST1, bbc3, Sax, BIK, and BID), cytokines (e.g., GM-CSF, G-CSF, IL-la, IL-113, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, EL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32 IFN-a, IFNI, MIP-1 a, MIP-113, TGF-13, TNF-a, TNF-13, PDGF, and mda7), oncogenes (e.g., ABLI, BLC1, BCL6, CBFA1, CBL, CSFIR, ERBA, ERBB, EBRB2, ETS1, ETS1, ETV6, FGR, FOX, FYN, HCR, HRAS, JUN, KRAS, LCK, LYN, MDM2, MLL, IvIYB, MYC, MYCL1, MYCN, NRAS, PIM1, PML, RET, SRC, TAL1, TCL3 and YES), and enzymes (e.g., ACP
desaturases and hycroxylases, ADP-glucose pyrophorylases, ATPases, alcohol dehycrogenases, amylases, amyloglucosidases, catalases, cellulases, cyclooxygenases, decarboxylases, dextrinases, esterases, DNA and RNA polymerases, galactosidases, glucanases, glucose oxidases, GTPases, helicases, hemicellulases, integrases, invertases, isomersases, kinases, lactases, lipases, lipoxygenases, lysozymes, nucleases, pectinesterases, peroxidases, phosphatases, phospholipases, phosphorylases, polygalacturonases, proteinases and peptideases, pullanases, recombinases, reverse transcriptases, topoisomerases, xylanases). In some cases, sh/siRNA may be designed to specifically target a mutant version of a gene expressed in a cancer cell while not affecting the expression of the corresponding wild-type version. In fact, any inhibitory nucleic acid that can be applied in the compositions and methods of the present invention if such inhibitory nucleic acid has been found by any source to be a validated downregulator of a protein of interest.
100801 In designing RNAi there are several factors that need to be considered, such as the nature of the siRNA, the durability of the silencing effect, and the choice of delivery system. To produce an RNAi effect, the siRNA that is introduced into the organism will typically contain exonic sequences. Furthermore, the RNAi process is homology dependent, so the sequences must be carefully selected so as to maximize gene specificity, while minimizing the possibility of cross-interference between homologous, but not gene-specific sequences. Preferably the siRNA exhibits greater than 80%, 85%, 90%, 95%, 98%, or even 100% identity between the sequence of the siRNA and the gene to be inhibited.
Sequences less than about 80% identical to the target gene are substantially less effective. Thus, the greater homology between the siRNA and the gene to be inhibited, the less likely expression of unrelated genes will be affected.
100811 Exosomes may also be engineered to comprise a gene editing system, such as a CRISPR/Cas system. In general, "CRISPR system" refers collectively to transcripts and other elements involved in the expression of or directing the activity of CRISPR-associated ("Cas") genes, including sequences encoding a Cas gene, a tracr (trans-activating CRISPR) sequence (e.g. tracrRNA or an active partial tracrRNA), a tracr-mate sequence (encompassing a "direct repeat" and a tracrRNA-processed partial direct repeat in the context of an endogenous CRISPR system), a guide sequence (also referred to as a "spacer" in the context of an endogenous CRISPR system), and/or other sequences and transcripts from a CRISPR
locus. In some aspects, a Cas nuclease and gRNA (including a fusion of crRNA
specific for the target sequence and fixed tracrRNA) are introduced into the cell. In general, target sites at the 5' end of the gRNA target the Cas nuclease to the target site, e.g., the gene, using complementary base pairing. The target site may be selected based on its location immediately 5' of a protospacer adjacent motif (PAM) sequence, such as typically NGG, or NAG. In this respect, the gRNA is targeted to the desired sequence by modifying the first 20, 19, 18, 17, 16, 15, 14, 14, 12, 11, or 10 nucleotides of the guide RNA to correspond to the target DNA sequence. In general, a CRISPR system is characterized by elements that promote the formation of a CRISPR complex at the site of a target sequence.
Typically, "target sequence" generally refers to a sequence to which a guide sequence is designed to have complementarity, where hybridization between the target sequence and a guide sequence promotes the formation of a CRISPR complex. Full complementarity is not necessarily required, provided there is sufficient complementarity to cause hybridization and promote formation of a CRISPR complex. The CRISPR system in exosomes engineered to comprise such a system may function to edit the genomic DNA inside a target cell, or the system may edit the DNA inside the exosomes itself.
100821 In addition to protein- and nucleic acid-based therapeutics, exosomes may be used to deliver small molecule drugs, either alone or in combination with any protein- or nucleic acid-based therapeutic. Exemplary small molecule drugs that are contemplated for use in the present embodiments include, but are not limited to, toxins, chemotherapeutic agents, agents that inhibit the activity of an intracellular protein, agents that activate the activity of intracellular proteins, agents for the prevention of restenosis, agents for treating renal disease, agents used for intermittent claudication, agents used in the treatment of hypotension and shock, angiotensin converting enzyme inhibitors, antianginal agents, anti-arrhythmics, anti-hypertensive agents, antiotensin ii receptor antagonists, antiplatelet drugs, b-blockers b I selective, beta blocking agents, botanical product for cardiovascular indication, calcium channel blockers, cardiovascular/diagnostics, central alpha-2 agonists, coronary vasodilators, diuretics and renal tubule inhibitors, neutral endopeptidase/angiotensin converting enzyme inhibitors, peripheral vasodilators, potassium channel openers, potassium .. salts, anticonvulsants, antiemetics, antinauseants, anti-parkinson agents, antispasticity agents, cerebral stimulants, agents that can be applied in the treatment of trauma, agents that can be applied in the treatment of Alzheimer disease or dementia, agents that can be applied in the treatment of migraine, agents that can be applied in the treatment of neurodegenerative diseases, agents that can be applied in the treatment of kaposi's sarcoma, agents that can be applied in the treatment of AIDS, cancer chemotherapeutic agents, agents that can be applied in the treatment of immune disorders, agents that can be applied in the treatment of psychiatric disorders, analgesics, epidural and intrathecal anesthetic agents, general, local, regional neuromuscular blocking agents sedatives, preanesthetic adrenal/acth, anabolic steroids, agents that can be applied in the treatment of diabetes, dopamine agonists, growth hormone and analogs, hyperglycemic agents, hypoglycemic agents, oral insulins, large volume parenterals (lvps), lipid-altering agents, metabolic studies and inborn errors of metabolism, nutrients/amino acids, nutritional lvps, obesity drugs (anorectics), somatostatin, thyroid agents, vasopressin, vitamins, corticosteroids, mucolytic agents, pulmonary anti-inflammatory agents, pulmonary surfactants, antacids, anticholinergics, antidiarrheals, antiemetics, cholelitholytic agents, inflammatory bowel disease agents, irritable bowel syndrome agents, liver agents, metal chelators, miscellaneous gastric secretory agents, pancreatitis agents, pancreatic enzymes, prostaglandins, prostaglandins, proton pump inhibitors, sclerosing agents, sucralfate, anti-progestins, contraceptives, oral contraceptives, not oral dopamine agonists, estrogens, gonadotropins, GNRH agonists, GHRH
antagonists, oxytocics, progestins, uterine-acting agents, anti-anemia drugs, anticoagulants, antifibrinolytics, antiplatelet agents, antithrombin drugs, coagulants, fibrinolytics, hematology, heparin inhibitors, metal chelators, prostaglandins, vitamin K, anti-androgens, aminoglycosides, antibacterial agents, sulfonamides, cephalosporins, clindamycins, dermatologics, detergents, erythromycins, anthelmintic agents, antifungal agents, antimalarial s, anti mycobacteri al agents, anti parasitic agents, an ti protozoal agents, antitrichomonads, antituberculosis agents, immunomodulators, immunostimulatory agents, macrolides, antiparasitic agents, corticosteroids, cyclooxygenase inhibitors, enzyme blockers, immunomodulators for rheumatic diseases, metalloproteinase inhibitors, nonsteroidal anti-inflammatory agents, analgesics, antipyretics, alpha adrenergic agonists/blockers, antibiotics, antivirals, beta adrenergic blockers, carbonic anhydrase inhibitors, corticosteroids, immune system regulators, mast cell inhibitors, nonsteroidal anti-inflammatory agents, and prostaglandi ns.
100831 Exosomes may also be used to deliver diagnostic agents. Exemplary diagnostic agents include, but are not limited to, magnetic resonance image enhancement agents, positron emission tomography products, radioactive diagnostic agents, radioactive therapeutic agents, radio-opaque contrast agents, radiopharmaceuticals, ultrasound imaging agents, and angiographic diagnostic agents.
100841 The term "subject" as used herein refers to any individual or patient to which the subject methods are performed. Generally the subject is human, although as will be appreciated by those in the art, the subject may be an animal. Thus other animals, including mammals, such as rodents (including mice, rats, hamsters, and guinea pigs), cats, dogs, rabbits, farm animals (including cows, horses, goats, sheep, pigs, etc.), and primates (including monkeys, chimpanzees, orangutans, and gorillas) are included within the definition of subject.
100851 "Treatment" and "treating" refer to administration or application of a therapeutic agent to a subject or performance of a procedure or modality on a subject for the purpose of obtaining a therapeutic benefit of a disease or health-related condition. For example, a treatment may include administration of chemotherapy, immunotherapy, or radiotherapy, performance of surgery, or any combination thereof.
100861 The term "therapeutic benefit" or "therapeutically effective" as used throughout this application refers to anything that promotes or enhances the well-being of the subject with respect to the medical treatment of this condition. This includes, but is not limited to, a reduction in the frequency or severity of the signs or symptoms of a disease. For example, treatment of cancer may involve, for example, a reduction in the invasiveness of a tumor, reduction in the growth rate of the cancer, or prevention of metastasis. Treatment of cancer may also refer to prolonging survival of a subject with cancer.
100871 The term "cancer," as used herein, may be used to describe a solid tumor, metastatic cancer, or non-metastatic cancer. In certain embodiments, the cancer may originate in the bladder, blood, bone, bone marrow, brain, breast, colon, esophagus, duodenum, small intestine, large intestine, colon, rectum, anus, gum, head, kidney, liver, lung, nasopharynx, neck, ovary, pancreas, prostate, skin, stomach, testis, tongue, or uterus.
100881 The cancer may specifically be of the following histological type, though it is not limited to these: neoplasm, malignant; carcinoma; carcinoma, undifferentiated; giant and spindle cell carcinoma; small cell carcinoma; papillary carcinoma; squamous cell carcinoma;
lymphoepithelial carcinoma; basal cell carcinoma; pilomatrix carcinoma;
transitional cell carcinoma; papillary transitional cell carcinoma; adenocarcinoma; gastrinoma, malignant;
cholangiocarcinoma; hepatocellular carcinoma; combined hepatocellular carcinoma and cholangiocarcinoma; trabecular adenocarcinoma; adenoid cystic carcinoma;
adenocarcinoma in adenomatous polyp; adenocarcinoma, familial polyposis coli; solid carcinoma; carcinoid tumor, malignant; branchiolo-alveol ar adenocarci noma; papillary adenocarci noma;
chromophobe carcinoma; acidophil carcinoma; oxyphilic adenocarcinoma; basophil carcinoma; clear cell adenocarcinoma; granular cell carcinoma; follicular adenocarcinoma;
papillary and follicular adenocarcinoma; nonencapsulating sclerosing carcinoma; adrenal cortical carcinoma; endometroid carcinoma; skin appendage carcinoma; apocrine adenocarcinoma; sebaceous adenocarcinoma; ceruminous adenocarcinoma;
mucoepidermoid carcinoma; cystadenocarcinoma; papillary cystadenocarcinoma; papillary serous cystadenocarcinoma; mucinous cystadenocarcinoma; mucinous adenocarcinoma;
signet ring cell carcinoma; infiltrating duct carcinoma; medullary carcinoma; lobular carcinoma;
inflammatory carcinoma; paget's disease, mammary; acinar cell carcinoma;
adenosquamous carcinoma; adenocarcinoma w/squamous metaplasia; thymoma, malignant; ovarian stromal tumor, malignant; thecoma, malignant; granulosa cell tumor, malignant;
androblastoma, malignant; sertoli cell carcinoma; leydig cell tumor, malignant; lipid cell tumor, malignant;
paraganglioma, malignant; extra-mammary paraganglioma, malignant;
pheochromocytoma;
glomangiosarcoma; malignant melanoma; amelanotic melanoma; superficial spreading melanoma; malignant melanoma in giant pigmented nevus; epithelioid cell melanoma; blue nevus, malignant; sarcoma; fibrosarcoma; fibrous histiocytoma, malignant;
myxosarcoma;
liposarcoma; leiomyosarcoma; rhabdomyosarcoma; embryonal rhabdomyosarcoma;
alveolar rhabdomyosarcoma; stromal sarcoma; mixed tumor, malignant; mullerian mixed tumor;
nephroblastoma; hepatoblastoma; carcinosarcoma; mesenchymoma, malignant;
brenner tumor, malignant; phyllodes tumor, malignant; synovial sarcoma; mesothelioma, malignant;
dysgerminoma; embryonal carcinoma; teratoma, malignant; struma ovarii, malignant;
choriocarcinoma; mesonephroma, malignant; hemangiosarcoma;
hemangioendothelioma, malignant; kaposi's sarcoma; hemangiopericytoma, malignant; lymphangiosarcoma;
osteosarcoma; juxtacortical osteosarcoma; chondrosarcoma; chondroblastoma, malignant;
mesenchymal chondrosarcoma; giant cell tumor of bone; ewing's sarcoma;
odontogenic tumor, malignant; ameloblastic odontosarcoma; ameloblastoma, malignant;
ameloblastic fibrosarcoma; pinealoma, malignant; chordoma; glioma, malignant; ependymoma;
astrocytoma; protoplasmic astrocytoma; fibrillary astrocytoma; astroblastoma;
glioblastoma;
oligodendroglioma; oligodendroblastoma; primitive neuroectodermal; cerebellar sarcoma;
ganglioneuroblastoma; neuroblastoma; retinoblastoma; olfactory neurogenic tumor;
meningioma, malignant; neurofibrosarcoma; neurilemmoma, malignant; granular cell tumor, malignant; malignant lymphoma; hodgkin's disease; hodgkin's; paragranuloma;
malignant lymphoma, small lymphocytic; malignant lymphoma, large cell, diffuse;
malignant lymphoma, follicular; mycosis fungoides; other specified non-hodgkin's lymphomas, malignant histiocytosis; multiple myeloma; mast cell sarcoma;
immunoproliferative small intestinal disease; leukemia; lymphoid leukemia; plasma cell leukemia;
erythroleukemia;
lymphosarcoma cell leukemia; myeloid leukemia; basophilic leukemia;
eosinophilic leukemia; monocytic leukemia; mast cell leukemia; megakaryoblastic leukemia;
myeloid sarcoma; and hairy cell leukemia.
100891 The terms "contacted" and "exposed," when applied to a cell, are used herein to describe the process by which a therapeutic agent are delivered to a target cell or are placed in direct juxtaposition with the target cell. To achieve cell killing, for example, one or more agents are delivered to a cell in an amount effective to kill the cell or prevent it from dividing.
An effective response of a patient or a patient's "responsiveness" to treatment refers to the clinical or therapeutic benefit imparted to a patient at risk for, or suffering from, a disease or disorder. Such benefit may include cellular or biological responses, a complete response, a partial response, a stable disease (without progression or relapse), or a response with a later relapse. For example, an effective response can be reduced tumor size or progression-free survival in a patient diagnosed with cancer.
Treatment outcomes can be predicted and monitored and/or patients benefiting from such treatments can be identified or selected via the methods described herein.
Regarding neoplastic condition treatment, depending on the stage of the neoplastic condition, neoplastic condition treatment involves one or a combination of the following therapies: surgery to remove the neoplastic tissue, radiation therapy, and chemotherapy. Other therapeutic regimens may be combined with the administration of the anticancer agents, e.g., therapeutic compositions and chemotherapeutic agents.
For example, the patient to be treated with such anti-cancer agents may also receive radiation therapy and/or may undergo surgery.
For the treatment of disease, the appropriate dosage of a therapeutic composition will depend on the type of disease to be treated, as defined above, the severity and course of the disease, the patient's clinical history and response to the agent, and the discretion of the attending physician. The agent is suitably administered to the patient at one time or over a series of treatments.
100941 Therapeutic and prophylactic methods and compositions can be provided in a combined amount effective to achieve the desired effect. A tissue, tumor, or cell can be contacted with one or more compositions or pharmacological formulation(s) comprising one or more of the agents, or by contacting the tissue, tumor, and/or cell with two or more distinct compositions or formulations. Also, it is contemplated that such a combination therapy can be used in conjunction with chemotherapy, radiotherapy, surgical therapy, or immunotherapy.
Administration in combination can include simultaneous administration of two or more agents in the same dosage form, simultaneous administration in separate dosage forms, and separate administration. That is, the subject therapeutic composition and another therapeutic agent can be formulated together in the same dosage form and administered simultaneously. Alternatively, subject therapeutic composition and another therapeutic agent can be simultaneously administered, wherein both the agents are present in separate formulations. In another alternative, the therapeutic agent can be administered just followed by the other therapeutic agent or vice versa. In the separate administration protocol, the subject therapeutic composition and another therapeutic agent may be administered a few minutes apart, or a few hours apart, or a few days apart.
100961 A first anti-cancer treatment (e.g., exosomes that express a recombinant protein or with a recombinant protein isolated from exosomes) may be administered before, during, after, or in various combinations relative to a second anti-cancer treatment. The administrations may be in intervals ranging from concurrently to minutes to days to weeks.
In embodiments where the first treatment is provided to a patient separately from the second treatment, one would generally ensure that a significant period of time did not expire between the time of each delivery, such that the two compounds would still be able to exert an advantageously combined effect on the patient. In such instances, it is contemplated that one may provide a patient with the first therapy and the second therapy within about 12 to 24 or 72 h of each other and, more particularly, within about 6-12 h of each other.
In some situations it may be desirable to extend the time period for treatment significantly where several days (2, 3, 4, 5, 6, or 7) to several weeks (1, 2, 3, 4, 5, 6, 7, or 8) lapse between respective administrations.
100971 In certain embodiments, a course of treatment will last 1-90 days or more (this such range includes intervening days). It is contemplated that one agent may be given on any day of day 1 to day 90 (this such range includes intervening days) or any combination thereof, and another agent is given on any day of day 1 to day 90 (this such range includes intervening days) or any combination thereof. Within a single day (24-hour period), the patient may be given one or multiple administrations of the agent(s).
Moreover, after a course of treatment, it is contemplated that there is a period of time at which no anti-cancer treatment is administered. This time period may last 1-7 days, and/or 1-5 weeks, and/or 1-12 months or more (this such range includes intervening days), depending on the condition of the patient, such as their prognosis, strength, health, etc. It is expected that the treatment cycles would be repeated as necessary.
[0098] Various combinations may be employed. For the example below a first anti-cancer therapy is "A" and a second anti-cancer therapy is "B":
A/B/A B/A/B B/B/A A/A/B AJB/B B/A/A A/B/B/B B/A/B/B
B/B/B/A B/B/A/B A/A/B/B A/B/A/B A/B/B/A B/B/A/A
B/A/B/A B/A/A/B A/A/A/B B/A/A/A A/B/A/A A/A/B/A
[0099] Administration of any compound or therapy of the present invention to a patient will follow general protocols for the administration of such compounds, taking into account the toxicity, if any, of the agents. Therefore, in some embodiments there is a step of .. monitoring toxicity that is attributable to combination therapy.
1. Chemotherapy [00100]
A wide variety of chemotherapeutic agents may be used in accordance with the present invention. The term "chemotherapy" refers to the use of drugs to treat cancer. A "chemotherapeutic agent" is used to connote a compound or composition that is administered in the treatment of cancer. These agents or drugs are categorized by their mode of activity within a cell, for example, whether and at what stage they affect the cell cycle.
Alternatively, an agent may be characterized based on its ability to directly cross-link DNA, to intercalate into DNA, or to induce chromosomal and mitotic aberrations by affecting nucleic acid synthesis.
[00101] Examples of chemotherapeutic agents include alkylating agents, such as thiotepa and cyclosphosphamide; alkyl sulfonates, such as busulfan, improsulfan, and piposulfan; aziridines, such as benzodopa, carboquone, meturedopa, and uredopa;
ethylenimines and methylamelamines, including altretamine, triethylenemelamine, tri etyl enephosphorami de, tri ethi y I en ethi ophosphorami de, and trimethylol om el ami ne;
acetogenins (especially bullatacin and bullatacinone); a camptothecin (including the synthetic analogue topotecan); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogues, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards, such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, and uracil mustard; nitrosureas, such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics, such as the enediyne antibiotics (e.g., calicheamicin, especially calicheamicin gammall and calicheamicin omegall ); dynemicin, including dynemicin A; bisphosphonates, such as clodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne anti obi oti c chromophores, acl aci n om y sins, acti nomycin, authrarnycin, azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins, such as mitomycin C, mycophenolic acid, nogalarnycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, and zorubicin; anti-metabolites, such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues, such as denopterin, pteropterin, and trimetrexate;
purine analogs, such as fludarabine, 6-mercaptopurine, thiamiprine, and thioguanine;
pyrimidine analogs, such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, and floxuridine; androgens, such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, and testolactone; anti-adrenals, such as mitotane and trilostane; folic acid replenisher, such as frolinic acid;
aceglatone;
aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine;
bestrabucil;
bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elformithine;
elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan;
lonidainine;
maytansinoids, such as maytansine and ansamitocins; mitoguazone; mitoxantrone;
mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone;
podophyllinic acid; 2-ethylhydrazide; procarbazine; PSKpolysaccharide complex; razoxane;
rhizoxin;
sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2"-trichlorotriethylamine, trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine);
urethan;
vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman;
gacytosine;
arabinoside ("Ara-C"); cyclophosphamide; taxoids, e.g., paclitaxel and docetaxel gemcitabine; 6-thioguanine; mercaptopurine; platinum coordination complexes, such as cisplatin, oxaliplatin, and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide;
mitoxantrone; vincristine; vinorelbine; novantrone; teniposide; edatrexate;
daunomycin;
aminopterin; xeloda; ibandronate; irinotecan (e.g., CPT-11); topoisomerase inhibitor RFS
2000; difluorometlhylornithine (DNIF0); retinoids, such as retinoic acid;
capecitabine;
carboplatin, procarbazine,plicomycin, gemcitabi en, navelbine, farnesyl -protein tansferase inhibitors, transplatinum, and pharmaceutically acceptable salts, acids, or derivatives of any of the above.
2. Radiotherapy 1001021 Other factors that cause DNA damage and have been used extensively include what are commonly known as y-rays, X-rays, and/or the directed delivery of radioisotopes to tumor cells. Other forms of DNA damaging factors are also contemplated, such as microwaves, proton beam irradiation (U.S. Patents 5,760,395 and 4,870,287), and UV-irradiation. It is most likely that all of these factors affect a broad range of damage on DNA, on the precursors of DNA, on the replication and repair of DNA, and on the assembly and maintenance of chromosomes. Dosage ranges for X-rays range from daily doses of 50 to 200 roentgens for prolonged periods of time (3 to 4 wk), to single doses of 2000 to 6000 roentgens. Dosage ranges for radioisotopes vary widely, and depend on the half-life of the isotope, the strength and type of radiation emitted, and the uptake by the neoplastic cells.
3. Immunotherapy 1001031 The skilled artisan will understand that additional immunotherapies may be used in combination or in conjunction with methods of the invention. In the context of cancer treatment, immunotherapeutics, generally, rely on the use of immune effector cells and molecules to target and destroy cancer cells. Rituximab (Rituxane) is such an example.
The immune effector may be, for example, an antibody specific for some marker on the surface of a tumor cell. The antibody alone may serve as an effector of therapy or it may recruit other cells to actually affect cell killing. The antibody also may be conjugated to a drug or toxin (chemotherapeutic, radionuclide, ricin A chain, cholera toxin, pertussis toxin, etc.) and serve merely as a targeting agent. Alternatively, the effector may be a lymphocyte carrying a surface molecule that interacts, either directly or indirectly, with a tumor cell target. Various effector cells include cytotoxic T cells and NK cells.
In one aspect of immunotherapy, the tumor cell must bear some marker that is amenable to targeting, i.e., is not present on the majority of other cells. Many tumor markers exist and any of these may be suitable for targeting in the context of the present invention. Common tumor markers include CD20, carcinoembryonic antigen, tyrosinase (p97), gp68, TAG-72, HMFG, Sialyl Lewis Antigen, MucA, MucB, PLAP, laminin receptor, erb B, and p155. An alternative aspect of immunotherapy is to combine anticancer effects with immune stimulatory effects. Immune stimulating molecules also exist including:
cytokines, such as IL-2, IL-4, 1L-12, GM-CSF, gamma-IFN, chemokines, such as M1P-1, MCP-1, IL-8, and growth factors, such as FLT3 ligand.
1001051 Examples of immunotherapies currently under investigation or in use are immune adjuvants, e.g., Mycobacterium bovis, Plasmodium .fakiparum, dinitrochlorobenzene, and aromatic compounds (U.S. Patents 5,801,005 and 5,739,169; Hui and Hashimoto, 1998; Christodoulides et al., 1998); cytokine therapy, e.g., interferons a, 13, and 7, IL-1, GM-CSF, and TNF (Bukowski et al., 1998; Davidson et al., 1998;
Hellstrand et al., 1998); gene therapy, e.g., TNF, IL-1, IL-2, and p53 (Qin et al., 1998;
Austin-Ward and Villaseca, 1998; U.S. Patents 5,830,880 and 5,846,945); and monoclonal antibodies, e.g., anti-CD20, anti-ganglioside GM2, and anti-p185 (Hollander, 2012; Hanibuchi et al., 1998;
U.S. Patent 5,824,311). It is contemplated that one or more anti-cancer therapies may be employed with the antibody therapies described herein.
In some embodiments, the immunotherapy may be an immune checkpoint inhibitor. Immune checkpoints either turn up a signal (e.g., co-stimulatory molecules) or turn down a signal. Inhibitory immune checkpoints that may be targeted by immune checkpoint blockade include adenosine A2A receptor (AZAR), B7-H3 (also known as CD276), B and T lymphocyte attenuator (BTLA), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4, also known as CD152), indoleamine 2,3-dioxygenase (ID0), killer-cell immunoglobulin (KIR), lymphocyte activation gene-3 (LAG3), programmed death 1 (PD-1), T-cell immunoglobulin domain and mucin domain 3 (TIM-3) and V-domain 1g suppressor of T cell activation (VISTA). In particular, the immune checkpoint inhibitors target the PD-1 axis and/or CTLA-4.
The immune checkpoint inhibitors may be drugs such as small molecules, recombinant forms of ligand or receptors, or, in particular, are antibodies, such as human antibodies (e.g., International Patent Publication W02015016718;
Pardo11, Nat Rev Cancer, 12(4): 252-64, 2012; both incorporated herein by reference). Known inhibitors of the immune checkpoint proteins or analogs thereof may be used, in particular chimerized, humanized or human forms of antibodies may be used. As the skilled person will know, alternative and/or equivalent names may be in use for certain antibodies mentioned in the present disclosure. Such alternative and/or equivalent names are interchangeable in the context of the present disclosure. For example, it is known that lambrolizumab is also known under the alternative and equivalent names MK-3475 and pembrolizumab.
In some embodiments, the PD-1 binding antagonist is a molecule that inhibits the binding of PD-1 to its ligand binding partners. In a specific aspect, the PD-1 ligand binding partners are PDL1 and/or PDL2. In another embodiment, a PDL1 binding antagonist is a molecule that inhibits the binding of PDL1 to its binding partners. In a specific aspect, PDL1 binding partners are PD-1 and/or B7-1. In another embodiment, the binding antagonist is a molecule that inhibits the binding of PDL2 to its binding partners. In a specific aspect, a PDL2 binding partner is PD-1. The antagonist may be an antibody, an antigen binding fragment thereof, an immunoadhesin, a fusion protein, or oligopeptide.
Exemplary antibodies are described in U.S. Patent Nos. 8,735,553, 8,354,509, and 8,008,449, all incorporated herein by reference. Other PD-1 axis antagonists for use in the methods provided herein are known in the art such as described in U.S. Patent Publication Nos.
20140294898, 2014022021, and 20110008369, all incorporated herein by reference.
[00109]
In some embodiments, the PD-1 binding antagonist is an anti-PD-1 antibody (e.g., a human antibody, a humanized antibody, or a chimeric antibody). In some embodiments, the anti-PD-1 antibody is selected from the group consisting of nivolumab, pembrolizumab, and CT-011. In some embodiments, the PD-1 binding antagonist is an immunoadhesin (e.g., an immunoadhesin comprising an extracellular or PD-1 binding portion of PDL1 or PDL2 fused to a constant region (e.g., an Fc region of an immunoglobulin sequence). In some embodiments, the PD-1 binding antagonist is AMP- 224.
Nivolumab, also known as MDX-1106-04, MDX-1106, ONO-4538, BMS-936558, and OPDIVO , is an anti-PD-1 antibody described in W02006/121168. Pembrolizumab, also known as MK-3475, Merck 3475, lambrolizumab, KEYTRUDA , and SCH-900475, is an anti-PD-1 antibody described in W02009/114335. CT-011, also known as hBAT or hBAT-1, is an anti-antibody described in W02009/101611. AMP-224, also known as B7-DCIg, is a PDL2-Fc fusion soluble receptor described in W02010/027827 and W02011/066342.
[00110]
Another immune checkpoint that can be targeted in the methods provided herein is the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also known as CD152. The complete cDNA sequence of human CTLA-4 has the Genbank accession number L15006. CTLA-4 is found on the surface of T cells and acts as an "off' switch when bound to CD80 or CD86 on the surface of antigen-presenting cells. CTLA4 is a member of the immunoglobulin superfamily that is expressed on the surface of Helper T
cells and transmits an inhibitory signal to T cells. CTLA4 is similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and respectively, on antigen-presenting cells. CTLA4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Intracellular CTLA4 is also found in regulatory T cells and may be important to their function. T cell activation through the T cell receptor and CD28 leads to increased expression of CTLA-4, an inhibitory receptor for B7 molecules.
[00111]
In some embodiments, the immune checkpoint inhibitor is an anti-CTLA-4 antibody (e.g., a human antibody, a humanized antibody, or a chimeric antibody), an antigen binding fragment thereof, an immunoadhesin, a fusion protein, or oligopeptide.
Anti-human-CTLA-4 antibodies (or VI-1 and/or VL domains derived therefrom) suitable for use in the present methods can be generated using methods well known in the art. Alternatively, art recognized anti-CTLA-4 antibodies can be used. For example, the anti-CTLA-4 antibodies disclosed in: US Patent No. 8,119,129, WO
01/14424, WO 98/42752; WO 00/37504 (CP675,206, also known as tremelimumab; formerly ticilimumab), U.S. Patent No. 6,207,156; Hurwitz et al. (1998) Proc Nat! Acad Sci USA
95(17): 10067-10071; Camacho et al. (2004) J Clin Oncology 22(145): Abstract No. 2505 (antibody CP-675206); and Mokyr etal. (1998) Cancer Res 58:5301-5304 can be used in the methods disclosed herein. The teachings of each of the aforementioned publications are hereby incorporated by reference. Antibodies that compete with any of these art-recognized antibodies for binding to CTLA-4 also can be used. For example, a humanized antibody is described in International Patent Application No. W02001014424, W02000037504, and U.S. Patent No. 8,017,114; all incorporated herein by reference.
An exemplary anti-CTLA-4 antibody is ipilimumab (also known as 10D1, MDX- 010, MDX- 101, and Yervoye) or antigen binding fragments and variants thereof (see, e.g., WO 01/14424). In other embodiments, the antibody comprises the heavy and light chain CDRs or VRs of ipilimumab. Accordingly, in one embodiment, the antibody comprises the CDR1, CDR2, and CDR3 domains of the VH region of ipilimumab, and the CDR1, CDR2 and CDR3 domains of the VL region of ipilimumab. In another embodiment, the antibody competes for binding with and/or binds to the same epitope on CTLA-4 as the above- mentioned antibodies. In another embodiment, the antibody has at least about 90%
variable region amino acid sequence identity with the above-mentioned antibodies (e.g., at least about 90%, 95%, or 99% variable region identity with ipilimumab).
Other molecules for modulating CTLA-4 include CTLA-4 ligands and receptors such as described in U.S. Patent Nos. 5844905, 5885796 and International Patent Application Nos. W01995001994 and W01998042752; all incorporated herein by reference, and immunoadhesins such as described in U.S. Patent No. 8329867, incorporated herein by reference.
In some embodiment, the immune therapy could be adoptive immunotherapy, which involves the transfer of autologous antigen-specific T
cells generated ex vivo. The T cells used for adoptive immunotherapy can be generated either by expansion of antigen-specific T cells or redirection of T cells through genetic engineering (Park, Rosenberg et al. 2011). Isolation and transfer of tumor specific T cells has been shown to be successful in treating melanoma. Novel specificities in T cells have been successfully generated through the genetic transfer of transgenic T cell receptors or chimeric antigen receptors (CARs) (Jena, Dofti et al. 2010). CARs are synthetic receptors consisting of a targeting moiety that is associated with one or more signaling domains in a single fusion molecule. In general, the binding moiety of a CAR consists of an antigen-binding domain of a single-chain antibody (scFv), comprising the light and variable fragments of a monoclonal antibody joined by a flexible linker. Binding moieties based on receptor or ligand domains have also been used successfully. The signaling domains for first generation CARs are derived from the cytoplasmic region of the CD3zeta or the Fc receptor gamma chains. CARs have successfully allowed T cells to be redirected against antigens expressed at the surface of tumor cells from various malignancies including lymphomas and solid tumors (Jena, Dotti et al. 2010).
[00116]
In one embodiment, the present application provides for a combination therapy for the treatment of cancer wherein the combination therapy comprises adoptive 1-cell therapy and a checkpoint inhibitor. In one aspect, the adoptive 1-cell therapy comprises autologous and/or allogenic T cells. In another aspect, the autologous and/or allogenic T cells are targeted against tumor antigens.
4. Surgery [00117]
Approximately 60% of persons with cancer will undergo surgery of some type, which includes preventative, diagnostic or staging, curative, and palliative surgery. Curative surgery includes resection in which all or part of cancerous tissue is physically removed, excised, and/or destroyed and may be used in conjunction with other therapies, such as the treatment of the present invention, chemotherapy, radiotherapy, hormonal therapy, gene therapy, immunotherapy, and/or alternative therapies.Tumor resection refers to physical removal of at least part of a tumor. In addition to tumor resection, treatment by surgery includes laser surgery, cryosurgery, electrosurgery, and microscopically-controlled surgery (Mohs' surgery).
[00118]
Upon excision of part or all of cancerous cells, tissue, or tumor, a cavity may be formed in the body. Treatment may be accomplished by perfiision, direct injection, or local application of the area with an additional anti-cancer therapy. Such treatment may be repeated, for example, every 1, 2, 3, 4, 5, 6, or 7 days, or every 1, 2, 3, 4, and 5 weeks or every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months. These treatments may be of varying dosages as well.
5. Other Agents It is contemplated that other agents may be used in combination with certain aspects of the present invention to improve the therapeutic efficacy of treatment.
These additional agents include agents that affect the upregulation of cell surface receptors and GAP junctions, cytostatic and differentiation agents, inhibitors of cell adhesion, agents that increase the sensitivity of the hyperproliferative cells to apoptotic inducers, or other biological agents. Increases in intercellular signaling by elevating the number of GAP
junctions would increase the anti-hyperproliferative effects on the neighboring hyperproliferative cell population. In other embodiments, cytostatic or differentiation agents can be used in combination with certain aspects of the present invention to improve the anti-hyperproliferative efficacy of the treatments. Inhibitors of cell adhesion are contemplated to improve the efficacy of the present invention. Examples of cell adhesion inhibitors are focal adhesion kinase (FAKs) inhibitors and Lovastatin. It is further contemplated that other agents that increase the sensitivity of a hyperproliferative cell to apoptosis, such as the antibody c225, could be used in combination with certain aspects of the present invention to improve the treatment efficacy.
III. Pharmaceutical Compositions 1001201 It is contemplated that exosomes that express or comprise a therapeutic protein, inhibitory RNA, and/or small molecule drug can be administered systemically or locally to inhibit tumor cell growth and, most preferably, to kill cancer cells in cancer patients with locally advanced or metastatic cancers. They can be administered intravenously, intrathecally, and/or intraperitoneally. They can be administered alone or in combination with anti-proliferative drugs. In one embodiment, they are administered to reduce the cancer load in the patient prior to surgery or other procedures. Alternatively, they can be administered after surgery to ensure that any remaining cancer (e.g., cancer that the surgery failed to eliminate) does not survive.
It is not intended that the present invention be limited by the particular nature of the therapeutic preparation. For example, such compositions can be provided in formulations together with physiologically tolerable liquid, gel, solid carriers, diluents, or excipients. These therapeutic preparations can be administered to mammals for veterinary use, such as with domestic animals, and clinical use in humans in a manner similar to other therapeutic agents. In general, the dosage required for therapeutic efficacy will vary according to the type of use and mode of administration, as well as the particular requirements of individual subjects.
Where clinical applications are contemplated, it may be necessary to prepare pharmaceutical compositions comprising recombinant proteins and/or exosomes in a form appropriate for the intended application. Generally, pharmaceutical compositions may comprise an effective amount of one or more recombinant proteins and/or exosomes or additional agents dissolved or dispersed in a pharmaceutically acceptable carrier. The phrases "pharmaceutical or pharmacologically acceptable" refers to molecular entities and compositions that do not produce an adverse, allergic, or other untoward reaction when administered to an animal, such as, for example, a human, as appropriate. The preparation of a pharmaceutical composition comprising a recombinant protein and/or exosomes as disclosed herein, or additional active ingredient will be known to those of skill in the art in light of the present disclosure, as exemplified by Remington's Pharmaceutical Sciences, 18th Ed., 1990, incorporated herein by reference. Moreover, for animal (e.g., human) administration, it will be understood that preparations should meet sterility, pyrogenicity, general safety, and purity standards as required by the FDA Office of Biological Standards.
1001231 Further in accordance with certain aspects of the present invention, the composition suitable for administration may be provided in a pharmaceutically acceptable carrier with or without an inert diluent. As used herein, "pharmaceutically acceptable carrier" includes any and all aqueous solvents (e.g., water, alcoholic/aqueous solutions, ethanol, saline solutions, parenteral vehicles, such as sodium chloride, Ringer's dextrose, eic.), non-aqueous solvents (e.g., fats, oils, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), vegetable oil, and injectable organic esters, such as ethyloleate), lipids, liposomes, dispersion media, coatings (e.g., lecithin), surfactants, antioxidants, preservatives (e.g., antibacterial or antifungal agents, anti-oxidants, chelating agents, inert gases, parabens (e.g., methylparabens, propylparabens), chlorobutanol, phenol, sorbic acid, thimerosal or combinations thereof), isotonic agents (e.g., sugars and sodium chloride), absorption delaying agents (e.g., aluminum monostearate and gelatin), salts, drugs, drug stabilizers, gels, resins, fillers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, fluid and nutrient replenishers, such like materials and combinations thereof, as would be known to one of ordinary skill in the art. The carrier should be assimilable and includes liquid, semi-solid, i.e., pastes, or solid carriers. In addition, if desired, the compositions may contain minor amounts of auxiliary substances, such as wetting or emulsifying agents, stabilizing agents, or pH buffering agents. The pH and exact concentration of the various components in a pharmaceutical composition are adjusted according to well-known parameters. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion, and by the use of surfactants.
pharmaceutically acceptable carrier is particularly formulated for administration to a human, although in certain embodiments it may be desirable to use a pharmaceutically acceptable carrier that is formulated for administration to a non-human animal but that would not be acceptable (e.g., due to governmental regulations) for administration to a human. Except insofar as any conventional carrier is incompatible with the active ingredient (e.g., detrimental to the recipient or to the therapeutic effectiveness of a composition contained therein), its use in the therapeutic or pharmaceutical compositions is contemplated. In accordance with certain aspects of the present invention, the composition is combined with the carrier in any convenient and practical manner, i.e., by solution, suspension, emulsification, admixture, encapsulation, absorption, and the like. Such procedures are routine for those skilled in the art.
Certain embodiments of the present invention may comprise different types of carriers depending on whether it is to be administered in solid, liquid, or aerosol form, and whether it needs to be sterile for the route of administration, such as injection. The compositions can be administered intravenously, intradermally, transdermally, intrathecally, intraarterially, intraperitoneally, intranasally, intravaginally, intrarectally, intramuscularly, subcutaneously, mucosally, orally, topically, locally, by inhalation (e.g., aerosol inhalation), by injection, by infusion, by continuous infusion, by localized perfusion bathing target cells directly, via a catheter, via a lavage, in lipid compositions (e.g., liposomes), or by other methods or any combination of the forgoing as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed., 1990, incorporated herein by reference).
[00126]
The active compounds can be formulated for parenteral administration, e.g., formulated for injection via the intravenous, intramuscular, sub-cutaneous, or even intraperitoneal routes. Typically, such compositions can be prepared as either liquid solutions or suspensions; solid forms suitable for use to prepare solutions or suspensions upon the addition of a liquid prior to injection can also be prepared; and the preparations can also be emulsified.
The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil, or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that it may be easily injected. It also should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
The therapeutics may be formulated into a composition in a free base, neutral, or salt form. Pharmaceutically acceptable salts include the acid addition salts, e.g., those formed with the free amino groups of a proteinaceous composition, or which are formed with inorganic acids, such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, or mandelic acid and the like.
Salts formed with the free carboxyl groups can also be derived from inorganic bases, such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides; or such organic bases as isopropylamine, trimethylamine, histidine, or procaine and the like. Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms, such as formulated for parenteral administrations, such as injectable solutions, or aerosols for delivery to the lungs, or formulated for alimentary administrations, such as drug release capsules and the like.
[00129]
In a specific embodiment of the present invention, the composition is combined or mixed thoroughly with a semi-solid or solid carrier. The mixing can be carried out in any convenient manner, such as grinding. Stabilizing agents can be also added in the mixing process in order to protect the composition from loss of therapeutic activity, i.e., denaturation in the stomach. Examples of stabilizers for use in a composition include buffers, amino acids, such as glycine and lysine, carbohydrates, such as dextrose, mannose, galactose, fructose, lactose, sucrose, maltose, sorbitol, mannitol, etc.
[00130]
In further embodiments, the present invention may concern the use of a pharmaceutical lipid vehicle composition comprising one or more lipids and an aqueous solvent. As used herein, the term "lipid" will be defined to include any of a broad range of substances that is characteristically insoluble in water and extractable with an organic solvent. This broad class of compounds is well known to those of skill in the art, and as the term "lipid" is used herein, it is not limited to any particular structure.
Examples include compounds that contain long-chain aliphatic hydrocarbons and their derivatives. A lipid may be naturally occurring or synthetic (i.e., designed or produced by man).
However, a lipid is usually a biological substance. Biological lipids are well known in the art, and include for example, neutral fats, phospholipids, phosphoglycerides, steroids, terpenes, lysolipids, glycosphingolipids, glycolipids, sulphatides, lipids with ether- and ester-linked fatty acids, polymerizable lipids, and combinations thereof. Of course, compounds other than those specifically described herein that are understood by one of skill in the art as lipids are also encompassed by the compositions and methods.
[00131]
One of ordinary skill in the art would be familiar with the range of techniques that can be employed for dispersing a composition in a lipid vehicle. For example, the therapeutic agent may be dispersed in a solution containing a lipid, dissolved with a lipid, emulsified with a lipid, mixed with a lipid, combined with a lipid, covalently bonded to a lipid, contained as a suspension in a lipid, contained or complexed with a micelle or liposome, or otherwise associated with a lipid or lipid structure by any means known to those of ordinary skill in the art. The dispersion may or may not result in the formation of liposomes.
[00132] The term "unit dose" or "dosage" refers to physically discrete units suitable for use in a subject, each unit containing a predetermined quantity of the therapeutic composition calculated to produce the desired responses discussed above in association with its administration, i.e., the appropriate route and treatment regimen. The quantity to be administered, both according to number of treatments and unit dose, depends on the effect desired. The actual dosage amount of a composition of the present invention administered to a patient or subject can be determined by physical and physiological factors, such as body weight, the age, health, and sex of the subject, the type of disease being treated, the extent of disease penetration, previous or concurrent therapeutic interventions, idiopathy of the patient, the route of administration, and the potency, stability, and toxicity of the particular therapeutic substance. For example, a dose may also comprise from about 1 jig/kg/body weight to about 1.000 mg/kg/body weight (this such range includes intervening doses) or more per administration, and any range derivable therein. In non-limiting examples of a derivable range from the numbers listed herein, a range of about 5 jig/kg/body weight to about 100 mg/kg/body weight, about 5 jig/kg/body weight to about 500 mg/kg/body weight, etc., can be administered. The practitioner responsible for administration will, in any event, determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual subject.
The actual dosage amount of a composition administered to an animal patient can be determined by physical and physiological factors, such as body weight, severity of condition, the type of disease being treated, previous or concurrent therapeutic interventions, idiopathy of the patient, and on the route of administration.
Depending upon the dosage and the route of administration, the number of administrations of a preferred dosage and/or an effective amount may vary according to the response of the subject. The practitioner responsible for administration will, in any event, determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual subject.
In certain embodiments, pharmaceutical compositions may comprise, for example, at least about 0.1% of an active compound. In other embodiments, an active compound may comprise between about 2% to about 75% of the weight of the unit, or between about 25% to about 60%, for example, and any range derivable therein.
Naturally, the amount of active compound(s) in each therapeutically useful composition may be prepared in such a way that a suitable dosage will be obtained in any given unit dose of the compound. Factors, such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations, will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable.
In other non-limiting examples, a dose may also comprise from about 1 microgram/kg/body weight, about 5 microgram/kg/body weight, about 10 microgram/kg/body weight, about 50 microgram/kg/body weight, about 100 microgram/kg/body weight, about 200 microgram/kg/body weight, about 350 microgram/kg/body weight, about 500 microgram/kg/body weight, about 1 milligram/kg/body weight, about 5 milligram/kg/body weight, about 10 milligram/kg/body weight, about 50 milligram/kg/body weight, about 100 milligram/kg/body weight, about 200 milligram/kg/body weight, about 350 milligram/kg/body weight, about 500 milligram/kg/body weight, to about 1000 milligram/kg/body weight or more per administration, and any range derivable therein. In non-limiting examples of a derivable range from the numbers listed herein, a range of about 5 milligram/kg/body weight to about 100 milligram/kg/body weight, about 5 microgram/kg/body weight to about 500 milligram/kg/body weight, etc., can be administered, based on the numbers described above.
IV. Nucleic Acids and Vectors 1001361 In certain aspects of the invention, nucleic acid sequences encoding a therapeutic protein or a fusion protein containing a therapeutic protein may be disclosed.
Depending on which expression system is used, nucleic acid sequences can be selected based on conventional methods. For example, the respective genes or variants thereof may be codon optimized for expression in a certain system. Various vectors may be also used to express the protein of interest. Exemplary vectors include, but are not limited, plasmid vectors, viral vectors, transposon, or liposome-based vectors.
V. Recombinant Proteins, Inhibitory RNAs, and Gene Editing Systems A. Recombinant Proteins 1001371 Some embodiments concern recombinant proteins and polypeptides.
Particular embodiments concern a recombinant protein or polypeptide that exhibits at least one therapeutic activity. In some embodiments, a recombinant protein or polypeptide may be a therapeutic antibody. In some aspects, a therapeutic antibody may be an antibody that specifically or selectively binds to an intracellular protein. In further aspects, the protein or polypeptide may be modified to increase serum stability. Thus, when the present application refers to the function or activity of "modified protein" or a "modified polypeptide," one of ordinary skill in the art would understand that this includes, for example, a protein or polypeptide that possesses an additional advantage over the unmodified protein or polypeptide. It is specifically contemplated that embodiments concerning a "modified protein" may be implemented with respect to a "modified polypeptide," and vice versa.
[00138]
Recombinant proteins may possess deletions and/or substitutions of amino acids; thus, a protein with a deletion, a protein with a substitution, and a protein with a deletion and a substitution are modified proteins. In some embodiments, these proteins may further include insertions or added amino acids, such as with fusion proteins or proteins with linkers, for example. A "modified deleted protein" lacks one or more residues of the native protein, but may possess the specificity and/or activity of the native protein. A "modified deleted protein" may also have reduced immunogenicity or antigenicity. An example of a modified deleted protein is one that has an amino acid residue deleted from at least one antigenic region that is, a region of the protein determined to be antigenic in a particular organism, such as the type of organism that may be administered the modified protein.
[00139]
Substitution or replacement variants typically contain the exchange of one amino acid for another at one or more sites within the protein and may be designed to modulate one or more properties of the polypeptide, particularly its effector functions and/or bioavailability. Substitutions may or may not be conservative, that is, one amino acid is replaced with one of similar shape and charge. Conservative substitutions are well known in the art and include, for example, the changes of: alanine to serine; arginine to lysine;
asparagine to glutamine or histidine; aspartate to glutamate; cysteine to serine; glutamine to asparagine; glutamate to aspartate; glycine to proline; histidine to asparagine or glutamine;
isoleucine to leucine or valine; leucine to valine or isoleucine; lysine to arginine; methionine to leucine or isoleucine; phenylalanine to tyrosine, leucine, or methionine;
serine to threonine; threonine to serine; tryptophan to tyrosine; tyrosine to tryptophan or phenylalanine; and valine to isoleucine or leucine.
In addition to a deletion or substitution, a modified protein may possess an insertion of residues, which typically involves the addition of at least one residue in the polypeptide. This may include the insertion of a targeting peptide or polypeptide or simply a single residue. Terminal additions, called fusion proteins, are discussed below.
[00141]
The term "biologically functional equivalent" is well understood in the art and is further defined in detail herein. Accordingly, sequences that have between about 70% and about 80%, or between about 81% and about 90%, or even between about 91% and about 99% of amino acids that are identical or functionally equivalent to the amino acids of a control polypeptide are included, provided the biological activity of the protein is maintained.
A recombinant protein may be biologically functionally equivalent to its native counterpart in certain aspects.
It also will be understood that amino acid and nucleic acid sequences may include additional residues, such as additional N- or C-terminal amino acids or 5' or 3' sequences, and yet still be essentially as set forth in one of the sequences disclosed herein, so long as the sequence meets the criteria set forth above, including the maintenance of biological protein activity where protein expression is concerned. The addition of terminal sequences particularly applies to nucleic acid sequences that may, for example, include various non-coding sequences flanking either of the 5' or 3' portions of the coding region or may include various internal sequences, i.e., introns, which are known to occur within genes.
As used herein, a protein or peptide generally refers, but is not limited to, a protein of greater than about 200 amino acids, up to a full length sequence translated from a gene; a polypeptide of greater than about 100 amino acids; and/or a peptide of from about 3 to about 100 amino acids. For convenience, the terms "protein,"
"polypeptide," and "peptide are used interchangeably herein.
As used herein, an "amino acid residue" refers to any naturally occurring amino acid, any amino acid derivative, or any amino acid mimic known in the art.
In certain embodiments, the residues of the protein or peptide are sequential, without any non-amino acids interrupting the sequence of amino acid residues. In other embodiments, the sequence may comprise one or more non-amino acid moieties. In particular embodiments, the sequence of residues of the protein or peptide may be interrupted by one or more non-amino acid moieties.
Accordingly, the term "protein or peptide" encompasses amino acid sequences comprising at least one of the 20 common amino acids found in naturally occurring proteins, or at least one modified or unusual amino acid.
Certain embodiments of the present invention concern fusion proteins.
These molecules may have a therapeutic protein linked at the N- or C-terminus to a heterologous domain. For example, fusions may also employ leader sequences from other species to permit the recombinant expression of a protein in a heterologous host. Another useful fusion includes the addition of a protein affinity tag, such as a serum albumin affinity tag or six histidine residues, or an immunologically active domain, such as an antibody epitope, preferably cleavable, to facilitate purification of the fusion protein. Non-limiting affinity tags include polyhistidine, chitin binding protein (CBP), maltose binding protein (MBP), and glutathione-S-transferase (GST).
In a particular embodiment, the therapeutic protein may be linked to a peptide that increases the in vivo half-life, such as an XTEN polypeptide (Schellenberger et al., 2009), IgG Fc domain, albumin, or albumin binding peptide.
Methods of generating fusion proteins are well known to those of skill in the art. Such proteins can be produced, for example, by de novo synthesis of the complete fusion protein, or by attachment of the DNA sequence encoding the heterologous domain, followed by expression of the intact fusion protein.
Production of fusion proteins that recover the functional activities of the parent proteins may be facilitated by connecting genes with a bridging DNA
segment encoding a peptide linker that is spliced between the polypeptides connected in tandem. The linker would be of sufficient length to allow proper folding of the resulting fusion protein.
B. Inhibitory RNAs siNA (e.g., siRNA) are well known in the art. For example, siRNA and double-stranded RNA have been described in U.S. Pat. Nos. 6,506,559 and 6,573,099, as well as in U.S. Patent Applications 2003/0051263, 2003/0055020, 2004/0265839, 2002/0168707, 2003/0159161, and 2004/0064842, all of which are herein incorporated by reference in their entirety.
Within a siNA, the components of a nucleic acid need not be of the same type or homogenous throughout (e.g., a siNA may comprise a nucleotide and a nucleic acid or nucleotide analog). Typically, siNA form a double-stranded structure;
the double-stranded structure may result from two separate nucleic acids that are partially or completely complementary. In certain embodiments of the present invention, the siNA may comprise only a single nucleic acid (polynucleotide) or nucleic acid analog and form a double-stranded structure by complementing with itself (e.g., forming a hairpin loop). The double-stranded structure of the siNA may comprise 16, 20, 25, 30, 35, 40, 45, 50, 60, 65, 70, 75, 80, 85, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500 or more contiguous nucleobases, including all ranges therein. The siNA may comprise 17 to 35 contiguous nucleobases, more preferably 18 to 30 contiguous nucleobases, more preferably 19 to 25 nucleobases, more preferably 20 to 23 contiguous nucleobases, or 20 to 22 contiguous nucleobases, or 21 contiguous nucleobases that hybridize with a complementary nucleic acid (which may be another part of the same nucleic acid or a separate complementary nucleic acid) to form a double-stranded structure.
[00152] Agents of the present invention useful for practicing the methods of the present invention include, but are not limited to siRNAs. Typically, introduction of double-stranded RNA (dsRNA), which may alternatively be referred to herein as small interfering RNA (siRNA), induces potent and specific gene silencing, a phenomena called RNA
interference or RNAi. RNA interference has been referred to as "cosuppression," "post-transcriptional gene silencing," "sense suppression," and "quelling." RNAi is an attractive biotechnological tool because it provides a means for knocking out the activity of specific genes.
In designing RNAi there are several factors that need to be considered, such as the nature of the siRNA, the durability of the silencing effect, and the choice of delivery system. To produce an RNAi effect, the siRNA that is introduced into the organism will typically contain exonic sequences. Furthermore, the RNAi process is homology dependent, so the sequences must be carefully selected so as to maximize gene specificity, while minimizing the possibility of cross-interference between homologous, but not gene-specific sequences. Preferably the siRNA exhibits greater than 80%, 85 A, 90 A, 95%, 98%, or even 100% identity between the sequence of the siRNA and the gene to be inhibited.
Sequences less than about 80% identical to the target gene are substantially less effective.
Thus, the greater homology between the siRNA and the gene to be inhibited, the less likely expression of unrelated genes will be affected.
[00154]
In addition, the size of the siRNA is an important consideration. In some embodiments, the present invention relates to siRNA molecules that include at least about 19-25 nucleotides and are able to modulate gene expression. In the context of the present invention, the siRNA is preferably less than 500, 200, 100, 50, or 25 nucleotides in length. More preferably, the siRNA is from about 19 nucleotides to about 25 nucleotides in length.
[00155] A target gene generally means a polynucleotide comprising a region that encodes a polypeptide, or a polynucleotide region that regulates replication, transcription, or translation or other processes important to expression of the polypeptide, or a polynucleotide comprising both a region that encodes a polypeptide and a region operably linked thereto that regulates expression. Any gene being expressed in a cell can be targeted.
Preferably, a target gene is one involved in or associated with the progression of cellular activities important to disease or of particular interest as a research object.
siRNA can be obtained from commercial sources, natural sources, or can be synthesized using any of a number of techniques well-known to those of ordinary skill in the art. For example, one commercial source of predesigned siRNA is Ambion , Austin, Tex. Another is Qiagene (Valencia, Calif.). An inhibitory nucleic acid that can be applied in the compositions and methods of the present invention may be any nucleic acid sequence that has been found by any source to be a validated downregulator of a protein of interest.
Without undue experimentation and using the disclosure of this invention, it is understood that additional siRNAs can be designed and used to practice the methods of the invention.
The siRNA may also comprise an alteration of one or more nucleotides. Such alterations can include the addition of non-nucleotide material, such as to the end(s) of the 19 to 25 nucleotide RNA or internally (at one or more nucleotides of the RNA). In certain aspects, the RNA molecule contains a 3'-hydroxyl group.
Nucleotides in the RNA molecules of the present invention can also comprise non-standard nucleotides, including non-naturally occurring nucleotides or deoxyribonucleotides. The double-stranded oligonucleotide may contain a modified backbone, for example, phosphorothioate, phosphorodithioate, or other modified backbones known in the art, or may contain non-natural internucleoside linkages. Additional modifications of siRNAs (e.g., 2'-0-methyl ribonucleotides, 2'-deoxy-2'-fluoro ribonucleotides, "universal base"
nucleotides, 5-C-methyl nucleotides, one or more phosphorothioate internucleotide linkages, and inverted deoxyabasic residue incorporation) can be found in U.S. Application Publication 2004/0019001 and U.S.
Pat. No. 6,673,611 (each of which is incorporated by reference in its entirety). Collectively, all such altered nucleic acids or RNAs described above are referred to as modified siRNAs.
C. Gene Editing Systems In general, "CRISPR system" refers collectively to transcripts and other elements involved in the expression of or directing the activity of CRISPR-associated ("Cas") genes, including sequences encoding a Cas gene, a tracr (trans-activating CRISPR) sequence (e.g. tracrRNA or an active partial tracrRNA), a tracr-mate sequence (encompassing a "direct repeat" and a tracrRNA-processed partial direct repeat in the context of an endogenous CRISPR system), a guide sequence (also referred to as a "spacer" in the context of an endogenous CRISPR system), and/or other sequences and transcripts from a CRISPR
locus.
1001591 The CRISPR/Cas nuclease or CRISPR/Cas nuclease system can include a non-coding RNA molecule (guide) RNA, which sequence-specifically binds to DNA, and a Cas protein (e.g., Cas9), with nuclease functionality (e.g., two nuclease domains). One or more elements of a CRISPR system can derive from a type I, type II, or type HI CRISPR system, e.g., derived from a particular organism comprising an endogenous CRISPR system, such as Streptococcus pyogenes.
In some aspects, a Cas nuclease and gRNA (including a fusion of crRNA specific for the target sequence and fixed tracrRNA) are introduced into the cell. In general, target sites at the 5' end of the gRNA target the Cas nuclease to the target site, e.g., the gene, using complementary base pairing. The target site may be selected based on its location immediately 5' of a protospacer adjacent motif (PAM) sequence, such as typically NGG, or NAG. In this respect, the gRNA is targeted to the desired sequence by modifying the first 20, 19, 18, 17, 16, 15, 14, 14, 12, 11, or 10 nucleotides of the guide RNA to correspond to the target DNA sequence. In general, a CRISPR system is characterized by elements that promote the formation of a CRISPR complex at the site of a target sequence.
Typically, "target sequence" generally refers to a sequence to which a guide sequence is designed to have complementarity, where hybridization between the target sequence and a guide sequence promotes the formation of a CRISPR complex. Full complementarity is not necessarily required, provided there is sufficient complementarity to cause hybridization and promote formation of a CRISPR complex.
1001611 The CRISPR system can induce double stranded breaks (DSBs) at the target site, followed by disruptions as discussed herein. In other embodiments, Cas9 variants, deemed "nickases," are used to nick a single strand at the target site. Paired nickases can be used, e.g., to improve specificity, each directed by a pair of different gRNAs targeting sequences such that upon introduction of the nicks simultaneously, a 5' overhang is introduced. In other embodiments, catalytically inactive Cas9 is fused to a heterologous effector domain such as a transcriptional repressor or activator, to affect gene expression.
The target sequence may comprise any polynucleotide, such as DNA
or RNA polynucleotides. The target sequence may be located in the nucleus or cytoplasm of the cell, such as within an organelle of the cell. Generally, a sequence or template that may be used for recombination into the targeted locus comprising the target sequences is referred to as an "editing template" or "editing polynucleotide" or "editing sequence". In some aspects, an exogenous template polynucleotide may be referred to as an editing template. In some aspects, the recombination is homologous recombination.
Typically, in the context of an endogenous CRISPR system, formation of the CRISPR complex (comprising the guide sequence hybridized to the target sequence and complexed with one or more Cas proteins) results in cleavage of one or both strands in or near (e.g. within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs from) the target sequence. The tracr sequence, which may comprise or consist of all or a portion of a wild-type tracr sequence (e.g. about or more than about 20, 26, 32, 45, 48, 54, 63, 67, 85, or more nucleotides of a wild-type tracr sequence), may also form part of the CRISPR
complex, such as by hybridization along at least a portion of the tracr sequence to all or a portion of a tracr mate sequence that is operably linked to the guide sequence. The tracr sequence has sufficient complementarity to a tracr mate sequence to hybridize and participate in formation of the CRISPR complex, such as at least 50%, 60%, 70%, 80%, 90%, 95% or 99% of sequence complementarity along the length of the tracr mate sequence when optimally aligned.
1001641 One or more vectors driving expression of one or more elements of the CRISPR system can be introduced into the cell such that expression of the elements of the CRISPR system direct formation of the CRISPR complex at one or more target sites.
Components can also be delivered to cells as proteins and/or RNA. For example, a Cas enzyme, a guide sequence linked to a tracr-mate sequence, and a tracr sequence could each be operably linked to separate regulatory elements on separate vectors.
Alternatively, two or more of the elements expressed from the same or different regulatory elements, may be combined in a single vector, with one or more additional vectors providing any components of the CRISPR system not included in the first vector. The vector may comprise one or more insertion sites, such as a restriction endonuclease recognition sequence (also referred to as a "cloning site"). In some embodiments, one or more insertion sites are located upstream and/or downstream of one or more sequence elements of one or more vectors.
When multiple different guide sequences are used, a single expression construct may be used to target CRISPR activity to multiple different, corresponding target sequences within a cell.
A vector may comprise a regulatory element operably linked to an enzyme-coding sequence encoding the CRISPR enzyme, such as a Cas protein. Non-limiting examples of Cas proteins include Casl, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csnl and Csx12), Cas10, Csy 1, Csy2, Csy3, Csel, Cse2, Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Csbl, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csxl, Csx15, Csfl, Cst'2, Csf3, Csf4, homologs thereof, or modified versions thereof These enzymes are known; for example, the amino acid sequence of S. pyogenes Cas9 protein may be found in the SwissProt database under accession number Q99ZW2.
[00166]
The CRISPR enzyme can be Cas9 (e.g., from S. pyogenes or S.
pneumonia). The CRISPR enzyme can direct cleavage of one or both strands at the location of a target sequence, such as within the target sequence and/or within the complement of the target sequence. The vector can encode a CRISPR enzyme that is mutated with respect to a corresponding wild-type enzyme such that the mutated CRISPR enzyme lacks the ability to cleave one or both strands of a target polynucleotide containing a target sequence. For example, an aspartate-to-alanine substitution (D10A) in the RuvC I catalytic domain of Cas9 from S. pyogenes converts Cas9 from a nuclease that cleaves both strands to a nickase (cleaves a single strand). In some embodiments, a Cas9 nickase may be used in combination with guide sequence(s), e.g., two guide sequences, which target respectively sense and antisense strands of the DNA target. This combination allows both strands to be nicked and used to induce 1=THEI or IlDR.
In some embodiments, an enzyme coding sequence encoding the CRISPR enzyme is codon optimized for expression in particular cells, such as eukaryotic cells. The eukaryotic cells may be those of or derived from a particular organism, such as a mammal, including but not limited to human, mouse, rat, rabbit, dog, or non-human primate.
In general, codon optimization refers to a process of modifying a nucleic acid sequence for enhanced expression in the host cells of interest by replacing at least one codon of the native sequence with codons that are more frequently or most frequently used in the genes of that host cell while maintaining the native amino acid sequence. Various species exhibit particular bias for certain codons of a particular amino acid. Codon bias (differences in codon usage between organisms) often correlates with the efficiency of translation of messenger RNA
(mRNA), which is in turn believed to be dependent on, among other things, the properties of the codons being translated and the availability of particular transfer RNA
(tRNA) molecules.
The predominance of selected tRNAs in a cell is generally a reflection of the codons used most frequently in peptide synthesis. Accordingly, genes can be tailored for optimal gene expression in a given organism based on codon optimization.
In general, a guide sequence is any polynucleotide sequence having sufficient complementarity with a target polynucleotide sequence to hybridize with the target sequence and direct sequence-specific binding of the CRISPR complex to the target sequence. In some embodiments, the degree of complementarity between a guide sequence and its corresponding target sequence, when optimally aligned using a suitable alignment algorithm, is about or more than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or more.
Optimal alignment may be determined with the use of any suitable algorithm for aligning sequences, non-limiting example of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g. the Burrows Wheeler Aligner), Clustal W, Clustal X, BLAT, Novoalign (Novocraft Technologies, ELAND (IIlumina, San Diego, Calif.), SOAP
(available at soap.genomics.org.cn), and Maq (available at maq.sourceforge.net).
1001701 The CRISPR enzyme may be part of a fusion protein comprising one or more heterologous protein domains. A CRISPR enzyme fusion protein may comprise any additional protein sequence, and optionally a linker sequence between any two domains.
Examples of protein domains that may be fused to a CRISPR enzyme include, without limitation, epitope tags, reporter gene sequences, and protein domains having one or more of the following activities: methylase activity, demethylase activity, transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, RNA cleavage activity and nucleic acid binding activity. Non-limiting examples of epitope tags include histidine (His) tags, V5 tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags.
Examples of reporter genes include, but are not limited to, glutathione-5- transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT) beta galactosidase, beta-glucuronidase, luciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), and autofluorescent proteins including blue fluorescent protein (BFP). A CRISPR enzyme may be fused to a gene sequence encoding a protein or a fragment of a protein that bind DNA molecules or bind other cellular molecules, including but not limited to maltose binding protein (MBP), S-tag, Lex A DNA
binding domain (DBD) fusions, GAL4A DNA binding domain fusions, and herpes simplex virus (HSV) BP16 protein fusions. Additional domains that may form part of a fusion protein comprising a CRISPR enzyme are described in US 20110059502, incorporated herein by reference.
VI. Kits and Diagnostics 1901711 In various aspects of the invention, a kit is envisioned containing the necessary components to purify exosomes from a body fluid or tissue culture medium. In other aspects, a kit is envisioned containing the necessary components to isolate exosomes and transfect them with a therapeutic nucleic acid, therapeutic protein, or a nucleic acid encoding a therapeutic protein therein. The kit may comprise one or more sealed vials containing any of such components. In some embodiments, the kit may also comprise a suitable container means, which is a container that will not react with components of the kit, such as an eppendorf tube, an assay plate, a syringe, a bottle, or a tube. The container may be made from sterilizable materials such as plastic or glass. The kit may further include an instruction sheet that outlines the procedural steps of the methods set forth herein, and will follow substantially the same procedures as described herein or are known to those of ordinary skill. The instruction information may be in a computer readable media containing machine-readable instructions that, when executed using a computer, cause the display of a real or virtual procedure of purifying exosomes from a sample and transfecting a therapeutic nucleic acid therein, expressing a recombinant protein therein, or electroporating a recombinant protein therein.
VII. Examples 1001721 The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.
Materials and Methods 1001731 Cell Culture. MCF7, MDA-MB231, E10, HDF, and BJ human cell lines, as well as the Nil-1 3T3 murine cell line were cultured in DME/VI with 100/o FBS. The 4T1 and 67NR murine cell lines were cultured in RPMI with 100/o FBS. MCF10A
human mammary epithelial cell line was cultured in DMEM/F12 media with 5% Horse Serum, 20 ng/ml EGF, 0.5 mg/ml Hydrocortisone, 100 ng/ml Cholera Toxin, and 10 gg/ml Insulin. All cells originated from the American Type Culture Collection ¨ ATCC.
Isolation and purification of exosomes. Exosomes were purified by differential centrifugation as described previously (Luga et al., 2012; Thery et al., 2006).
Supernatant from cells cultured for 48 h were subjected to sequential centrifugation steps of 800g and 2000g. The resulting supernatant was filtered using a 0.2 gm filter.
A pellet was recovered after ultracentrifugation in an SW40Ti swinging bucket rotor at 100,000g for 3 h (Beckman-Coulter). Supernatant was removed and the pellet was re-suspended in PBS, followed by a second ultracentrifugation at 100,000g for 3 h. The resulting pellet was analyzed for exosomes content. Exosomes used for RNA extraction were resuspended in 500 gL of Trizol; exosomes used for protein extraction were resuspended in Urea/SDS lysis buffer (8M Urea, 2.5% SDS, 5 gg/mL leupeptin, 1 gg/mL pepstatin, and 1 mM
phenylmethylsulphonyl fluoride); and exosomes used for delivery to cells were re-suspended in serum-free DMEM culture medium. For other applications, isolated exosomes were processed as described in the remaining experimental procedures.
Imaging Flow cytometry analysis (ImageStream). Exosomes were attached to 4 gm aldehyde/sulfate latex beads (Invitrogen, Carlsbad, CA, USA) in NaC1 0.9%
saline solution (B. Braun Medical Inc, Bethlehem, PA, USA). The reaction was stopped with 100 mM glycine and 2% BSA in saline and blocked with 10% BSA with rotation at room temperature for 30 min. After washing in saline/2% BSA, bead-bound exosomes were centrifuged for 2 min at 10,000 rpm and incubated with 1:200 anti-CD63 (Santa Cruz), anti-CD9 (Abcam), anti-CD81 (Abcam), anti-CD82 (Abcam), and anti-FLOT1 (Santa Cruz) for 30 min rotating at 4 C. Beads were centrifuged for 2 min at 10,000 rpm, washed in saline/2%
BSA and incubated with 1:400 Alexa-488 secondary antibodies (Life Technologies, NY
14072) for 30 min rotating at 4 C. After three washes the beads were resuspended in saline solution and analyzed on the ImageStream (Merck Millipore). The image acquisition gain (%) was set using a positive sample, in order to avoid pixel saturation. Image processing was done using the IDEAS (Merck Millipore) software. Gates were defined to exclude out-of-focus beads and select single beads. Alexa-488 positive bead gates were defined on the negative control sample. Percentage of positive beads is relative to the number of events analyzed per sample.
immunogold Labeling and Electron Microscopy. Pelleted exosomes were fixed by re-suspending in 2.5% Glutaraldehyde in 0.1 M Phosphate buffer.
Fixed specimens at an optimal concentration were placed onto a 300 mesh carbon/formvar coated grids and allowed to absorb to the formvar for a minimum of 1 minute. For immunogold staining the grids were placed into a blocking buffer for a block/permeabilization step for 1 h.
Without rinsing, the grids were immediately placed into the primary antibody at the appropriate dilution overnight at 4 C (polyclonal anti-GFP 1:10, Abcam). As controls, some grids were not exposed to the primary antibody. The next day all grids were rinsed with PBS
and floated on drops of the appropriate secondary antibody attached with 10 nm gold particles (AURION, Hatfield, PA) for 2 h at room temperature. Grids were rinsed with PBS
and placed in 2.5% Glutaraldehyde in 0.1 M Phosphate buffer for 15 minutes.
After rinsing in PBS and distilled water, the grids were allowed to dry and stained for contrast using uranyl acetate. The samples were viewed with a Tecnai Bio Twin transmission electron microscope (FEI, Hillsboro, OR) and images were taken with an AMT CCD Camera (Advanced Microscopy Techniques, Danvers, MA).
EGF stimulation of exosomes. Exosomes were collected from MBA-MB-23I cells as described above. 1-3 x 109 exosomes were resuspended in 1 mL
PBS and different concentrations of rEGF were added. Exosomes suspensions, with or without EGF, were incubated at 37 C with 5% CO2 for 15 minutes and then placed on ice.
Three replicates were pooled and PBS was added to a total volume of 11 mL and stimulated exosomes were collected through ultracentrifugation in an SW40Ti swinging bucket rotor at 100,000g for 3 h, as before. Protein extracts were collected from the pelleted stimulated exosomes in Urea/SDS lysis buffer (with 100 mM NaF and 1 mM Na0V4) for immunoblot analysis or a Triton X-100 buffer (150 mM NaCl, 1% (v/v) Triton X-100, 10 mM Na2HPO4, 2 mM
KH2PO4, pH 7.4, 50 mM 6-aminohexanoic acid, 10 mM EDTA, 5 mM N-ethylmaleimide, mM benzamidine, 5 1.1g/mL leupeptin, 1 lig/mL pepstatin, 1 mM
phenylmethylsulphonyl fluoride, 100 mM NaF, and 1 mM Na0V4) for immunoprecipitation assays.
Protein Western Blot and Antibodies. Exosomes protein extracts were loaded according to a Bicinchoninic Acid (BCA) protein assay kit (Pierce, Thermo Fisher Scientific) onto acrylamide gels and transferred onto PVDF membranes (ImmobilonP) by wet electrophoretic transfer. Blots were blocked for 1 h at RT with 5% non-fat dry milk in TBS/0.05% Tween20 and incubated overnight at 4 C with the following primary antibodies:
1:300 anti-CD9 ab92726 (Abeam); 1:300 anti-TSG101 ab83 (Abeam); 1:1000 anti-EGFR
4267S (CST); 1:300 anti-CD63 sc-365604, (Santa Cruz); 1:200 anti-CD81 cs-166029 (Santa Cruz); 1:1000 anti-pEGFR Tyr1068 3777S (CST); 1:2000 anti-GRB2 610111 (BD
Biosciences); 1:1000 anti-Shc 06-203 (Millipore); 1:5000 anti-GFP ab13970 (Abeam);
1:1000 GAPDH ab9483 (Abcam); 1:10,000 HRPconjugated I3-actin a3854 (Sigma);
1:400 anti-RNA Pol II cat#39097 (Active Motif); 1:500 anti-Hsp90 ab1429 (Abcam);
1:500 anti-elF3A ab86146 (Abeam); 1:500 anti-elF4A1 ab31217 (Abeam). HRP-conjugated secondary antibodies (Sigma, 1:2000) were incubated for 1 h at room temperature. Washes after antibody incubations were done on an orbital shaker, four times at 10 min intervals, with 1 x TBS 0.05% Tween20. Blots were developed with chemiluminescent reagents from Pierce.
Immunoprecipitation. Exosomes and cell protein extracts gently rocked at 4 C for 2 h. The lysates were centrifuged at 14,000g in a pre-cooled centrifuge for 15 minutes and the pellet was discarded. Protein A or G agarose/sepharose beads were washed twice with PBS and restored to a 50% slurry with PBS. A bead/slurry mix (100 ill) was added to 100 lig of exosomes protein extracts or 20 lig of cells protein extracts and incubated at 4 C
for 10 min. Beads were removed by centrifugation at 14,000g at 4 C for 10 minutes and pellets discarded. 10 tig of anti-elF4A1 antibody was added to 100 AL of exosomal lysate and incubated overnight at 4 C on an orbital shaker. 100 pL of Protein A or G
agarose/sepharose bead slurry were added and left at 4 C overnight. After centrifugation the supernatant was discarded and beads washed 3 times with ice-cold Urea/SDS buffer. The agarose/sepharose beads were boiled for 5 minutes to dissociate the immunocomplexes from the beads. The beads were collected by centrifugation and immunoblot was performed on the supernatant.
Identification of amino acids using UPW-MS. Exosomes were mixed with 200 p1. of methanol spiked with the Internal Standard tryptophan-d5 and incubated for an hour at -20 C. After centrifugation at 16,000g for 15 min at 4 C, 190 RL
of the supernatants was collected and the solvent removed. Dried extracts were reconstituted in 15 RL of methanol, of which 10 IlL were transferred to microtubes and derivatized.
Chromatographic separation and mass spectrometric detection conditions employed are summarized in Table 1. The mass range, 50 - 1000 m/z, was calibrated with cluster ions of sodium formate. An appropriate test mixture of standard compounds was analyzed before and after the entire set of randomized duplicated sample injections, in order to examine the retention time stability and sensitivity of the LC/MS system throughout the course of the run.
Table 1. Chromatographic conditions for the amino acids platform.
System SQL) Column type UPLC BEH C18, 1.0 x 100 mm, 1.7 um Flow rate 0.14 ml/min Solvent A H20 + 10mM Ammonium Bicarbonate (+N1140H until pH: 8.8) Solvent B CAN
(%B), time 2%, 0 min (%B), time 8%, 6.5 min (%B), time 20%, 10 min (%B), time 30%, 11 min (%B), time 99.9%, 12 min (%B), time 2%, 14 min Column temperature 40 C
Injection volume 1 I
Ionisation ES+
Source temperature 120 C
Nebulisation N2 flow 600 1/ hour Nebulisation N2 temperature 350 C
Cone N2 flow 10 1/ hour Capillary voltage 3.2 kV
Cone voltage 30 V
1001811 Data were processed using the TargetLynx application manager for MassLynx 4.1 software (Waters Corp., Milford, USA). A set of predefined retention time, mass-to-charge ratio pairs, Rt-m/z, corresponding to metabolites included in the analysis are fed into the program. Associated extracted ion chromatograms (mass tolerance window =
0.05 Da) are then peak-detected and noise-reduced in both the LC and MS
domains such that only true metabolite related features are processed by the software. A list of chromatographic peak areas is then generated for each sample injection, using the Rt-m/z data pairs (retention time tolerance = 6 s) as identifiers. Normalization factors were calculated for each metabolite by dividing their intensities in each sample by the recorded intensity of the internal standard in that same sample.
Digital ql)CR. Digital RNA reaction was performed using 3 ng of cDNA, TaqMan Universal Master mix and QuantStudioTm 3D Digital PCR Master Mix vi (Applied Biosystems) according to manufacture recommendations. Using QuantStudioTm 3D
Digital PCR Chip Loader (Applied Biosystems) a total of 14.5 of the mix were loaded to a QuantStudioTm 3D Digital PCR 20K Chip Kit vi (Applied Biosystems). PCR
reaction was performed on GeneAmp 9700 (Applied Biosystems) following manufacture protocol. The chips were imaged using QuantStudion4 3D Digital PCR Instrument (Applied Biosystems).
Table 2. Digital PCR Primers.
Name Sequence SEQ ID
NO
Met AGTAGGTAGCGCGTCAGTCTCATAATCTGAAGGTCGTGAGT 1 TCGATCCTCACACGGGGCA
Leu AGGCGCTGGATTAAGGCTCCAGTCTCTTCGGAGGCGTGGGT 2 TCGAATCCCACCGCTGCCA
Val AGTGGTTATCACGTTCGCCTAACACGCGAAAGGTCCCCGGT 3 TCGAAACCGGGCGGAAACA
Ser GGC G ATGGACTAGA A ATC C ATMGGGITTCC CCG CGCAGGT 4 TCGA ATCCTGCCGACTACG
[355:Imethionine labeling of exosomes. Exosomes were isolated as previously described and resuspended in methionine-free culture medium without FBS with 0.1 ¨ 1.0 mCi/m1 trans label [355]-L-methionine (Amersham Biosciences) and incubated overnight. Alternatively exosomes were incubated in the presence of cycloheximide (Sigma, 100 1.tg/mL). Exosomes were pelleted, washed in ice-cold PBS and resuspended in Urea/SDS
lysis buffer as previously described. Protein extracts were quantified using a BCA protein assay kit, run on acrylamide gels and transferred onto PVDF membranes (ImmobilonP) by wet electrophoretic transfer, after which the membranes were analyzed by autoradiography using the EN3HANCE autoradiography enhancer according to the manufacturer's instructions (Perkin-Elmer).
Real-time PSI? Analysis. DNase treated RNA was retro-transcribed with MultiScribe Reverse Transcriptase (Applied Biosystems) and oligo-d(T) primers following total exosomes RNA purification with Trizol (Invitrogen). Real-time PCR was performed on an ABI PRISM 7300HT Sequence Detection System Instrument using SYBR
Green Master Mix (Applied Biosystems) and 13-actin as the control. 28S rRNA
primer pairs (QF00318857) and 18S rRNA primer pairs (QF00530467) were purchased as ready specific primer pairs from Qiagen. Other primers are listed below. Each measurement was performed in triplicate. Threshold cycle (Rothstein et al.), the fractional cycle number at which the amount of amplified target reached a fixed threshold, was determined and expression was measured using the 2-ACt formula, as previously reported (Livak and Schmittgen, 2001).
Table 3. qPCR Probes.
Name Sequence SEQ ID NO
p21 F 5' TACCCTTGTGCCTCGCTC AG3' 5 p21 R 5' GAGAA GATC AGCC GGCGTTT3 ' 6 lisa-Actin F 5'CATGTACGTICiCIATCCAGGC3 7 hsa-Actin R 5'CICCITAATGICACGCACGAT3' 8 mmu-Actin F 5' GGCIGTATTCCCCICCATCG3 ' 9 mmu-Actin R 5'CCAGITGGTAACAATGCCAIGT3' 10 [00185] Lysate preparation for in vitro transcription and translation.
Exosomes and cell pellets were washed once in ice-cold PBS and resuspended in an equal volume of ice-cold 20 mM HEPES (pH 7.5), 100 mM potassium acetate, 1 mM
magnesium acetate, 2 mM dithiothreitol, and 100 g/mL lysolecithin. After 1 min on ice, they were again pelleted and resuspended in an equal volume of ice-cold hypotonic extraction buffer. After 5 min on ice, the lysates were disrupted by passing 10 times through a 26-gauge needle attached to a 1-mL syringe. The resulting homogenates were centrifuged at 1000g for 5 min at 4 C. The supernatant was collected, and aliquots were frozen in liquid nitrogen and stored at ¨80 C for use in the in vitro translation assay.
[00186]
In vitro coupled transcription and translation. Lysates obtained from cells and exosomes as previously described were used for in vitro translation in reaction volumes of 12 AL. Standard reaction conditions were as follows: cell lysate (final protein concentration 10 pg) or exosomes lysate (final concentration 100 ig), 1 pEMT7-GFP
cDNA expression plasmid, 20 mM HEPES-KOH (pH 7.6), 80 mM potassium acetate, 1 mM
magnesium acetate, 1 mM ATP, 0.12 m/VI GTP, 17 mM creatine phosphate, 0.1 mWmL
creatine phosphokinase, 2 mM dithiothreitol, 40 pM of each of the 20 amino acids, 0.15 mM
spermidine, and 400 U/mL RNAsin (Promega). Incubations were carried out for 3 h at 37 C.
Electroporation and culture of exosomes. Exosomes were pelleted and resuspended in 400 pi, of electroporation buffer (1.15 mM potassium phosphate pH 7.2, 25 mM potassium chloride, 21% Optiprep), with 20 g of plasmid (pCMV-GFP, pEGFP-p53 Addgene plasmid 12091, pcDNA3-RLUC-POLIRES-FLUC and pcDNA-FLUC). Exosomes were electroporated using a 4 mm cuvette using a Gene Pulser Xcell Electroporation System (BioRad), as previously described (Alvarez-Erviti et al., 2011). When appropriate, exosomes were electroporated in the presence of cycloheximide (Sigma, 100 mg/mL) or a-amanitin (Sigma, 30 g/mL), for inhibition of translation and transcription, respectively.
Electroporated exosomes were cultured in serum-free DMEM at 37 C for the time points indicated.
Flow cytometry analysis of electroporated exosomes. Exosomes preparations (5 ¨10 g) were incubated with 5 pi, of 4 JIM diameter aldehyde/sulfate latex beads (Interfacial Dynamics, Portland, OR) and resuspended into 600 tiL.
Exosomes-coated beads were analyzed on a FACS Calibur flow cytometer (BD Biosciences) and analyzed for green fluorescence.
Exosomes delivery and cortfocal microscopy. MCF10A cells were plated at an appropriate confluency in 12-well plates on inserted coverslips and cultured overnight. The following day cells were incubated with MDA-MB-231 exosomes resuspended in serum-free culture DMEM for 2 h, washed with cold PBS lx and fixed for 20 min at room temperature with 4 /o PFA/PBS. Slides were permeabilized for 10 min at RT
with PBS 0.5% Triton X-100 and counterstained with DAPI. Images were obtained using a Zeiss LSM510 Upright Confocal System using the recycle tool to maintain identical settings.
For data analysis, images were selected from a pool drawn from at least two independent experiments. Figures show representative fields.
1001901 Reverse transwell assay. Exosomes were isolated from MDA-MB-231 cells as previously described, and resuspended in PBS and quantified using Nanosight NTA.
Immunoblot of GFP protein expression in exosomes electroporated with a pCMV-GFP
plasmid and cultured with the translation inhibitor cycloheximide. Exosomes only and exosomes mock electroporated were used as negative controls. TSG101 was used as a loading control for the presence of exosomes. Band densitometry was performed using ImageJ software. FIG. 4G - Immunoblot of GFP protein expression in exosomes electroporated with a GFP plasmid and cultured with the transcription inhibitor a-amanitin.
Exosomes only and exosomes mock electroporated were used as negative controls.
was used as a loading control for the presence of exosomes. Band densitometry was performed using ImageJ software. FIG. 4H - Schematic representation of the bicistronic plasmid used as a reporter for cap-dependent or cap-independent translation (pCDNA3-rLuc-polIRESfLuc). FIG. 41 - Activities of renilla (r-Luc) and firefly luciferase (f-Luc) measured by bioluminescence after 48 h incubation of exosomes electroporated with the bicistronic plasmid. Non-electroporated exosomes were used as negative controls. FIG. 4J -Luminescence counts measured from exosomes incubated for 48 h after electroporation with or without a plasmid with firefly luciferase expressed under a CMV promoter.
100311 FIGS. 5A-E. Protein translation in exosomes generates functional proteins and can be increased by growth factor stimulation. FIG. 5A - Confocal microscopy showing the presence of GFP in MCF10A electroporated cells as well as in MCF10A cells, previously treated with cycloheximide, incubated with MDA-MB-231-derived exosomes electroporated with a pCMV-GFP plasmid and pre-incubated for 48 h. MCF10A cells treated with non-electroporated MDA-MB-231-derived exosomes were used as a negative control.
FIG. 5B -Immunoblot analysis of GFP expression on protein lysates from MDA-MB-231-derived exosomes electroporated with a p53-GFP expression plasmid. Non-electroporated exosomes were used as negative controls. TSG101 was used as a loading control for the presence of exosomes. FIG.5C - p21 mRNA expression in MDA-MB-231 cells treated with mock electroporated MDA-MB-231-derived exosomes or exosomes electroporated with the p53-GFP plasmid with and without the presence of cycloheximide. Expression levels were normalized to the housekeeping gene GAPDH. FIG. 5D - Immunoblot of exosomes isolated from MDA-MB-231 cells, incubated with 100 [tg/m1 of the translation inhibitor cycloheximide. Exosomes lysates were probed for I3-actin and GAPDH. Band densitometry quantification was performed using ImageJ software. FIG. 5E - Immunoblot of GFP protein expression in exosomes electroporated with a pCMV-GFP plasmid, and then incubated in the presence of different concentrations of rhEGF at 37 C for 48 h. Exosomes mock electroporated and exosomes without rhEGF incubation are shown as negative controls. The exosomes marker CD81 is used as a loading control. Band densitometry quantification was performed using ImageJ software.
100321 FIG. 6A-C. Exosomes derived from MDA-MB-231 cells demonstrate chemotaxis towards a gradient of growth factors. FIG. 6A - Schematic demonstrating the set up for exosomes retrograde migration assay. In short, 10 x 109 exosomes isolated from MDA-MB-231 cells were placed in the bottom well of a Corning Transwell system. An HIS Transwelle insert with 400 nm pores was placed on top of the exosomes suspension containing either PBS, 20% FBS, or 10,000 ng/ml rhEGF and incubated at 37 C.
The number of exosomes on the top insert was measured by Nanosight NTA after different time points to assess exosomes motility. FIGS. 6B&6C - Quantification of MDA-MB-231 exosomes on the top insert of the retrograde migration assay, after 4 h (FIG. 6B) and 24 h (FIG. 6C) incubation at 37 C, by Nanosight NTA. Significance was determined with a one-way ANOVA
followed by Newman-Keuls multiple comparison test. (*p <0.05, **p <0.01, ***p <0.005, ****p <
0.0001, n = 3).
100331 FIGS. 7A-D. Tumor-bearing mice show increased protein synthesis in delivered exosomes. FIG. 7A - Schematic depicting the experimental plan for the in vivo translation experiment. In short, female Balb/C mice were injected with 411 tumor orthotopically and the tumor was allowed to grow to 500 mm3, after which mice were injected with 30 billion MDA-MB-231 exosomes electroporated with a pCMV-mCherry plasmid. The mice were euthanized 12 h after exosomes injection and serum was collected for exosomes extraction. FIG. 7B - Graphic showing the tumor growth of mice injected with 411 tumors and electroporated exosomes, or 411 tumors alone, showing comparable growth kinetics. FIG. 7C - Nanosight NTA analysis of exosomes extracted from the serum of healthy mice injected with electroporated exosomes, as well as 411 tumor-bearing mice injected with electroporated exosomes and 411 tumor bearing mice with no exosomes injection.
All exosomes show similar size peaks, around 100 nm. FIG. 7D - Nanosight NTA
quantification of serum exosomes shown in FIG. 7C, showing no significant differences in the exosomes amount obtained from the serum of different animals, but a trend towards more exosomes in 411 tumor-bearing mice injected with MDA-MB-231 electroporated exosomes.
100341 FIGS. 8A-G. Exosomes characterization. FIG. 8A ¨ Nanoparticle tracking analysis of exosomes collected from MDA-MB-231 cells, obtained using the Nanosight NTA
2.1 Analytical Software. Left graph represents the size distribution of particles in solution showing a mean size of 104 nm and also showing no peaks at larger sizes. Right graph represents the distribution by size and concentration of particles in solution. FIG. 8B ¨
Atomic Force Microscopy image of exosomes (left image). Right graph represents the distribution of particles in the area analyzed. FIG. 8C ¨ Transmission electron micrograph of MDA-MB-231 exosomes. Scale bar ¨ 100 nm. FIG. 8D ¨ Transmission electron micrograph of immunogold labeled MDA-MB-231 exosomes using anti-CD9 antibody. Gold particles are depicted as black dots. Scale bar ¨ 100 nm. FIG. 8E ¨ Immunoblot analysis of exosomes markers CD9, CD63, and TSG101 in protein extracts of exosomes obtained from different cell lines. FIG. 8F ¨ Imaging Flow Cytometry analysis of exosomes from MDA-MB-cells coupled to 0.4 gm beads, using antibodies for markers CD9, CD81, CD82, and CD63.
FIG. 8G ¨ Representative images of LB culture plates incubated with E. coli and either MDA-MB-231 (top) or MCF10A (bottom) exosomes, showing colony formation on the E.
coli inoculated sides (left) and not on the exosomes inoculated sides (right).
100351 FIGS. 9A-B. EGFR phosphorylation and downstream biological activity in exosomes from MDA-MB-231 cells. FIG. 9A ¨ Immunoblot of protein extracts obtained from MDA-MB-231 cells and probed for p-EGFR and GRB2. 13-actin is used as a loading control. FIG. 9B ¨ Immunoblot of immunocomplexes obtained with an anti-EGFR
antibody pull down of protein lysates from MDA-MB-231 exosomes with or without incubation with 500 ng/ml at 37 C for 15 minutes. Immuncomplexes were probed for GRB2. Non-specific isotype control IgG was used as a negative control for the GRB2 pulldown.
Equal volumes of the stimulated and unstimulated extracts were probed for -actin as input control.
100361 FIG. 10. Proteomics analysis of exosomes derived from various cells.
Heatmap representing the binary identification of all individual proteins included in the Protein Translation pathway in the Reactome (Croft et al., 2014) database, in mass spectrometry data obtained from mouse liver cells (Valadi et al., 2007), mouse fibroblasts (Luga et al., 2012), human colorectal cancer cells (Choi et al., 2012), human plasma (Kalra et al., 2013), human thymic tissue (Skogberg et al., 2013), and human urine (Gonzales et al., 2009). Black represents the presence and white represents the absence of each protein in each dataset. The summary column represents how ubiquitous each protein is in all analyzed datasets, with warmer colors representing a more widespread distribution among different types of exosomes.
100371 FIGS. 11A-B. Proteomics analysis of exosomes from various origins. FIG.
11A ¨ Heatmap representing the number of proteins identified in mass spectrometry data obtained from mouse liver cells (Valadi et al., 2007), mouse fibroblasts (Luga et al., 2012), human colorectal cancer cells (Choi et al., 2012), human plasma (Kalra et al., 2013), human thymic tissue (Skogberg et al., 2013), and human urine (Gonzales et al., 2009) that associate with different pathways related to protein translation in the Reactome (Croft et al., 2014) database. Warmer colors represent higher numbers of proteins identified per pathway. FIG.
11B ¨ Heatmap representing the protein score of proteins associated with protein translation identified in mass spectrometry obtained from exosomes isolated from HDF, NIH
3T3, MDA-MB231, MCF10A, and E10 cells. Warmer colors represent a higher protein score.
100381 FIGS. 12A-C. Exosomes contain nucleic acids and proteins associated with the protein translation machinery. FIG. 12A ¨ RNA extracted from exosomes of NTH-3T3, E10, 67NR, 4T1, HDF, MCF10A, MCF7, and MDA-MB-231 cell lines were used to quantify 18S and 28S rRNAs by qPCR. Expression levels of the rRNAs were normalized to snRNA expression. The bars in each group represent, from left to right, N1H
313, E10, 67NR, 4T1, HDF, MCF10A, MCF7, and IvIDA-MB-231. FIG. 12B ¨ RNA extracted from 4T1 exosomes and cells were used to identify the presence of tRNAMet, tRNAGly, tRNALeu, tRNASer, and tRNAVal by digital qPCR. The bars in each group represent, from left to right, Leu, Met, Val, Ser, and Gly. FIG. 12C ¨ Immunoprecipitation of eIF4A1 showing presence of elF3A MCF10A and MDA-MB-231-derived exosomes. MB231 and MCF10A cell lysates were used as positive controls. The exosomes marker CD82 was used as a loading control.
100391 FIGS. 13A-E. DNA transcription and mRNA translation in exosomes derived from MCF10A and MDA-MB-231 cells. FIG. 13A ¨ Immunoblot of GFP protein expression in exosomes isolated from MCF10A cells, electroporated with a pCMV-GFP plasmid and incubated at 37 C for different periods of time. Exosomes only and mock electroporated exosomes were used as negative controls. CD63 was used as a loading control and to confirm the presence of exosomes. FIG. 13B ¨ Plot depicting the amount of green exosomes detected by NanoSight in MCF10A-derived exosomes electroporated with a GFP plasmid.
MCFIOA-derived exosomes, MCF 10A-derived mock electroporated exosomes as well as exosomes electroporated with a-amanitin and cycloheximide were used as negative controls. FIG. 13C
¨ Flow cytometry analysis of beads attached to exosomes after electroporation with a GFP
plasmid using increasing voltages, showing the percentages of beads with green fluorescent signal. FIG. 13D ¨ Immunoblot of ovalbumin protein levels in MDA-MB-231 exosomes electroporated with a pCMV-Ova plasmid and incubated at 37 C for 48 h. 0-actin was used as a loading control. FIG. 13E ¨ p21 mRNA expression in MDA-MB-231 cells treated with mock electroporated MDA-MB-231-derived exosomes or exosomes electroporated with the p53-GFP plasmid and either added to the cells immediately (0 h) or allowed to incubate in cell conditions at 37 C for 48 h before treatment (48 h). Exosomes were added to the cells for either 30 minutes or 48 hours before RNA extraction. Expression levels were normalized to the housekeeping gene GAPDH.
DETAILED DESCRIPTION
[0040] Extracellular vesicles (EVs), including exosomes, are nano-sized intercellular communication vehicles having a lipid bilayer that encloses cytosol-like material. Exosomes participate in several physiological processes and contain DNA, RNA, and proteins. It is generally assumed that all contents in exosomes are derived from cells and they remain as such in the exosomes until they enter other cells and deposit their contents.
Exosomes are released by all cells in large numbers and are considered as garbage bags that carry cellular constituents into the extracellular space as a payload without any biological significance for exosomes themselves per se.
[0041] Provided here are exosomes that behave like minicells and exhibit the ability to biologically respond to stimuli and multiply and migrate just as cells do but without a defined nucleus. These exosomes exhibit chemotaxis towards serum factors and upon stimulation with growth factors such as EGF, will phosphorylate the EGFR
receptor on their surface and initiate a signaling cascade that leads to transcription and translation of new proteins. When these exosomes are injected into tumor bearing mice, they preferentially accumulate in the tumors. Collectively, the capacity for protein translation and growth factor response by these exosomes provides them a functional role in tissue homeostasis and modulation of disease.
I. Aspects of the Present invention 100421 Extracellular vesicles, and in particular exosomes, have gained much attention over the last few years with identification of several constituents such as DNA, RNA, and proteins. Moreover, exosomes have been implicated in influencing many diverse biological processes via transfer of its content into recipient cells in different tissues, and facilitating a unique form of cell-cell communication (Bastos et al., 2017). Alternatively, the potential of exosomes as delivery vehicles for therapeutics, particularly in the context of cancer or neurological pathologies was also reported (El-Andaloussi et al., 2012;
Kamerkar et al., 2017). However, the exact patterns of systemic distribution and organ tropism of exosomes are still not fully understood.
100431 However, the nuclear and cytoplasmic components of the exosomes are not just used for passive transfer to recipient cells but can respond to external stimuli to phosphorylate growth factor receptors, such as EGFR, and generate new proteins via active transcription and translation. External stimulation of exosomes can initiate de novo biological activities such as retrograde migration. It is conceivable that exosomes may function like mini cells, albeit primitive with respect to their fine-tuned operations in response to external stimuli. In fact, recently it has been suggested that exosomes could potentially constitute extant representations of protocellular ribosomes, for which they would need to contain rRNAs, which is confirm in this study (Sinkovics, 2015). Exosomes are biologically responsive and migrate towards growth factor gradients in an active manner.
Actin remodeling might be involved. The patterns of actin polymerization could therefore constitute an interesting target in the modulation of exosomes biodistribution.
100441 Vesicles such as prostasomes obtained from different species have been shown to contain different components of the glycolytic pathway, which allow them to produce ATP
in cell-free conditions (Ronquist et al., 2013a; Ronquist et al., 2013b).
While direct transcription in exosomes has not been previously reported, a study showed that exosomes from bovine milk infected with bovine leukemia virus have been shown to exhibit reverse transaiptase activity (Yamada et al., 2013). It was also recently demonstrated that independent production of mature miRNAs in exosomes isolated from cancer cells is possible (Melo et al., 2014). Here, exosomes were demonstrated to possess an intrinsic capacity for de novo synthesis of functional proteins via DNA transcription coupled with mRNA
translation.
Platelets can translate proteins from mRNA molecules remaining within them after megakaryocyte differentiation (Weyrich et al., 2004). Nevertheless, DNA
transcription resulting in new mRNA molecules is not reported in platelets. Additionally, foci of mRNA
translation activity, associated with polyribosomes and mRNA binding proteins, is observed in dendritic spines even when severed from the major body of the cell (Aakalu et al., 2001;
Smith et al., 2001; Steward and Levy, 1982). It is therefore clear that some cellular structures have preserved the capacity for protein biosynthesis in the absence of a nucleus, perhaps in order to support their specific biological functions in a rapid manner. Apart from protein translation, exosomes are capable of DNA transcription via RNA polymerase II.
It is well established that basic transcription of naked DNA in nucleosome-free regions is possible with minimal components of transcriptional machinery, namely only RNA Pol II and a cocktail of six general transcription factors (GTFs) (Lorch et al., 2014; Nagai et al., 2017). It has also been shown that exosomes contain a plethora of transcription factors that can be delivered to cells in order to alter their patterns of protein expression (Ung et al., 2014). It is therefore conceivable that exosomes contain naked DNA residues unbound by chromatin, which could undergo transcription in the presence of these minimal transcriptional components.
100451 This study also suggests that the required components for transcription/translation are likely exhausted within 24 h, resulting in a limited rate of transcription and translation. Since it has been suggested that different subpopulations of exosomes may possess distinct molecular characteristics (Willms et al., 2016), it is possible that only a small subset of exosomes possess the capacity for de novo protein synthesis. The newly synthetized proteins in exosomes are functionally active, suggestive of an appropriate protein conformation. It has been shown that exosomes contain not only the components of ribosomes, but also several molecular chaperones, such as Hsp60 and Hsp70. The ribosome itself has an important role in co-translational protein folding, for instance, it can promote the formation of secondary structures in newly formed proteins. The ribosome also acts as a platform for the association of chaperones that can assist with the appropriate folding of nascent proteins (Kramer et al., 2009). It is conceivable that these exosomes components could contribute to the stabilization of newly formed proteins. Physical confinement, as would be the case in the lumen of exosomes, can also have a stabilizing effect on the folding of proteins (Rao and Cruz, 2013). The possibility, however, cannot be ruled out that many proteins might exhibit inappropriate conformation or mis-folding. These could still have important biological implications, as demonstrated with the recent unraveling of unexpected features of the "dark proteome" (Perdigao et al., 2015), which suggested that proteins with unknown structure or intrinsically disordered regions may have important physiological functions.
100461 A meticulous and quantitative identification of the proteins naturally synthetized in exosomes is necessary to fully appreciate the biological significance of this process. It is clear, however, that this could have significant impact in re-evaluating the understanding of eukaryotic biology. Recent studies suggest that cells can selectively incorporate mRNAs into exosomes (Raposo and Stoorvogel, 2013). This raises the possibility that mRNAs selectively packaged into exosomes could be translated into proteins whose expression is repressed in their cell of origin, as shown in this study as a proof of concept.
The identification of newly synthetized proteins in exosomes up to one month after translation, suggests that exosomes-mediated production of proteins could lead to a significantly increased protein half-life, possibly due to lower levels of protein degradation enzymes.
100471 Taken together, these results collectively demonstrate exosomes possess previously unappreciated biological activity with a potentially profound impact on body homeostasis and tissue pathogenesis. One could speculate that growth factor gradients could play a role on the systemic tropism of exosomes in the body. A disruption of the naturally occurring pattern of growth factor production could have immediate consequences on both the redistribution and delivery patterns of exosomes. These patterns of response could have potential implications in determining cell-cell communication, particularly between distant body sites. The fact that they can change their patterns of protein expression in response to these extracellular cues would suggest that exosomes could act as the primary responders in tissue injury. In conclusion, these findings provide a novel insight into the basic biology of exosomes and inform on their biological functions in organism homeostasis and their potential impact in disease states.
I. Lipid-based Nanoparticles 100481 In some embodiments, a lipid-based nanoparticle is a liposomes, an exosomes, lipid preparations, or another lipid-based nanoparticle, such as a lipid-based vesicle (e.g., a DOTAP:cholesterol vesicle). Lipid-based nanoparticles may be positively charged, negatively charged or neutral. Lipid-based nanoparticles may comprise the necessary components to allow for transcription and translation, signal transduction, chemotaxis, or other cellular functions.
A. Liposomes 100491 A "liposome" is a generic term encompassing a variety of single and multilamellar lipid vehicles formed by the generation of enclosed lipid bilayers or aggregates.
Liposomes may be characterized as having vesicular structures with a bilayer membrane, generally comprising a phospholipid, and an inner medium that generally comprises an aqueous composition. Liposomes provided herein include unilamellar liposomes, multilamellar liposomes, and multivesicular liposomes. Liposomes provided herein may be positively charged, negatively charged, or neutrally charged. In certain embodiments, the liposomes are neutral in charge.
100501 A multilamellar liposome has multiple lipid layers separated by aqueous medium. Such liposomes form spontaneously when lipids comprising phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before the formation of closed structures and entrap water and dissolved solutes between the lipid bilayers. Lipophilic molecules or molecules with lipophilic regions may also dissolve in or associate with the lipid bilayer.
100511 In specific aspects, a polypeptide, a nucleic acid, or a small molecule drug may be, for example, encapsulated in the aqueous interior of a liposome, interspersed within the lipid bilayer of a liposome, attached to a liposome via a linking molecule that is associated with both the liposome and the polypeptide/nucleic acid, entrapped in a liposome, complexed with a liposome, or the like.
100521 A liposome used according to the present embodiments can be made by different methods, as would be known to one of ordinary skill in the art. For example, a phospholipid, such as for example the neutral phospholipid dioleoylphosphatidylcholine (DOPC), is dissolved in tert-butanol. The lipid(s) is then mixed with a polypeptide, nucleic acid, and/or other component(s). Tween 20 is added to the lipid mixture such that Tween 20 is about 5% of the composition's weight. Excess tert-butanol is added to this mixture such that the volume of tert-butanol is at least 95%. The mixture is vortexed, frozen in a dry ice/acetone bath and lyophilized overnight. The lyophilized preparation is stored at -20 C
and can be used up to three months. When required the lyophilized liposomes are reconstituted in 0.9% saline.
100531 Alternatively, a liposome can be prepared by mixing lipids in a solvent in a container, e.g., a glass, pear-shaped flask. The container should have a volume ten-times greater than the volume of the expected suspension of liposomes. Using a rotary evaporator, the solvent is removed at approximately 40 C under negative pressure. The solvent normally is removed within about 5 min to 2 h, depending on the desired volume of the liposomes.
The composition can be dried further in a desiccator under vacuum. The dried lipids generally are discarded after about 1 week because of a tendency to deteriorate with time.
100541 Dried lipids can be hydrated at approximately 25-50 niM phospholipid in sterile, pyrogen-free water by shaking until all the lipid film is resuspended. The aqueous liposomes can be then separated into aliquots, each placed in a vial, lyophilized and sealed under vacuum.
100551 The dried lipids or lyophilized liposomes prepared as described above may be dehydrated and reconstituted in a solution of a protein or peptide and diluted to an appropriate concentration with a suitable solvent, e.g., DPBS. The mixture is then vigorously shaken in a vortex mixer. Unencapsulated additional materials, such as agents including but not limited to hormones, drugs, nucleic acid constructs and the like, are removed by centrifugation at 29,000 x g and the liposomal pellets washed. The washed liposomes are resuspended at an appropriate total phospholipid concentration, e.g., about 50-200 tnM. The amount of additional material or active agent encapsulated can be determined in accordance with standard methods. After determination of the amount of additional material or active agent encapsulated in the liposome preparation, the liposomes may be diluted to appropriate concentrations and stored at 4 C until use. A pharmaceutical composition comprising the liposomes will usually include a sterile, pharmaceutically acceptable carrier or diluent, such as water or saline solution.
100561 Additional liposomes which may be useful with the present embodiments include cationic liposomes, for example, as described in W002/100435A1, U.S
Patent 5,962,016, U.S. Application 2004/0208921, W003/015757A1, W004029213A2, U.S.
Patent 5,030,453, and U.S. Patent 6,680,068, all of which are hereby incorporated by reference in their entirety without disclaimer.
100571 In preparing such liposomes, any protocol described herein, or as would be known to one of ordinary skill in the art may be used. Additional non-limiting examples of preparing liposomes are described in U.S. Patents 4,728,578, 4,728,575, 4,737,323, 4,533,254, 4,162,282, 4,310,505, and 4,921,706; International Applications PCT/US85/01161 and PCT/U589/05040, each incorporated herein by reference.
100581 In certain embodiments, the lipid based nanoparticle is a neutral liposorne (e.g., a DOPC liposome). "Neutral liposomes" or "non-charged liposomes", as used herein, are defined as liposomes having one or more lipid components that yield an essentially-neutral, net charge (substantially non-charged). By "essentially neutral" or "essentially non-charged", it is meant that few, if any, lipid components within a given population (e.g., a population of liposomes) include a charge that is not canceled by an opposite charge of another component (i.e., fewer than 10% of components include a non-canceled charge, more preferably fewer than 5%, and most preferably fewer than 1%). In certain embodiments, neutral liposomes may include mostly lipids and/or phospholipids that are themselves neutral under physiological conditions (i.e., at about pH 7).
100591 Liposomes and/or lipid-based nanoparticles of the present embodiments may comprise a phospholipid. In certain embodiments, a single kind of phospholipid may be used in the creation of liposomes (e.g., a neutral phospholipid, such as DOPC, may be used to generate neutral liposomes). In other embodiments, more than one kind of phospholipid may be used to create liposomes. Phospholipids may be from natural or synthetic sources.
Phospholipids include, for example, phosphatidylcholines, phosphatidylglycerols, and phosphatidylethanolamines; because phosphatidylethanolamines and phosphatidyl cholines are non-charged under physiological conditions (i.e., at about pH 7), these compounds may be particularly useful for generating neutral liposomes. In certain embodiments, the phospholipid DOPC is used to produce non-charged liposomes. In certain embodiments, a lipid that is not a phospholipid (e.g., a cholesterol) may be used 100601 Phospholipids include glycerophospholipids and certain sphingolipids.
Phospholipids include, but are not limited to, dioleoylphosphatidylycholine ("DOPC"), egg phosphatidylcholine ("EPC"), di lauryloylphosphati dyl choline ("DLPC"), dimyristoylphosphatidylcholine ("DMPC"), dipalmitoylphosphafidylcholine ("DPPC"), di stearoylphosphatidylcholi ne (" DSPC"), 1-my ri stoy1-2-palmitoyl phosphatidyl choline ("MPPC"), 1-palmitoy1-2-myristoyl phosphatidylcholine ("PMPC"), 1-palmitoy1-2-stearoyl ph osphati dylch ol i ne ("PSPC"), 1-stearoy1-2-pal mitoyl phosphatidylcholine ("SPPC"), dilauryloylphosphatidylglycerol ("DLPG"), dimyristoylphosphatidylglycerol ("DMPG"), di pal mi toylphosph atidylgl ycerol ("DPPG"), di stearoylphosphati dyl gl y cerol ("DSPG"), di stearoyl sphingomyelin ("DSSP"), di stearoyl phophati dylethanol ami ne ("DSPE"), dioleoylphosphatidylglycerol ("DOPG"), dimyristoyl phosphatidic acid ("DMPA"), dipalmitoyl phosphatidic acid ("DPPA"), dimyristoyl phosphatidylethanolamine ("DMPE"), dipalmitoyl phosphatidylethanolamine ("DPPE"), dimyristoyl phosphatidylserine ("DMPS"), dipalmitoyl phosphatidylserine ("DPPS"), brain phosphatidylserine ("BPS"), brain sphingomyelin ("BSP"), dipalmitoyl sphingomyelin ("DPSP"), dimyristyl ph osphati dylch ol i ne (" DMPC"), 1,2-di stearoyl-sn-glycero-3-phosphocholi ne ("DAPC"), 1,2-diarachidoyl-sn-glycero-3-phosphocholine ("DBPC"), 1,2-dieicosenoyl-sn-glycero-3-phosphochol me ("DEPC"), di ol eoyl ph osphati dylethanol am i ne ("DOPE"), pal mitoyloeoyl phosphatidylcholine ("POPC"), palmitoyloeoyl phosphatidylethanolamine ("POPE"), lysophosphatidylcholine, lysophosphatidylethanolamine, and dilinoleoylphosphatidylcholine.
B. Exosomes 100611 The terms "microvesicle" and "exosomes," as used herein, refer to a membranous particle having a diameter (or largest dimension where the particles is not spheroid) of between about 10 nm to about 5000 nm, more typically between 30 nm and 1000 nm, and most typically between about 50 nm and 750 nm, wherein at least part of the membrane of the exosomes is directly obtained from a cell. Most commonly, exosomes will have a size (average diameter) that is up to 5% of the size of the donor cell.
Therefore, especially contemplated exosomes include those that are shed from a cell.
100621 Exosomes may be detected in or isolated from any suitable sample type, such as, for example, body fluids. As used herein, the term "isolated" refers to separation out of its natural environment and is meant to include at least partial purification and may include substantial purification. As used herein, the term "sample" refers to any sample suitable for the methods provided by the present invention. The sample may be any sample that includes exosomes suitable for detection or isolation. Sources of samples include blood, bone marrow, pleural fluid, peritoneal fluid, cerebrospinal fluid, urine, saliva, amniotic fluid, malignant ascites, broncho-alveolar lavage fluid, synovial fluid, breast milk, sweat, tears, joint fluid, and bronchial washes. In one aspect, the sample is a blood sample, including, for example, whole blood or any fraction or component thereof. A blood sample suitable for use with the present invention may be extracted from any source known that includes blood cells or components thereof, such as venous, arterial, peripheral, tissue, cord, and the like. For example, a sample may be obtained and processed using well-known and routine clinical methods (e.g., procedures for drawing and processing whole blood). In one aspect, an exemplary sample may be peripheral blood drawn from a subject with cancer.
100631 Exosomes may also be isolated from tissue samples, such as surgical samples, biopsy samples, tissues, feces, and cultured cells. When isolating exosomes from tissue sources it may be necessary to homogenize the tissue in order to obtain a single cell suspension followed by lysis of the cells to release the exosomes. When isolating exosomes from tissue samples it is important to select homogenization and lysis procedures that do not result in disruption of the exosomes. Exosomes contemplated herein are preferably isolated from body fluid in a physiologically acceptable solution, for example, buffered saline, growth medium, various aqueous medium, etc 100641 Exosomes may be isolated from freshly collected samples or from samples that have been stored frozen or refrigerated. In some embodiments, exosomes may be isolated from cell culture medium. Although not necessary, higher purity exosomes may be obtained if fluid samples are clarified before precipitation with a volume-excluding polymer, to remove any debris from the sample. Methods of clarification include centrifugation, ultracentrifugation, filtration, or ultrafiltration. Most typically, exosomes can be isolated by numerous methods well-known in the art. One preferred method is differential centrifugation from body fluids or cell culture supernatants. Exemplary methods for isolation of exosomes are described in (Losche et al., 2004; Mesri and Alfieri, 1998; Morel et al., 2004).
Alternatively, exosomes may also be isolated via flow cytometry as described in (Combes et al., 1997).
100651 One accepted protocol for isolation of exosomes includes ultracentrifugation, often in combination with sucrose density gradients or sucrose cushions to float the relatively low-density exosomes. Isolation of exosomes by sequential differential centrifugations is complicated by the possibility of overlapping size distributions with other microvesicles or macromolecular complexes. Furthermore, centrifugation may provide insufficient means to separate vesicles based on their sizes. However, sequential centrifugations, when combined with sucrose gradient ultracentrifugation, can provide high enrichment of exosomes.
100661 Isolation of exosomes based on size, using alternatives to the ultracentrifugation routes, is another option. Successful purification of exosomes using ultrafiltration procedures that are less time consuming than ultracentrifugation, and do not require use of special equipment have been reported. Similarly, a commercial kit is available (EXOMIRTm, Bioo Scientific) which allows removal of cells, platelets, and cellular debris on one microfilter and capturing of vesicles bigger than 30 nm on a second microfilter using positive pressure to drive the fluid. However, for this process, the exosomes are not recovered, their RNA content is directly extracted from the material caught on the second microfilter, which can then be used for PCR analysis. HPLC-based protocols could potentially allow one to obtain highly pure exosomes, though these processes require dedicated equipment and are difficult to scale up. A significant problem is that both blood and cell culture media contain large numbers of nanoparticles (some non-vesicular) in the same size range as exosomes. For example, some miRNAs may be contained within extracellular protein complexes rather than exosomes; however, treatment with protease (e.g., proteinase K) can be performed to eliminate any possible contamination with "extraexosomal" protein.
100671 In another embodiment, cancer cell-derived exosomes may be captured by techniques commonly used to enrich a sample for exosomes, such as those involving immunospecific interactions (e.g., immunomagnetic capture). Immunomagnetic capture, also known as immunomagnetic cell separation, typically involves attaching antibodies directed to proteins found on a particular cell type to small paramagnetic beads. When the antibody-coated beads are mixed with a sample, such as blood, they attach to and surround the particular cell. The sample is then placed in a strong magnetic field, causing the beads to pellet to one side. After removing the blood, captured cells are retained with the beads. Many variations of this general method are well-known in the art and suitable for use to isolate exosomes. In one example, the exosomes may be attached to magnetic beads (e.g., aldehyde/sulphate beads) and then an antibody is added to the mixture to recognize an epitope on the surface of the exosomes that are attached to the beads.
Exemplary proteins that are known to be found on cancer cell-derived exosomes include ATP-binding cassette sub-family A member 6 (ABCA6), tetraspanin-4 (TSPAN4), SLIT and NTRK-like protein 4 (SLITRK4), putative protocadherin beta-18 (PCDHB18), myeloid cell surface antigen CD33 (CD33), and glypican-1 (GPC1). Cancer cell-derived exosomes may be isolated using, for example, antibodies or aptamers to one or more of these proteins.
100681 As used herein, analysis includes any method that allows direct or indirect visualization of exosomes and may be in vivo or ex vivo. For example, analysis may include, but not limited to, ex vivo microscopic or cytometric detection and visualization of exosomes bound to a solid substrate, flow cytometry, fluorescent imaging, and the like.
In an exemplary aspect, cancer cell-derived exosomes are detected using antibodies directed to one or more of ATP-binding cassette sub-family A member 6 (ABCA6), tetraspanin-4 (TSPAN4), SLIT and NTRK-like protein 4 (SLITRK4), putative protocadherin beta-18 (PCDHB18), myeloid cell surface antigen CD33 (CD33), glypican-1 (GPC1), Histone H2A type 2-A
(HIST1H2AA), Histone H2A type 1-A (HI ST1H1AA), Histone H3.3 (H3F3A), Histone H3.1 (HI5T1H3A), Zinc finger protein 37 homolog (ZFP37), Laminin subunit beta-1 (LAMB1), Tubulointerstitial nephritis antigen-like (TINAGL1), Peroxiredeoxin-4 (PRDX4), Collagen alpha-2(IV) chain (COL4A2), Putative protein C3P1 (C3P1), Hemicentin-1 (HMCN1), Putative rhophilin-2-like protein (RHPN2P1), Ankyrin repeat domain-containing protein 62 (ANKRD62), Tripartite motif-containing protein 42 (TRIM42), Junction plakoglobin (JUP), Tubulin beta-2B chain (TUBB2B), Endoribonuclease Dicer (DICER1), E3 ubiquitin-protein ligase TRIM71 (TRI1v171), Katanin p60 ATPase-containing subunit A-like 2 (KATNAL2), Protein S100-A6 (S100A6), 5'-nucleotidase domain-containing protein 3 (NT5DC3), Valine-tRNA ligase (VARS), Kazrin (KAZN), ELAV-like protein 4 (ELAVL4), RING finger protein 166 (RNF166), FERM and PDZ domain-containing protein 1 (FRMPD1), 78 kDa glucose-regulated protein (HSPA5), Trafficking protein particle complex subunit 6A
(TRAPPC6A), Squalene monooxygenase (SQLE), Tumor susceptibility gene 101 protein (TSG101), Vacuolar protein sorting 28 homolog (VPS28), Prostaglandin F2 receptor negative regulator (PTGFRN), Isobutyryl-CoA dehydrogenase, mitochondrial (ACAD8), 26S
protease regulatory subunit 6B (PS/vIC4), Elongation factor 1-gamma (EEF1G), Titin (TTN), Tyrosine-protein phosphatase type 13 (PTPN13), Triosephosphate isomerase (TPI1), or Carboxypeptidase E (CPE) and subsequently bound to a solid substrate and/or visualized using microscopic or cytometric detection.
100691 It should be noted that not all proteins expressing in a cell are found in exosomes secreted by that cell (see FIG. 11). For example, calnexin, GM130, and LAMP-2 are all proteins expressed in MCF-7 cells but not found in exosomes secreted by MCF-7 cells (Baietti et al., 2012). As another example, one study found that 190/190 pancreatic ductal adenocarcinoma patients had higher levels of GPC1+ exosomes than healthy controls (Melo et al., 2015, which is incorporated herein by reference in its entirety).
Notably, only 2.3% of healthy controls, on average, had GPC1+ exosomes.
1. Exemplary Protocol for Collecting Exosomes from Cell Culture 100701 On Day 1, seed enough cells (e.g., about five million cells) in T225 flasks in media containing 10% FBS so that the next day the cells will be about 70%
confluent. On Day 2, aspirate the media on the cells, wash the cells twice with PBS, and then add 25-30 mL
base media (i.e., no PenStrep or FBS) to the cells. Incubate the cells for 24-48 hours. A 48 hour incubation is preferred, but some cells lines are more sensitive to serum-free media and so the incubation time should be reduced to 24 hours. Note that FBS contains exosomes that will heavily skew NanoSight results.
100711 On Day 3/4, collect the media and centrifuge at room temperature for five minutes at 800 x g to pellet dead cells and large debris. Transfer the supernatant to new conical tubes and centrifuge the media again for 10 minutes at 2000 x g to remove other large debris and large vesicles. Pass the media through a 0.2 gm filter and then aliquot into ultracentrifuge tubes (e.g., 25 x 89 mm Beckman Ultra-Clear) using 35 mL per tube. If the volume of media per tube is less than 35 mL, fill the remainder of the tube with PBS to reach 35 mL. Ultracentrifuge the media for 2-4 hours at 28,000 rpm at 4 C using a SW
32 Ti rotor (k-factor 266.7, RCF max 133,907). Carefully aspirate the supernatant until there is roughly 1-inch of liquid remaining. Tilt the tube and allow remaining media to slowly enter aspirator pipette. If desired, the exosomes pellet can be resuspended in PBS and the ultracentrifugation at 28,000 rpm repeated for 1-2 hours to further purify the population of exosomes.
100721 Finally, resuspend the exosomes pellet in 210 ML PBS. If there are multiple ultracentrifuge tubes for each sample, use the same 210 ML PBS to serially resuspend each exosomes pellet. For each sample, take 10 pi and add to 990 pi, H20 to use for nanoparticle tracking analysis. Use the remaining 200 gL exosomes-containing suspension for downstream processes or immediately store at -80 C.
2. Exemplary Protocol for Extracting Exosomes from Serum Samples 100731 First, allow serum samples to thaw on ice. Then, dilute 250 ML of cell-free serum samples in 11 mL PBS; filter through a 0.2 gm pore filter.
Ultracentrifuge the diluted sample at 150,000 x g overnight at 4 C. The following day, carefully discard the supernatant and wash the exosomes pellet in 11 mL PBS. Perform a second round of ultracentrifugation at 150,000 x g at 4 C for 2 hours. Finally, carefully discard the supernatant and resuspend the exosomes pellet in 100 !IL PBS for analysis C. Exemplary Protocol for Electroporation of Exosomes and Liposomes 100741 Mix 1 x 108 exosomes (measured by NanoSight analysis) or 100 nm liposomes (e.g., purchased from Encapsula Nano Sciences) and 1 1.1g of siRNA
(Qiagen) or shRNA in 400 jiL of electroporation buffer (1.15 mM potassium phosphate, pH
7.2, 25 mM
potassium chloride, 21% Optiprep). Electroporate the exosomes or liposomes using a 4 mm cuvette (see, e.g., Alvarez-Erviti et a, 2011; El-Andaloussi et al., 2012).
After electroporation, treat the exosomes or liposomes with protease-free RNAse followed by addition of 10x concentrated RNase inhibitor. Finally, wash the exosomes or liposomes with PBS under ultracentrifugation methods, as described above.
H. Diagnosis, Prognosis, and Treatment of Diseases 190751 Certain aspects of the present invention provide for treating a patient with exosomes that express or comprise a therapeutic agent or a diagnostic agent. A
"therapeutic agent" as used herein is an atom, molecule, or compound that is useful in the treatment of cancer or other conditions. Examples of therapeutic agents include, but are not limited to, drugs, chemotherapeutic agents, therapeutic antibodies and antibody fragments, toxins, radioisotopes, enzymes, nucleases, hormones, immunomodulators, anti sense oligonucleotides, chelators, boron compounds, photoactive agents, and dyes. A
"diagnostic agent" as used herein is an atom, molecule, or compound that is useful in diagnosing, detecting or visualizing a disease. According to the embodiments described herein, diagnostic agents may include, but are not limited to, radioactive substances (e.g., radioisotopes, radionuclides, radiolabels or radiotracers), dyes, contrast agents, fluorescent compounds or molecules, bioluminescent compounds or molecules, enzymes and enhancing agents (e.g., paramagnetic ions).
100761 In some aspects, a therapeutic recombinant protein may be a protein having an activity that has been lost in a cell of the patient, a protein having a desired enzymatic activity, a protein having a desired inhibitory activity, etc. For example, the protein may be a transcription factor, an enzyme, a proteinaceous toxin, an antibody, a monoclonal antibody, etc. The monoclonal antibody may specifically or selectively bind to an intracellular antigen.
The monoclonal antibody may inhibit the function of the intracellular antigen and/or disrupt a protein-protein interaction. Other aspects of the present invention provide for diagnosing a disease based on the presence of cancer cell-derived exosomes in a patient sample.
100771 As exosomes are known to comprise the machinery necessary to complete mRNA transcription and protein translation (see PCT/US2014/068630, which is incorporated herein by reference in its entirety), mRNA or DNA nucleic acids encoding a therapeutic protein may be transfected into exosomes. Alternatively, the therapeutic protein itself may be electroporated into the exosomes or incorporated directly into a liposome.
Exemplary therapeutic proteins include, but are not limited to, a tumor suppressor protein, peptides, a wild type protein counterparts of a mutant protein, a DNA repair protein, a proteolytic enzyme, proteinaceous toxin, a protein that can inhibit the activity of an intracellular protein, a protein that can activate the activity of an intracellular protein, or any protein whose loss of function needs to be reconstituted. Specific examples of exemplary therapeutic proteins include 123F2, Abcb4, Abccl, Abcg2, Actb, Ada, Ahr, Akt, Aktl, Akt2, Akt3, Amhr2, Anxa7, Apc, Ar, Atm, Axin2, B2m, Bardl, Bc1211, Becnl, Bhlhal5, Binl, Blm, Braf, Brcal, Brca2, Brca3, Brat Brcata, Brinp3, Bripi, Bublb, Bwscrla, Cadm3, Cascl, Casp3, Casp7, Casp8, Cavl, Ccam, Ccndl, Ccr4, Ccsl, Cd28, Cdc25a, Cd95, Cdhl, Cdknla, Cdknlb, Cdkn2a, Cdkn2b, CdIcn2c, Cftr, Chekl, Chek2, Crcsl, Crcs10, Crcsl 1, Crcs2, Crcs3, Crcs4, Crcs5, Crcs6, Crcs7, Crcs8, Crcs9, Ctnnbl, Ctsl, Cyplal, Cyp2a6, Cyp2b2, Cyld, Dcc, Dkcl, Dicerl, Dmtfl, Dnmtl, Dpc4, E2f1, Eaf2, Eefl al, Egfr, Egfr4, Erbb2, Erbb4, Ercc2, Ercc6, Ercc8, Errfil, Esrl, Etv4, Faslg, Fbxol 0, Fcc, Fgfr3, Fntb, Foxml, Foxnl, Fus1, Fzd6, Fzd7, Fzrl, Gadd45a, Gast, Gnai2, Gpcl, Gpr124, Gpr87, Gprc5a, Gprc5d, Grb2, Gstml, Gstm5, Gstpl, Gstt1, H19, H2afx, Hck, Lims1, Hdac, Hexa, Hid, Hini, Hmmr, Hnpcc8, Hprt, Hras, Htatip2, 111b, 1110, 112, 116, 118rb Inha, Itgav, Jun, Jak3, Kit, Klf4, Kras, Kras2, Kras2b, Ligl, Lig4, Lkbl, Lmo7, Lncrl, Lncr2, Lncr3, Lncr4, Ltbp4, Lucal, Luca2, Lyz2, Lztsl, Madill, Mad211, Madr2/Jv18, Mapk14, Mcc, Mcm4, Menl, Men2, Met, Mgat5, Mif, Mlhl, Mlh3, Mmacl, Mmp8, Mnt, Mpo, Msh2, Msh3, Msh6, Msmb, Mthfr, Mtsl, Mutyh, Myhll, Nat2, Nbn, Ncoa3, Neill, Nfl, Nf2, Nfe211, Nhej 1, Nkx2-1, Nkx2-9, Nkx3-1, Npr12, Nqol, Nras, Nudtl, Oggl, Oxgrl, p16, p19, p21, p27, p27mt, p57, p 1 4ARF, Pa1b2, Park2, Pggtlb, Pgr, Pi3k, Pik3ca, Piwil2, P16, Pla2g2a, Plg, Plk3, Pmsl, Pms2, Poldl, Pole, Ppard, Pparg, Ppfia2, Ppmld, Prdm2, Prdxl, Prkarl a, Ptch, Pten, Prom 1, Psca, Ptchl, Ptfl a, Ptger2, Ptpn13, Ptprj, Rara, Rad51, Rassfl, Rb, Rbl, Rblccl, Rb12, Recg14, Ret, Rgs5, Rhoc, Rintl, Robol, Rp138, Si 00a4, SCGB 1 Al, Skp2, Smad2, Smad3, Smad4, Smarcbl, Smo, Snx25, Spata13, Srpx, Ssic I, Sstr2, Sstr5, Stat3, St5, St7, St14, Stkl 1, Suds3, Tapl, Tbx21, Terc, Tnf, Tp53, Tp73, Trpm5, Tsc2, Tscl, Vhl, Wrn, Wtl, Wt2, Xrccl, Xrcc5, Xrcc6, and Zacl.
100781 One specific type of protein that it may be desirable to introduce into the intracellular space of a diseased cell is an antibody (e.g., a monoclonal antibody). Such an antibody may disrupt the function of an intracellular protein and/or disrupt an intracellular protein-protein interaction. Exemplary targets of such monoclonal antibodies include, but are not limited to, proteins involved in the RNAi pathway, telomerase, transcription factors that control disease processes, kinases, phosphatases, proteins required for DNA
synthesis, protein required for protein translation. Specific examples of exemplary therapeutic antibody targets include proteins encoded by the following genes: Dicer, Ago!, Ago2, Trbp, Ras, raf, wnt, btk, BcI-2, Akt, Sis, src, Notch, Stathmin, mdm2, abl, hTERT, c-fos, c-jun, c-myc, erbB, HER2/Neu, HER3,VEGFR, PDGFR, c-kit, c-met, c-ret, flt3, API, AML1, axl, alk, fins, fps, gip, lck, Stat, Hox, MLM, PRAD-I, and trk. In addition to monoclonal antibodies, any antigen binding fragment there of, such as a scFv, a Fab fragment, a Fab', a F(ab')2, a Fv, a peptibody, a diabody, a triabody, or a minibody, is also contemplated. Any such antibodies or antibody fragment may be either glycosylated or aglycosylated.
100791 As exosomes are known to comprise DICER and active RNA processing RISC complex (see PCT PubIn. WO 2014/152622, which is incorporated herein by reference in its entirety), shRNA transfected into exosomes can mature into RISC-complex bound siRNA with the exosomes themselves. Alternatively, mature siRNA can itself be transfected into exosomes or liposomes. Thus, by way of example, the following are classes of possible target genes that may be used in the methods of the present invention to modulate or attenuate target gene expression: wild-type or mutant versions of developmental genes (e.g., adhesion molecules, cyclin kinase inhibitors, Wnt family members, Pax family members, Winged helix family members, Hox family members, cytokines/lymphokines and their receptors, growth or differentiation factors and their receptors, neurotransmitters and their receptors), tumor suppressor genes (e.g., APC, CYLD, HIN-1, KRAS2b, p16, p19, p21, p27, p27mt, p53, p57, p73, PTEN, Rb, Uteroglobin, Skp2, BRCA-1, BRCA-2, CHK2, CDKN2A, DCC, DPC4, MADR2/JV18, MEN1, MEN2, MTS1, NF1, NF2, VHL, WRN, WTI, CFTR, C-CAM, CTS-1, zacl, ras, MMAC1, FCC, MCC, FUS1, Gene 26 (CACNA2D2), PL6, Beta* (BLU), Luca-1 (HYAL1), Luca-2 (HYAL2), 123F2 (RASSF1), 101F6, Gene 21 (NPRL2), or a gene encoding a SEM A3 polypeptide), pro-apoptotic genes (e.g.. CD95, caspase-3, Bax, Bag-1, CRADD, TSSC3, bax, hid, Bak, MKP-7, PARP, bad, bc1-2, MST1, bbc3, Sax, BIK, and BID), cytokines (e.g., GM-CSF, G-CSF, IL-la, IL-113, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, EL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32 IFN-a, IFNI, MIP-1 a, MIP-113, TGF-13, TNF-a, TNF-13, PDGF, and mda7), oncogenes (e.g., ABLI, BLC1, BCL6, CBFA1, CBL, CSFIR, ERBA, ERBB, EBRB2, ETS1, ETS1, ETV6, FGR, FOX, FYN, HCR, HRAS, JUN, KRAS, LCK, LYN, MDM2, MLL, IvIYB, MYC, MYCL1, MYCN, NRAS, PIM1, PML, RET, SRC, TAL1, TCL3 and YES), and enzymes (e.g., ACP
desaturases and hycroxylases, ADP-glucose pyrophorylases, ATPases, alcohol dehycrogenases, amylases, amyloglucosidases, catalases, cellulases, cyclooxygenases, decarboxylases, dextrinases, esterases, DNA and RNA polymerases, galactosidases, glucanases, glucose oxidases, GTPases, helicases, hemicellulases, integrases, invertases, isomersases, kinases, lactases, lipases, lipoxygenases, lysozymes, nucleases, pectinesterases, peroxidases, phosphatases, phospholipases, phosphorylases, polygalacturonases, proteinases and peptideases, pullanases, recombinases, reverse transcriptases, topoisomerases, xylanases). In some cases, sh/siRNA may be designed to specifically target a mutant version of a gene expressed in a cancer cell while not affecting the expression of the corresponding wild-type version. In fact, any inhibitory nucleic acid that can be applied in the compositions and methods of the present invention if such inhibitory nucleic acid has been found by any source to be a validated downregulator of a protein of interest.
100801 In designing RNAi there are several factors that need to be considered, such as the nature of the siRNA, the durability of the silencing effect, and the choice of delivery system. To produce an RNAi effect, the siRNA that is introduced into the organism will typically contain exonic sequences. Furthermore, the RNAi process is homology dependent, so the sequences must be carefully selected so as to maximize gene specificity, while minimizing the possibility of cross-interference between homologous, but not gene-specific sequences. Preferably the siRNA exhibits greater than 80%, 85%, 90%, 95%, 98%, or even 100% identity between the sequence of the siRNA and the gene to be inhibited.
Sequences less than about 80% identical to the target gene are substantially less effective. Thus, the greater homology between the siRNA and the gene to be inhibited, the less likely expression of unrelated genes will be affected.
100811 Exosomes may also be engineered to comprise a gene editing system, such as a CRISPR/Cas system. In general, "CRISPR system" refers collectively to transcripts and other elements involved in the expression of or directing the activity of CRISPR-associated ("Cas") genes, including sequences encoding a Cas gene, a tracr (trans-activating CRISPR) sequence (e.g. tracrRNA or an active partial tracrRNA), a tracr-mate sequence (encompassing a "direct repeat" and a tracrRNA-processed partial direct repeat in the context of an endogenous CRISPR system), a guide sequence (also referred to as a "spacer" in the context of an endogenous CRISPR system), and/or other sequences and transcripts from a CRISPR
locus. In some aspects, a Cas nuclease and gRNA (including a fusion of crRNA
specific for the target sequence and fixed tracrRNA) are introduced into the cell. In general, target sites at the 5' end of the gRNA target the Cas nuclease to the target site, e.g., the gene, using complementary base pairing. The target site may be selected based on its location immediately 5' of a protospacer adjacent motif (PAM) sequence, such as typically NGG, or NAG. In this respect, the gRNA is targeted to the desired sequence by modifying the first 20, 19, 18, 17, 16, 15, 14, 14, 12, 11, or 10 nucleotides of the guide RNA to correspond to the target DNA sequence. In general, a CRISPR system is characterized by elements that promote the formation of a CRISPR complex at the site of a target sequence.
Typically, "target sequence" generally refers to a sequence to which a guide sequence is designed to have complementarity, where hybridization between the target sequence and a guide sequence promotes the formation of a CRISPR complex. Full complementarity is not necessarily required, provided there is sufficient complementarity to cause hybridization and promote formation of a CRISPR complex. The CRISPR system in exosomes engineered to comprise such a system may function to edit the genomic DNA inside a target cell, or the system may edit the DNA inside the exosomes itself.
100821 In addition to protein- and nucleic acid-based therapeutics, exosomes may be used to deliver small molecule drugs, either alone or in combination with any protein- or nucleic acid-based therapeutic. Exemplary small molecule drugs that are contemplated for use in the present embodiments include, but are not limited to, toxins, chemotherapeutic agents, agents that inhibit the activity of an intracellular protein, agents that activate the activity of intracellular proteins, agents for the prevention of restenosis, agents for treating renal disease, agents used for intermittent claudication, agents used in the treatment of hypotension and shock, angiotensin converting enzyme inhibitors, antianginal agents, anti-arrhythmics, anti-hypertensive agents, antiotensin ii receptor antagonists, antiplatelet drugs, b-blockers b I selective, beta blocking agents, botanical product for cardiovascular indication, calcium channel blockers, cardiovascular/diagnostics, central alpha-2 agonists, coronary vasodilators, diuretics and renal tubule inhibitors, neutral endopeptidase/angiotensin converting enzyme inhibitors, peripheral vasodilators, potassium channel openers, potassium .. salts, anticonvulsants, antiemetics, antinauseants, anti-parkinson agents, antispasticity agents, cerebral stimulants, agents that can be applied in the treatment of trauma, agents that can be applied in the treatment of Alzheimer disease or dementia, agents that can be applied in the treatment of migraine, agents that can be applied in the treatment of neurodegenerative diseases, agents that can be applied in the treatment of kaposi's sarcoma, agents that can be applied in the treatment of AIDS, cancer chemotherapeutic agents, agents that can be applied in the treatment of immune disorders, agents that can be applied in the treatment of psychiatric disorders, analgesics, epidural and intrathecal anesthetic agents, general, local, regional neuromuscular blocking agents sedatives, preanesthetic adrenal/acth, anabolic steroids, agents that can be applied in the treatment of diabetes, dopamine agonists, growth hormone and analogs, hyperglycemic agents, hypoglycemic agents, oral insulins, large volume parenterals (lvps), lipid-altering agents, metabolic studies and inborn errors of metabolism, nutrients/amino acids, nutritional lvps, obesity drugs (anorectics), somatostatin, thyroid agents, vasopressin, vitamins, corticosteroids, mucolytic agents, pulmonary anti-inflammatory agents, pulmonary surfactants, antacids, anticholinergics, antidiarrheals, antiemetics, cholelitholytic agents, inflammatory bowel disease agents, irritable bowel syndrome agents, liver agents, metal chelators, miscellaneous gastric secretory agents, pancreatitis agents, pancreatic enzymes, prostaglandins, prostaglandins, proton pump inhibitors, sclerosing agents, sucralfate, anti-progestins, contraceptives, oral contraceptives, not oral dopamine agonists, estrogens, gonadotropins, GNRH agonists, GHRH
antagonists, oxytocics, progestins, uterine-acting agents, anti-anemia drugs, anticoagulants, antifibrinolytics, antiplatelet agents, antithrombin drugs, coagulants, fibrinolytics, hematology, heparin inhibitors, metal chelators, prostaglandins, vitamin K, anti-androgens, aminoglycosides, antibacterial agents, sulfonamides, cephalosporins, clindamycins, dermatologics, detergents, erythromycins, anthelmintic agents, antifungal agents, antimalarial s, anti mycobacteri al agents, anti parasitic agents, an ti protozoal agents, antitrichomonads, antituberculosis agents, immunomodulators, immunostimulatory agents, macrolides, antiparasitic agents, corticosteroids, cyclooxygenase inhibitors, enzyme blockers, immunomodulators for rheumatic diseases, metalloproteinase inhibitors, nonsteroidal anti-inflammatory agents, analgesics, antipyretics, alpha adrenergic agonists/blockers, antibiotics, antivirals, beta adrenergic blockers, carbonic anhydrase inhibitors, corticosteroids, immune system regulators, mast cell inhibitors, nonsteroidal anti-inflammatory agents, and prostaglandi ns.
100831 Exosomes may also be used to deliver diagnostic agents. Exemplary diagnostic agents include, but are not limited to, magnetic resonance image enhancement agents, positron emission tomography products, radioactive diagnostic agents, radioactive therapeutic agents, radio-opaque contrast agents, radiopharmaceuticals, ultrasound imaging agents, and angiographic diagnostic agents.
100841 The term "subject" as used herein refers to any individual or patient to which the subject methods are performed. Generally the subject is human, although as will be appreciated by those in the art, the subject may be an animal. Thus other animals, including mammals, such as rodents (including mice, rats, hamsters, and guinea pigs), cats, dogs, rabbits, farm animals (including cows, horses, goats, sheep, pigs, etc.), and primates (including monkeys, chimpanzees, orangutans, and gorillas) are included within the definition of subject.
100851 "Treatment" and "treating" refer to administration or application of a therapeutic agent to a subject or performance of a procedure or modality on a subject for the purpose of obtaining a therapeutic benefit of a disease or health-related condition. For example, a treatment may include administration of chemotherapy, immunotherapy, or radiotherapy, performance of surgery, or any combination thereof.
100861 The term "therapeutic benefit" or "therapeutically effective" as used throughout this application refers to anything that promotes or enhances the well-being of the subject with respect to the medical treatment of this condition. This includes, but is not limited to, a reduction in the frequency or severity of the signs or symptoms of a disease. For example, treatment of cancer may involve, for example, a reduction in the invasiveness of a tumor, reduction in the growth rate of the cancer, or prevention of metastasis. Treatment of cancer may also refer to prolonging survival of a subject with cancer.
100871 The term "cancer," as used herein, may be used to describe a solid tumor, metastatic cancer, or non-metastatic cancer. In certain embodiments, the cancer may originate in the bladder, blood, bone, bone marrow, brain, breast, colon, esophagus, duodenum, small intestine, large intestine, colon, rectum, anus, gum, head, kidney, liver, lung, nasopharynx, neck, ovary, pancreas, prostate, skin, stomach, testis, tongue, or uterus.
100881 The cancer may specifically be of the following histological type, though it is not limited to these: neoplasm, malignant; carcinoma; carcinoma, undifferentiated; giant and spindle cell carcinoma; small cell carcinoma; papillary carcinoma; squamous cell carcinoma;
lymphoepithelial carcinoma; basal cell carcinoma; pilomatrix carcinoma;
transitional cell carcinoma; papillary transitional cell carcinoma; adenocarcinoma; gastrinoma, malignant;
cholangiocarcinoma; hepatocellular carcinoma; combined hepatocellular carcinoma and cholangiocarcinoma; trabecular adenocarcinoma; adenoid cystic carcinoma;
adenocarcinoma in adenomatous polyp; adenocarcinoma, familial polyposis coli; solid carcinoma; carcinoid tumor, malignant; branchiolo-alveol ar adenocarci noma; papillary adenocarci noma;
chromophobe carcinoma; acidophil carcinoma; oxyphilic adenocarcinoma; basophil carcinoma; clear cell adenocarcinoma; granular cell carcinoma; follicular adenocarcinoma;
papillary and follicular adenocarcinoma; nonencapsulating sclerosing carcinoma; adrenal cortical carcinoma; endometroid carcinoma; skin appendage carcinoma; apocrine adenocarcinoma; sebaceous adenocarcinoma; ceruminous adenocarcinoma;
mucoepidermoid carcinoma; cystadenocarcinoma; papillary cystadenocarcinoma; papillary serous cystadenocarcinoma; mucinous cystadenocarcinoma; mucinous adenocarcinoma;
signet ring cell carcinoma; infiltrating duct carcinoma; medullary carcinoma; lobular carcinoma;
inflammatory carcinoma; paget's disease, mammary; acinar cell carcinoma;
adenosquamous carcinoma; adenocarcinoma w/squamous metaplasia; thymoma, malignant; ovarian stromal tumor, malignant; thecoma, malignant; granulosa cell tumor, malignant;
androblastoma, malignant; sertoli cell carcinoma; leydig cell tumor, malignant; lipid cell tumor, malignant;
paraganglioma, malignant; extra-mammary paraganglioma, malignant;
pheochromocytoma;
glomangiosarcoma; malignant melanoma; amelanotic melanoma; superficial spreading melanoma; malignant melanoma in giant pigmented nevus; epithelioid cell melanoma; blue nevus, malignant; sarcoma; fibrosarcoma; fibrous histiocytoma, malignant;
myxosarcoma;
liposarcoma; leiomyosarcoma; rhabdomyosarcoma; embryonal rhabdomyosarcoma;
alveolar rhabdomyosarcoma; stromal sarcoma; mixed tumor, malignant; mullerian mixed tumor;
nephroblastoma; hepatoblastoma; carcinosarcoma; mesenchymoma, malignant;
brenner tumor, malignant; phyllodes tumor, malignant; synovial sarcoma; mesothelioma, malignant;
dysgerminoma; embryonal carcinoma; teratoma, malignant; struma ovarii, malignant;
choriocarcinoma; mesonephroma, malignant; hemangiosarcoma;
hemangioendothelioma, malignant; kaposi's sarcoma; hemangiopericytoma, malignant; lymphangiosarcoma;
osteosarcoma; juxtacortical osteosarcoma; chondrosarcoma; chondroblastoma, malignant;
mesenchymal chondrosarcoma; giant cell tumor of bone; ewing's sarcoma;
odontogenic tumor, malignant; ameloblastic odontosarcoma; ameloblastoma, malignant;
ameloblastic fibrosarcoma; pinealoma, malignant; chordoma; glioma, malignant; ependymoma;
astrocytoma; protoplasmic astrocytoma; fibrillary astrocytoma; astroblastoma;
glioblastoma;
oligodendroglioma; oligodendroblastoma; primitive neuroectodermal; cerebellar sarcoma;
ganglioneuroblastoma; neuroblastoma; retinoblastoma; olfactory neurogenic tumor;
meningioma, malignant; neurofibrosarcoma; neurilemmoma, malignant; granular cell tumor, malignant; malignant lymphoma; hodgkin's disease; hodgkin's; paragranuloma;
malignant lymphoma, small lymphocytic; malignant lymphoma, large cell, diffuse;
malignant lymphoma, follicular; mycosis fungoides; other specified non-hodgkin's lymphomas, malignant histiocytosis; multiple myeloma; mast cell sarcoma;
immunoproliferative small intestinal disease; leukemia; lymphoid leukemia; plasma cell leukemia;
erythroleukemia;
lymphosarcoma cell leukemia; myeloid leukemia; basophilic leukemia;
eosinophilic leukemia; monocytic leukemia; mast cell leukemia; megakaryoblastic leukemia;
myeloid sarcoma; and hairy cell leukemia.
100891 The terms "contacted" and "exposed," when applied to a cell, are used herein to describe the process by which a therapeutic agent are delivered to a target cell or are placed in direct juxtaposition with the target cell. To achieve cell killing, for example, one or more agents are delivered to a cell in an amount effective to kill the cell or prevent it from dividing.
An effective response of a patient or a patient's "responsiveness" to treatment refers to the clinical or therapeutic benefit imparted to a patient at risk for, or suffering from, a disease or disorder. Such benefit may include cellular or biological responses, a complete response, a partial response, a stable disease (without progression or relapse), or a response with a later relapse. For example, an effective response can be reduced tumor size or progression-free survival in a patient diagnosed with cancer.
Treatment outcomes can be predicted and monitored and/or patients benefiting from such treatments can be identified or selected via the methods described herein.
Regarding neoplastic condition treatment, depending on the stage of the neoplastic condition, neoplastic condition treatment involves one or a combination of the following therapies: surgery to remove the neoplastic tissue, radiation therapy, and chemotherapy. Other therapeutic regimens may be combined with the administration of the anticancer agents, e.g., therapeutic compositions and chemotherapeutic agents.
For example, the patient to be treated with such anti-cancer agents may also receive radiation therapy and/or may undergo surgery.
For the treatment of disease, the appropriate dosage of a therapeutic composition will depend on the type of disease to be treated, as defined above, the severity and course of the disease, the patient's clinical history and response to the agent, and the discretion of the attending physician. The agent is suitably administered to the patient at one time or over a series of treatments.
100941 Therapeutic and prophylactic methods and compositions can be provided in a combined amount effective to achieve the desired effect. A tissue, tumor, or cell can be contacted with one or more compositions or pharmacological formulation(s) comprising one or more of the agents, or by contacting the tissue, tumor, and/or cell with two or more distinct compositions or formulations. Also, it is contemplated that such a combination therapy can be used in conjunction with chemotherapy, radiotherapy, surgical therapy, or immunotherapy.
Administration in combination can include simultaneous administration of two or more agents in the same dosage form, simultaneous administration in separate dosage forms, and separate administration. That is, the subject therapeutic composition and another therapeutic agent can be formulated together in the same dosage form and administered simultaneously. Alternatively, subject therapeutic composition and another therapeutic agent can be simultaneously administered, wherein both the agents are present in separate formulations. In another alternative, the therapeutic agent can be administered just followed by the other therapeutic agent or vice versa. In the separate administration protocol, the subject therapeutic composition and another therapeutic agent may be administered a few minutes apart, or a few hours apart, or a few days apart.
100961 A first anti-cancer treatment (e.g., exosomes that express a recombinant protein or with a recombinant protein isolated from exosomes) may be administered before, during, after, or in various combinations relative to a second anti-cancer treatment. The administrations may be in intervals ranging from concurrently to minutes to days to weeks.
In embodiments where the first treatment is provided to a patient separately from the second treatment, one would generally ensure that a significant period of time did not expire between the time of each delivery, such that the two compounds would still be able to exert an advantageously combined effect on the patient. In such instances, it is contemplated that one may provide a patient with the first therapy and the second therapy within about 12 to 24 or 72 h of each other and, more particularly, within about 6-12 h of each other.
In some situations it may be desirable to extend the time period for treatment significantly where several days (2, 3, 4, 5, 6, or 7) to several weeks (1, 2, 3, 4, 5, 6, 7, or 8) lapse between respective administrations.
100971 In certain embodiments, a course of treatment will last 1-90 days or more (this such range includes intervening days). It is contemplated that one agent may be given on any day of day 1 to day 90 (this such range includes intervening days) or any combination thereof, and another agent is given on any day of day 1 to day 90 (this such range includes intervening days) or any combination thereof. Within a single day (24-hour period), the patient may be given one or multiple administrations of the agent(s).
Moreover, after a course of treatment, it is contemplated that there is a period of time at which no anti-cancer treatment is administered. This time period may last 1-7 days, and/or 1-5 weeks, and/or 1-12 months or more (this such range includes intervening days), depending on the condition of the patient, such as their prognosis, strength, health, etc. It is expected that the treatment cycles would be repeated as necessary.
[0098] Various combinations may be employed. For the example below a first anti-cancer therapy is "A" and a second anti-cancer therapy is "B":
A/B/A B/A/B B/B/A A/A/B AJB/B B/A/A A/B/B/B B/A/B/B
B/B/B/A B/B/A/B A/A/B/B A/B/A/B A/B/B/A B/B/A/A
B/A/B/A B/A/A/B A/A/A/B B/A/A/A A/B/A/A A/A/B/A
[0099] Administration of any compound or therapy of the present invention to a patient will follow general protocols for the administration of such compounds, taking into account the toxicity, if any, of the agents. Therefore, in some embodiments there is a step of .. monitoring toxicity that is attributable to combination therapy.
1. Chemotherapy [00100]
A wide variety of chemotherapeutic agents may be used in accordance with the present invention. The term "chemotherapy" refers to the use of drugs to treat cancer. A "chemotherapeutic agent" is used to connote a compound or composition that is administered in the treatment of cancer. These agents or drugs are categorized by their mode of activity within a cell, for example, whether and at what stage they affect the cell cycle.
Alternatively, an agent may be characterized based on its ability to directly cross-link DNA, to intercalate into DNA, or to induce chromosomal and mitotic aberrations by affecting nucleic acid synthesis.
[00101] Examples of chemotherapeutic agents include alkylating agents, such as thiotepa and cyclosphosphamide; alkyl sulfonates, such as busulfan, improsulfan, and piposulfan; aziridines, such as benzodopa, carboquone, meturedopa, and uredopa;
ethylenimines and methylamelamines, including altretamine, triethylenemelamine, tri etyl enephosphorami de, tri ethi y I en ethi ophosphorami de, and trimethylol om el ami ne;
acetogenins (especially bullatacin and bullatacinone); a camptothecin (including the synthetic analogue topotecan); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogues, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards, such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, and uracil mustard; nitrosureas, such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics, such as the enediyne antibiotics (e.g., calicheamicin, especially calicheamicin gammall and calicheamicin omegall ); dynemicin, including dynemicin A; bisphosphonates, such as clodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne anti obi oti c chromophores, acl aci n om y sins, acti nomycin, authrarnycin, azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins, such as mitomycin C, mycophenolic acid, nogalarnycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, and zorubicin; anti-metabolites, such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues, such as denopterin, pteropterin, and trimetrexate;
purine analogs, such as fludarabine, 6-mercaptopurine, thiamiprine, and thioguanine;
pyrimidine analogs, such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, and floxuridine; androgens, such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, and testolactone; anti-adrenals, such as mitotane and trilostane; folic acid replenisher, such as frolinic acid;
aceglatone;
aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine;
bestrabucil;
bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elformithine;
elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan;
lonidainine;
maytansinoids, such as maytansine and ansamitocins; mitoguazone; mitoxantrone;
mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone;
podophyllinic acid; 2-ethylhydrazide; procarbazine; PSKpolysaccharide complex; razoxane;
rhizoxin;
sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2"-trichlorotriethylamine, trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine);
urethan;
vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman;
gacytosine;
arabinoside ("Ara-C"); cyclophosphamide; taxoids, e.g., paclitaxel and docetaxel gemcitabine; 6-thioguanine; mercaptopurine; platinum coordination complexes, such as cisplatin, oxaliplatin, and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide;
mitoxantrone; vincristine; vinorelbine; novantrone; teniposide; edatrexate;
daunomycin;
aminopterin; xeloda; ibandronate; irinotecan (e.g., CPT-11); topoisomerase inhibitor RFS
2000; difluorometlhylornithine (DNIF0); retinoids, such as retinoic acid;
capecitabine;
carboplatin, procarbazine,plicomycin, gemcitabi en, navelbine, farnesyl -protein tansferase inhibitors, transplatinum, and pharmaceutically acceptable salts, acids, or derivatives of any of the above.
2. Radiotherapy 1001021 Other factors that cause DNA damage and have been used extensively include what are commonly known as y-rays, X-rays, and/or the directed delivery of radioisotopes to tumor cells. Other forms of DNA damaging factors are also contemplated, such as microwaves, proton beam irradiation (U.S. Patents 5,760,395 and 4,870,287), and UV-irradiation. It is most likely that all of these factors affect a broad range of damage on DNA, on the precursors of DNA, on the replication and repair of DNA, and on the assembly and maintenance of chromosomes. Dosage ranges for X-rays range from daily doses of 50 to 200 roentgens for prolonged periods of time (3 to 4 wk), to single doses of 2000 to 6000 roentgens. Dosage ranges for radioisotopes vary widely, and depend on the half-life of the isotope, the strength and type of radiation emitted, and the uptake by the neoplastic cells.
3. Immunotherapy 1001031 The skilled artisan will understand that additional immunotherapies may be used in combination or in conjunction with methods of the invention. In the context of cancer treatment, immunotherapeutics, generally, rely on the use of immune effector cells and molecules to target and destroy cancer cells. Rituximab (Rituxane) is such an example.
The immune effector may be, for example, an antibody specific for some marker on the surface of a tumor cell. The antibody alone may serve as an effector of therapy or it may recruit other cells to actually affect cell killing. The antibody also may be conjugated to a drug or toxin (chemotherapeutic, radionuclide, ricin A chain, cholera toxin, pertussis toxin, etc.) and serve merely as a targeting agent. Alternatively, the effector may be a lymphocyte carrying a surface molecule that interacts, either directly or indirectly, with a tumor cell target. Various effector cells include cytotoxic T cells and NK cells.
In one aspect of immunotherapy, the tumor cell must bear some marker that is amenable to targeting, i.e., is not present on the majority of other cells. Many tumor markers exist and any of these may be suitable for targeting in the context of the present invention. Common tumor markers include CD20, carcinoembryonic antigen, tyrosinase (p97), gp68, TAG-72, HMFG, Sialyl Lewis Antigen, MucA, MucB, PLAP, laminin receptor, erb B, and p155. An alternative aspect of immunotherapy is to combine anticancer effects with immune stimulatory effects. Immune stimulating molecules also exist including:
cytokines, such as IL-2, IL-4, 1L-12, GM-CSF, gamma-IFN, chemokines, such as M1P-1, MCP-1, IL-8, and growth factors, such as FLT3 ligand.
1001051 Examples of immunotherapies currently under investigation or in use are immune adjuvants, e.g., Mycobacterium bovis, Plasmodium .fakiparum, dinitrochlorobenzene, and aromatic compounds (U.S. Patents 5,801,005 and 5,739,169; Hui and Hashimoto, 1998; Christodoulides et al., 1998); cytokine therapy, e.g., interferons a, 13, and 7, IL-1, GM-CSF, and TNF (Bukowski et al., 1998; Davidson et al., 1998;
Hellstrand et al., 1998); gene therapy, e.g., TNF, IL-1, IL-2, and p53 (Qin et al., 1998;
Austin-Ward and Villaseca, 1998; U.S. Patents 5,830,880 and 5,846,945); and monoclonal antibodies, e.g., anti-CD20, anti-ganglioside GM2, and anti-p185 (Hollander, 2012; Hanibuchi et al., 1998;
U.S. Patent 5,824,311). It is contemplated that one or more anti-cancer therapies may be employed with the antibody therapies described herein.
In some embodiments, the immunotherapy may be an immune checkpoint inhibitor. Immune checkpoints either turn up a signal (e.g., co-stimulatory molecules) or turn down a signal. Inhibitory immune checkpoints that may be targeted by immune checkpoint blockade include adenosine A2A receptor (AZAR), B7-H3 (also known as CD276), B and T lymphocyte attenuator (BTLA), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4, also known as CD152), indoleamine 2,3-dioxygenase (ID0), killer-cell immunoglobulin (KIR), lymphocyte activation gene-3 (LAG3), programmed death 1 (PD-1), T-cell immunoglobulin domain and mucin domain 3 (TIM-3) and V-domain 1g suppressor of T cell activation (VISTA). In particular, the immune checkpoint inhibitors target the PD-1 axis and/or CTLA-4.
The immune checkpoint inhibitors may be drugs such as small molecules, recombinant forms of ligand or receptors, or, in particular, are antibodies, such as human antibodies (e.g., International Patent Publication W02015016718;
Pardo11, Nat Rev Cancer, 12(4): 252-64, 2012; both incorporated herein by reference). Known inhibitors of the immune checkpoint proteins or analogs thereof may be used, in particular chimerized, humanized or human forms of antibodies may be used. As the skilled person will know, alternative and/or equivalent names may be in use for certain antibodies mentioned in the present disclosure. Such alternative and/or equivalent names are interchangeable in the context of the present disclosure. For example, it is known that lambrolizumab is also known under the alternative and equivalent names MK-3475 and pembrolizumab.
In some embodiments, the PD-1 binding antagonist is a molecule that inhibits the binding of PD-1 to its ligand binding partners. In a specific aspect, the PD-1 ligand binding partners are PDL1 and/or PDL2. In another embodiment, a PDL1 binding antagonist is a molecule that inhibits the binding of PDL1 to its binding partners. In a specific aspect, PDL1 binding partners are PD-1 and/or B7-1. In another embodiment, the binding antagonist is a molecule that inhibits the binding of PDL2 to its binding partners. In a specific aspect, a PDL2 binding partner is PD-1. The antagonist may be an antibody, an antigen binding fragment thereof, an immunoadhesin, a fusion protein, or oligopeptide.
Exemplary antibodies are described in U.S. Patent Nos. 8,735,553, 8,354,509, and 8,008,449, all incorporated herein by reference. Other PD-1 axis antagonists for use in the methods provided herein are known in the art such as described in U.S. Patent Publication Nos.
20140294898, 2014022021, and 20110008369, all incorporated herein by reference.
[00109]
In some embodiments, the PD-1 binding antagonist is an anti-PD-1 antibody (e.g., a human antibody, a humanized antibody, or a chimeric antibody). In some embodiments, the anti-PD-1 antibody is selected from the group consisting of nivolumab, pembrolizumab, and CT-011. In some embodiments, the PD-1 binding antagonist is an immunoadhesin (e.g., an immunoadhesin comprising an extracellular or PD-1 binding portion of PDL1 or PDL2 fused to a constant region (e.g., an Fc region of an immunoglobulin sequence). In some embodiments, the PD-1 binding antagonist is AMP- 224.
Nivolumab, also known as MDX-1106-04, MDX-1106, ONO-4538, BMS-936558, and OPDIVO , is an anti-PD-1 antibody described in W02006/121168. Pembrolizumab, also known as MK-3475, Merck 3475, lambrolizumab, KEYTRUDA , and SCH-900475, is an anti-PD-1 antibody described in W02009/114335. CT-011, also known as hBAT or hBAT-1, is an anti-antibody described in W02009/101611. AMP-224, also known as B7-DCIg, is a PDL2-Fc fusion soluble receptor described in W02010/027827 and W02011/066342.
[00110]
Another immune checkpoint that can be targeted in the methods provided herein is the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also known as CD152. The complete cDNA sequence of human CTLA-4 has the Genbank accession number L15006. CTLA-4 is found on the surface of T cells and acts as an "off' switch when bound to CD80 or CD86 on the surface of antigen-presenting cells. CTLA4 is a member of the immunoglobulin superfamily that is expressed on the surface of Helper T
cells and transmits an inhibitory signal to T cells. CTLA4 is similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and respectively, on antigen-presenting cells. CTLA4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Intracellular CTLA4 is also found in regulatory T cells and may be important to their function. T cell activation through the T cell receptor and CD28 leads to increased expression of CTLA-4, an inhibitory receptor for B7 molecules.
[00111]
In some embodiments, the immune checkpoint inhibitor is an anti-CTLA-4 antibody (e.g., a human antibody, a humanized antibody, or a chimeric antibody), an antigen binding fragment thereof, an immunoadhesin, a fusion protein, or oligopeptide.
Anti-human-CTLA-4 antibodies (or VI-1 and/or VL domains derived therefrom) suitable for use in the present methods can be generated using methods well known in the art. Alternatively, art recognized anti-CTLA-4 antibodies can be used. For example, the anti-CTLA-4 antibodies disclosed in: US Patent No. 8,119,129, WO
01/14424, WO 98/42752; WO 00/37504 (CP675,206, also known as tremelimumab; formerly ticilimumab), U.S. Patent No. 6,207,156; Hurwitz et al. (1998) Proc Nat! Acad Sci USA
95(17): 10067-10071; Camacho et al. (2004) J Clin Oncology 22(145): Abstract No. 2505 (antibody CP-675206); and Mokyr etal. (1998) Cancer Res 58:5301-5304 can be used in the methods disclosed herein. The teachings of each of the aforementioned publications are hereby incorporated by reference. Antibodies that compete with any of these art-recognized antibodies for binding to CTLA-4 also can be used. For example, a humanized antibody is described in International Patent Application No. W02001014424, W02000037504, and U.S. Patent No. 8,017,114; all incorporated herein by reference.
An exemplary anti-CTLA-4 antibody is ipilimumab (also known as 10D1, MDX- 010, MDX- 101, and Yervoye) or antigen binding fragments and variants thereof (see, e.g., WO 01/14424). In other embodiments, the antibody comprises the heavy and light chain CDRs or VRs of ipilimumab. Accordingly, in one embodiment, the antibody comprises the CDR1, CDR2, and CDR3 domains of the VH region of ipilimumab, and the CDR1, CDR2 and CDR3 domains of the VL region of ipilimumab. In another embodiment, the antibody competes for binding with and/or binds to the same epitope on CTLA-4 as the above- mentioned antibodies. In another embodiment, the antibody has at least about 90%
variable region amino acid sequence identity with the above-mentioned antibodies (e.g., at least about 90%, 95%, or 99% variable region identity with ipilimumab).
Other molecules for modulating CTLA-4 include CTLA-4 ligands and receptors such as described in U.S. Patent Nos. 5844905, 5885796 and International Patent Application Nos. W01995001994 and W01998042752; all incorporated herein by reference, and immunoadhesins such as described in U.S. Patent No. 8329867, incorporated herein by reference.
In some embodiment, the immune therapy could be adoptive immunotherapy, which involves the transfer of autologous antigen-specific T
cells generated ex vivo. The T cells used for adoptive immunotherapy can be generated either by expansion of antigen-specific T cells or redirection of T cells through genetic engineering (Park, Rosenberg et al. 2011). Isolation and transfer of tumor specific T cells has been shown to be successful in treating melanoma. Novel specificities in T cells have been successfully generated through the genetic transfer of transgenic T cell receptors or chimeric antigen receptors (CARs) (Jena, Dofti et al. 2010). CARs are synthetic receptors consisting of a targeting moiety that is associated with one or more signaling domains in a single fusion molecule. In general, the binding moiety of a CAR consists of an antigen-binding domain of a single-chain antibody (scFv), comprising the light and variable fragments of a monoclonal antibody joined by a flexible linker. Binding moieties based on receptor or ligand domains have also been used successfully. The signaling domains for first generation CARs are derived from the cytoplasmic region of the CD3zeta or the Fc receptor gamma chains. CARs have successfully allowed T cells to be redirected against antigens expressed at the surface of tumor cells from various malignancies including lymphomas and solid tumors (Jena, Dotti et al. 2010).
[00116]
In one embodiment, the present application provides for a combination therapy for the treatment of cancer wherein the combination therapy comprises adoptive 1-cell therapy and a checkpoint inhibitor. In one aspect, the adoptive 1-cell therapy comprises autologous and/or allogenic T cells. In another aspect, the autologous and/or allogenic T cells are targeted against tumor antigens.
4. Surgery [00117]
Approximately 60% of persons with cancer will undergo surgery of some type, which includes preventative, diagnostic or staging, curative, and palliative surgery. Curative surgery includes resection in which all or part of cancerous tissue is physically removed, excised, and/or destroyed and may be used in conjunction with other therapies, such as the treatment of the present invention, chemotherapy, radiotherapy, hormonal therapy, gene therapy, immunotherapy, and/or alternative therapies.Tumor resection refers to physical removal of at least part of a tumor. In addition to tumor resection, treatment by surgery includes laser surgery, cryosurgery, electrosurgery, and microscopically-controlled surgery (Mohs' surgery).
[00118]
Upon excision of part or all of cancerous cells, tissue, or tumor, a cavity may be formed in the body. Treatment may be accomplished by perfiision, direct injection, or local application of the area with an additional anti-cancer therapy. Such treatment may be repeated, for example, every 1, 2, 3, 4, 5, 6, or 7 days, or every 1, 2, 3, 4, and 5 weeks or every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months. These treatments may be of varying dosages as well.
5. Other Agents It is contemplated that other agents may be used in combination with certain aspects of the present invention to improve the therapeutic efficacy of treatment.
These additional agents include agents that affect the upregulation of cell surface receptors and GAP junctions, cytostatic and differentiation agents, inhibitors of cell adhesion, agents that increase the sensitivity of the hyperproliferative cells to apoptotic inducers, or other biological agents. Increases in intercellular signaling by elevating the number of GAP
junctions would increase the anti-hyperproliferative effects on the neighboring hyperproliferative cell population. In other embodiments, cytostatic or differentiation agents can be used in combination with certain aspects of the present invention to improve the anti-hyperproliferative efficacy of the treatments. Inhibitors of cell adhesion are contemplated to improve the efficacy of the present invention. Examples of cell adhesion inhibitors are focal adhesion kinase (FAKs) inhibitors and Lovastatin. It is further contemplated that other agents that increase the sensitivity of a hyperproliferative cell to apoptosis, such as the antibody c225, could be used in combination with certain aspects of the present invention to improve the treatment efficacy.
III. Pharmaceutical Compositions 1001201 It is contemplated that exosomes that express or comprise a therapeutic protein, inhibitory RNA, and/or small molecule drug can be administered systemically or locally to inhibit tumor cell growth and, most preferably, to kill cancer cells in cancer patients with locally advanced or metastatic cancers. They can be administered intravenously, intrathecally, and/or intraperitoneally. They can be administered alone or in combination with anti-proliferative drugs. In one embodiment, they are administered to reduce the cancer load in the patient prior to surgery or other procedures. Alternatively, they can be administered after surgery to ensure that any remaining cancer (e.g., cancer that the surgery failed to eliminate) does not survive.
It is not intended that the present invention be limited by the particular nature of the therapeutic preparation. For example, such compositions can be provided in formulations together with physiologically tolerable liquid, gel, solid carriers, diluents, or excipients. These therapeutic preparations can be administered to mammals for veterinary use, such as with domestic animals, and clinical use in humans in a manner similar to other therapeutic agents. In general, the dosage required for therapeutic efficacy will vary according to the type of use and mode of administration, as well as the particular requirements of individual subjects.
Where clinical applications are contemplated, it may be necessary to prepare pharmaceutical compositions comprising recombinant proteins and/or exosomes in a form appropriate for the intended application. Generally, pharmaceutical compositions may comprise an effective amount of one or more recombinant proteins and/or exosomes or additional agents dissolved or dispersed in a pharmaceutically acceptable carrier. The phrases "pharmaceutical or pharmacologically acceptable" refers to molecular entities and compositions that do not produce an adverse, allergic, or other untoward reaction when administered to an animal, such as, for example, a human, as appropriate. The preparation of a pharmaceutical composition comprising a recombinant protein and/or exosomes as disclosed herein, or additional active ingredient will be known to those of skill in the art in light of the present disclosure, as exemplified by Remington's Pharmaceutical Sciences, 18th Ed., 1990, incorporated herein by reference. Moreover, for animal (e.g., human) administration, it will be understood that preparations should meet sterility, pyrogenicity, general safety, and purity standards as required by the FDA Office of Biological Standards.
1001231 Further in accordance with certain aspects of the present invention, the composition suitable for administration may be provided in a pharmaceutically acceptable carrier with or without an inert diluent. As used herein, "pharmaceutically acceptable carrier" includes any and all aqueous solvents (e.g., water, alcoholic/aqueous solutions, ethanol, saline solutions, parenteral vehicles, such as sodium chloride, Ringer's dextrose, eic.), non-aqueous solvents (e.g., fats, oils, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), vegetable oil, and injectable organic esters, such as ethyloleate), lipids, liposomes, dispersion media, coatings (e.g., lecithin), surfactants, antioxidants, preservatives (e.g., antibacterial or antifungal agents, anti-oxidants, chelating agents, inert gases, parabens (e.g., methylparabens, propylparabens), chlorobutanol, phenol, sorbic acid, thimerosal or combinations thereof), isotonic agents (e.g., sugars and sodium chloride), absorption delaying agents (e.g., aluminum monostearate and gelatin), salts, drugs, drug stabilizers, gels, resins, fillers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, fluid and nutrient replenishers, such like materials and combinations thereof, as would be known to one of ordinary skill in the art. The carrier should be assimilable and includes liquid, semi-solid, i.e., pastes, or solid carriers. In addition, if desired, the compositions may contain minor amounts of auxiliary substances, such as wetting or emulsifying agents, stabilizing agents, or pH buffering agents. The pH and exact concentration of the various components in a pharmaceutical composition are adjusted according to well-known parameters. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion, and by the use of surfactants.
pharmaceutically acceptable carrier is particularly formulated for administration to a human, although in certain embodiments it may be desirable to use a pharmaceutically acceptable carrier that is formulated for administration to a non-human animal but that would not be acceptable (e.g., due to governmental regulations) for administration to a human. Except insofar as any conventional carrier is incompatible with the active ingredient (e.g., detrimental to the recipient or to the therapeutic effectiveness of a composition contained therein), its use in the therapeutic or pharmaceutical compositions is contemplated. In accordance with certain aspects of the present invention, the composition is combined with the carrier in any convenient and practical manner, i.e., by solution, suspension, emulsification, admixture, encapsulation, absorption, and the like. Such procedures are routine for those skilled in the art.
Certain embodiments of the present invention may comprise different types of carriers depending on whether it is to be administered in solid, liquid, or aerosol form, and whether it needs to be sterile for the route of administration, such as injection. The compositions can be administered intravenously, intradermally, transdermally, intrathecally, intraarterially, intraperitoneally, intranasally, intravaginally, intrarectally, intramuscularly, subcutaneously, mucosally, orally, topically, locally, by inhalation (e.g., aerosol inhalation), by injection, by infusion, by continuous infusion, by localized perfusion bathing target cells directly, via a catheter, via a lavage, in lipid compositions (e.g., liposomes), or by other methods or any combination of the forgoing as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed., 1990, incorporated herein by reference).
[00126]
The active compounds can be formulated for parenteral administration, e.g., formulated for injection via the intravenous, intramuscular, sub-cutaneous, or even intraperitoneal routes. Typically, such compositions can be prepared as either liquid solutions or suspensions; solid forms suitable for use to prepare solutions or suspensions upon the addition of a liquid prior to injection can also be prepared; and the preparations can also be emulsified.
The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil, or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that it may be easily injected. It also should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
The therapeutics may be formulated into a composition in a free base, neutral, or salt form. Pharmaceutically acceptable salts include the acid addition salts, e.g., those formed with the free amino groups of a proteinaceous composition, or which are formed with inorganic acids, such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, or mandelic acid and the like.
Salts formed with the free carboxyl groups can also be derived from inorganic bases, such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides; or such organic bases as isopropylamine, trimethylamine, histidine, or procaine and the like. Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms, such as formulated for parenteral administrations, such as injectable solutions, or aerosols for delivery to the lungs, or formulated for alimentary administrations, such as drug release capsules and the like.
[00129]
In a specific embodiment of the present invention, the composition is combined or mixed thoroughly with a semi-solid or solid carrier. The mixing can be carried out in any convenient manner, such as grinding. Stabilizing agents can be also added in the mixing process in order to protect the composition from loss of therapeutic activity, i.e., denaturation in the stomach. Examples of stabilizers for use in a composition include buffers, amino acids, such as glycine and lysine, carbohydrates, such as dextrose, mannose, galactose, fructose, lactose, sucrose, maltose, sorbitol, mannitol, etc.
[00130]
In further embodiments, the present invention may concern the use of a pharmaceutical lipid vehicle composition comprising one or more lipids and an aqueous solvent. As used herein, the term "lipid" will be defined to include any of a broad range of substances that is characteristically insoluble in water and extractable with an organic solvent. This broad class of compounds is well known to those of skill in the art, and as the term "lipid" is used herein, it is not limited to any particular structure.
Examples include compounds that contain long-chain aliphatic hydrocarbons and their derivatives. A lipid may be naturally occurring or synthetic (i.e., designed or produced by man).
However, a lipid is usually a biological substance. Biological lipids are well known in the art, and include for example, neutral fats, phospholipids, phosphoglycerides, steroids, terpenes, lysolipids, glycosphingolipids, glycolipids, sulphatides, lipids with ether- and ester-linked fatty acids, polymerizable lipids, and combinations thereof. Of course, compounds other than those specifically described herein that are understood by one of skill in the art as lipids are also encompassed by the compositions and methods.
[00131]
One of ordinary skill in the art would be familiar with the range of techniques that can be employed for dispersing a composition in a lipid vehicle. For example, the therapeutic agent may be dispersed in a solution containing a lipid, dissolved with a lipid, emulsified with a lipid, mixed with a lipid, combined with a lipid, covalently bonded to a lipid, contained as a suspension in a lipid, contained or complexed with a micelle or liposome, or otherwise associated with a lipid or lipid structure by any means known to those of ordinary skill in the art. The dispersion may or may not result in the formation of liposomes.
[00132] The term "unit dose" or "dosage" refers to physically discrete units suitable for use in a subject, each unit containing a predetermined quantity of the therapeutic composition calculated to produce the desired responses discussed above in association with its administration, i.e., the appropriate route and treatment regimen. The quantity to be administered, both according to number of treatments and unit dose, depends on the effect desired. The actual dosage amount of a composition of the present invention administered to a patient or subject can be determined by physical and physiological factors, such as body weight, the age, health, and sex of the subject, the type of disease being treated, the extent of disease penetration, previous or concurrent therapeutic interventions, idiopathy of the patient, the route of administration, and the potency, stability, and toxicity of the particular therapeutic substance. For example, a dose may also comprise from about 1 jig/kg/body weight to about 1.000 mg/kg/body weight (this such range includes intervening doses) or more per administration, and any range derivable therein. In non-limiting examples of a derivable range from the numbers listed herein, a range of about 5 jig/kg/body weight to about 100 mg/kg/body weight, about 5 jig/kg/body weight to about 500 mg/kg/body weight, etc., can be administered. The practitioner responsible for administration will, in any event, determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual subject.
The actual dosage amount of a composition administered to an animal patient can be determined by physical and physiological factors, such as body weight, severity of condition, the type of disease being treated, previous or concurrent therapeutic interventions, idiopathy of the patient, and on the route of administration.
Depending upon the dosage and the route of administration, the number of administrations of a preferred dosage and/or an effective amount may vary according to the response of the subject. The practitioner responsible for administration will, in any event, determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual subject.
In certain embodiments, pharmaceutical compositions may comprise, for example, at least about 0.1% of an active compound. In other embodiments, an active compound may comprise between about 2% to about 75% of the weight of the unit, or between about 25% to about 60%, for example, and any range derivable therein.
Naturally, the amount of active compound(s) in each therapeutically useful composition may be prepared in such a way that a suitable dosage will be obtained in any given unit dose of the compound. Factors, such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations, will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable.
In other non-limiting examples, a dose may also comprise from about 1 microgram/kg/body weight, about 5 microgram/kg/body weight, about 10 microgram/kg/body weight, about 50 microgram/kg/body weight, about 100 microgram/kg/body weight, about 200 microgram/kg/body weight, about 350 microgram/kg/body weight, about 500 microgram/kg/body weight, about 1 milligram/kg/body weight, about 5 milligram/kg/body weight, about 10 milligram/kg/body weight, about 50 milligram/kg/body weight, about 100 milligram/kg/body weight, about 200 milligram/kg/body weight, about 350 milligram/kg/body weight, about 500 milligram/kg/body weight, to about 1000 milligram/kg/body weight or more per administration, and any range derivable therein. In non-limiting examples of a derivable range from the numbers listed herein, a range of about 5 milligram/kg/body weight to about 100 milligram/kg/body weight, about 5 microgram/kg/body weight to about 500 milligram/kg/body weight, etc., can be administered, based on the numbers described above.
IV. Nucleic Acids and Vectors 1001361 In certain aspects of the invention, nucleic acid sequences encoding a therapeutic protein or a fusion protein containing a therapeutic protein may be disclosed.
Depending on which expression system is used, nucleic acid sequences can be selected based on conventional methods. For example, the respective genes or variants thereof may be codon optimized for expression in a certain system. Various vectors may be also used to express the protein of interest. Exemplary vectors include, but are not limited, plasmid vectors, viral vectors, transposon, or liposome-based vectors.
V. Recombinant Proteins, Inhibitory RNAs, and Gene Editing Systems A. Recombinant Proteins 1001371 Some embodiments concern recombinant proteins and polypeptides.
Particular embodiments concern a recombinant protein or polypeptide that exhibits at least one therapeutic activity. In some embodiments, a recombinant protein or polypeptide may be a therapeutic antibody. In some aspects, a therapeutic antibody may be an antibody that specifically or selectively binds to an intracellular protein. In further aspects, the protein or polypeptide may be modified to increase serum stability. Thus, when the present application refers to the function or activity of "modified protein" or a "modified polypeptide," one of ordinary skill in the art would understand that this includes, for example, a protein or polypeptide that possesses an additional advantage over the unmodified protein or polypeptide. It is specifically contemplated that embodiments concerning a "modified protein" may be implemented with respect to a "modified polypeptide," and vice versa.
[00138]
Recombinant proteins may possess deletions and/or substitutions of amino acids; thus, a protein with a deletion, a protein with a substitution, and a protein with a deletion and a substitution are modified proteins. In some embodiments, these proteins may further include insertions or added amino acids, such as with fusion proteins or proteins with linkers, for example. A "modified deleted protein" lacks one or more residues of the native protein, but may possess the specificity and/or activity of the native protein. A "modified deleted protein" may also have reduced immunogenicity or antigenicity. An example of a modified deleted protein is one that has an amino acid residue deleted from at least one antigenic region that is, a region of the protein determined to be antigenic in a particular organism, such as the type of organism that may be administered the modified protein.
[00139]
Substitution or replacement variants typically contain the exchange of one amino acid for another at one or more sites within the protein and may be designed to modulate one or more properties of the polypeptide, particularly its effector functions and/or bioavailability. Substitutions may or may not be conservative, that is, one amino acid is replaced with one of similar shape and charge. Conservative substitutions are well known in the art and include, for example, the changes of: alanine to serine; arginine to lysine;
asparagine to glutamine or histidine; aspartate to glutamate; cysteine to serine; glutamine to asparagine; glutamate to aspartate; glycine to proline; histidine to asparagine or glutamine;
isoleucine to leucine or valine; leucine to valine or isoleucine; lysine to arginine; methionine to leucine or isoleucine; phenylalanine to tyrosine, leucine, or methionine;
serine to threonine; threonine to serine; tryptophan to tyrosine; tyrosine to tryptophan or phenylalanine; and valine to isoleucine or leucine.
In addition to a deletion or substitution, a modified protein may possess an insertion of residues, which typically involves the addition of at least one residue in the polypeptide. This may include the insertion of a targeting peptide or polypeptide or simply a single residue. Terminal additions, called fusion proteins, are discussed below.
[00141]
The term "biologically functional equivalent" is well understood in the art and is further defined in detail herein. Accordingly, sequences that have between about 70% and about 80%, or between about 81% and about 90%, or even between about 91% and about 99% of amino acids that are identical or functionally equivalent to the amino acids of a control polypeptide are included, provided the biological activity of the protein is maintained.
A recombinant protein may be biologically functionally equivalent to its native counterpart in certain aspects.
It also will be understood that amino acid and nucleic acid sequences may include additional residues, such as additional N- or C-terminal amino acids or 5' or 3' sequences, and yet still be essentially as set forth in one of the sequences disclosed herein, so long as the sequence meets the criteria set forth above, including the maintenance of biological protein activity where protein expression is concerned. The addition of terminal sequences particularly applies to nucleic acid sequences that may, for example, include various non-coding sequences flanking either of the 5' or 3' portions of the coding region or may include various internal sequences, i.e., introns, which are known to occur within genes.
As used herein, a protein or peptide generally refers, but is not limited to, a protein of greater than about 200 amino acids, up to a full length sequence translated from a gene; a polypeptide of greater than about 100 amino acids; and/or a peptide of from about 3 to about 100 amino acids. For convenience, the terms "protein,"
"polypeptide," and "peptide are used interchangeably herein.
As used herein, an "amino acid residue" refers to any naturally occurring amino acid, any amino acid derivative, or any amino acid mimic known in the art.
In certain embodiments, the residues of the protein or peptide are sequential, without any non-amino acids interrupting the sequence of amino acid residues. In other embodiments, the sequence may comprise one or more non-amino acid moieties. In particular embodiments, the sequence of residues of the protein or peptide may be interrupted by one or more non-amino acid moieties.
Accordingly, the term "protein or peptide" encompasses amino acid sequences comprising at least one of the 20 common amino acids found in naturally occurring proteins, or at least one modified or unusual amino acid.
Certain embodiments of the present invention concern fusion proteins.
These molecules may have a therapeutic protein linked at the N- or C-terminus to a heterologous domain. For example, fusions may also employ leader sequences from other species to permit the recombinant expression of a protein in a heterologous host. Another useful fusion includes the addition of a protein affinity tag, such as a serum albumin affinity tag or six histidine residues, or an immunologically active domain, such as an antibody epitope, preferably cleavable, to facilitate purification of the fusion protein. Non-limiting affinity tags include polyhistidine, chitin binding protein (CBP), maltose binding protein (MBP), and glutathione-S-transferase (GST).
In a particular embodiment, the therapeutic protein may be linked to a peptide that increases the in vivo half-life, such as an XTEN polypeptide (Schellenberger et al., 2009), IgG Fc domain, albumin, or albumin binding peptide.
Methods of generating fusion proteins are well known to those of skill in the art. Such proteins can be produced, for example, by de novo synthesis of the complete fusion protein, or by attachment of the DNA sequence encoding the heterologous domain, followed by expression of the intact fusion protein.
Production of fusion proteins that recover the functional activities of the parent proteins may be facilitated by connecting genes with a bridging DNA
segment encoding a peptide linker that is spliced between the polypeptides connected in tandem. The linker would be of sufficient length to allow proper folding of the resulting fusion protein.
B. Inhibitory RNAs siNA (e.g., siRNA) are well known in the art. For example, siRNA and double-stranded RNA have been described in U.S. Pat. Nos. 6,506,559 and 6,573,099, as well as in U.S. Patent Applications 2003/0051263, 2003/0055020, 2004/0265839, 2002/0168707, 2003/0159161, and 2004/0064842, all of which are herein incorporated by reference in their entirety.
Within a siNA, the components of a nucleic acid need not be of the same type or homogenous throughout (e.g., a siNA may comprise a nucleotide and a nucleic acid or nucleotide analog). Typically, siNA form a double-stranded structure;
the double-stranded structure may result from two separate nucleic acids that are partially or completely complementary. In certain embodiments of the present invention, the siNA may comprise only a single nucleic acid (polynucleotide) or nucleic acid analog and form a double-stranded structure by complementing with itself (e.g., forming a hairpin loop). The double-stranded structure of the siNA may comprise 16, 20, 25, 30, 35, 40, 45, 50, 60, 65, 70, 75, 80, 85, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500 or more contiguous nucleobases, including all ranges therein. The siNA may comprise 17 to 35 contiguous nucleobases, more preferably 18 to 30 contiguous nucleobases, more preferably 19 to 25 nucleobases, more preferably 20 to 23 contiguous nucleobases, or 20 to 22 contiguous nucleobases, or 21 contiguous nucleobases that hybridize with a complementary nucleic acid (which may be another part of the same nucleic acid or a separate complementary nucleic acid) to form a double-stranded structure.
[00152] Agents of the present invention useful for practicing the methods of the present invention include, but are not limited to siRNAs. Typically, introduction of double-stranded RNA (dsRNA), which may alternatively be referred to herein as small interfering RNA (siRNA), induces potent and specific gene silencing, a phenomena called RNA
interference or RNAi. RNA interference has been referred to as "cosuppression," "post-transcriptional gene silencing," "sense suppression," and "quelling." RNAi is an attractive biotechnological tool because it provides a means for knocking out the activity of specific genes.
In designing RNAi there are several factors that need to be considered, such as the nature of the siRNA, the durability of the silencing effect, and the choice of delivery system. To produce an RNAi effect, the siRNA that is introduced into the organism will typically contain exonic sequences. Furthermore, the RNAi process is homology dependent, so the sequences must be carefully selected so as to maximize gene specificity, while minimizing the possibility of cross-interference between homologous, but not gene-specific sequences. Preferably the siRNA exhibits greater than 80%, 85 A, 90 A, 95%, 98%, or even 100% identity between the sequence of the siRNA and the gene to be inhibited.
Sequences less than about 80% identical to the target gene are substantially less effective.
Thus, the greater homology between the siRNA and the gene to be inhibited, the less likely expression of unrelated genes will be affected.
[00154]
In addition, the size of the siRNA is an important consideration. In some embodiments, the present invention relates to siRNA molecules that include at least about 19-25 nucleotides and are able to modulate gene expression. In the context of the present invention, the siRNA is preferably less than 500, 200, 100, 50, or 25 nucleotides in length. More preferably, the siRNA is from about 19 nucleotides to about 25 nucleotides in length.
[00155] A target gene generally means a polynucleotide comprising a region that encodes a polypeptide, or a polynucleotide region that regulates replication, transcription, or translation or other processes important to expression of the polypeptide, or a polynucleotide comprising both a region that encodes a polypeptide and a region operably linked thereto that regulates expression. Any gene being expressed in a cell can be targeted.
Preferably, a target gene is one involved in or associated with the progression of cellular activities important to disease or of particular interest as a research object.
siRNA can be obtained from commercial sources, natural sources, or can be synthesized using any of a number of techniques well-known to those of ordinary skill in the art. For example, one commercial source of predesigned siRNA is Ambion , Austin, Tex. Another is Qiagene (Valencia, Calif.). An inhibitory nucleic acid that can be applied in the compositions and methods of the present invention may be any nucleic acid sequence that has been found by any source to be a validated downregulator of a protein of interest.
Without undue experimentation and using the disclosure of this invention, it is understood that additional siRNAs can be designed and used to practice the methods of the invention.
The siRNA may also comprise an alteration of one or more nucleotides. Such alterations can include the addition of non-nucleotide material, such as to the end(s) of the 19 to 25 nucleotide RNA or internally (at one or more nucleotides of the RNA). In certain aspects, the RNA molecule contains a 3'-hydroxyl group.
Nucleotides in the RNA molecules of the present invention can also comprise non-standard nucleotides, including non-naturally occurring nucleotides or deoxyribonucleotides. The double-stranded oligonucleotide may contain a modified backbone, for example, phosphorothioate, phosphorodithioate, or other modified backbones known in the art, or may contain non-natural internucleoside linkages. Additional modifications of siRNAs (e.g., 2'-0-methyl ribonucleotides, 2'-deoxy-2'-fluoro ribonucleotides, "universal base"
nucleotides, 5-C-methyl nucleotides, one or more phosphorothioate internucleotide linkages, and inverted deoxyabasic residue incorporation) can be found in U.S. Application Publication 2004/0019001 and U.S.
Pat. No. 6,673,611 (each of which is incorporated by reference in its entirety). Collectively, all such altered nucleic acids or RNAs described above are referred to as modified siRNAs.
C. Gene Editing Systems In general, "CRISPR system" refers collectively to transcripts and other elements involved in the expression of or directing the activity of CRISPR-associated ("Cas") genes, including sequences encoding a Cas gene, a tracr (trans-activating CRISPR) sequence (e.g. tracrRNA or an active partial tracrRNA), a tracr-mate sequence (encompassing a "direct repeat" and a tracrRNA-processed partial direct repeat in the context of an endogenous CRISPR system), a guide sequence (also referred to as a "spacer" in the context of an endogenous CRISPR system), and/or other sequences and transcripts from a CRISPR
locus.
1001591 The CRISPR/Cas nuclease or CRISPR/Cas nuclease system can include a non-coding RNA molecule (guide) RNA, which sequence-specifically binds to DNA, and a Cas protein (e.g., Cas9), with nuclease functionality (e.g., two nuclease domains). One or more elements of a CRISPR system can derive from a type I, type II, or type HI CRISPR system, e.g., derived from a particular organism comprising an endogenous CRISPR system, such as Streptococcus pyogenes.
In some aspects, a Cas nuclease and gRNA (including a fusion of crRNA specific for the target sequence and fixed tracrRNA) are introduced into the cell. In general, target sites at the 5' end of the gRNA target the Cas nuclease to the target site, e.g., the gene, using complementary base pairing. The target site may be selected based on its location immediately 5' of a protospacer adjacent motif (PAM) sequence, such as typically NGG, or NAG. In this respect, the gRNA is targeted to the desired sequence by modifying the first 20, 19, 18, 17, 16, 15, 14, 14, 12, 11, or 10 nucleotides of the guide RNA to correspond to the target DNA sequence. In general, a CRISPR system is characterized by elements that promote the formation of a CRISPR complex at the site of a target sequence.
Typically, "target sequence" generally refers to a sequence to which a guide sequence is designed to have complementarity, where hybridization between the target sequence and a guide sequence promotes the formation of a CRISPR complex. Full complementarity is not necessarily required, provided there is sufficient complementarity to cause hybridization and promote formation of a CRISPR complex.
1001611 The CRISPR system can induce double stranded breaks (DSBs) at the target site, followed by disruptions as discussed herein. In other embodiments, Cas9 variants, deemed "nickases," are used to nick a single strand at the target site. Paired nickases can be used, e.g., to improve specificity, each directed by a pair of different gRNAs targeting sequences such that upon introduction of the nicks simultaneously, a 5' overhang is introduced. In other embodiments, catalytically inactive Cas9 is fused to a heterologous effector domain such as a transcriptional repressor or activator, to affect gene expression.
The target sequence may comprise any polynucleotide, such as DNA
or RNA polynucleotides. The target sequence may be located in the nucleus or cytoplasm of the cell, such as within an organelle of the cell. Generally, a sequence or template that may be used for recombination into the targeted locus comprising the target sequences is referred to as an "editing template" or "editing polynucleotide" or "editing sequence". In some aspects, an exogenous template polynucleotide may be referred to as an editing template. In some aspects, the recombination is homologous recombination.
Typically, in the context of an endogenous CRISPR system, formation of the CRISPR complex (comprising the guide sequence hybridized to the target sequence and complexed with one or more Cas proteins) results in cleavage of one or both strands in or near (e.g. within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs from) the target sequence. The tracr sequence, which may comprise or consist of all or a portion of a wild-type tracr sequence (e.g. about or more than about 20, 26, 32, 45, 48, 54, 63, 67, 85, or more nucleotides of a wild-type tracr sequence), may also form part of the CRISPR
complex, such as by hybridization along at least a portion of the tracr sequence to all or a portion of a tracr mate sequence that is operably linked to the guide sequence. The tracr sequence has sufficient complementarity to a tracr mate sequence to hybridize and participate in formation of the CRISPR complex, such as at least 50%, 60%, 70%, 80%, 90%, 95% or 99% of sequence complementarity along the length of the tracr mate sequence when optimally aligned.
1001641 One or more vectors driving expression of one or more elements of the CRISPR system can be introduced into the cell such that expression of the elements of the CRISPR system direct formation of the CRISPR complex at one or more target sites.
Components can also be delivered to cells as proteins and/or RNA. For example, a Cas enzyme, a guide sequence linked to a tracr-mate sequence, and a tracr sequence could each be operably linked to separate regulatory elements on separate vectors.
Alternatively, two or more of the elements expressed from the same or different regulatory elements, may be combined in a single vector, with one or more additional vectors providing any components of the CRISPR system not included in the first vector. The vector may comprise one or more insertion sites, such as a restriction endonuclease recognition sequence (also referred to as a "cloning site"). In some embodiments, one or more insertion sites are located upstream and/or downstream of one or more sequence elements of one or more vectors.
When multiple different guide sequences are used, a single expression construct may be used to target CRISPR activity to multiple different, corresponding target sequences within a cell.
A vector may comprise a regulatory element operably linked to an enzyme-coding sequence encoding the CRISPR enzyme, such as a Cas protein. Non-limiting examples of Cas proteins include Casl, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csnl and Csx12), Cas10, Csy 1, Csy2, Csy3, Csel, Cse2, Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Csbl, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csxl, Csx15, Csfl, Cst'2, Csf3, Csf4, homologs thereof, or modified versions thereof These enzymes are known; for example, the amino acid sequence of S. pyogenes Cas9 protein may be found in the SwissProt database under accession number Q99ZW2.
[00166]
The CRISPR enzyme can be Cas9 (e.g., from S. pyogenes or S.
pneumonia). The CRISPR enzyme can direct cleavage of one or both strands at the location of a target sequence, such as within the target sequence and/or within the complement of the target sequence. The vector can encode a CRISPR enzyme that is mutated with respect to a corresponding wild-type enzyme such that the mutated CRISPR enzyme lacks the ability to cleave one or both strands of a target polynucleotide containing a target sequence. For example, an aspartate-to-alanine substitution (D10A) in the RuvC I catalytic domain of Cas9 from S. pyogenes converts Cas9 from a nuclease that cleaves both strands to a nickase (cleaves a single strand). In some embodiments, a Cas9 nickase may be used in combination with guide sequence(s), e.g., two guide sequences, which target respectively sense and antisense strands of the DNA target. This combination allows both strands to be nicked and used to induce 1=THEI or IlDR.
In some embodiments, an enzyme coding sequence encoding the CRISPR enzyme is codon optimized for expression in particular cells, such as eukaryotic cells. The eukaryotic cells may be those of or derived from a particular organism, such as a mammal, including but not limited to human, mouse, rat, rabbit, dog, or non-human primate.
In general, codon optimization refers to a process of modifying a nucleic acid sequence for enhanced expression in the host cells of interest by replacing at least one codon of the native sequence with codons that are more frequently or most frequently used in the genes of that host cell while maintaining the native amino acid sequence. Various species exhibit particular bias for certain codons of a particular amino acid. Codon bias (differences in codon usage between organisms) often correlates with the efficiency of translation of messenger RNA
(mRNA), which is in turn believed to be dependent on, among other things, the properties of the codons being translated and the availability of particular transfer RNA
(tRNA) molecules.
The predominance of selected tRNAs in a cell is generally a reflection of the codons used most frequently in peptide synthesis. Accordingly, genes can be tailored for optimal gene expression in a given organism based on codon optimization.
In general, a guide sequence is any polynucleotide sequence having sufficient complementarity with a target polynucleotide sequence to hybridize with the target sequence and direct sequence-specific binding of the CRISPR complex to the target sequence. In some embodiments, the degree of complementarity between a guide sequence and its corresponding target sequence, when optimally aligned using a suitable alignment algorithm, is about or more than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or more.
Optimal alignment may be determined with the use of any suitable algorithm for aligning sequences, non-limiting example of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g. the Burrows Wheeler Aligner), Clustal W, Clustal X, BLAT, Novoalign (Novocraft Technologies, ELAND (IIlumina, San Diego, Calif.), SOAP
(available at soap.genomics.org.cn), and Maq (available at maq.sourceforge.net).
1001701 The CRISPR enzyme may be part of a fusion protein comprising one or more heterologous protein domains. A CRISPR enzyme fusion protein may comprise any additional protein sequence, and optionally a linker sequence between any two domains.
Examples of protein domains that may be fused to a CRISPR enzyme include, without limitation, epitope tags, reporter gene sequences, and protein domains having one or more of the following activities: methylase activity, demethylase activity, transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, RNA cleavage activity and nucleic acid binding activity. Non-limiting examples of epitope tags include histidine (His) tags, V5 tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags.
Examples of reporter genes include, but are not limited to, glutathione-5- transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT) beta galactosidase, beta-glucuronidase, luciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), and autofluorescent proteins including blue fluorescent protein (BFP). A CRISPR enzyme may be fused to a gene sequence encoding a protein or a fragment of a protein that bind DNA molecules or bind other cellular molecules, including but not limited to maltose binding protein (MBP), S-tag, Lex A DNA
binding domain (DBD) fusions, GAL4A DNA binding domain fusions, and herpes simplex virus (HSV) BP16 protein fusions. Additional domains that may form part of a fusion protein comprising a CRISPR enzyme are described in US 20110059502, incorporated herein by reference.
VI. Kits and Diagnostics 1901711 In various aspects of the invention, a kit is envisioned containing the necessary components to purify exosomes from a body fluid or tissue culture medium. In other aspects, a kit is envisioned containing the necessary components to isolate exosomes and transfect them with a therapeutic nucleic acid, therapeutic protein, or a nucleic acid encoding a therapeutic protein therein. The kit may comprise one or more sealed vials containing any of such components. In some embodiments, the kit may also comprise a suitable container means, which is a container that will not react with components of the kit, such as an eppendorf tube, an assay plate, a syringe, a bottle, or a tube. The container may be made from sterilizable materials such as plastic or glass. The kit may further include an instruction sheet that outlines the procedural steps of the methods set forth herein, and will follow substantially the same procedures as described herein or are known to those of ordinary skill. The instruction information may be in a computer readable media containing machine-readable instructions that, when executed using a computer, cause the display of a real or virtual procedure of purifying exosomes from a sample and transfecting a therapeutic nucleic acid therein, expressing a recombinant protein therein, or electroporating a recombinant protein therein.
VII. Examples 1001721 The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.
Materials and Methods 1001731 Cell Culture. MCF7, MDA-MB231, E10, HDF, and BJ human cell lines, as well as the Nil-1 3T3 murine cell line were cultured in DME/VI with 100/o FBS. The 4T1 and 67NR murine cell lines were cultured in RPMI with 100/o FBS. MCF10A
human mammary epithelial cell line was cultured in DMEM/F12 media with 5% Horse Serum, 20 ng/ml EGF, 0.5 mg/ml Hydrocortisone, 100 ng/ml Cholera Toxin, and 10 gg/ml Insulin. All cells originated from the American Type Culture Collection ¨ ATCC.
Isolation and purification of exosomes. Exosomes were purified by differential centrifugation as described previously (Luga et al., 2012; Thery et al., 2006).
Supernatant from cells cultured for 48 h were subjected to sequential centrifugation steps of 800g and 2000g. The resulting supernatant was filtered using a 0.2 gm filter.
A pellet was recovered after ultracentrifugation in an SW40Ti swinging bucket rotor at 100,000g for 3 h (Beckman-Coulter). Supernatant was removed and the pellet was re-suspended in PBS, followed by a second ultracentrifugation at 100,000g for 3 h. The resulting pellet was analyzed for exosomes content. Exosomes used for RNA extraction were resuspended in 500 gL of Trizol; exosomes used for protein extraction were resuspended in Urea/SDS lysis buffer (8M Urea, 2.5% SDS, 5 gg/mL leupeptin, 1 gg/mL pepstatin, and 1 mM
phenylmethylsulphonyl fluoride); and exosomes used for delivery to cells were re-suspended in serum-free DMEM culture medium. For other applications, isolated exosomes were processed as described in the remaining experimental procedures.
Imaging Flow cytometry analysis (ImageStream). Exosomes were attached to 4 gm aldehyde/sulfate latex beads (Invitrogen, Carlsbad, CA, USA) in NaC1 0.9%
saline solution (B. Braun Medical Inc, Bethlehem, PA, USA). The reaction was stopped with 100 mM glycine and 2% BSA in saline and blocked with 10% BSA with rotation at room temperature for 30 min. After washing in saline/2% BSA, bead-bound exosomes were centrifuged for 2 min at 10,000 rpm and incubated with 1:200 anti-CD63 (Santa Cruz), anti-CD9 (Abcam), anti-CD81 (Abcam), anti-CD82 (Abcam), and anti-FLOT1 (Santa Cruz) for 30 min rotating at 4 C. Beads were centrifuged for 2 min at 10,000 rpm, washed in saline/2%
BSA and incubated with 1:400 Alexa-488 secondary antibodies (Life Technologies, NY
14072) for 30 min rotating at 4 C. After three washes the beads were resuspended in saline solution and analyzed on the ImageStream (Merck Millipore). The image acquisition gain (%) was set using a positive sample, in order to avoid pixel saturation. Image processing was done using the IDEAS (Merck Millipore) software. Gates were defined to exclude out-of-focus beads and select single beads. Alexa-488 positive bead gates were defined on the negative control sample. Percentage of positive beads is relative to the number of events analyzed per sample.
immunogold Labeling and Electron Microscopy. Pelleted exosomes were fixed by re-suspending in 2.5% Glutaraldehyde in 0.1 M Phosphate buffer.
Fixed specimens at an optimal concentration were placed onto a 300 mesh carbon/formvar coated grids and allowed to absorb to the formvar for a minimum of 1 minute. For immunogold staining the grids were placed into a blocking buffer for a block/permeabilization step for 1 h.
Without rinsing, the grids were immediately placed into the primary antibody at the appropriate dilution overnight at 4 C (polyclonal anti-GFP 1:10, Abcam). As controls, some grids were not exposed to the primary antibody. The next day all grids were rinsed with PBS
and floated on drops of the appropriate secondary antibody attached with 10 nm gold particles (AURION, Hatfield, PA) for 2 h at room temperature. Grids were rinsed with PBS
and placed in 2.5% Glutaraldehyde in 0.1 M Phosphate buffer for 15 minutes.
After rinsing in PBS and distilled water, the grids were allowed to dry and stained for contrast using uranyl acetate. The samples were viewed with a Tecnai Bio Twin transmission electron microscope (FEI, Hillsboro, OR) and images were taken with an AMT CCD Camera (Advanced Microscopy Techniques, Danvers, MA).
EGF stimulation of exosomes. Exosomes were collected from MBA-MB-23I cells as described above. 1-3 x 109 exosomes were resuspended in 1 mL
PBS and different concentrations of rEGF were added. Exosomes suspensions, with or without EGF, were incubated at 37 C with 5% CO2 for 15 minutes and then placed on ice.
Three replicates were pooled and PBS was added to a total volume of 11 mL and stimulated exosomes were collected through ultracentrifugation in an SW40Ti swinging bucket rotor at 100,000g for 3 h, as before. Protein extracts were collected from the pelleted stimulated exosomes in Urea/SDS lysis buffer (with 100 mM NaF and 1 mM Na0V4) for immunoblot analysis or a Triton X-100 buffer (150 mM NaCl, 1% (v/v) Triton X-100, 10 mM Na2HPO4, 2 mM
KH2PO4, pH 7.4, 50 mM 6-aminohexanoic acid, 10 mM EDTA, 5 mM N-ethylmaleimide, mM benzamidine, 5 1.1g/mL leupeptin, 1 lig/mL pepstatin, 1 mM
phenylmethylsulphonyl fluoride, 100 mM NaF, and 1 mM Na0V4) for immunoprecipitation assays.
Protein Western Blot and Antibodies. Exosomes protein extracts were loaded according to a Bicinchoninic Acid (BCA) protein assay kit (Pierce, Thermo Fisher Scientific) onto acrylamide gels and transferred onto PVDF membranes (ImmobilonP) by wet electrophoretic transfer. Blots were blocked for 1 h at RT with 5% non-fat dry milk in TBS/0.05% Tween20 and incubated overnight at 4 C with the following primary antibodies:
1:300 anti-CD9 ab92726 (Abeam); 1:300 anti-TSG101 ab83 (Abeam); 1:1000 anti-EGFR
4267S (CST); 1:300 anti-CD63 sc-365604, (Santa Cruz); 1:200 anti-CD81 cs-166029 (Santa Cruz); 1:1000 anti-pEGFR Tyr1068 3777S (CST); 1:2000 anti-GRB2 610111 (BD
Biosciences); 1:1000 anti-Shc 06-203 (Millipore); 1:5000 anti-GFP ab13970 (Abeam);
1:1000 GAPDH ab9483 (Abcam); 1:10,000 HRPconjugated I3-actin a3854 (Sigma);
1:400 anti-RNA Pol II cat#39097 (Active Motif); 1:500 anti-Hsp90 ab1429 (Abcam);
1:500 anti-elF3A ab86146 (Abeam); 1:500 anti-elF4A1 ab31217 (Abeam). HRP-conjugated secondary antibodies (Sigma, 1:2000) were incubated for 1 h at room temperature. Washes after antibody incubations were done on an orbital shaker, four times at 10 min intervals, with 1 x TBS 0.05% Tween20. Blots were developed with chemiluminescent reagents from Pierce.
Immunoprecipitation. Exosomes and cell protein extracts gently rocked at 4 C for 2 h. The lysates were centrifuged at 14,000g in a pre-cooled centrifuge for 15 minutes and the pellet was discarded. Protein A or G agarose/sepharose beads were washed twice with PBS and restored to a 50% slurry with PBS. A bead/slurry mix (100 ill) was added to 100 lig of exosomes protein extracts or 20 lig of cells protein extracts and incubated at 4 C
for 10 min. Beads were removed by centrifugation at 14,000g at 4 C for 10 minutes and pellets discarded. 10 tig of anti-elF4A1 antibody was added to 100 AL of exosomal lysate and incubated overnight at 4 C on an orbital shaker. 100 pL of Protein A or G
agarose/sepharose bead slurry were added and left at 4 C overnight. After centrifugation the supernatant was discarded and beads washed 3 times with ice-cold Urea/SDS buffer. The agarose/sepharose beads were boiled for 5 minutes to dissociate the immunocomplexes from the beads. The beads were collected by centrifugation and immunoblot was performed on the supernatant.
Identification of amino acids using UPW-MS. Exosomes were mixed with 200 p1. of methanol spiked with the Internal Standard tryptophan-d5 and incubated for an hour at -20 C. After centrifugation at 16,000g for 15 min at 4 C, 190 RL
of the supernatants was collected and the solvent removed. Dried extracts were reconstituted in 15 RL of methanol, of which 10 IlL were transferred to microtubes and derivatized.
Chromatographic separation and mass spectrometric detection conditions employed are summarized in Table 1. The mass range, 50 - 1000 m/z, was calibrated with cluster ions of sodium formate. An appropriate test mixture of standard compounds was analyzed before and after the entire set of randomized duplicated sample injections, in order to examine the retention time stability and sensitivity of the LC/MS system throughout the course of the run.
Table 1. Chromatographic conditions for the amino acids platform.
System SQL) Column type UPLC BEH C18, 1.0 x 100 mm, 1.7 um Flow rate 0.14 ml/min Solvent A H20 + 10mM Ammonium Bicarbonate (+N1140H until pH: 8.8) Solvent B CAN
(%B), time 2%, 0 min (%B), time 8%, 6.5 min (%B), time 20%, 10 min (%B), time 30%, 11 min (%B), time 99.9%, 12 min (%B), time 2%, 14 min Column temperature 40 C
Injection volume 1 I
Ionisation ES+
Source temperature 120 C
Nebulisation N2 flow 600 1/ hour Nebulisation N2 temperature 350 C
Cone N2 flow 10 1/ hour Capillary voltage 3.2 kV
Cone voltage 30 V
1001811 Data were processed using the TargetLynx application manager for MassLynx 4.1 software (Waters Corp., Milford, USA). A set of predefined retention time, mass-to-charge ratio pairs, Rt-m/z, corresponding to metabolites included in the analysis are fed into the program. Associated extracted ion chromatograms (mass tolerance window =
0.05 Da) are then peak-detected and noise-reduced in both the LC and MS
domains such that only true metabolite related features are processed by the software. A list of chromatographic peak areas is then generated for each sample injection, using the Rt-m/z data pairs (retention time tolerance = 6 s) as identifiers. Normalization factors were calculated for each metabolite by dividing their intensities in each sample by the recorded intensity of the internal standard in that same sample.
Digital ql)CR. Digital RNA reaction was performed using 3 ng of cDNA, TaqMan Universal Master mix and QuantStudioTm 3D Digital PCR Master Mix vi (Applied Biosystems) according to manufacture recommendations. Using QuantStudioTm 3D
Digital PCR Chip Loader (Applied Biosystems) a total of 14.5 of the mix were loaded to a QuantStudioTm 3D Digital PCR 20K Chip Kit vi (Applied Biosystems). PCR
reaction was performed on GeneAmp 9700 (Applied Biosystems) following manufacture protocol. The chips were imaged using QuantStudion4 3D Digital PCR Instrument (Applied Biosystems).
Table 2. Digital PCR Primers.
Name Sequence SEQ ID
NO
Met AGTAGGTAGCGCGTCAGTCTCATAATCTGAAGGTCGTGAGT 1 TCGATCCTCACACGGGGCA
Leu AGGCGCTGGATTAAGGCTCCAGTCTCTTCGGAGGCGTGGGT 2 TCGAATCCCACCGCTGCCA
Val AGTGGTTATCACGTTCGCCTAACACGCGAAAGGTCCCCGGT 3 TCGAAACCGGGCGGAAACA
Ser GGC G ATGGACTAGA A ATC C ATMGGGITTCC CCG CGCAGGT 4 TCGA ATCCTGCCGACTACG
[355:Imethionine labeling of exosomes. Exosomes were isolated as previously described and resuspended in methionine-free culture medium without FBS with 0.1 ¨ 1.0 mCi/m1 trans label [355]-L-methionine (Amersham Biosciences) and incubated overnight. Alternatively exosomes were incubated in the presence of cycloheximide (Sigma, 100 1.tg/mL). Exosomes were pelleted, washed in ice-cold PBS and resuspended in Urea/SDS
lysis buffer as previously described. Protein extracts were quantified using a BCA protein assay kit, run on acrylamide gels and transferred onto PVDF membranes (ImmobilonP) by wet electrophoretic transfer, after which the membranes were analyzed by autoradiography using the EN3HANCE autoradiography enhancer according to the manufacturer's instructions (Perkin-Elmer).
Real-time PSI? Analysis. DNase treated RNA was retro-transcribed with MultiScribe Reverse Transcriptase (Applied Biosystems) and oligo-d(T) primers following total exosomes RNA purification with Trizol (Invitrogen). Real-time PCR was performed on an ABI PRISM 7300HT Sequence Detection System Instrument using SYBR
Green Master Mix (Applied Biosystems) and 13-actin as the control. 28S rRNA
primer pairs (QF00318857) and 18S rRNA primer pairs (QF00530467) were purchased as ready specific primer pairs from Qiagen. Other primers are listed below. Each measurement was performed in triplicate. Threshold cycle (Rothstein et al.), the fractional cycle number at which the amount of amplified target reached a fixed threshold, was determined and expression was measured using the 2-ACt formula, as previously reported (Livak and Schmittgen, 2001).
Table 3. qPCR Probes.
Name Sequence SEQ ID NO
p21 F 5' TACCCTTGTGCCTCGCTC AG3' 5 p21 R 5' GAGAA GATC AGCC GGCGTTT3 ' 6 lisa-Actin F 5'CATGTACGTICiCIATCCAGGC3 7 hsa-Actin R 5'CICCITAATGICACGCACGAT3' 8 mmu-Actin F 5' GGCIGTATTCCCCICCATCG3 ' 9 mmu-Actin R 5'CCAGITGGTAACAATGCCAIGT3' 10 [00185] Lysate preparation for in vitro transcription and translation.
Exosomes and cell pellets were washed once in ice-cold PBS and resuspended in an equal volume of ice-cold 20 mM HEPES (pH 7.5), 100 mM potassium acetate, 1 mM
magnesium acetate, 2 mM dithiothreitol, and 100 g/mL lysolecithin. After 1 min on ice, they were again pelleted and resuspended in an equal volume of ice-cold hypotonic extraction buffer. After 5 min on ice, the lysates were disrupted by passing 10 times through a 26-gauge needle attached to a 1-mL syringe. The resulting homogenates were centrifuged at 1000g for 5 min at 4 C. The supernatant was collected, and aliquots were frozen in liquid nitrogen and stored at ¨80 C for use in the in vitro translation assay.
[00186]
In vitro coupled transcription and translation. Lysates obtained from cells and exosomes as previously described were used for in vitro translation in reaction volumes of 12 AL. Standard reaction conditions were as follows: cell lysate (final protein concentration 10 pg) or exosomes lysate (final concentration 100 ig), 1 pEMT7-GFP
cDNA expression plasmid, 20 mM HEPES-KOH (pH 7.6), 80 mM potassium acetate, 1 mM
magnesium acetate, 1 mM ATP, 0.12 m/VI GTP, 17 mM creatine phosphate, 0.1 mWmL
creatine phosphokinase, 2 mM dithiothreitol, 40 pM of each of the 20 amino acids, 0.15 mM
spermidine, and 400 U/mL RNAsin (Promega). Incubations were carried out for 3 h at 37 C.
Electroporation and culture of exosomes. Exosomes were pelleted and resuspended in 400 pi, of electroporation buffer (1.15 mM potassium phosphate pH 7.2, 25 mM potassium chloride, 21% Optiprep), with 20 g of plasmid (pCMV-GFP, pEGFP-p53 Addgene plasmid 12091, pcDNA3-RLUC-POLIRES-FLUC and pcDNA-FLUC). Exosomes were electroporated using a 4 mm cuvette using a Gene Pulser Xcell Electroporation System (BioRad), as previously described (Alvarez-Erviti et al., 2011). When appropriate, exosomes were electroporated in the presence of cycloheximide (Sigma, 100 mg/mL) or a-amanitin (Sigma, 30 g/mL), for inhibition of translation and transcription, respectively.
Electroporated exosomes were cultured in serum-free DMEM at 37 C for the time points indicated.
Flow cytometry analysis of electroporated exosomes. Exosomes preparations (5 ¨10 g) were incubated with 5 pi, of 4 JIM diameter aldehyde/sulfate latex beads (Interfacial Dynamics, Portland, OR) and resuspended into 600 tiL.
Exosomes-coated beads were analyzed on a FACS Calibur flow cytometer (BD Biosciences) and analyzed for green fluorescence.
Exosomes delivery and cortfocal microscopy. MCF10A cells were plated at an appropriate confluency in 12-well plates on inserted coverslips and cultured overnight. The following day cells were incubated with MDA-MB-231 exosomes resuspended in serum-free culture DMEM for 2 h, washed with cold PBS lx and fixed for 20 min at room temperature with 4 /o PFA/PBS. Slides were permeabilized for 10 min at RT
with PBS 0.5% Triton X-100 and counterstained with DAPI. Images were obtained using a Zeiss LSM510 Upright Confocal System using the recycle tool to maintain identical settings.
For data analysis, images were selected from a pool drawn from at least two independent experiments. Figures show representative fields.
1001901 Reverse transwell assay. Exosomes were isolated from MDA-MB-231 cells as previously described, and resuspended in PBS and quantified using Nanosight NTA.
10 x 109 exosomes in 150 I, PBS were added to each bottom well of a 96-well Corningrm HTSTranswell system. PBS alone was added to bottom wells as a negative control. An insert containing a polycarbonate membrane with 40 nm pores was added to each well, and 100 L of PBS alone, PBS with 20% FBS, or PBS with 10,000 ng/ml of EGF were added to the insert. Trasnswell plates were incubated at 37 C with 5% CO2, and at samples were collected from the upper inserts after 4 h and 24 h incubation for exosomes quantification using Nanosight NTA.
[00191]
Statistics. Error bars indicate s.d. between biological replicates.
Technical as well as biological triplicates of each experiment were performed.
Statistical significance was calculated by Student's t-test, ANOVA or Mann-Whitney test, as appropriate and specified in the description of the figures.
Example 1 ¨ EGFR phosphorylation is detected in exosomes derived from MDA-MB-231, triple negative human breast cancer cells [00192]
Exosomes were isolated from different murine and human cell lines using established ultracentrifugation techniques (Melo et al., 2015; Melo et al., 2014). The isolated exosomes represent a heterogeneous mix, with the same size distribution being consistently observed between preparations. NanoSight nanoparticle tracking analysis (NTA) as well as atomic force microscopy (AFM) revealed particles with a size distribution averaging 104 1.5 nm in diameter, and ranging roughly between 30 and 200 nm.
This was confirmed by transmission electron microscopy (TEM) showing extracellular vesicles surrounded by a lipid bilayer (FIGS. 8A-C). The isolated exosomes were further shown by immunogold/TEM imaging, immunoblot analysis and imaging flow cytometry to possess known markers of exosomes (Raposo and Stoorvogel, 2013) (FIGS. 8D-F). To further confirm their purity, exosomes samples were inoculated onto solidified LB
plates, showing no colony formation when compared to bacterial controls obtained from mouth swabs. This demonstrates the absence of bacterial contamination in the isolated exosomes (FIG. 8G).
[00193]
Exosomes obtained from different cell lines were probed by immunoblotting for their EGFR content. While exosomes from all cell lines show low levels of EGFR expression, exosomes derived from the BJ fibroblast cell line and MDA-triple negative breast cancer cell line showed strong expression of the receptor. The known exosomes marker CD81 is shown as a loading control (FIG. 1A). Given the importance of EGFR for the progression of triple negative breast cancer (Lim et al., 2016;
Liu et al., 2012;
Nakai et al., 2016), its functional role in MDA-MB-231 derived exosomes was further explored. Exosomes were derived from MDA-MB-231 and MCF10A cells, and 1 billion exosomes were incubated with 500 ng/ml of recombinant human EGF (rhEGF) for 15 minutes at 37 C in serum-free culture media. Immunoblotting of protein extracts obtained from these exosomes with an antibody specific for the Tyr1068 residue of EGFR
revealed an increase in the phosphorylation levels of this receptor in exosomes derived from MDA-MB-231, but not non-tumorigenic MCF10A breast epithelial cells (FIG. 1B).
Baseline levels of EGFR did not change in any of the samples, confirming the specificity of the observed increase in phosphorylation. Recombinant human EGF (rhEGF) stimulation also lead to an increase in the levels of phosphorylated ERIC, suggesting that the observed EGFR
phosphorylation triggers downstream signaling events within the exosomes (FIG.
1C).
Further probing of the protein content of MDA-MB-231 exosomes showed that they also contained downstream effectors of EGFR, namely GRB2 and Shc (FIG. 1C).
1001941 It was then investigated whether upon rhEGF stimulation, exosomal EGFR could engage its downstream adaptors. Exosomes were stimulated with rhEGF
for 15 minutes at 37 C. The exosomal protein extracts were subjected to pull down assays using specific antibodies for GRB2 and Shc, and it was detected that upon EGF
stimulation they showed increased co-immunoprecipitation with EGFR (FIGS. 1D,E). Isotype IgGs were used as a negative control for the pull down, and did not reveal EGFR co-immunoprecipitation.
Additionally, by reversing the assay and pulling down EGFR, it was also possible to detect coimmunoprecipitated GRB2 only in EGF stimulated exosomes (FIG. 8B). Taken together these results demonstrate that exosomes from MDA-MB-231 cells contain EGFR
that can be phosphorylated by incubation with its ligand in cell-free conditions, leading to putative downstream signaling events within the exosomes.
Example 2 ¨ EGF stimulation of exosoines alters their protein content Receptor tyrosine kinases require ATP as a substrate for their kinase activity, and prostate-derived exosomes have been shown to have the capacity to generate ATP (Ronquist et al., 2013a). To further confirm the existence of phosphorylation activity in the absence of cells, an ATP quantification assay was performed on exosomes with or without rhEGF stimulation. Using a luminescence based kit, ATP was detected in exosomes from both MDA-MB-231 cells and MCF10A cells, albeit in smaller quantities in the latter.
Exosomes from MDA-103-231 cells, but not MCF10A cells, demonstrated a slight decrease in their ATP quantity upon stimulation with EGF (FIG. 2A). To further investigate the impact of EGF stimulation on exosomes, they were incubated them in cell-free conditions for a period of 48 h. The levels of GRB2 protein levels were consistently higher in exosomes stimulated with EGF for 48 h, compared to their unstimulated counterparts (FIG. 2B). This raised the intriguing possibility that the protein content of exosomes might have changed upon growth factor stimulation. To further investigate this possibility, mass spectrometry analysis was performed on protein extracts obtained from rhEGF unstimulated or stimulated exosomes. Protein extracts were subjected to bypsin digestion and evaluated using an ESI-TRAP mass spectrometer to obtain an MS/MS peptide spectrum for each sample.
The obtained spectra were then evaluated against a SwissProt database for peptide identification to obtain a list of proteins for each exosomes sample. Using the open access FunRich functional enrichment analysis tool (Pathan et al., 2015) it was observed that the majority of identified hits in both the unstimulated and stimulated exosomes matched proteins previously identified in exosomes (Vesiclepedia database) (FIG. 2C). A higher number of proteins were identified in exosomes stimulated with rhEGF when compared to the unstimulated ones (491 vs. 371, FIG. 2D). While the majority of these proteins were common to both stimulated and unstimulated exosomes, 224 out of 491 proteins were detected only upon rhEGF
stimulation.
While EGFR was identified on both samples, GRB2 was only identified in rhEGF
stimulated exosomes (FIG. 2E). It should be stressed however that this does not mean that GRB2 is not present in unstimulated exosomes, but it might be present at a level under the detectable threshold for this type of analysis. The Exponentially Modified Protein Abundance Index (emPAI), which allows for label-free quantification of relative changes in protein content based on the observable peptide matches, was employed (Ishihama et al., 2005).
The top 15 proteins that revealed a stronger increase in rhEGF stimulated exosomes when compared to their unstimulated counterparts included several participants of actin remodeling and membrane dynamics, such as a-actinin, MARCKS, ezrin, moesin, and integrin alpha-2 (Tables 4&5). A gene ontology (GO) analysis was then performed using the PANTHER
overrepresentation test. Interestingly, among the top GO biological processes enriched in the rhEGF stimulated exosomes, several were related to actin remodeling and migration (5 out of the 20 top pathways, Table 6).
Table 4. Top 15 proteins identified as upregulated in exosomes from MDA-MB-231 cells incubated with 500 ng/ml of EGF at 37 C for 48 h compared to control exosomes, based on the protein scores using the emPAI method (Ishihama et al., 2005).
Protein Name Description Control EGF- Fold Treatment Change CHMP2A Charged multivesicular body 0.4 2.25 5.625 protein 2a OS=Homo spapiens GN=CHMP2A PE::::1 S V :::1 C'HM1)2B Charged multivesicular body 0.19 1.03 5.421052632 Protein Name Description Control EGF- Fold Treatment Change protein 2b OS=Homo sapiens GN:=CHMP2B PE=1 SV=1 ACSL4 Long-chain-fatty-acid--CoAligase 0.06 0.31 5.166666667 4 OS=Homo sapiens GN=ACSL4 PE=1 SV=2 LDHB L-lactate dehydrogenase B chain 0.12 0.59 4.916666667 OS=Homo sapiens GN=LDHB
PE=1 SV=2 ACTN1 Alpha-actinin-1 OS=Homo 0.04 0.18 4.5 sapiens GN=ACTN1 PE=1 SV=2 ITGA2 Integrin alpha-2 OS=Homo 0.07 0.26 3.714285714 sapiens GN=ITGA2 PE=1 SV-1 HIST2H2AA3 Histone H2A type 2-A OS=Homo 6.9 24.85 3.601449275 sapiens GN-HIST2H2AA3 PE:::1 SV=3 MARCKS Myristoylated alanine-rich C- 0.14 0.5 3.571428571 kinase substrate OS=Homo sapiens GN=MARCKS PE=1 SV=4 VPS37B Vacuolar protein sorting- 0.14 0.5 3.571428571 associated protein 37B OS=Homo sapiens GN:::VPS37B PE=1 SV:=1 RPL5 60S ribosomal protein L5 0.13 0.45 3.461538462 OS=Homo sapiens GN=RPL5 PE=1 SV=3 EHD2 EH domain-containing protein 2 0.07 0.23 3.285714286 OS=Homo sapiens GN=EHD2 PE=1 SV=2 DNAJA1 DnaJ homolog subfamily A 0.61 1.84 3.016393443 member 1 OS=Homo sapiens GN-1)NAJA1 PE-1 SV=2 EZR Ezrin OS:-.Homo sapiens 1.23 3.39 2.756097561 GN:=EZR PE:::1 SV=4 MSN .Moesin OS=Homo sapiens 1.74 4.48 2.574712644 GN=MSN PE=1 SV=3 ARF I ADP-ribosylation factor 1 0.5 1.26 2.52 OS=Homo sapiens GN=ARF1 PE=1 SV=2 Table 5. Top 15 proteins identified as downregulated in exosomes from MDA-MB-231 cells incubated with 500 ng/ml of EGF at 37 C for 48 h compared to control exosomes, based on the protein scores using the emPAI method (Ishihama et al., 2005).
Protein Name Description Control EGF- Fold Treatment Change KRT9 "Keratin, type 1 cytoskeletal 9 6.86 1.28 0.186588921 OS=Homo sapiens GN=KRT9 Protein Name Description Control EGF- Fold Treatment Change PE=1 SV=3"
KRT2 "Keratin, type II cytoskeletal 2 2.46 0.92 0.37398374 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2"
GOLGA7 Golgin subfamily A member 7 0.7 0.3 0.428571429 OS=Homo sapiens GN=GOLGA7 PE-1 SV=2 CALMI Calmodulin OS=Homo sapiens 0.64 0.28 0.4375 GN=CALM1 PE=1 SV=2 HRAS GTPase HRas OS=Homo sapiens 0.48 0.22 0.458333333 GN=HRAS PE=1 SV=1 SCAMP2 Secretory carrier-associated 0.26 0.12 0.461538462 membrane protein 2 OS=Homo sapiens GN=SCAMP2 PE=1 SV=2 RGSI9 Regulator of G-protein signaling 0.41 0.19 0.463414634 19 OS=Homo sapiens GN=RGS19 PE:::1 SV=1 RAB5B Ras-related protein Rab-5B 0.43 0.2 0.465116279 OS=Homo sapiens GN=RAB5B
PE=1 SV=1 CORO 1 C Coronin-1C OS=Homo sapiens 0.17 0.08 0.470588235 GN=COROIC PE=1 SV=1 SLC7A1l Cystine/glutamate transporter 0.17 0.08 0.470588235 OS=Homo sapiens GN=SLC7A1 I
PE=1 SV=1 PACSIN3 Protein kinase C and casein kinase 0.19 0.09 0.473684211 substrate in neurons protein 3 OS=Homo sapiens GN=PACSIN3 PE=1 SV=2 VPS4B Vacuolar protein sorting- 0.19 0.09 0.473684211 associated protein 4B OS=Homo sapiens GN=VPS4B PE=1 SV=2 OR51E1 Olfactory receptor 51E1 0.27 0.13 0.481481481 OS=Homo sapiens GN=OR51E1 PE=2 SV=1 Table 6. Top 20 gene ontology (GO) pathways identified based on the differential protein scores between control exosomes and exosomes incubated with 500 ng/ml EGF at 37 C for 48 h. A list of differentially expressed proteins was obtained using the emPAI
method and used as input for GO analysis using the PANTHER overrepresentation test.
GO Homo upload _l upload 1 upload_l upload_l upload_l biological sapiens - (113) (expected) (over/under) (fold (P-value) process REFLIST Enrichment) complete (21002) actomyosin 3 3 0.02 > 100 5.77E-03 GO Homo upload_l upload _l upload _1 upload ...1 upload _l biological sapiens ¨ (113) (expected) (over/under) (fold (P-value) process REFLIST Enrichment) complete (21002) contractile ring organization (GO:0044837) actomyosin 3 3 0.02 > 100 5.77E-03 contractile ring assembly (GO:0000915) assembly of 3 3 0.02 > 100 5.77E-03 actomyosin apparatus involved in cytokinesis (GO:0000912) positive 4 3 0.02 >1.00 1.36E-03 regulation of extracellular exosome assembly (GO:1903553) regulation of 6 4 0.03 > 100 3.58E-04 extracellular exosome assembly (GO:1903551) viral release 6 3 0.03 92.93 4.56E-02 from host cell (GO:0019076) movement in 6 3 0.03 92.93 4.56E-02 environment of other organism involved in symbiotic interaction (GO:0052192) movement in 6 3 0.03 92.93 4.56E-02 host environment (GO:0052126) exit from host 6 3 0.03 92.93 4.56E-02 cell (GO:0035891) exit from host 6 3 0.03 92.93 4.56E-02 (GO:0035890) cell separation 17 7 0.09 76.53 6.98E-08 GO Homo upload_l upload _l upload _1 upload _1 upload 1 biological sapiens ¨ (113) (expected) (over/under) (fold (P-value) process REFLIST Enrichment) complete (21002) after cytokinesis (GO:0000920) ESCRT Ill 10 4 0.05 74.34 2.72E-03 complex disassembly (GO:1904903) ESCRT 10 4 0.05 74.34 2.72E-03 complex disassembly (GO:1904896) positive 15 6 0.08 74.34 2.69E-06 regulation of exosomal secretion (GO:1903543) regulation of 16 6 0.09 69.7 3.94E-06 exosomal secretion (GO:1903541) regulation of 15 5 0.08 61.95 2.09E-04 mitotic spindle assembly (GO:1901673) positive 16 5 0.09 58.08 2.88E-04 regulation of viral release from host cell (GO:1902188) viral budding 23 7 0.12 56.57 5.64E-07 (GO:0046755) viral budding 20 6 0.11 55.76 1.48E-05 via host ESCRT
complex (GO:0039702) [00196] Taken together, these mass spectrometry data suggest that MDA-MB-231 exosomes can alter their protein content upon rhEGF stimulation. These data also suggest that the same exosomes stimulated with rhEGF could undergo actomyosin remodeling and migration, indicative of a motility phenotype in response to rhEGF
stimulation. A
bicinchoninic acid (BCA) assay for protein quantification confirmed the increase in protein content in exosomes stimulated with rhEGF, when compared with unstimulated controls (FIG. 2F). Immunoblotting for 13-actin also shows an increase in the levels of polymerized actin in exosomes stimulated with different amounts of rhEGF when compared with control unstimulated exosomes (FIG. 2G). Collectively, these observations indicate an unexpected degree of biological activity in exosomes. Therefore, the possibility that exosomes are capable of synthesizing proteins de novo under permissive conditions was further investigated and the potential induction of exosomes motility upon growth factor stimulation was explored.
Example 3 ¨ Exosomes derived from different cell types contain the functional constituents required for transcription and translation [00197]
Analysis of proteomics data from exosomes of different cellular origins revealed the presence of several constituents of the protein synthesis machinery, such as eukaryotic initiation factors, ADP ribosylation factors, and ribosomal proteins (Choi et al., 2012; Melo et al., 2015; Pisitkun et al., 2004; Valadi et al., 2007) (FIGS.
10, 11A,B). This information, taken together with the knowledge that mRNAs and their corresponding proteins are found in exosomes, further suggested that isolated exosomes could possess the capacity to translate InRNA into proteins.
[00198]
Using quantitative PCR (qPCR) analysis, the presence of both 18S and 28S rRNAs was confirmed, as well as tRNAs for methionine, glycine, leucine, serine, and valine in all analyzed exosomes (FIGS. 12A,B). Additionally, Ultra Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS) analysis of exosomes revealed the existence of all free amino acids (FIG. 3A). Immunoblotting analysis identified the presence of different members of the translation initiation complex in exosomes, including elF4A, elF3A, and elF1A (FIG. 3B), confirming the observations made through mass spectrometry analysis. In addition, initiation factors elF4A and elF3A co-immunoprecipitate in protein extracts obtained from exosomes (Morino et al., 2000) (FIG. 12C).
[00199]
To functionally address the relevance of constituents for protein production present in exosomes, total protein extracts of exosomes isolated from MCF10A
and MDA-MB-231 cells were incubated with a cDNA expression plasmid for green fluorescent protein (GFP plasmid) and a coupled in vitro transcription and translation assay was performed. Western Blot analysis of the extracts after incubation with the GFP encoding plasmid revealed production of GFP protein (FIG. 3C). The fact that exosomes lysates from both MDA-MB-231 and MCF10A cells allowed for the synthesis of protein from the GFP
expression plasmid confirmed that exosomes derived from different cells likely contain all the necessary functional components for both DNA transcription and mRNA
translation.
Consistent with the potential for DNA transcription, additional immunoblot analysis of protein extracts from exosomes isolated from different cell sources identified the presence of RNA polymerase II subunits, both in its phosphorylated and non-phosphorylated forms (FIG.
3D).
Example 4 Exosomes are capable of cell-independent protein synthesis 1002001 To further validate the finding that exosomes have the autonomous capability for de novo mRNA translation, isolated exosomes obtained from MDAMB-cells as well as the murine lung cancer El 0 cell line were incubated with 35S-methionine to enable labeling of newly synthesized proteins by the exosomes. The assay was performed at 37 C in order to activate the putative biosynthetic processes and potential autoctine stimulation. Autoradiography of protein extracts from exosomes incubated for 72 h in the presence of 35S-methionine exhibited the incorporation of the radioactive amino acid into several proteins in the range of 40 to 300 kDa. This was largely inhibited when exosomes were incubated with the protein translation inhibitor cycloheximide along with methionine (FIG. 3E). A distinct pattern of labeled proteins was observed when exosomes derived from different cancer cells were incubated with 35S-methionine.
Additionally, total protein content was quantified from freshly isolated exosomes incubated in cell-free culture media. After 48 h of incubation, the total exosomal protein content was significantly increased (FIG. 3F).
Next, whether transcription and translation can take place in intact exosomes, rather than just their lysates, was confirmed by setting up a protocol of exosomes in vitro translation. A pCMV-GFP expression plasmid was electroporated directly into exosomes derived from MDA-MB-231 cells (Borges et al., 2013; El-Andaloussi et al., 2012;
Kamerkar et al., 2017) and the electroporated exosomes were incubated at 37 C
in serum-free culture media, for 48 h. qPCR analysis of isolated exosomal RNA after digestion with DNAse revealed the presence of GFP mRNA in exosomes electroporated with the pCMV-GFP expression plasmid (FIG. 4A). Transmission electron microscopy showed that the structure of the exosomes electroporated with the pCMV-GFP plasmid was intact, and immunogold labeling using an anti-GFP antibody showed that the protein could only be detected in the GFP plasmid-containing exosomes (FIG. 4B). Immunoblot analysis of exosomes protein extracts using a GFP antibody further confirmed the presence of GFP in pCMV-GFP plasmid electroporated exosomes, observed as early as 12 h after electroporation (FIG. 4C). GFP could be observed in exosomes electroporated with the expression plasmid after 1 week and up to 1 month (FIGS. 4C,D), albeit without any increase over the levels observed at 24 h. The same pattern was also observed in exosomes derived from cells, confirming that exosomes derived from different cells, not just tumorigenic, contain all the required constituents and have the capacity for de novo protein synthesis (FIG. 13A).
Immunoblot analysis of exosomes electroporated with a GFP plasmid showed a reduction of about 80% in GFP levels when incubated in the presence of the protein translation inhibitor cycloheximide (FIG. 4E). GFP production was also decreased in the presence of a-amanitin, a transcription inhibitor of RNA polymerase II (FIGS.
4E,F).
NanoSight NTA of electroporated exosomes using a 488 nm laser also detected green fluorescence in exosomes electroporated with the pCMV-GFP plasmid but not in mock-electroporated exosomes or exosomes electroporated with the plasmid and cycloheximide or a-amanitin (FIG. 13B). Additionally, beads based flow cytometry analysis of plasmid-containing exosomes using different electroporation conditions detected the presence of GFP
(FIG. 13C). Next, exosomes were incubated for 24 h at 37 C to initiate biological processes, before electroporation with pCMV-GFP plasmid. The GFP production, as detected by immunoblotting, was impaired, suggesting an exhaustion of the required components for transcription and translation in the exosomes that are pre-incubated at 37 C.
(FIG. 4G).
To confirm that these results were not specific to just GFP, an ovalbumin expression plasmid (pCMV-Ova), a protein that is also not expressed in mammalian cells, was used. As with GFP, immunoblotting analysis of exosomes after electroporation and incubation at 37 C for 48 h showed production of ovalbumin only in exosomes electroporated with the pCMV-Ova plasmid (FIG. 13D).
Initiation of protein translation of most mRNAs in eukaryotes involves recognition of the 5' cap structure by the elF4F complex (Merrick, 2004). To determine whether protein translation in exosomes is cap-dependent, a cDNA bicistronic construct was employed consisting of two different luciferase cistrons separated by an internal ribosome entry site (FIG. 4H) (Poulin et al., 1998). In this system, translation of Renilla luciferase is cap-dependent, whereas translation of firefly luciferase is directed by the poliovirus IRES, and is therefore cap-independent (FIG. 4H). Electroporation of the plasmid directly into exosomes led to an increase in Renilla Luciferase activity with no apparent change in Firefly Luciferase activity (FIG. 41) (Poulin et al., 1998), suggesting that protein translation in exosomes occurs in a cap-dependent manner. Since Firefly and Renilla Luciferase enzymes have different activity requirements, this assay was repeated using a plasmid where Firefly luciferase is expressed under the control of a CMV promoter. The luciferase activity was also observed in the pCMV-Fluc electroporated exosomes (FIG. 4.1).
Example 5¨ mRNA translation in exosomes generates functional proteins and can be stimulated by growth factors MCF10A cells pretreated with cycloheximide were incubated with MDA-MB-231 exosomes that were directly electroporated with the pCMV-GFP
plasmid.
Imaging by confocal microscopy detected green fluorescence in the MCF10A
cells, likely contributed by the GFP protein (after transcription and translation) delivered by MDAMB-231 exosomes (FIG. 5A, top and bottom panels). Interestingly, cells directly electroporated with the pCMV-GFP plasmid show a GFP fluorescence pattern distinct from fluorescence pattern observed in cells incubated with pCMV-GFP plasmid containing exosomes (FIG. 5A, middle and bottom panels).
MDA-MB-231 cells overexpress an inactive mutant form of the tumor suppressor protein p53, which is therefore unable to activate the p21 promoter (Gartel et al., 2003). Wild-type (wt) p53 typically responds to DNA damage by direct induction of p21, facilitating cell cycle arrest (Zilfou and Lowe, 2009). Exosomes isolated from cells were electroporated with a plasmid encoding for wt p53 fused to GFP. The electroporated exosomes were incubated in culture media for 48 h to allow transcription and translation to generate wt p53 protein (FIG. 5B). Subsequently, exosomes containing the newly formed wt p53 were incubated with recipient MDA-103-231 cells under the influence of cycloheximide. The recipient MDA-MB-231 cells revealed a substantial increase in expression of p21 (FIG. 5C), confirming the functionality of wt p53 protein that was exclusively synthetized by the exosomes (FIG. 5B). To additionally confirm that this increase in p21 expression was indeed due to wt p53 protein newly translated by exosomes rather than due to delivery of the plasmid, MDA-MB-231 derived exosomes were electroporated with the p53-GFP plasmid and either allowed to incubate for 48 h to synthesize the wt p53 protein prior to incubation with the recipient MDA-MB-231 cells (48 h), or delivered immediately to the recipient MDA-MB-231 cells without allowing them to produce the wt p53 protein (0 h, FIG. 13E). Exosomes that were allowed to actively synthesize wt p53 protein 48 h prior to delivery induced p21 expression in the recipient MDA-MB-231 cells as early as 30 minutes post exosomes incubation, higher than when compared to exosomes with just the plasmid, which show the same baseline p21 expression observed in control MDA-MB-231 cells (FIG.
13E).
In order to further demonstrate that exosomes from MDA-MB-231 cells exhibit a baseline capacity for intrinsic protein synthesis, exosomes were incubated at 37 C, with and without the presence of cycloheximide. Immunoblotting of protein extracts from these exosomes showed a consistent reduction in the expression levels of small cytoplasmic proteins, 13-actin and GAPDH, upon incubation with cycloheximide, again demonstrating the existence of a baseline level of protein synthesis in these exosomes (FIG.
5D).
1002081 In order to determine which proteins are produced by the /VIDA-MB-231 exosomes in the absence of external stimuli, an adapted version of stable isotope labeling with amino acids in culture (SILAC) was performed. Exosomes derived from /VIDA-cells were incubated in SILAC medium supplemented with heavy labeled '3C-Lysine and 15N-Arginine. IVIDA-MB-231 exosomes were incubated in heavy labeled SILAC
medium for 5 days and protein extracts were obtained, trypsin digested, and subjected to mass spectrometry analysis. While only a small number of heavy-labeled peptides matched the obtained MS/MS spectra, 11 proteins were able to be identified each matching 1 or 2 peptides containing the heavy-labeled amino acids (Table 7). This confirms that, albeit at low levels, baseline mRNA translation occurs in exosomes leading to the formation of very small amounts of newly synthesized proteins.
Table 7. List of proteins containing peptides matching spectra with heavy isotopes, obtained from mass spectrometry analysis of protein extracts of MDA-MB-231 exosomes incubated with 13C-Lysine and 15N-Arginine SILAC medium for 5 days. Each protein listed contains at g least 1 peptide matching a 13C-Lysine or 15N-Arginine heavy-labeled spectra.
N
Acession Description Score Coverage # # Unique #
# PSMs # AAs MW calc. PE 1 -,..T..
-Proteins peptides Peptides IkDal Q7Z4S6 Kinesin-like protein 51.34 1.31% 1 1 3 4 1674 187.1 6.42 4.=
KIF21A OS=Homo sapiens GN=KIF21A
PE=1 SV=2 -[KI21A HUMAN) 076038 Secretagogin 32.14 5.80% 1 1 1 2 276 32 5.41 OS=Homo sapiens GN=SCGN PE=1 Q
SV=2 -.
w co [SEGN HUMAN]
.
'=. Q9NQYO Bridging integrator 3 26.41 4.35% 1 1 1 4 253 29.6 7.47 OS=Homo sapiens .
, GN=BIN3 PE=1 ' , S V=1 -A
[BIN3 HUMAN]
P05305 Endothelin-1. 57.22 8.96% 1 -, 3 3 212 24.4 9.41 OS=Homo sapiens GN=EDN1 PE=1 SV=1 -[EDN1 HUMAN]
9:1 en P07476 Involucrin OS=Homo 40.81 1.71% 1 1 1 ..? 585 68.4 4.61 - 3 sapiens GN=IVL
cil b.) PE=1 SV=2 -[INVO HUMAN]
-.
b.) 015014 Zinc finger protein 40.51 1.49% 1 1 2 1 1411 151.1 8.03 4.
o o 609 OS=Human w Acession Description Score Coverage # # Unique #
# PSMs # AAs MW calc. PI
Proteins peptides Peptides IkDal sapiens GN=ZNF609 ,..) PE=1 SV=2 -¨
`&:=
[ZN609 HUMAN]
,..T..
Q9H013 Coiled-coil domain- 40.91 4.51% 1 1 7 2 377 44.2 8.73 4, 4.
containing protein 113 OS= Homo sapiens GN=CCDC113 PE=2 SV=1 -[CC113 HUMAN]
Q8IYE0 Coiled-coil domain 57.08 3.87% 1 1 3 5 955 112.7 8.48 containing protein Q
146 OS=Homo w ce sapiens , w . 0 GN=CCDC146 PE=2 SV=2 -,s9 , [CC146 HUMAN]
, Q96KM6 Zinc finger protein 23.93 1.23% 1 1 1 1 892 97.2 9.83 A
512B OS=Homo sapiens GN=1NF512B PE=1 S V=1 -[Z512B HUMAN] .
015018 PDZ domain- 81.48 1.62% 1 1 4 5 2839 301.5 7.43 9:1 n containing protein 2 OS=Homo sapiens cil b.) GN=PDZD2 PE=1 o SV=1 -, o b.) [PDZD2 HUMAN]
4, o o P43308 Translocon- 24.02 3.83% 1 1 1 1 183 20.1 8.35 (..e _ Acession Description Score Coverage # # Unique #
# PSMs # AAs MW calc. PI
Proteins peptides Peptides IkDal associated protein subunit beta OS=Homo sapiens GN=SSR2 PE=1 SV= 1 -4.=
[SSRB HUMAN]
La 9:1 =
Next, the protein translation assay was repeated using exosomes derived from MDA-MB-231 cells with electroporated pCMV-GFP plasmid. The exosomes were incubated in serum-free culture media at 37 C for 48 h with or without stimulation with rhEGF. While the unstimulated exosomes presented with a baseline level of GFP
production, the GFP levels increased upon incubation with different concentrations of rhEGF (FIG. 5E).
This again confirmed that, while all exosomes can synthetize proteins, growth factor stimulation can alter their rate of production by leading to increased levels of protein synthesis.
Example 6 ¨ Exosomes actively migrate in response to stimulation by rhEGF and serum factors In order to determine whether growth factors can induce a motility phonotype in exosomes, a reverse migration assay based on the Boyden chamber system was designed including rhEGF and serum factors. Ten billion exosomes isolated from MDA-MB-231 cells were placed in the culture wells of a 96-well plate, covered by a polycarbonate surface insert containing 400 nm pores. The insert contained either PBS, PBS
with 10 0/1 rhEGF, or PBS with 20% exosomes-depleted FBS (FIG. 6A). Because exosomes-depleted FBS could still contain trace amounts of exosomes (data not shown), 20% FBS
was placed on the top insert with no exosomes in the bottom well, as a control. After incubation at 37 C, samples were obtained from the top insert at different time points and exosomes quantified using Nanosight NTA.
After a 4 h incubation, the levels of exosomes on the top insert were comparable across all experimental groups (FIG. 6B). After a 24 h incubation, 20% FBS
significantly increased migration of the exosomes from the bottom to the top, suggesting a sustained chemotactic influence on MDA-MB-231 exosomes towards the higher serum growth factor gradient (FIG. 6C). The inserts with 20% FBS over wells with no exosomes had significantly fewer exosomes after 24 h, confirming the identity of the migrating exosomes as being from MDA-MB-231 cells (FIG. 6C). PBS resulted in negligible amounts of exosomes migration but rhEGF alone also induced motility of exosomes, albeit at a lower level when compared to complete serum associated growth factors (FIG. 6C).
Taken together, these results suggest that exosomes exhibit functional chemotactic capacity that can be induced by growth factors.
Example 7 ¨ Exosornes specifically exhibit enhanced protein production in tumor bearing mice To address whether the capacity of exosomes to respond to the growth factor gradient induced by tumors involves intrinsic production of new proteins with functional consequences, a reference mouse model was generated. Mice with established 4T1 mammary tumors were injected with 5 billion MDA-MD 231/CD63-mCherry exosomes electroporated with either GFP or ovalbumin expression plasmids. Control experimental arms of this study included CD63-mCherry exosomes without the plasmids and CD63-mCherry exosomes electroporated with plasmid and cyclohexamide. Twenty-four hours after the I.P.
injection of exosomes in tumor-bearing mice or non-tumor-bearing mice, the tumor, serum, and several other organs were collected. Exosomes were FACS isolated using the mCherry tag and evaluated for GFP or ovalbumin protein. GFP and ovalbumin were predominantly detected in the tumor, lung, bone, brain, and serum of mice with tumors, but were found only at very low levels in the tissues of non-tumor bearing mice and in tumor bearing mice that were injected with cyclohexamide-containing exosomes. These results demonstrate that while exosomes might be detected in the liver, lung, and brain of the non-tumor bearing mice, the exosomes enter these organs and more robustly (presumably via enhanced motility) including the tumor tissue, and biologically respond by generating de novo proteins. Additionally, the serum-derived exosomes from tumor bearing mice exhibit protein production, suggesting that tumors biologically influence exosomes at a systemic level.
* * *
All of the methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved.
All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.
The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.
U.S. Patent 4,870,287 U.S. Patent 5,739,169 U.S. Patent 5,760,395 U.S. Patent 5,801,005 U.S. Patent 5,824,311 U.S. Patent 5,830,880 U.S. Patent 5,846,945 Aakalu et al., Dynamic visualization of local protein synthesis in hippocampal neurons.
Neuron, 30:489-502, 2001.
Almoguera et al., Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell, 53:549-554, 1988.
Al-Nedawi et al., Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc. Natl. Acad. Sci.
U.S.A., 106:3794-3799, 2009.
Alvarez-Erviti et al., Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nature Biotechnology, 29:341-345, 2011.
Austin-Ward & Villaseca, Gene therapy and its applications. Rev. Med ChiL, 126:838-845, 1998.
Baietti et al., Syndecan-syntenin-ALIX regulated the biogenesis of exosomes.
Nat. Cell Biol., 14:677-685, 2012.
Bastos et al., Exosomes in cancer: Use them or target them? Semin. Cell Dev.
BioL, 78:13-21, 2018.
Biankin et al., Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes.
Nature, 491:399-405, 2012.
Borges et al., TGF-betal-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis. J. Amer.
Soc.
Nephrology, 24:385-392, 2013.
Bukowski et al., Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy.
Clin.
Cancer Res., 4:2337-2347, 1998.
Chang et al., Pancreatic cancer genomics. Current Opinion in Genetics &
Development, 24:74-81, 2014.
Choi et al., The protein interaction network of extracellular vesicles derived from human colorectal cancer cells. J Proteome Res., 11:1144-1151, 2012.
Christodoulides et al., Immunization with recombinant class 1 outer-membrane protein from Neisseria meningitidis: influence of liposomes and adjuvants on antibody avidity, recognition of native protein and the induction of a bactericidal immune response against meningococci. Microbiology, 144:3027-3037, 1998.
Clayton et al., Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59. Eur. J. Immunology, 33:522-531, 2003.
Collins et al., Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J. Clinical Investigation, 122:639-653, 2012a.
Collins et al., Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. PLoS
One, 7:e49707, 2012b.
Colombo et al., Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu. Rev. Cell. Dev. Biol., 30:255-289, 2014.
Combes et al., A new flow cytometry method of platelet-derived microvesicle quantitation in plasma, Thromb. Haemost., 77:220, 1997.
Cooper et al., Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Movement Disorders, 29:1476-1485, 2014.
Croft et al., The Reactome pathway knowledgebase. Nuc. Acids Res., 42:D472-477, 2014.
Davidson et al., Intralesional cytokine therapy in cancer: a pilot study of GM-CSF infusion in mesothelioma../. Immunother., 21:389-398, 1998.
Du et al., A systematic analysis of the silencing effects of an active siRNA
at all single-nucleotide mismatched target sites. Nuc. Acids Res., 33:1671-1677, 2005.
El-Andaloussi et al., Extracellular vesicles: biology and emerging therapeutic opportunities.
Nature Reviews Drug Discovery, 12:347-357, 2013.
El-Andaloussi et al., Exosome-mediated delivery of siRNA in vitro and in vivo.
Nature Protocols, 7:2112-2126, 2012.
Eser et al., Oncogenic KRAS signalling in pancreatic cancer. British Journal of Cancer, 111:817-822,2014.
Gartel et al., A new method for determining the status of p53 in tumor cell lines of different origin. Oncology Research, 13:405-408, 2003.
Gomes-da-Silva et al., Lipid-based nanoparticles for siRNA delivery in cancer therapy:
paradigms and challenges. Accounts of Chemical Research, 45:1163-1171, 2012.
Gonzales et al., Large-scale proteomics and phosphoproteomics of urinary exosomes. J.
Amer. Soc. Nephrology, 20:363-379, 2009.
Gysin et al., Therapeutic strategies for targeting ras proteins. Genes &
Cancer, 2:359-372, 2011.
Hanibuchi et al., Therapeutic efficacy of mouse-human chimeric anti-ganglioside GM2 monoclonal antibody against multiple organ micrometastases of human lung cancer in NK cell-depleted SC1D mice. Mt. J. Cancer, 78:480-485, 1998.
Harding et al., Endocytosis and intracellular processing of transferrin and colloidal gold-transferrin in rat reticulocytes: demonstration of a pathway for receptor shedding.
European J. Cell Biol., 35:256-263, 1984.
Hazan-Halevy et al., Cell-specific uptake of mantle cell lymphoma-derived exosomes by malignant and non-malignant B-lymphocytes. Cancer Lett., 364:59-69, 2015.
Hellstrand et at., Histamine and cytokine therapy. Acta Oncol., 37:347-353, 1998.
Hingorani et al., Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell, 7:469-483, 2005.
Hollander, Immunotherapy for B-cell lymphoma: current status and prospective advances.
Front M1117111tol., 3:3, 2013.
Howlader et at., SEER Cancer Statistics Review, 1975-2011, National Cancer Institute.
Bethesda, MD. On the World Wide Web at seercancergov/csr/1975_2011/, 2013.
Hruban et at., K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. American J.
Pathology, 143:545-554, 1993.
Huang et at., Epidermal growth factor receptor-containing exosomes induce tumor-specific regulatory T cells. Cancer Invest., 31:330-335, 2013.
Hui & Hashimoto, Pathways for Potentiation of Immunogenicity during Adjuvant-Assisted Immunizations with Plasmodium falciparum Major Merozoite Surface Protein 1.
Mfec. 'MUM , 66:5329-5336, 1998.
Ishihama et al., Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. MoL Cell. Proteomics, 4:1265-1272, 2005.
Ji et al., Ras activity levels control the development of pancreatic diseases.
Gastroenterology, 137:1072-1082, 82 el-6, 2009.
Johnsen et al., A comprehensive overview of exosomes as drug delivery vehicles -endogenous nanocarriers for targeted cancer therapy. Biochimica et Biophy.sica Ada, 1846:75-87, 2014.
Kahlert et al., Identification of Double Stranded Genomic DNA Spanning all Chromosomes with Mutated KRAS and p53 DNA in the Serum Exosomes of Patients with Pancreatic Cancer. J. Biol. Chem., 289:3869-3875, 2014.
Kalra et al., Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma.
Proteomics, 13:3354-3364, 2013.
Kalluri, The biology and function of exosomes in cancer. J. Clin. Invest., 126:1208-1215, 2016.
Kamerkar et al., Exosomes facilitate therapeutic targeting of oncogenic KRAS
in pancreatic cancer. Nature, 546:498-503, 2017.
Kowal et al., Biogenesis and secretion of exosomes. Current Opinion in Cell Biology, 29:116-125, 2014.
Kramer et al., The ribosome as a platform for co-translational processing, folding and targeting of newly synthesized proteins. Nat. Struct. MoL Biol., 16:589-597, 2009.
Li et al., Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy. Oncotarget, 7:24585-24595, 2016.
Lim et al., EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. Cancer Research, 76:1284-1296, 2016.
Liu et al.,. EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol, 29:401-405, 2012.
Livak & Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25:402-408, 2001.
Lorch et al., Role of DNA sequence in chromatin remodeling and the formation of nucleosome-free regions. Genes Dev., 28:2492-2497, 2014.
Luga et al., Exosomes mediate stromal mobilization of autocrine Wnt-PCP
signaling in breast cancer cell migration. Cell, 151:1542-1556, 2012.
Ma et al., Structural basis for overhang-specific small interfering RNA
recognition by the PAZ domain. Nature, 429:318-322, 2004.
Marcus & Leonard, FedExosomes: Engineering Therapeutic Biological Nanoparticles that Truly Deliver. Pharmaceuticals (Basel), 6:659-680, 2013.
Masuda et al., Role of epidermal growth factor receptor in breast cancer.
Breast Cancer Res.
Treat., 136:331-345, 2012.
Melo et al., Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesi s. Cancer ('dl, 26:707-721, 2014.
Melo et al., Glypican-1 identifies cancer exosomes and detects early pancreatic cancer.
Nature, 523:177-182, 2015.
Merrick, Cap-dependent and cap-independent translation in eukaryotic systems.
Gene, 332:1-
[00191]
Statistics. Error bars indicate s.d. between biological replicates.
Technical as well as biological triplicates of each experiment were performed.
Statistical significance was calculated by Student's t-test, ANOVA or Mann-Whitney test, as appropriate and specified in the description of the figures.
Example 1 ¨ EGFR phosphorylation is detected in exosomes derived from MDA-MB-231, triple negative human breast cancer cells [00192]
Exosomes were isolated from different murine and human cell lines using established ultracentrifugation techniques (Melo et al., 2015; Melo et al., 2014). The isolated exosomes represent a heterogeneous mix, with the same size distribution being consistently observed between preparations. NanoSight nanoparticle tracking analysis (NTA) as well as atomic force microscopy (AFM) revealed particles with a size distribution averaging 104 1.5 nm in diameter, and ranging roughly between 30 and 200 nm.
This was confirmed by transmission electron microscopy (TEM) showing extracellular vesicles surrounded by a lipid bilayer (FIGS. 8A-C). The isolated exosomes were further shown by immunogold/TEM imaging, immunoblot analysis and imaging flow cytometry to possess known markers of exosomes (Raposo and Stoorvogel, 2013) (FIGS. 8D-F). To further confirm their purity, exosomes samples were inoculated onto solidified LB
plates, showing no colony formation when compared to bacterial controls obtained from mouth swabs. This demonstrates the absence of bacterial contamination in the isolated exosomes (FIG. 8G).
[00193]
Exosomes obtained from different cell lines were probed by immunoblotting for their EGFR content. While exosomes from all cell lines show low levels of EGFR expression, exosomes derived from the BJ fibroblast cell line and MDA-triple negative breast cancer cell line showed strong expression of the receptor. The known exosomes marker CD81 is shown as a loading control (FIG. 1A). Given the importance of EGFR for the progression of triple negative breast cancer (Lim et al., 2016;
Liu et al., 2012;
Nakai et al., 2016), its functional role in MDA-MB-231 derived exosomes was further explored. Exosomes were derived from MDA-MB-231 and MCF10A cells, and 1 billion exosomes were incubated with 500 ng/ml of recombinant human EGF (rhEGF) for 15 minutes at 37 C in serum-free culture media. Immunoblotting of protein extracts obtained from these exosomes with an antibody specific for the Tyr1068 residue of EGFR
revealed an increase in the phosphorylation levels of this receptor in exosomes derived from MDA-MB-231, but not non-tumorigenic MCF10A breast epithelial cells (FIG. 1B).
Baseline levels of EGFR did not change in any of the samples, confirming the specificity of the observed increase in phosphorylation. Recombinant human EGF (rhEGF) stimulation also lead to an increase in the levels of phosphorylated ERIC, suggesting that the observed EGFR
phosphorylation triggers downstream signaling events within the exosomes (FIG.
1C).
Further probing of the protein content of MDA-MB-231 exosomes showed that they also contained downstream effectors of EGFR, namely GRB2 and Shc (FIG. 1C).
1001941 It was then investigated whether upon rhEGF stimulation, exosomal EGFR could engage its downstream adaptors. Exosomes were stimulated with rhEGF
for 15 minutes at 37 C. The exosomal protein extracts were subjected to pull down assays using specific antibodies for GRB2 and Shc, and it was detected that upon EGF
stimulation they showed increased co-immunoprecipitation with EGFR (FIGS. 1D,E). Isotype IgGs were used as a negative control for the pull down, and did not reveal EGFR co-immunoprecipitation.
Additionally, by reversing the assay and pulling down EGFR, it was also possible to detect coimmunoprecipitated GRB2 only in EGF stimulated exosomes (FIG. 8B). Taken together these results demonstrate that exosomes from MDA-MB-231 cells contain EGFR
that can be phosphorylated by incubation with its ligand in cell-free conditions, leading to putative downstream signaling events within the exosomes.
Example 2 ¨ EGF stimulation of exosoines alters their protein content Receptor tyrosine kinases require ATP as a substrate for their kinase activity, and prostate-derived exosomes have been shown to have the capacity to generate ATP (Ronquist et al., 2013a). To further confirm the existence of phosphorylation activity in the absence of cells, an ATP quantification assay was performed on exosomes with or without rhEGF stimulation. Using a luminescence based kit, ATP was detected in exosomes from both MDA-MB-231 cells and MCF10A cells, albeit in smaller quantities in the latter.
Exosomes from MDA-103-231 cells, but not MCF10A cells, demonstrated a slight decrease in their ATP quantity upon stimulation with EGF (FIG. 2A). To further investigate the impact of EGF stimulation on exosomes, they were incubated them in cell-free conditions for a period of 48 h. The levels of GRB2 protein levels were consistently higher in exosomes stimulated with EGF for 48 h, compared to their unstimulated counterparts (FIG. 2B). This raised the intriguing possibility that the protein content of exosomes might have changed upon growth factor stimulation. To further investigate this possibility, mass spectrometry analysis was performed on protein extracts obtained from rhEGF unstimulated or stimulated exosomes. Protein extracts were subjected to bypsin digestion and evaluated using an ESI-TRAP mass spectrometer to obtain an MS/MS peptide spectrum for each sample.
The obtained spectra were then evaluated against a SwissProt database for peptide identification to obtain a list of proteins for each exosomes sample. Using the open access FunRich functional enrichment analysis tool (Pathan et al., 2015) it was observed that the majority of identified hits in both the unstimulated and stimulated exosomes matched proteins previously identified in exosomes (Vesiclepedia database) (FIG. 2C). A higher number of proteins were identified in exosomes stimulated with rhEGF when compared to the unstimulated ones (491 vs. 371, FIG. 2D). While the majority of these proteins were common to both stimulated and unstimulated exosomes, 224 out of 491 proteins were detected only upon rhEGF
stimulation.
While EGFR was identified on both samples, GRB2 was only identified in rhEGF
stimulated exosomes (FIG. 2E). It should be stressed however that this does not mean that GRB2 is not present in unstimulated exosomes, but it might be present at a level under the detectable threshold for this type of analysis. The Exponentially Modified Protein Abundance Index (emPAI), which allows for label-free quantification of relative changes in protein content based on the observable peptide matches, was employed (Ishihama et al., 2005).
The top 15 proteins that revealed a stronger increase in rhEGF stimulated exosomes when compared to their unstimulated counterparts included several participants of actin remodeling and membrane dynamics, such as a-actinin, MARCKS, ezrin, moesin, and integrin alpha-2 (Tables 4&5). A gene ontology (GO) analysis was then performed using the PANTHER
overrepresentation test. Interestingly, among the top GO biological processes enriched in the rhEGF stimulated exosomes, several were related to actin remodeling and migration (5 out of the 20 top pathways, Table 6).
Table 4. Top 15 proteins identified as upregulated in exosomes from MDA-MB-231 cells incubated with 500 ng/ml of EGF at 37 C for 48 h compared to control exosomes, based on the protein scores using the emPAI method (Ishihama et al., 2005).
Protein Name Description Control EGF- Fold Treatment Change CHMP2A Charged multivesicular body 0.4 2.25 5.625 protein 2a OS=Homo spapiens GN=CHMP2A PE::::1 S V :::1 C'HM1)2B Charged multivesicular body 0.19 1.03 5.421052632 Protein Name Description Control EGF- Fold Treatment Change protein 2b OS=Homo sapiens GN:=CHMP2B PE=1 SV=1 ACSL4 Long-chain-fatty-acid--CoAligase 0.06 0.31 5.166666667 4 OS=Homo sapiens GN=ACSL4 PE=1 SV=2 LDHB L-lactate dehydrogenase B chain 0.12 0.59 4.916666667 OS=Homo sapiens GN=LDHB
PE=1 SV=2 ACTN1 Alpha-actinin-1 OS=Homo 0.04 0.18 4.5 sapiens GN=ACTN1 PE=1 SV=2 ITGA2 Integrin alpha-2 OS=Homo 0.07 0.26 3.714285714 sapiens GN=ITGA2 PE=1 SV-1 HIST2H2AA3 Histone H2A type 2-A OS=Homo 6.9 24.85 3.601449275 sapiens GN-HIST2H2AA3 PE:::1 SV=3 MARCKS Myristoylated alanine-rich C- 0.14 0.5 3.571428571 kinase substrate OS=Homo sapiens GN=MARCKS PE=1 SV=4 VPS37B Vacuolar protein sorting- 0.14 0.5 3.571428571 associated protein 37B OS=Homo sapiens GN:::VPS37B PE=1 SV:=1 RPL5 60S ribosomal protein L5 0.13 0.45 3.461538462 OS=Homo sapiens GN=RPL5 PE=1 SV=3 EHD2 EH domain-containing protein 2 0.07 0.23 3.285714286 OS=Homo sapiens GN=EHD2 PE=1 SV=2 DNAJA1 DnaJ homolog subfamily A 0.61 1.84 3.016393443 member 1 OS=Homo sapiens GN-1)NAJA1 PE-1 SV=2 EZR Ezrin OS:-.Homo sapiens 1.23 3.39 2.756097561 GN:=EZR PE:::1 SV=4 MSN .Moesin OS=Homo sapiens 1.74 4.48 2.574712644 GN=MSN PE=1 SV=3 ARF I ADP-ribosylation factor 1 0.5 1.26 2.52 OS=Homo sapiens GN=ARF1 PE=1 SV=2 Table 5. Top 15 proteins identified as downregulated in exosomes from MDA-MB-231 cells incubated with 500 ng/ml of EGF at 37 C for 48 h compared to control exosomes, based on the protein scores using the emPAI method (Ishihama et al., 2005).
Protein Name Description Control EGF- Fold Treatment Change KRT9 "Keratin, type 1 cytoskeletal 9 6.86 1.28 0.186588921 OS=Homo sapiens GN=KRT9 Protein Name Description Control EGF- Fold Treatment Change PE=1 SV=3"
KRT2 "Keratin, type II cytoskeletal 2 2.46 0.92 0.37398374 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2"
GOLGA7 Golgin subfamily A member 7 0.7 0.3 0.428571429 OS=Homo sapiens GN=GOLGA7 PE-1 SV=2 CALMI Calmodulin OS=Homo sapiens 0.64 0.28 0.4375 GN=CALM1 PE=1 SV=2 HRAS GTPase HRas OS=Homo sapiens 0.48 0.22 0.458333333 GN=HRAS PE=1 SV=1 SCAMP2 Secretory carrier-associated 0.26 0.12 0.461538462 membrane protein 2 OS=Homo sapiens GN=SCAMP2 PE=1 SV=2 RGSI9 Regulator of G-protein signaling 0.41 0.19 0.463414634 19 OS=Homo sapiens GN=RGS19 PE:::1 SV=1 RAB5B Ras-related protein Rab-5B 0.43 0.2 0.465116279 OS=Homo sapiens GN=RAB5B
PE=1 SV=1 CORO 1 C Coronin-1C OS=Homo sapiens 0.17 0.08 0.470588235 GN=COROIC PE=1 SV=1 SLC7A1l Cystine/glutamate transporter 0.17 0.08 0.470588235 OS=Homo sapiens GN=SLC7A1 I
PE=1 SV=1 PACSIN3 Protein kinase C and casein kinase 0.19 0.09 0.473684211 substrate in neurons protein 3 OS=Homo sapiens GN=PACSIN3 PE=1 SV=2 VPS4B Vacuolar protein sorting- 0.19 0.09 0.473684211 associated protein 4B OS=Homo sapiens GN=VPS4B PE=1 SV=2 OR51E1 Olfactory receptor 51E1 0.27 0.13 0.481481481 OS=Homo sapiens GN=OR51E1 PE=2 SV=1 Table 6. Top 20 gene ontology (GO) pathways identified based on the differential protein scores between control exosomes and exosomes incubated with 500 ng/ml EGF at 37 C for 48 h. A list of differentially expressed proteins was obtained using the emPAI
method and used as input for GO analysis using the PANTHER overrepresentation test.
GO Homo upload _l upload 1 upload_l upload_l upload_l biological sapiens - (113) (expected) (over/under) (fold (P-value) process REFLIST Enrichment) complete (21002) actomyosin 3 3 0.02 > 100 5.77E-03 GO Homo upload_l upload _l upload _1 upload ...1 upload _l biological sapiens ¨ (113) (expected) (over/under) (fold (P-value) process REFLIST Enrichment) complete (21002) contractile ring organization (GO:0044837) actomyosin 3 3 0.02 > 100 5.77E-03 contractile ring assembly (GO:0000915) assembly of 3 3 0.02 > 100 5.77E-03 actomyosin apparatus involved in cytokinesis (GO:0000912) positive 4 3 0.02 >1.00 1.36E-03 regulation of extracellular exosome assembly (GO:1903553) regulation of 6 4 0.03 > 100 3.58E-04 extracellular exosome assembly (GO:1903551) viral release 6 3 0.03 92.93 4.56E-02 from host cell (GO:0019076) movement in 6 3 0.03 92.93 4.56E-02 environment of other organism involved in symbiotic interaction (GO:0052192) movement in 6 3 0.03 92.93 4.56E-02 host environment (GO:0052126) exit from host 6 3 0.03 92.93 4.56E-02 cell (GO:0035891) exit from host 6 3 0.03 92.93 4.56E-02 (GO:0035890) cell separation 17 7 0.09 76.53 6.98E-08 GO Homo upload_l upload _l upload _1 upload _1 upload 1 biological sapiens ¨ (113) (expected) (over/under) (fold (P-value) process REFLIST Enrichment) complete (21002) after cytokinesis (GO:0000920) ESCRT Ill 10 4 0.05 74.34 2.72E-03 complex disassembly (GO:1904903) ESCRT 10 4 0.05 74.34 2.72E-03 complex disassembly (GO:1904896) positive 15 6 0.08 74.34 2.69E-06 regulation of exosomal secretion (GO:1903543) regulation of 16 6 0.09 69.7 3.94E-06 exosomal secretion (GO:1903541) regulation of 15 5 0.08 61.95 2.09E-04 mitotic spindle assembly (GO:1901673) positive 16 5 0.09 58.08 2.88E-04 regulation of viral release from host cell (GO:1902188) viral budding 23 7 0.12 56.57 5.64E-07 (GO:0046755) viral budding 20 6 0.11 55.76 1.48E-05 via host ESCRT
complex (GO:0039702) [00196] Taken together, these mass spectrometry data suggest that MDA-MB-231 exosomes can alter their protein content upon rhEGF stimulation. These data also suggest that the same exosomes stimulated with rhEGF could undergo actomyosin remodeling and migration, indicative of a motility phenotype in response to rhEGF
stimulation. A
bicinchoninic acid (BCA) assay for protein quantification confirmed the increase in protein content in exosomes stimulated with rhEGF, when compared with unstimulated controls (FIG. 2F). Immunoblotting for 13-actin also shows an increase in the levels of polymerized actin in exosomes stimulated with different amounts of rhEGF when compared with control unstimulated exosomes (FIG. 2G). Collectively, these observations indicate an unexpected degree of biological activity in exosomes. Therefore, the possibility that exosomes are capable of synthesizing proteins de novo under permissive conditions was further investigated and the potential induction of exosomes motility upon growth factor stimulation was explored.
Example 3 ¨ Exosomes derived from different cell types contain the functional constituents required for transcription and translation [00197]
Analysis of proteomics data from exosomes of different cellular origins revealed the presence of several constituents of the protein synthesis machinery, such as eukaryotic initiation factors, ADP ribosylation factors, and ribosomal proteins (Choi et al., 2012; Melo et al., 2015; Pisitkun et al., 2004; Valadi et al., 2007) (FIGS.
10, 11A,B). This information, taken together with the knowledge that mRNAs and their corresponding proteins are found in exosomes, further suggested that isolated exosomes could possess the capacity to translate InRNA into proteins.
[00198]
Using quantitative PCR (qPCR) analysis, the presence of both 18S and 28S rRNAs was confirmed, as well as tRNAs for methionine, glycine, leucine, serine, and valine in all analyzed exosomes (FIGS. 12A,B). Additionally, Ultra Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS) analysis of exosomes revealed the existence of all free amino acids (FIG. 3A). Immunoblotting analysis identified the presence of different members of the translation initiation complex in exosomes, including elF4A, elF3A, and elF1A (FIG. 3B), confirming the observations made through mass spectrometry analysis. In addition, initiation factors elF4A and elF3A co-immunoprecipitate in protein extracts obtained from exosomes (Morino et al., 2000) (FIG. 12C).
[00199]
To functionally address the relevance of constituents for protein production present in exosomes, total protein extracts of exosomes isolated from MCF10A
and MDA-MB-231 cells were incubated with a cDNA expression plasmid for green fluorescent protein (GFP plasmid) and a coupled in vitro transcription and translation assay was performed. Western Blot analysis of the extracts after incubation with the GFP encoding plasmid revealed production of GFP protein (FIG. 3C). The fact that exosomes lysates from both MDA-MB-231 and MCF10A cells allowed for the synthesis of protein from the GFP
expression plasmid confirmed that exosomes derived from different cells likely contain all the necessary functional components for both DNA transcription and mRNA
translation.
Consistent with the potential for DNA transcription, additional immunoblot analysis of protein extracts from exosomes isolated from different cell sources identified the presence of RNA polymerase II subunits, both in its phosphorylated and non-phosphorylated forms (FIG.
3D).
Example 4 Exosomes are capable of cell-independent protein synthesis 1002001 To further validate the finding that exosomes have the autonomous capability for de novo mRNA translation, isolated exosomes obtained from MDAMB-cells as well as the murine lung cancer El 0 cell line were incubated with 35S-methionine to enable labeling of newly synthesized proteins by the exosomes. The assay was performed at 37 C in order to activate the putative biosynthetic processes and potential autoctine stimulation. Autoradiography of protein extracts from exosomes incubated for 72 h in the presence of 35S-methionine exhibited the incorporation of the radioactive amino acid into several proteins in the range of 40 to 300 kDa. This was largely inhibited when exosomes were incubated with the protein translation inhibitor cycloheximide along with methionine (FIG. 3E). A distinct pattern of labeled proteins was observed when exosomes derived from different cancer cells were incubated with 35S-methionine.
Additionally, total protein content was quantified from freshly isolated exosomes incubated in cell-free culture media. After 48 h of incubation, the total exosomal protein content was significantly increased (FIG. 3F).
Next, whether transcription and translation can take place in intact exosomes, rather than just their lysates, was confirmed by setting up a protocol of exosomes in vitro translation. A pCMV-GFP expression plasmid was electroporated directly into exosomes derived from MDA-MB-231 cells (Borges et al., 2013; El-Andaloussi et al., 2012;
Kamerkar et al., 2017) and the electroporated exosomes were incubated at 37 C
in serum-free culture media, for 48 h. qPCR analysis of isolated exosomal RNA after digestion with DNAse revealed the presence of GFP mRNA in exosomes electroporated with the pCMV-GFP expression plasmid (FIG. 4A). Transmission electron microscopy showed that the structure of the exosomes electroporated with the pCMV-GFP plasmid was intact, and immunogold labeling using an anti-GFP antibody showed that the protein could only be detected in the GFP plasmid-containing exosomes (FIG. 4B). Immunoblot analysis of exosomes protein extracts using a GFP antibody further confirmed the presence of GFP in pCMV-GFP plasmid electroporated exosomes, observed as early as 12 h after electroporation (FIG. 4C). GFP could be observed in exosomes electroporated with the expression plasmid after 1 week and up to 1 month (FIGS. 4C,D), albeit without any increase over the levels observed at 24 h. The same pattern was also observed in exosomes derived from cells, confirming that exosomes derived from different cells, not just tumorigenic, contain all the required constituents and have the capacity for de novo protein synthesis (FIG. 13A).
Immunoblot analysis of exosomes electroporated with a GFP plasmid showed a reduction of about 80% in GFP levels when incubated in the presence of the protein translation inhibitor cycloheximide (FIG. 4E). GFP production was also decreased in the presence of a-amanitin, a transcription inhibitor of RNA polymerase II (FIGS.
4E,F).
NanoSight NTA of electroporated exosomes using a 488 nm laser also detected green fluorescence in exosomes electroporated with the pCMV-GFP plasmid but not in mock-electroporated exosomes or exosomes electroporated with the plasmid and cycloheximide or a-amanitin (FIG. 13B). Additionally, beads based flow cytometry analysis of plasmid-containing exosomes using different electroporation conditions detected the presence of GFP
(FIG. 13C). Next, exosomes were incubated for 24 h at 37 C to initiate biological processes, before electroporation with pCMV-GFP plasmid. The GFP production, as detected by immunoblotting, was impaired, suggesting an exhaustion of the required components for transcription and translation in the exosomes that are pre-incubated at 37 C.
(FIG. 4G).
To confirm that these results were not specific to just GFP, an ovalbumin expression plasmid (pCMV-Ova), a protein that is also not expressed in mammalian cells, was used. As with GFP, immunoblotting analysis of exosomes after electroporation and incubation at 37 C for 48 h showed production of ovalbumin only in exosomes electroporated with the pCMV-Ova plasmid (FIG. 13D).
Initiation of protein translation of most mRNAs in eukaryotes involves recognition of the 5' cap structure by the elF4F complex (Merrick, 2004). To determine whether protein translation in exosomes is cap-dependent, a cDNA bicistronic construct was employed consisting of two different luciferase cistrons separated by an internal ribosome entry site (FIG. 4H) (Poulin et al., 1998). In this system, translation of Renilla luciferase is cap-dependent, whereas translation of firefly luciferase is directed by the poliovirus IRES, and is therefore cap-independent (FIG. 4H). Electroporation of the plasmid directly into exosomes led to an increase in Renilla Luciferase activity with no apparent change in Firefly Luciferase activity (FIG. 41) (Poulin et al., 1998), suggesting that protein translation in exosomes occurs in a cap-dependent manner. Since Firefly and Renilla Luciferase enzymes have different activity requirements, this assay was repeated using a plasmid where Firefly luciferase is expressed under the control of a CMV promoter. The luciferase activity was also observed in the pCMV-Fluc electroporated exosomes (FIG. 4.1).
Example 5¨ mRNA translation in exosomes generates functional proteins and can be stimulated by growth factors MCF10A cells pretreated with cycloheximide were incubated with MDA-MB-231 exosomes that were directly electroporated with the pCMV-GFP
plasmid.
Imaging by confocal microscopy detected green fluorescence in the MCF10A
cells, likely contributed by the GFP protein (after transcription and translation) delivered by MDAMB-231 exosomes (FIG. 5A, top and bottom panels). Interestingly, cells directly electroporated with the pCMV-GFP plasmid show a GFP fluorescence pattern distinct from fluorescence pattern observed in cells incubated with pCMV-GFP plasmid containing exosomes (FIG. 5A, middle and bottom panels).
MDA-MB-231 cells overexpress an inactive mutant form of the tumor suppressor protein p53, which is therefore unable to activate the p21 promoter (Gartel et al., 2003). Wild-type (wt) p53 typically responds to DNA damage by direct induction of p21, facilitating cell cycle arrest (Zilfou and Lowe, 2009). Exosomes isolated from cells were electroporated with a plasmid encoding for wt p53 fused to GFP. The electroporated exosomes were incubated in culture media for 48 h to allow transcription and translation to generate wt p53 protein (FIG. 5B). Subsequently, exosomes containing the newly formed wt p53 were incubated with recipient MDA-103-231 cells under the influence of cycloheximide. The recipient MDA-MB-231 cells revealed a substantial increase in expression of p21 (FIG. 5C), confirming the functionality of wt p53 protein that was exclusively synthetized by the exosomes (FIG. 5B). To additionally confirm that this increase in p21 expression was indeed due to wt p53 protein newly translated by exosomes rather than due to delivery of the plasmid, MDA-MB-231 derived exosomes were electroporated with the p53-GFP plasmid and either allowed to incubate for 48 h to synthesize the wt p53 protein prior to incubation with the recipient MDA-MB-231 cells (48 h), or delivered immediately to the recipient MDA-MB-231 cells without allowing them to produce the wt p53 protein (0 h, FIG. 13E). Exosomes that were allowed to actively synthesize wt p53 protein 48 h prior to delivery induced p21 expression in the recipient MDA-MB-231 cells as early as 30 minutes post exosomes incubation, higher than when compared to exosomes with just the plasmid, which show the same baseline p21 expression observed in control MDA-MB-231 cells (FIG.
13E).
In order to further demonstrate that exosomes from MDA-MB-231 cells exhibit a baseline capacity for intrinsic protein synthesis, exosomes were incubated at 37 C, with and without the presence of cycloheximide. Immunoblotting of protein extracts from these exosomes showed a consistent reduction in the expression levels of small cytoplasmic proteins, 13-actin and GAPDH, upon incubation with cycloheximide, again demonstrating the existence of a baseline level of protein synthesis in these exosomes (FIG.
5D).
1002081 In order to determine which proteins are produced by the /VIDA-MB-231 exosomes in the absence of external stimuli, an adapted version of stable isotope labeling with amino acids in culture (SILAC) was performed. Exosomes derived from /VIDA-cells were incubated in SILAC medium supplemented with heavy labeled '3C-Lysine and 15N-Arginine. IVIDA-MB-231 exosomes were incubated in heavy labeled SILAC
medium for 5 days and protein extracts were obtained, trypsin digested, and subjected to mass spectrometry analysis. While only a small number of heavy-labeled peptides matched the obtained MS/MS spectra, 11 proteins were able to be identified each matching 1 or 2 peptides containing the heavy-labeled amino acids (Table 7). This confirms that, albeit at low levels, baseline mRNA translation occurs in exosomes leading to the formation of very small amounts of newly synthesized proteins.
Table 7. List of proteins containing peptides matching spectra with heavy isotopes, obtained from mass spectrometry analysis of protein extracts of MDA-MB-231 exosomes incubated with 13C-Lysine and 15N-Arginine SILAC medium for 5 days. Each protein listed contains at g least 1 peptide matching a 13C-Lysine or 15N-Arginine heavy-labeled spectra.
N
Acession Description Score Coverage # # Unique #
# PSMs # AAs MW calc. PE 1 -,..T..
-Proteins peptides Peptides IkDal Q7Z4S6 Kinesin-like protein 51.34 1.31% 1 1 3 4 1674 187.1 6.42 4.=
KIF21A OS=Homo sapiens GN=KIF21A
PE=1 SV=2 -[KI21A HUMAN) 076038 Secretagogin 32.14 5.80% 1 1 1 2 276 32 5.41 OS=Homo sapiens GN=SCGN PE=1 Q
SV=2 -.
w co [SEGN HUMAN]
.
'=. Q9NQYO Bridging integrator 3 26.41 4.35% 1 1 1 4 253 29.6 7.47 OS=Homo sapiens .
, GN=BIN3 PE=1 ' , S V=1 -A
[BIN3 HUMAN]
P05305 Endothelin-1. 57.22 8.96% 1 -, 3 3 212 24.4 9.41 OS=Homo sapiens GN=EDN1 PE=1 SV=1 -[EDN1 HUMAN]
9:1 en P07476 Involucrin OS=Homo 40.81 1.71% 1 1 1 ..? 585 68.4 4.61 - 3 sapiens GN=IVL
cil b.) PE=1 SV=2 -[INVO HUMAN]
-.
b.) 015014 Zinc finger protein 40.51 1.49% 1 1 2 1 1411 151.1 8.03 4.
o o 609 OS=Human w Acession Description Score Coverage # # Unique #
# PSMs # AAs MW calc. PI
Proteins peptides Peptides IkDal sapiens GN=ZNF609 ,..) PE=1 SV=2 -¨
`&:=
[ZN609 HUMAN]
,..T..
Q9H013 Coiled-coil domain- 40.91 4.51% 1 1 7 2 377 44.2 8.73 4, 4.
containing protein 113 OS= Homo sapiens GN=CCDC113 PE=2 SV=1 -[CC113 HUMAN]
Q8IYE0 Coiled-coil domain 57.08 3.87% 1 1 3 5 955 112.7 8.48 containing protein Q
146 OS=Homo w ce sapiens , w . 0 GN=CCDC146 PE=2 SV=2 -,s9 , [CC146 HUMAN]
, Q96KM6 Zinc finger protein 23.93 1.23% 1 1 1 1 892 97.2 9.83 A
512B OS=Homo sapiens GN=1NF512B PE=1 S V=1 -[Z512B HUMAN] .
015018 PDZ domain- 81.48 1.62% 1 1 4 5 2839 301.5 7.43 9:1 n containing protein 2 OS=Homo sapiens cil b.) GN=PDZD2 PE=1 o SV=1 -, o b.) [PDZD2 HUMAN]
4, o o P43308 Translocon- 24.02 3.83% 1 1 1 1 183 20.1 8.35 (..e _ Acession Description Score Coverage # # Unique #
# PSMs # AAs MW calc. PI
Proteins peptides Peptides IkDal associated protein subunit beta OS=Homo sapiens GN=SSR2 PE=1 SV= 1 -4.=
[SSRB HUMAN]
La 9:1 =
Next, the protein translation assay was repeated using exosomes derived from MDA-MB-231 cells with electroporated pCMV-GFP plasmid. The exosomes were incubated in serum-free culture media at 37 C for 48 h with or without stimulation with rhEGF. While the unstimulated exosomes presented with a baseline level of GFP
production, the GFP levels increased upon incubation with different concentrations of rhEGF (FIG. 5E).
This again confirmed that, while all exosomes can synthetize proteins, growth factor stimulation can alter their rate of production by leading to increased levels of protein synthesis.
Example 6 ¨ Exosomes actively migrate in response to stimulation by rhEGF and serum factors In order to determine whether growth factors can induce a motility phonotype in exosomes, a reverse migration assay based on the Boyden chamber system was designed including rhEGF and serum factors. Ten billion exosomes isolated from MDA-MB-231 cells were placed in the culture wells of a 96-well plate, covered by a polycarbonate surface insert containing 400 nm pores. The insert contained either PBS, PBS
with 10 0/1 rhEGF, or PBS with 20% exosomes-depleted FBS (FIG. 6A). Because exosomes-depleted FBS could still contain trace amounts of exosomes (data not shown), 20% FBS
was placed on the top insert with no exosomes in the bottom well, as a control. After incubation at 37 C, samples were obtained from the top insert at different time points and exosomes quantified using Nanosight NTA.
After a 4 h incubation, the levels of exosomes on the top insert were comparable across all experimental groups (FIG. 6B). After a 24 h incubation, 20% FBS
significantly increased migration of the exosomes from the bottom to the top, suggesting a sustained chemotactic influence on MDA-MB-231 exosomes towards the higher serum growth factor gradient (FIG. 6C). The inserts with 20% FBS over wells with no exosomes had significantly fewer exosomes after 24 h, confirming the identity of the migrating exosomes as being from MDA-MB-231 cells (FIG. 6C). PBS resulted in negligible amounts of exosomes migration but rhEGF alone also induced motility of exosomes, albeit at a lower level when compared to complete serum associated growth factors (FIG. 6C).
Taken together, these results suggest that exosomes exhibit functional chemotactic capacity that can be induced by growth factors.
Example 7 ¨ Exosornes specifically exhibit enhanced protein production in tumor bearing mice To address whether the capacity of exosomes to respond to the growth factor gradient induced by tumors involves intrinsic production of new proteins with functional consequences, a reference mouse model was generated. Mice with established 4T1 mammary tumors were injected with 5 billion MDA-MD 231/CD63-mCherry exosomes electroporated with either GFP or ovalbumin expression plasmids. Control experimental arms of this study included CD63-mCherry exosomes without the plasmids and CD63-mCherry exosomes electroporated with plasmid and cyclohexamide. Twenty-four hours after the I.P.
injection of exosomes in tumor-bearing mice or non-tumor-bearing mice, the tumor, serum, and several other organs were collected. Exosomes were FACS isolated using the mCherry tag and evaluated for GFP or ovalbumin protein. GFP and ovalbumin were predominantly detected in the tumor, lung, bone, brain, and serum of mice with tumors, but were found only at very low levels in the tissues of non-tumor bearing mice and in tumor bearing mice that were injected with cyclohexamide-containing exosomes. These results demonstrate that while exosomes might be detected in the liver, lung, and brain of the non-tumor bearing mice, the exosomes enter these organs and more robustly (presumably via enhanced motility) including the tumor tissue, and biologically respond by generating de novo proteins. Additionally, the serum-derived exosomes from tumor bearing mice exhibit protein production, suggesting that tumors biologically influence exosomes at a systemic level.
* * *
All of the methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved.
All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.
The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.
U.S. Patent 4,870,287 U.S. Patent 5,739,169 U.S. Patent 5,760,395 U.S. Patent 5,801,005 U.S. Patent 5,824,311 U.S. Patent 5,830,880 U.S. Patent 5,846,945 Aakalu et al., Dynamic visualization of local protein synthesis in hippocampal neurons.
Neuron, 30:489-502, 2001.
Almoguera et al., Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell, 53:549-554, 1988.
Al-Nedawi et al., Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc. Natl. Acad. Sci.
U.S.A., 106:3794-3799, 2009.
Alvarez-Erviti et al., Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nature Biotechnology, 29:341-345, 2011.
Austin-Ward & Villaseca, Gene therapy and its applications. Rev. Med ChiL, 126:838-845, 1998.
Baietti et al., Syndecan-syntenin-ALIX regulated the biogenesis of exosomes.
Nat. Cell Biol., 14:677-685, 2012.
Bastos et al., Exosomes in cancer: Use them or target them? Semin. Cell Dev.
BioL, 78:13-21, 2018.
Biankin et al., Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes.
Nature, 491:399-405, 2012.
Borges et al., TGF-betal-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis. J. Amer.
Soc.
Nephrology, 24:385-392, 2013.
Bukowski et al., Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy.
Clin.
Cancer Res., 4:2337-2347, 1998.
Chang et al., Pancreatic cancer genomics. Current Opinion in Genetics &
Development, 24:74-81, 2014.
Choi et al., The protein interaction network of extracellular vesicles derived from human colorectal cancer cells. J Proteome Res., 11:1144-1151, 2012.
Christodoulides et al., Immunization with recombinant class 1 outer-membrane protein from Neisseria meningitidis: influence of liposomes and adjuvants on antibody avidity, recognition of native protein and the induction of a bactericidal immune response against meningococci. Microbiology, 144:3027-3037, 1998.
Clayton et al., Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59. Eur. J. Immunology, 33:522-531, 2003.
Collins et al., Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J. Clinical Investigation, 122:639-653, 2012a.
Collins et al., Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. PLoS
One, 7:e49707, 2012b.
Colombo et al., Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu. Rev. Cell. Dev. Biol., 30:255-289, 2014.
Combes et al., A new flow cytometry method of platelet-derived microvesicle quantitation in plasma, Thromb. Haemost., 77:220, 1997.
Cooper et al., Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Movement Disorders, 29:1476-1485, 2014.
Croft et al., The Reactome pathway knowledgebase. Nuc. Acids Res., 42:D472-477, 2014.
Davidson et al., Intralesional cytokine therapy in cancer: a pilot study of GM-CSF infusion in mesothelioma../. Immunother., 21:389-398, 1998.
Du et al., A systematic analysis of the silencing effects of an active siRNA
at all single-nucleotide mismatched target sites. Nuc. Acids Res., 33:1671-1677, 2005.
El-Andaloussi et al., Extracellular vesicles: biology and emerging therapeutic opportunities.
Nature Reviews Drug Discovery, 12:347-357, 2013.
El-Andaloussi et al., Exosome-mediated delivery of siRNA in vitro and in vivo.
Nature Protocols, 7:2112-2126, 2012.
Eser et al., Oncogenic KRAS signalling in pancreatic cancer. British Journal of Cancer, 111:817-822,2014.
Gartel et al., A new method for determining the status of p53 in tumor cell lines of different origin. Oncology Research, 13:405-408, 2003.
Gomes-da-Silva et al., Lipid-based nanoparticles for siRNA delivery in cancer therapy:
paradigms and challenges. Accounts of Chemical Research, 45:1163-1171, 2012.
Gonzales et al., Large-scale proteomics and phosphoproteomics of urinary exosomes. J.
Amer. Soc. Nephrology, 20:363-379, 2009.
Gysin et al., Therapeutic strategies for targeting ras proteins. Genes &
Cancer, 2:359-372, 2011.
Hanibuchi et al., Therapeutic efficacy of mouse-human chimeric anti-ganglioside GM2 monoclonal antibody against multiple organ micrometastases of human lung cancer in NK cell-depleted SC1D mice. Mt. J. Cancer, 78:480-485, 1998.
Harding et al., Endocytosis and intracellular processing of transferrin and colloidal gold-transferrin in rat reticulocytes: demonstration of a pathway for receptor shedding.
European J. Cell Biol., 35:256-263, 1984.
Hazan-Halevy et al., Cell-specific uptake of mantle cell lymphoma-derived exosomes by malignant and non-malignant B-lymphocytes. Cancer Lett., 364:59-69, 2015.
Hellstrand et at., Histamine and cytokine therapy. Acta Oncol., 37:347-353, 1998.
Hingorani et al., Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell, 7:469-483, 2005.
Hollander, Immunotherapy for B-cell lymphoma: current status and prospective advances.
Front M1117111tol., 3:3, 2013.
Howlader et at., SEER Cancer Statistics Review, 1975-2011, National Cancer Institute.
Bethesda, MD. On the World Wide Web at seercancergov/csr/1975_2011/, 2013.
Hruban et at., K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. American J.
Pathology, 143:545-554, 1993.
Huang et at., Epidermal growth factor receptor-containing exosomes induce tumor-specific regulatory T cells. Cancer Invest., 31:330-335, 2013.
Hui & Hashimoto, Pathways for Potentiation of Immunogenicity during Adjuvant-Assisted Immunizations with Plasmodium falciparum Major Merozoite Surface Protein 1.
Mfec. 'MUM , 66:5329-5336, 1998.
Ishihama et al., Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. MoL Cell. Proteomics, 4:1265-1272, 2005.
Ji et al., Ras activity levels control the development of pancreatic diseases.
Gastroenterology, 137:1072-1082, 82 el-6, 2009.
Johnsen et al., A comprehensive overview of exosomes as drug delivery vehicles -endogenous nanocarriers for targeted cancer therapy. Biochimica et Biophy.sica Ada, 1846:75-87, 2014.
Kahlert et al., Identification of Double Stranded Genomic DNA Spanning all Chromosomes with Mutated KRAS and p53 DNA in the Serum Exosomes of Patients with Pancreatic Cancer. J. Biol. Chem., 289:3869-3875, 2014.
Kalra et al., Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma.
Proteomics, 13:3354-3364, 2013.
Kalluri, The biology and function of exosomes in cancer. J. Clin. Invest., 126:1208-1215, 2016.
Kamerkar et al., Exosomes facilitate therapeutic targeting of oncogenic KRAS
in pancreatic cancer. Nature, 546:498-503, 2017.
Kowal et al., Biogenesis and secretion of exosomes. Current Opinion in Cell Biology, 29:116-125, 2014.
Kramer et al., The ribosome as a platform for co-translational processing, folding and targeting of newly synthesized proteins. Nat. Struct. MoL Biol., 16:589-597, 2009.
Li et al., Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy. Oncotarget, 7:24585-24595, 2016.
Lim et al., EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. Cancer Research, 76:1284-1296, 2016.
Liu et al.,. EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol, 29:401-405, 2012.
Livak & Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25:402-408, 2001.
Lorch et al., Role of DNA sequence in chromatin remodeling and the formation of nucleosome-free regions. Genes Dev., 28:2492-2497, 2014.
Luga et al., Exosomes mediate stromal mobilization of autocrine Wnt-PCP
signaling in breast cancer cell migration. Cell, 151:1542-1556, 2012.
Ma et al., Structural basis for overhang-specific small interfering RNA
recognition by the PAZ domain. Nature, 429:318-322, 2004.
Marcus & Leonard, FedExosomes: Engineering Therapeutic Biological Nanoparticles that Truly Deliver. Pharmaceuticals (Basel), 6:659-680, 2013.
Masuda et al., Role of epidermal growth factor receptor in breast cancer.
Breast Cancer Res.
Treat., 136:331-345, 2012.
Melo et al., Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesi s. Cancer ('dl, 26:707-721, 2014.
Melo et al., Glypican-1 identifies cancer exosomes and detects early pancreatic cancer.
Nature, 523:177-182, 2015.
Merrick, Cap-dependent and cap-independent translation in eukaryotic systems.
Gene, 332:1-
11,2004.
Morgillo et at., Mechanisms of resistance to EGFR-targeted drugs: lung cancer.
ESMO Open, 1:e000060, 2016.
Morino et al., Eukaryotic translation initiation factor 4E (eIF4E) binding site and the middle one-third of elF4GI constitute the core domain for cap-dependent translation, and the C-terminal one-third functions as a modulatory region. Mol. Cell Biol., 20:468-477, 2000.
=Nagai et at., Chromatin potentiates transcription. Proc. Natl. Acad. Sci.
U.S.A., 114:1536-1541, 2017.
Nakai et al., A perspective on anti-EGFR therapies targeting triple-negative breast cancer.
Am. J. Cancer Res., 6:1609-1623, 2016.
Normanno et al., Epidermal growth factor receptor (EGFR) signaling in cancer.
Gene, 366:2-16, 2006.
Ozdemir et al., Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival.
Cancer Cell, 25:719-734, 2014.
Pardoll, Cancer immunotherapy through checkpoint blockade: the future of cancer treatment.
Medicographia, 36:274-284, 2014.
Pathan et al., FunRich: An open access standalone functional enrichment and interaction network analysis tool. Proteomics, 15:2597-2601, 2015.
Pecot et al., Therapeutic Silencing of KRAS using Systemically Delivered siRNAs.
Molecular Cancer Ihercpeutics, 13:2876-2885, 2014.
Peinado et al., Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature Medicine, 18:883-891, 2012.
Perdigao et al., Unexpected features of the dark proteome. Proc. Natl. Acad.
S'ci. U.S.A., 112:15898-5903, 2015.
Pico de Coana et al., Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. Trends in Molecular Medicine, 21:482-492, 2015.
Pisitkun et al., Identification and proteomic profiling of exosomes in human urine. Proc. Natl.
Acad. ScL U.S.A., 101:13368-13373, 2004.
Poliseno et al., A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature, 465:1033-1038, 2010.
Poulin et al., 4E-BP3, a new member of the eukaryotic initiation factor 4E-binding protein family. J. Biol. Chem., 273:14002-14007, 1998.
Qin et al., Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc. Nall. Acad. Sci. U.S.A., 95:14411-14416, 1998.
Rachagani et al., Activated KrasG12D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. Br. J. Cancer, 104:1038-1048, 2011.
Rao & Cruz, Effects of confinement on the structure and dynamics of an intrinsically disordered peptide: a molecular-dynamics study. J. Phys. Chem. B., 117:3707-3719, 2013.
Raposo & Stoorvogel, Extracellular vesicles: exosomes, microvesicles, and friends. J. Cell Biol., 200:373-383, 2013.
Rejiba et al., K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment. Cancer Science, 98:1128-1136, 2007.
Ronquist et al., Prostasomes from four different species are able to produce extracellular adenosine triphosphate (ATP). Biochim Biophys. Ada, 1830:4604-4610, 2013a.
Ronquist et al., Human prostasomes express glycolytic enzymes with capacity for ATP
production. Am. J. PhysioL Endocrinol. Metah., 304:E576-582, 2013b.
Rothstein et at, Targeting signal 1 through CD45RB synergizes with CD40 ligand blockade and promotes long term engraftment and tolerance in stringent transplant models. J.
Immunol., 166:322-329, 2001.
Seshachaiyulu et al., Targeting the EGFR signaling pathway in cancer therapy.
Expert Op/n.
flier. Targets, 16:15-31, 2012.
Siegel et at, Cancer statistics, 2014. CA: A cancer journal for clinicians, 64:9-29, 2014.
Simoes et al., Cationic liposomes for gene delivery. Expert Opinion on Drug Delivery, 2:237-254, 2005.
Sinkovics, The cell survival pathways of the primordial RNA-DNA complex remain conserved in the extant genomes and may function as proto-oncogenes. Eur. J.
Microbiol. Immunot (Bp), 5:25-43, 2015.
Skogberg et al., Characterization of human thymic exosomes. PLoS ONE, 8:e67554, 2013.
Smakman et al., Dual effect of Kras(D12) knockdown on tumorigenesis: increased immune-mediated tumor clearance and abrogation of tumor malignancy. Oncogene, 24:8338-8342, 2005.
Smith et al., Local protein synthesis in neurons. Curr. Biol., 11:R901-903, 2001.
Song et al., Cancer Cell-derived Exosomes Induce Mitogen-activated Protein Kinase-dependent Monocyte Survival by Transport of Functional Receptor Tyrosine Kinases.
J. Biol. Chem., 291:8453-8464, 2016.
Steward & Levy, Preferential localization of polyribosomes under the base of dendritic spines in granule cells of the dentate gyrus. J. Neurosci., 2:284-291, 1982.
Sun et al., Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines. Oncology Reports, 8:89-92, 2001.
Thery et al., Exosomes: composition, biogenesis and function. Nature Reviews Immunology, 2:569-579, 2002.
Thery et al., Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Current Protocols in Cell Biology, Chapter 3, Unit 3 22, 2006.
Tomas et al., EGF receptor trafficking: consequences for signaling and cancer.
Trends Cell Biol., 24:26-34, 2014.
Ung et al., Exosome proteomics reveals transcriptional regulator proteins with potential to mediate downstream pathways. Cancer Sci., 105:1384-1392, 2014.
Valadi et al., Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature Cell Biology, 9:654-659, 2007.
van den Boom et al., Exosomes as nucleic acid nanocarriers. Advanced Drug Delivery Reviews, 65:331-335, 2013.
van der Meel et al., Extracellular vesicles as drug delivery systems: Lessons from the liposome field-1. Controlled Release, 195:72-85, 2014.
Wahlgren et al., Plasma exosomes can deliver exogenous short interfering RNA
to monocytes and lymphocytes. Nucleic Acids Research, 40:e130, 2012.
Westphal et al., EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise. CNS
Drugs, 31:723-735, 2017.
Weyrich et al., Change in protein phenotype without a nucleus: translational control in platelets. Semin. Thromb. Hemost., 30:491-498, 2004.
Willms et al., Cells release subpopulations of exosomes with distinct molecular and biological properties. Sc!. Rep., 6:22519, 2016.
Wykes & Lewin, Immune checkpoint blockade in infectious diseases. Nat. Rev.
Immunology, 18:91-104, 2018.
.. Xue et al., Small RNA combination therapy for lung cancer. Proc. Natl. Acad Sci. U.S.A., 111:E3553-3561, 2014.
Yamada et al., Cell Infectivity in Relation to Bovine Leukemia Virus gp51 and p24 in Bovine Milk Exosomes. PLoS ONE, 8:e77359, 2013.
Ying et al., Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell, 149:656-670, 2012.
Yuan et al., Development of siRNA payloads to target KRAS-mutant cancer.
Cancer Discovery, 4:1182-1197, 2014.
Zhang et al., Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis. Nat. Commun., 8:15016, 2017.
Zhang et al., A mechanism for the upregulation of EGF receptor levels in glioblastomas. Cell.
Rep., 3:2008-2020, 2013.
Zilfou & Lowe, (2009). Tumor suppressive functions of p53. Cold Spring Harb.
Perspect.
Biol.,1:a001883, 2009.
Zorde Khvalevsky et al., Mutant KRAS is a druggable target for pancreatic cancer. Proc.
Natl. Acad. Sci. U.S.A., 110:20723-20728, 2013.
Morgillo et at., Mechanisms of resistance to EGFR-targeted drugs: lung cancer.
ESMO Open, 1:e000060, 2016.
Morino et al., Eukaryotic translation initiation factor 4E (eIF4E) binding site and the middle one-third of elF4GI constitute the core domain for cap-dependent translation, and the C-terminal one-third functions as a modulatory region. Mol. Cell Biol., 20:468-477, 2000.
=Nagai et at., Chromatin potentiates transcription. Proc. Natl. Acad. Sci.
U.S.A., 114:1536-1541, 2017.
Nakai et al., A perspective on anti-EGFR therapies targeting triple-negative breast cancer.
Am. J. Cancer Res., 6:1609-1623, 2016.
Normanno et al., Epidermal growth factor receptor (EGFR) signaling in cancer.
Gene, 366:2-16, 2006.
Ozdemir et al., Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival.
Cancer Cell, 25:719-734, 2014.
Pardoll, Cancer immunotherapy through checkpoint blockade: the future of cancer treatment.
Medicographia, 36:274-284, 2014.
Pathan et al., FunRich: An open access standalone functional enrichment and interaction network analysis tool. Proteomics, 15:2597-2601, 2015.
Pecot et al., Therapeutic Silencing of KRAS using Systemically Delivered siRNAs.
Molecular Cancer Ihercpeutics, 13:2876-2885, 2014.
Peinado et al., Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature Medicine, 18:883-891, 2012.
Perdigao et al., Unexpected features of the dark proteome. Proc. Natl. Acad.
S'ci. U.S.A., 112:15898-5903, 2015.
Pico de Coana et al., Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. Trends in Molecular Medicine, 21:482-492, 2015.
Pisitkun et al., Identification and proteomic profiling of exosomes in human urine. Proc. Natl.
Acad. ScL U.S.A., 101:13368-13373, 2004.
Poliseno et al., A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature, 465:1033-1038, 2010.
Poulin et al., 4E-BP3, a new member of the eukaryotic initiation factor 4E-binding protein family. J. Biol. Chem., 273:14002-14007, 1998.
Qin et al., Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc. Nall. Acad. Sci. U.S.A., 95:14411-14416, 1998.
Rachagani et al., Activated KrasG12D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. Br. J. Cancer, 104:1038-1048, 2011.
Rao & Cruz, Effects of confinement on the structure and dynamics of an intrinsically disordered peptide: a molecular-dynamics study. J. Phys. Chem. B., 117:3707-3719, 2013.
Raposo & Stoorvogel, Extracellular vesicles: exosomes, microvesicles, and friends. J. Cell Biol., 200:373-383, 2013.
Rejiba et al., K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment. Cancer Science, 98:1128-1136, 2007.
Ronquist et al., Prostasomes from four different species are able to produce extracellular adenosine triphosphate (ATP). Biochim Biophys. Ada, 1830:4604-4610, 2013a.
Ronquist et al., Human prostasomes express glycolytic enzymes with capacity for ATP
production. Am. J. PhysioL Endocrinol. Metah., 304:E576-582, 2013b.
Rothstein et at, Targeting signal 1 through CD45RB synergizes with CD40 ligand blockade and promotes long term engraftment and tolerance in stringent transplant models. J.
Immunol., 166:322-329, 2001.
Seshachaiyulu et al., Targeting the EGFR signaling pathway in cancer therapy.
Expert Op/n.
flier. Targets, 16:15-31, 2012.
Siegel et at, Cancer statistics, 2014. CA: A cancer journal for clinicians, 64:9-29, 2014.
Simoes et al., Cationic liposomes for gene delivery. Expert Opinion on Drug Delivery, 2:237-254, 2005.
Sinkovics, The cell survival pathways of the primordial RNA-DNA complex remain conserved in the extant genomes and may function as proto-oncogenes. Eur. J.
Microbiol. Immunot (Bp), 5:25-43, 2015.
Skogberg et al., Characterization of human thymic exosomes. PLoS ONE, 8:e67554, 2013.
Smakman et al., Dual effect of Kras(D12) knockdown on tumorigenesis: increased immune-mediated tumor clearance and abrogation of tumor malignancy. Oncogene, 24:8338-8342, 2005.
Smith et al., Local protein synthesis in neurons. Curr. Biol., 11:R901-903, 2001.
Song et al., Cancer Cell-derived Exosomes Induce Mitogen-activated Protein Kinase-dependent Monocyte Survival by Transport of Functional Receptor Tyrosine Kinases.
J. Biol. Chem., 291:8453-8464, 2016.
Steward & Levy, Preferential localization of polyribosomes under the base of dendritic spines in granule cells of the dentate gyrus. J. Neurosci., 2:284-291, 1982.
Sun et al., Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines. Oncology Reports, 8:89-92, 2001.
Thery et al., Exosomes: composition, biogenesis and function. Nature Reviews Immunology, 2:569-579, 2002.
Thery et al., Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Current Protocols in Cell Biology, Chapter 3, Unit 3 22, 2006.
Tomas et al., EGF receptor trafficking: consequences for signaling and cancer.
Trends Cell Biol., 24:26-34, 2014.
Ung et al., Exosome proteomics reveals transcriptional regulator proteins with potential to mediate downstream pathways. Cancer Sci., 105:1384-1392, 2014.
Valadi et al., Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature Cell Biology, 9:654-659, 2007.
van den Boom et al., Exosomes as nucleic acid nanocarriers. Advanced Drug Delivery Reviews, 65:331-335, 2013.
van der Meel et al., Extracellular vesicles as drug delivery systems: Lessons from the liposome field-1. Controlled Release, 195:72-85, 2014.
Wahlgren et al., Plasma exosomes can deliver exogenous short interfering RNA
to monocytes and lymphocytes. Nucleic Acids Research, 40:e130, 2012.
Westphal et al., EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise. CNS
Drugs, 31:723-735, 2017.
Weyrich et al., Change in protein phenotype without a nucleus: translational control in platelets. Semin. Thromb. Hemost., 30:491-498, 2004.
Willms et al., Cells release subpopulations of exosomes with distinct molecular and biological properties. Sc!. Rep., 6:22519, 2016.
Wykes & Lewin, Immune checkpoint blockade in infectious diseases. Nat. Rev.
Immunology, 18:91-104, 2018.
.. Xue et al., Small RNA combination therapy for lung cancer. Proc. Natl. Acad Sci. U.S.A., 111:E3553-3561, 2014.
Yamada et al., Cell Infectivity in Relation to Bovine Leukemia Virus gp51 and p24 in Bovine Milk Exosomes. PLoS ONE, 8:e77359, 2013.
Ying et al., Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell, 149:656-670, 2012.
Yuan et al., Development of siRNA payloads to target KRAS-mutant cancer.
Cancer Discovery, 4:1182-1197, 2014.
Zhang et al., Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis. Nat. Commun., 8:15016, 2017.
Zhang et al., A mechanism for the upregulation of EGF receptor levels in glioblastomas. Cell.
Rep., 3:2008-2020, 2013.
Zilfou & Lowe, (2009). Tumor suppressive functions of p53. Cold Spring Harb.
Perspect.
Biol.,1:a001883, 2009.
Zorde Khvalevsky et al., Mutant KRAS is a druggable target for pancreatic cancer. Proc.
Natl. Acad. Sci. U.S.A., 110:20723-20728, 2013.
Claims (46)
1. A. method of treating a disease or disorder in a patient in need thereof, the method comprising:
(a) obtaining exosomes having a growth factor receptor on their surface;
(b) transfecting the exosomes with a nucleic acid encoding a therapeutic protein;
(c) administering the transfected exosomes to a patient;
(d) providing a growth factor gradient at a site of the disease or disorder to attract the exosomes to the site and stimulate production of the therapeutic protein at the site, thereby treating the disease in the patient.
(a) obtaining exosomes having a growth factor receptor on their surface;
(b) transfecting the exosomes with a nucleic acid encoding a therapeutic protein;
(c) administering the transfected exosomes to a patient;
(d) providing a growth factor gradient at a site of the disease or disorder to attract the exosomes to the site and stimulate production of the therapeutic protein at the site, thereby treating the disease in the patient.
2. The method of claim 1, wherein the method is further defined as a method of administering a therapeutic protein to a diseased cell in a patient.
3. The method of claim 1, wherein the exosomes obtained in step (a) are obtained from a body fluid sample obtained from the patient.
4. The method of claim 3, wherein the body fluid sample is blood, lymph, saliva, urine, cerebrospinal fluid, bone marrow aspirates, eye exudate/tears, or serum.
5. The method of claim 1, wherein the nucleic acid is an mRNA.
6. The method of claim 1, wherein the nucleic acid is a plasmid.
7. The method of claim 1, wherein the nucleic acid is a cDNA.
8. The method of claim 1, wherein the disease or disorder is cancer, an injury, an autoimmune disorder, a neurological disorder, a gastrointestinal disorder, an infectious disease, a kidney disease, a cardiovascular disorder, an ophthalmic disorder, a skin disease or disorder, a urogenital disorder, or a bone disease or disorder.
9. The method of claim 8, wherein the cancer is a breast cancer, lung cancer, head &
neck cancer, prostate cancer, esophageal cancer, tracheal cancer, brain cancer, liver cancer, bladder cancer, stomach cancer, pancreatic cancer, ovarian cancer, uterine cancer, cervical cancer, testicular cancer, colon cancer, rectal cancer or skin cancer
neck cancer, prostate cancer, esophageal cancer, tracheal cancer, brain cancer, liver cancer, bladder cancer, stomach cancer, pancreatic cancer, ovarian cancer, uterine cancer, cervical cancer, testicular cancer, colon cancer, rectal cancer or skin cancer
10. The method of claim 8, wherein the site of the disease or disorder is a tumor.
11. The rnethod of clairn 8, wherein the cancer is metastatic.
12. The method of claim 11, wherein the site of the disease or disorder is a metastatic node.
13. The method of claim 1, wherein the therapeutic protein is a kinase, a phosphatase, or a transcription factor.
14. The method of claim 1, wherein the therapeutic protein corresponds to a wildtype version of a protein that is mutated or inactivated in a cell at the site of the disease or disorder.
15. The method of claim 1, wherein the therapeutic protein corresponds to a dominant negative version of a protein that is hyperactive in a cell at the site of the disease or disorder.
16. The method of claim 1, wherein the disease or disorder is cancer, wherein the therapeutic protein is a tumor suppressor.
17. The method of claim 1, wherein the exosomes comprise CD47 on their surface.
18. The method of claim 1, wherein transfection comprises electroporation.
19. The method of clairn 1, further comprising administering at least a second therapy to the patient.
20. The method of claim 19, wherein the second therapy comprises a surgical therapy, chernotherapy, radiation therapy, cryotherapy, hormonal therapy, or immunotherapy.
21. The method of claim 1, wherein said exosomes are comprised in tissue scaffold matrix.
22. A method of treating a disease or disorder in a patient in need thereof, the method comprising:
(a) obtaining exosomes having a growth factor receptor on their surface;
(b) transfecting the exosomes with therapeutic agent;
(c) administering the transfected exosomes to a patient;
(d) providing a growth factor gradient at a site of the disease or disorder to attract the exosomes to the site and deliver the therapeutic agent to the site, thereby treating the disease in the patient
(a) obtaining exosomes having a growth factor receptor on their surface;
(b) transfecting the exosomes with therapeutic agent;
(c) administering the transfected exosomes to a patient;
(d) providing a growth factor gradient at a site of the disease or disorder to attract the exosomes to the site and deliver the therapeutic agent to the site, thereby treating the disease in the patient
23. The method of claim 22, wherein the method is further defined as a method of .. administering a therapeutic agent to a diseased cell in a patient.
24. The method of claim 22, wherein the exosomes obtained in step (a) are obtained from a body fluid sample obtained from the patient.
25. The method of claim 24, wherein the body fluid sample is blood, lymph, saliva, urine, cerebrospinal fluid, bone marrow aspirates, eye exudate/tears, or serum.
26. The method of claim 22, wherein the therapeutic agent is a therapeutic protein, an antibody, an inhibitory RNA, a gene editing system, or a small molecule drug.
27. The method of claim 26, wherein the antibody binds an intracellular antigen.
28. The method of claim 26, wherein the antibody is a full-length antibody, an scFv, a Fab fragment, a (Fab)2, a diabody, a triabody, or a minibody.
29. The method of claim 26, wherein the inhibitory RNA is a siRNA, shRNA, miRNA, or pre-miRNA.
30. The method of claim 26, wherein the gene editing system is a CRISPR/Cas system.
31. The method of claim 26, wherein the therapeutic protein is a kinase, a phosphatase, or a transcription factor.
32. The method of claim 26, wherein the therapeutic protein corresponds to a wildtype version of a protein that is mutated or inactivated in a cell at the site of the disease or disorder.
33. The method of claim 26, wherein the therapeutic protein corresponds to a dominant negative version of a protein that is hyperactive in a cell at the site of the disease or disorder.
34. The method of claim 26, wherein the small molecule drug is an imaging agent.
35. The method of claim 22, wherein the disease or disorder is cancer, an injury, an autoimmune disorder, a neurological disorder, a gastrointestinal disorder, an infectious disease, a kidney disease, a cardiovascular disorder, an ophthalmic disorder, a skin disease or disorder, a urogenital disorder, or a bone disease or disorder.
36. The method of claim 35, wherein the cancer is a breast cancer, lung cancer, head &
neck cancer, prostate cancer, esophageal cancer, tracheal cancer, brain cancer, liver cancer, bladder cancer, stomach cancer, pancreatic cancer, ovarian cancer, uterine cancer, cervical cancer, testicular cancer, colon cancer, rectal cancer or skin cancer
neck cancer, prostate cancer, esophageal cancer, tracheal cancer, brain cancer, liver cancer, bladder cancer, stomach cancer, pancreatic cancer, ovarian cancer, uterine cancer, cervical cancer, testicular cancer, colon cancer, rectal cancer or skin cancer
37. The method of claim 35, wherein the site of the disease or disorder is a tumor.
38. The method of claim 35, wherein the cancer is metastatic.
39. The method of claim 38, wherein the site of the disease or disorder is a metastatic node.
40. The method of claim 22, wherein the disease or disorder is cancer, wherein the therapeutic protein is a tumor suppressor.
41. The method of claim 22, wherein the disease or disorder is cancer, wherein the therapeutic agent is an inhibitory RNA targeting an oncogene.
42. The rnethod of claim 22, wherein the exosomes comprise CD47 on their surface.
43. The method of claim 22, wherein transfection comprises electroporation.
44. The method of claim 22, further comprising administering at least a second therapy to the patient.
45. The method of claim 44, wherein the second therapy comprises a surgical therapy, chemotherapy, radiation therapy, cryotherapy, hormonal therapy, or immunotherapy.
46. The method of claim 22, wherein said exosomes are comprised in tissue scaffold matrix.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862649057P | 2018-03-28 | 2018-03-28 | |
US62/649,057 | 2018-03-28 | ||
PCT/US2019/024603 WO2019191444A1 (en) | 2018-03-28 | 2019-03-28 | Use of exosomes for targeted delivery of therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3095136A1 true CA3095136A1 (en) | 2019-10-03 |
Family
ID=68060505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3095136A Pending CA3095136A1 (en) | 2018-03-28 | 2019-03-28 | Use of exosomes for targeted delivery of therapeutic agents |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP3773747A4 (en) |
JP (1) | JP2021519296A (en) |
KR (1) | KR20200136978A (en) |
CN (1) | CN112533643A (en) |
AU (1) | AU2019243179A1 (en) |
CA (1) | CA3095136A1 (en) |
WO (1) | WO2019191444A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201900007785A1 (en) * | 2019-05-31 | 2020-12-01 | Univ Degli Studi Milano | Extracellular vesicles to deliver therapeutic or diagnostic drugs |
CN115297850A (en) * | 2019-12-05 | 2022-11-04 | 得克萨斯州大学系统董事会 | Exosome-based treatment for liver fibrosis and other fibrosis-related diseases |
WO2021119552A1 (en) * | 2019-12-13 | 2021-06-17 | Lawrence Livermore National Security, Llc | Nanotube-vesicle compositions and uses thereof |
CN114774471A (en) * | 2022-05-10 | 2022-07-22 | 厦门星际诺康细胞科技有限公司 | IL 27-presenting stable cell and construction method thereof, IL 27-presenting engineered exosome and preparation method and application thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7473678B2 (en) * | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
US9085778B2 (en) * | 2006-05-03 | 2015-07-21 | VL27, Inc. | Exosome transfer of nucleic acids to cells |
GB201121069D0 (en) * | 2011-12-07 | 2012-01-18 | Isis Innovation | Delivery system |
CN105051192B (en) * | 2012-11-13 | 2020-04-17 | 科迪艾克生物科学公司 | Delivery of therapeutic agents |
EP2925359A2 (en) * | 2012-11-29 | 2015-10-07 | Yeda Research and Development Co., Ltd. | Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitors |
US9921223B2 (en) * | 2013-12-04 | 2018-03-20 | Board Of Regents, The University Of Texas System | Analysis of genomic DNA, RNA, and proteins in exosomes for diagnosis and theranosis |
AU2016275046B2 (en) * | 2015-06-10 | 2022-07-28 | Board Of Regents, The University Of Texas System | Use of exosomes for the treatment of disease |
WO2017117585A1 (en) * | 2015-12-30 | 2017-07-06 | The Regents Of The University Of California | Methods for enhanced production and isolation of cell-derived vesicles |
TWI601741B (en) * | 2016-07-11 | 2017-10-11 | 財團法人國家衛生研究院 | Method of producing exosomes by using ep4-antagonist to induce exosomes releasing from stem cells and the use thereof |
-
2019
- 2019-03-28 AU AU2019243179A patent/AU2019243179A1/en active Pending
- 2019-03-28 CN CN201980034058.9A patent/CN112533643A/en active Pending
- 2019-03-28 KR KR1020207030993A patent/KR20200136978A/en unknown
- 2019-03-28 WO PCT/US2019/024603 patent/WO2019191444A1/en unknown
- 2019-03-28 EP EP19776678.5A patent/EP3773747A4/en active Pending
- 2019-03-28 JP JP2020551798A patent/JP2021519296A/en active Pending
- 2019-03-28 CA CA3095136A patent/CA3095136A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20200136978A (en) | 2020-12-08 |
EP3773747A4 (en) | 2022-02-23 |
JP2021519296A (en) | 2021-08-10 |
EP3773747A1 (en) | 2021-02-17 |
AU2019243179A1 (en) | 2020-11-12 |
WO2019191444A1 (en) | 2019-10-03 |
CN112533643A (en) | 2021-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10959952B2 (en) | Use of exosomes for the treatment of disease | |
CA3095136A1 (en) | Use of exosomes for targeted delivery of therapeutic agents | |
WO2015085096A1 (en) | Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis | |
US20210369858A1 (en) | Use of exosomes for targeted delivery of therapeutic agents | |
US20200345648A1 (en) | Methods and compositions for treating cancer using exosomes-associated gene editing | |
WO2018226975A1 (en) | Cationic liquid crystalline nanoparticles | |
US20210024936A1 (en) | Therapeutic targeting of oncogenes using exosomes | |
US20210115449A1 (en) | Therapeutic modulation of tumor suppressors using exosomes | |
JP2024059816A (en) | Methods and compositions for treating cancer using exosome-associated gene editing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20240328 |